,datetime,title,source,link,sentiment_class,sentiment_score
0,1/23/2013 4:24:51 PM,Abbott results bode well for spun-off AbbVie,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/EFRmKj-o8TY/us-abbott-results-idUSBRE90M0O820130123,negative,0.9512851238250732
1,3/10/2013 11:11:46 PM,AbbVie seeks to stop EU agency releasing drug data,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/PRkXgsKvUqQ/us-abbvie-ema-idUSBRE9290HY20130310,neutral,0.7765364050865173
2,10/25/2013 8:23:21 PM,AbbVie beats forecast as Humira sales surge,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/fNGYtTbrcwU/story01.htm,negative,0.8464279770851135
3,7/11/2014 5:35:04 PM,"As Shire stays silent, some investors urge talks with AbbVie",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/dBn5GAQu3E0/story01.htm,positive,0.6007019281387329
4,7/11/2014 10:32:47 PM,Shire confirms in talks with AbbVie on takeover bid,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Aoz9rIYi2Ss/story01.htm,positive,0.8409590721130371
5,7/12/2014 11:29:15 PM,Shire seeks AbbVie bid of close to 53 pounds per share: sources,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/zYiM15DkSeI/story01.htm,positive,0.9311743378639221
6,7/17/2014 7:06:41 PM,"Shire, AbbVie to announce $53 billion merger by Friday: sources",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/P3YsXTi1N1I/story01.htm,positive,0.9437910914421082
7,7/18/2014 11:27:55 AM,AbbVie succeeds in Shire courtship with $53 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/QxaB5N0DFao/story01.htm,positive,0.550855278968811
8,7/19/2014 2:23:31 AM,U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/F_3ATlDSL_w/story01.htm,negative,0.7290130853652954
9,9/3/2014 7:11:17 PM,"AbbVie, Calico forge deal against age-related diseases",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/xnOVpwq6DOE/story01.htm,negative,0.5637621879577637
10,10/15/2014 4:00:43 AM,AbbVie says to reconsider recommendation for Shire acquisition,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/T4ZybHrrf4I/story01.htm,positive,0.885882556438446
11,10/15/2014 8:55:59 AM,Shire urges AbbVie to stick to original deal plan,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/_jlXqO2heCU/story01.htm,positive,0.8128215074539185
12,10/16/2014 6:59:05 AM,AbbVie recommends stockholders to reject Shire deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/qMP1o4zpeHk/story01.htm,positive,0.7828505635261536
13,10/20/2014 11:45:43 PM,AbbVie says $55 billion acquisition of Shire officially dead,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CFbVV1PdWE4/story01.htm,positive,0.895220935344696
14,10/29/2014 3:01:56 PM,U.S. law firm says investigating AbbVie over collapsed Shire deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/aEBpfW_KZWQ/story01.htm,neutral,0.9097303152084351
15,10/31/2014 6:36:44 PM,AbbVie says strong results lessen need for big deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/xDOVqaFjYHs/story01.htm,negative,0.9104862213134766
16,12/11/2014 1:07:56 AM,"Shire CEO eyes deals, but no urgency to spend AbbVie breakup fee",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/1fTfYJEhwMg/story01.htm,positive,0.8320441842079163
17,3/5/2015 6:01:13 AM,AbbVie to buy cancer drug maker Pharmacyclics in $21 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/wjQq6ormaQ0/story01.htm,positive,0.8697747588157654
18,3/5/2015 8:11:34 PM,AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/FmQKJNT-lmU/story01.htm,negative,0.8790745139122009
19,7/24/2015 2:29:23 PM,AbbVie profit jumps 24 percent as Humira sales rise,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/F40mjWS4sdU/story01.htm,negative,0.939463198184967
20,10/30/2015 8:58:19 PM,"Exclusive: Express Scripts reviews AbbVie, Teva ties to pharmacies",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/RreiB3rm4S0/story01.htm,positive,0.9219653010368347
21,4/28/2016 2:05:32 PM,"AbbVie forges deeper into cancer, as clock ticks for Humira",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ByZysH2iE6o/us-stemcentrx-m-a-abbvie-idUSKCN0XP1MW,positive,0.8286670446395874
22,11/9/2016 6:28:14 PM,"Drug stocks rip higher after Trump's upset victory signals easing pressure on prices (MRK, PFE, AMGN, JNJ, AGN, ABBV, SNY, NVS, AZN, GSK, IBB)",Business Insider,http://www.businessinsider.com/drug-company-stocks-morning-after-election-2016-11,negative,0.9015561938285828
23,1/11/2017 9:14:52 PM,Another huge drugmaker just said it'll put a lid on drug price increases (ABBV),Reuters,http://www.businessinsider.com/r-abbvie-vows-to-keep-drug-price-increases-below-10-percent-2017-1,positive,0.824665367603302
24,2/27/2017 10:00:00 AM,AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic...,PR Newswire,/news/stocks/abbvie-receives-chmp-positive-opinion-for-eight-week-treatment-option-with-viekirax-ombitasvir-paritaprevir-ritonavir-tablets-exviera-dasabuvir-tablets-for-patients-with-genotype-1b-chronic-1001784784,negative,0.9199954867362976
25,3/1/2017 2:00:00 PM,AbbVie to Present at the Barclays Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-barclays-global-healthcare-conference-1001794538,positive,0.9058839678764343
26,3/7/2017 1:25:00 PM,"Drug Makers Stocks Under Scanner -- Pfizer, Merck, AbbVie, and Johnson & Johnson",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-pfizer-merck-abbvie-and-johnson-johnson-1001810747,neutral,0.6821770071983337
27,3/14/2017 1:00:00 PM,AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C,PR Newswire,/news/stocks/abbvie-granted-priority-review-in-japan-for-its-investigational-regimen-of-glecaprevir-pibrentasvir-g-p-for-the-treatment-of-all-major-genotypes-of-chronic-hepatitis-c-1001833209,negative,0.9210540056228638
28,3/23/2017 12:45:00 PM,"Julianne Hough Empowers Women to ""Get in the Know"" About Endometriosis",PR Newswire,/news/stocks/julianne-hough-empowers-women-to-get-in-the-know-about-endometriosis-1001861689,positive,0.8545027375221252
29,3/28/2017 2:00:00 PM,AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program,PR Newswire,/news/stocks/abbvie-and-m2gen-announce-new-collaboration-for-the-oncology-research-information-exchange-network-orien-avatar-research-program-1001873527,negative,0.7910095453262329
30,3/30/2017 1:00:00 PM,U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information,PR Newswire,/news/stocks/u-s-fda-approves-addition-of-moderate-to-severe-fingernail-psoriasis-data-to-abbvie-s-humira-adalimumab-prescribing-information-1001881387,negative,0.7136911153793335
31,3/31/2017 3:00:00 PM,The Growth of Legal Cannabis Industry Sales,PR Newswire,/news/stocks/the-growth-of-legal-cannabis-industry-sales-1001886130,positive,0.7785070538520813
32,4/6/2017 2:00:00 PM,AbbVie to Host First-Quarter Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-first-quarter-earnings-conference-call-1001902450,positive,0.897003173828125
33,4/7/2017 2:00:00 PM,AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids,PR Newswire,/news/stocks/abbvie-announces-positive-phase-2b-data-demonstrating-investigational-medicine-elagolix-significantly-reduced-heavy-menstrual-bleeding-in-women-with-uterine-fibroids-1001906482,negative,0.9508062601089478
34,4/7/2017 2:22:32 PM,AbbVie: Data Shows Elagolix Reduces Menstrual Bleeding In Phase 2b Trial ,RTTNews,/news/stocks/abbvie-data-shows-elagolix-reduces-menstrual-bleeding-in-phase-2b-trial-1001906580,negative,0.9216419458389282
35,4/10/2017 1:30:22 AM,"AKRX Confirms Acquisition Talks, CBIO Plunges, Be All Ears For GERN ",RTTNews,/news/stocks/akrx-confirms-acquisition-talks-cbio-plunges-be-all-ears-for-gern-1001908672,positive,0.842041552066803
36,4/10/2017 12:10:00 PM,"Drug Makers Stocks on Investors' Radar -- Pfizer, Merck, Johnson & Johnson, and AbbVie",PR Newswire,/news/stocks/drug-makers-stocks-on-investors-radar-pfizer-merck-johnson-johnson-and-abbvie-1001909734,positive,0.9021657705307007
37,4/20/2017 1:30:00 PM,"AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis",PR Newswire,/news/stocks/abbvie-s-investigational-pan-genotypic-ribavirin-free-regimen-of-glecaprevir-pibrentasvir-g-p-achieved-99-percent-svr-12-rate-in-chronic-hepatitis-c-patients-with-compensated-cirrhosis-1001934277,negative,0.94711834192276
38,4/21/2017 7:00:00 AM,"Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C",PR Newswire,/news/stocks/eight-weeks-of-treatment-with-abbvie-s-investigational-pan-genotypic-regimen-of-glecaprevir-pibrentasvir-g-p-achieved-high-svr-12-rates-in-challenging-to-treat-genotype-3-chronic-hepatitis-c-1001936713,negative,0.9534387588500977
39,4/21/2017 2:00:00 PM,AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-deutsche-bank-42nd-annual-health-care-conference-586452,positive,0.8928315043449402
40,4/25/2017 2:00:00 PM,Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease,PR Newswire,/news/stocks/aquinnah-pharmaceuticals-receives-10-million-investment-from-pfizer-and-abbvie-to-research-breakthrough-approach-to-neurodegenerative-disease-1001946220,negative,0.7964536547660828
41,4/27/2017 1:38:00 PM,AbbVie Reports First-Quarter 2017 Financial Results,PR Newswire,/news/stocks/abbvie-reports-first-quarter-2017-financial-results-1001956385,positive,0.8457837104797363
42,4/27/2017 2:47:37 PM,Drugmaker AbbVie's profit and revenue beat as sales of a key drug rose (ABBV),Reuters,http://www.businessinsider.com/r-brief-abbvie-q1-adjusted-earnings-per-share-128-2017-4,negative,0.9548476934432983
43,5/4/2017 3:00:00 PM,AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week®,PR Newswire,/news/stocks/abbvie-demonstrates-leadership-in-gastroenterology-and-hepatology-with-new-data-and-late-breaking-studies-to-be-presented-at-digestive-disease-week-1001979825,negative,0.9325631856918335
44,5/5/2017 6:43:00 PM,AbbVie to Present at the UBS Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-ubs-global-healthcare-conference-1001984983,positive,0.903540849685669
45,5/8/2017 4:08:00 PM,United Airlines Increases Service Between San Francisco and 18 Destinations,PR Newswire,/news/stocks/united-airlines-increases-service-between-san-francisco-and-18-destinations-1001651360,negative,0.9282038807868958
46,5/9/2017 5:00:00 PM,"AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease",PR Newswire,/news/stocks/abbvie-announces-positive-phase-2-study-results-for-upadacitinib-abt-494-an-investigational-jak1-selective-inhibitor-in-crohn-s-disease-1001995051,negative,0.9422208070755005
47,5/14/2017 11:00:00 PM,IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),PR Newswire,/news/stocks/imbruvica-ibrutinib-pooled-outcomes-data-from-three-phase-3-studies-suggest-potential-clinical-efficacy-in-patients-with-high-risk-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-1002010355,negative,0.9022731781005859
48,5/15/2017 12:15:00 PM,"Drug Makers Stocks Under Scanner -- Alliqua BioMedical, AbbVie, Johnson & Johnson, and Merck",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-alliqua-biomedical-abbvie-johnson-johnson-and-merck-1002012055,neutral,0.4808368682861328
49,5/18/2017 4:23:04 AM,"Gainers & Losers Of May 17: SNDX, PULM, PBYI, CNCE, XLRN... ",RTTNews,/news/stocks/gainers-losers-of-may-17-sndx-pulm-pbyi-cnce-xlrn-1002022955,positive,0.9091120958328247
50,6/5/2017 1:00:00 PM,Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic...,PR Newswire,/news/stocks/long-term-imbruvica-ibrutinib-efficacy-and-safety-data-at-asco-2017-show-sustained-survival-rates-in-up-to-four-years-in-previously-treated-chronic-lymphocytic-leukemia-small-lymphocytic-1002066811,negative,0.9510971307754517
51,6/5/2017 1:00:00 PM,New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in...,PR Newswire,/news/stocks/new-data-presented-at-asco-2017-finds-imbruvica-ibrutinib-may-offer-a-more-targeted-approach-to-chronic-lymphocytic-leukemia-cll-treatment-than-chemotherapy-agent-chlorambucil-in-1002066812,negative,0.8188512921333313
52,6/8/2017 9:46:41 AM,"ABBV Hits A High Note, AGN Opens Wallet, TEVA's HALO Does An Encore ",RTTNews,/news/stocks/abbv-hits-a-high-note-agn-opens-wallet-teva-s-halo-does-an-encore-1002077173,negative,0.6018849015235901
53,6/12/2017 8:00:00 AM,AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress,PR Newswire,/news/stocks/abbvie-announces-new-data-evaluating-venetoclax-in-a-variety-of-hematologic-malignancies-at-the-22nd-european-hematology-association-congress-1002084172,positive,0.8082064986228943
54,6/14/2017 12:01:00 AM,AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis,PR Newswire,/news/stocks/abbvie-presents-real-world-data-evaluating-the-relationship-between-participation-in-a-patient-support-program-and-outcomes-in-patients-with-moderate-to-severe-rheumatoid-arthritis-1002090751,negative,0.7064705491065979
55,6/22/2017 9:52:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1001792223,neutral,0.5513123869895935
56,6/23/2017 8:30:00 AM,AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European...,PR Newswire,/news/stocks/abbvie-announces-pivotal-phase-2-trial-evaluating-venclyxto-venetoclax-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-cll-with-17p-deletion-to-be-presented-at-22nd-european-1002118525,negative,0.7528322339057922
57,6/23/2017 1:36:00 PM,AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6),PR Newswire,/news/stocks/abbvie-receives-chmp-positive-opinion-for-maviret-glecaprevir-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes-gt1-6-1002119406,negative,0.9183602929115295
58,6/23/2017 2:47:00 PM,AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6),PR Newswire,/news/stocks/abbvie-receives-chmp-positive-opinion-for-maviret-glecaprevir-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes-gt1-6-1002119709,negative,0.9183602929115295
59,6/26/2017 12:10:00 PM,"Breakfast Technical Briefing on Drug Makers Stocks -- Pfizer, Merck, AbbVie, and Johnson & Johnson",PR Newswire,/news/stocks/breakfast-technical-briefing-on-drug-makers-stocks-pfizer-merck-abbvie-and-johnson-johnson-1002123019,positive,0.9454298615455627
60,7/10/2017 10:46:11 PM,"Here’s how much the 10 largest pharmaceutical companies spend on R&D (PFE, AMGN, NVS, ROG, MRK, SNY, JNJ, GILD, GSK, ABBV)",Business Insider,http://www.businessinsider.com/largest-pharmaceutical-companies-by-prescription-sales-and-rd-2017-7,positive,0.9493331909179688
61,7/24/2017 5:21:39 AM,One Step Closer To EU Approval... ,RTTNews,/news/stocks/one-step-closer-to-eu-approval-1002197023,negative,0.5937835574150085
62,7/25/2017 3:56:50 AM,AbbVie Ordered To Pay $150 Mln In AndroGel Lawsuit ,RTTNews,/news/stocks/abbvie-ordered-to-pay-150-mln-in-androgel-lawsuit-1002200282,neutral,0.9443967342376709
63,7/31/2017 5:33:42 AM,"DVAX Surges On FDA Panel Vote, CYTR On Watch, EU Approves New HCV Drugs ",RTTNews,/news/stocks/dvax-surges-on-fda-panel-vote-cytr-on-watch-eu-approves-new-hcv-drugs-1002217153,negative,0.7946720123291016
64,7/31/2017 7:47:51 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1002217371,positive,0.6419674754142761
65,8/2/2017 7:07:00 PM,"U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition --...",PR Newswire,/news/stocks/u-s-fda-approves-imbruvica-ibrutinib-as-first-approved-treatment-specifically-for-adults-with-chronic-graft-versus-host-disease-cgvhd-a-serious-potentially-life-threatening-condition-1002227377,negative,0.8943645358085632
66,8/3/2017 9:28:00 PM,AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks,PR Newswire,/news/stocks/abbvie-receives-u-s-fda-approval-of-mavyret-glecaprevir-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes-gt-1-6-in-as-short-as-8-weeks-1002231750,negative,0.9138234853744507
67,8/4/2017 3:02:01 AM,FDA Approves AbbVie's Mavyret For Hepatitis C ,RTTNews,/news/stocks/fda-approves-abbvie-s-mavyret-for-hepatitis-c-1002232481,positive,0.5388193726539612
68,8/4/2017 8:47:30 AM,"DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar ",RTTNews,/news/stocks/dvax-plunges-on-delay-in-approval-fda-nod-for-abbv-s-hcv-drug-abio-on-radar-1002232943,neutral,0.9402093291282654
69,8/10/2017 12:15:00 PM,"Technical Snapshots for These Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson",PR Newswire,/news/stocks/technical-snapshots-for-these-drug-makers-stocks-abbvie-astrazeneca-bristol-myers-squibb-and-johnson-johnson-1002247897,positive,0.9072645306587219
70,8/22/2017 1:00:00 PM,"Global Smart Wearable Gloves Market to Grow at a CAGR of 15.2% by 2021: Key Vendors are Blue Infusion Technology, Neofect & ProGlove",PR Newswire,/news/stocks/global-smart-wearable-gloves-market-to-grow-at-a-cagr-of-15-2-by-2021-key-vendors-are-blue-infusion-technology-neofect-proglove-1001946147,negative,0.875080943107605
71,8/29/2017 2:23:52 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1002291346,positive,0.6874357461929321
72,8/29/2017 9:34:00 PM,"AT&T Pledges $350,000 to Aid Communities Impacted by Hurricane Harvey",PR Newswire,/news/stocks/at-t-pledges-350-000-to-aid-communities-impacted-by-hurricane-harvey-1001624722,negative,0.6878231167793274
73,9/4/2017 9:04:37 AM,"Inventiva, AbbVie Extend Deal To Develop Orally Available ROR? Inverse Agonists ",RTTNews,/news/stocks/inventiva-abbvie-extend-deal-to-develop-orally-available-ror-inverse-agonists-1002304987,negative,0.8971182107925415
74,9/6/2017 2:01:00 PM,AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain,PR Newswire,/news/stocks/abbvie-submits-new-drug-application-to-u-s-fda-for-investigational-oral-treatment-elagolix-for-the-management-of-endometriosis-with-associated-pain-1002345173,negative,0.8715782761573792
75,9/6/2017 2:14:08 PM,AbbVie Submits NDA To FDA For Investigational Oral Treatment Elagolix ,RTTNews,/news/stocks/abbvie-submits-nda-to-fda-for-investigational-oral-treatment-elagolix-1002345292,positive,0.881673276424408
76,9/7/2017 11:49:07 AM,New Drugs Approved In August ,RTTNews,/news/stocks/new-drugs-approved-in-august-1002348863,positive,0.5784369111061096
77,9/7/2017 1:30:00 PM,AbbVie to Present at the Morgan Stanley 15th Annual Global Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-morgan-stanley-15th-annual-global-health-care-conference-1002349355,positive,0.8726279139518738
78,9/7/2017 2:03:00 PM,AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis,PR Newswire,/news/stocks/abbvie-s-upadacitinib-abt-494-meets-primary-endpoint-in-phase-2b-study-in-atopic-dermatitis-1002349638,negative,0.7162310481071472
79,9/7/2017 2:11:38 PM,AbbVie'Upadacitinib Meets Primary Endpoint In Phase2b Study In Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-upadacitinib-meets-primary-endpoint-in-phase2b-study-in-atopic-dermatitis-1002349661,negative,0.7486984133720398
80,9/7/2017 2:57:00 PM,AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year,PR Newswire,/news/stocks/abbvie-leads-biotechnology-industry-on-dow-jones-sustainability-index-for-second-consecutive-year-1002349942,negative,0.6672013401985168
81,9/8/2017 8:46:56 AM,"Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High ",RTTNews,/news/stocks/christmas-comes-early-for-kura-anth-on-track-abbv-hits-all-time-high-1002352466,negative,0.9246618151664734
82,9/8/2017 5:03:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1002354607,neutral,0.5513123869895935
83,9/11/2017 2:01:00 PM,AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis,PR Newswire,/news/stocks/abbvie-s-upadacitinib-abt-494-meets-all-primary-and-ranked-secondary-endpoints-in-second-phase-3-study-in-rheumatoid-arthritis-1002358032,negative,0.8866787552833557
84,9/11/2017 3:00:00 PM,Little-Known Biotech Breakthrough Could Save Millions Of Lives,PR Newswire,/news/stocks/little-known-biotech-breakthrough-could-save-millions-of-lives-1002358262,positive,0.8199695348739624
85,9/12/2017 8:47:36 AM,"Keep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted ",RTTNews,/news/stocks/keep-close-watch-on-aldx-today-abbv-just-hit-another-high-fennec-uplisted-1002360289,negative,0.7966719269752502
86,9/13/2017 12:25:00 PM,"Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson",PR Newswire,/news/stocks/breakfast-technical-briefing-on-drug-makers-stocks-abbvie-astrazeneca-bristol-myers-squibb-and-johnson-johnson-1002365439,positive,0.9458073973655701
87,9/18/2017 5:29:00 PM,AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with...,PR Newswire,/news/stocks/abbvie-announces-positive-topline-results-from-phase-3-trial-evaluating-venclexta-venclyxto-venetoclax-tablets-in-combination-with-rituxan-rituximab-for-the-treatment-of-patients-with-1002379497,negative,0.9406383633613586
88,9/18/2017 7:41:00 PM,Deck Design 101,PR Newswire,/news/stocks/deck-design-101-679912,positive,0.9363757967948914
89,9/21/2017 4:50:00 PM,Soleil Capital Corp. Announces Qualifying Transaction,PR Newswire,/news/stocks/soleil-capital-corp-announces-qualifying-transaction-561563,positive,0.9089426398277283
90,9/22/2017 1:00:00 PM,AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors,PR Newswire,/news/stocks/abbvie-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-a-therapeutic-regimen-in-advanced-solid-tumors-1002421197,negative,0.8202074766159058
91,9/27/2017 6:53:00 AM,AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan,PR Newswire,/news/stocks/abbvie-announces-approval-of-maviret-glecaprevir-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes-gt1-6-in-japan-1002618216,negative,0.865307629108429
92,9/28/2017 2:00:00 PM,AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen,PR Newswire,/news/stocks/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-amgen-1002732110,neutral,0.6125564575195312
93,9/28/2017 2:09:04 PM,"Amgen, AbbVie Settle Litigation Regarding AMGEVITA - Quick Facts ",RTTNews,/news/stocks/amgen-abbvie-settle-litigation-regarding-amgevita-quick-facts-1002732219,positive,0.8847321271896362
94,9/28/2017 11:00:00 PM,AbbVie Inc. -- Moody's: AbbVie's Humira patent settlement reduces uncertainty,Moodys,/news/bonds/abbvie-inc-moody-s-abbvie-s-humira-patent-settlement-reduces-uncertainty-1002774871,negative,0.9286684989929199
95,10/2/2017 4:29:00 PM,Metro Supply Chain Group Appoints New U.S. Business Lead,PR Newswire,/news/stocks/metro-supply-chain-group-appoints-new-u-s-business-lead-479090,positive,0.8480919599533081
96,10/3/2017 3:00:00 PM,"Bryan Benjamin Joins The Conference Board of Canada as Vice-President, Organizational Performance",PR Newswire,/news/stocks/bryan-benjamin-joins-the-conference-board-of-canada-as-vice-president-organizational-performance-519809,positive,0.9304397106170654
97,10/5/2017 10:39:08 PM,"'Nobody's talking about' 2 medical conditions that affect 8 million women in America — but that could be about to change (AGN, MYOV, ABBV, BAYN)",Business Insider,http://www.businessinsider.com/womens-health-new-treatments-for-uterine-fibroids-endometriosis-2017-10,positive,0.9100484251976013
98,10/9/2017 2:00:00 PM,AbbVie to Host Third-Quarter 2017 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-third-quarter-2017-earnings-conference-call-1002070913,positive,0.917789876461029
99,10/10/2017 2:00:00 PM,AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology,PR Newswire,/news/stocks/abbvie-and-turnstone-biologics-announce-global-collaboration-on-viral-immunotherapies-in-oncology-1003657126,negative,0.7874242067337036
100,10/11/2017 8:57:00 PM,AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017,PR Newswire,/news/stocks/abbvie-demonstrates-leadership-in-hcv-with-new-mavyret-glecaprevir-pibrentasvir-data-to-be-presented-at-the-liver-meeting-2017-1003865799,negative,0.9326933026313782
101,10/18/2017 2:00:00 PM,AbbVie to Present at the 2017 Credit Suisse Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-2017-credit-suisse-health-care-conference-1004763325,positive,0.9128543138504028
102,10/18/2017 2:30:00 PM,AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration,PR Newswire,/news/stocks/abbvie-and-harpoon-therapeutics-announce-immuno-oncology-research-collaboration-1004766331,positive,0.8819620013237
103,10/24/2017 1:00:00 PM,Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease,PR Newswire,/news/stocks/alector-and-abbvie-announce-collaboration-to-advance-a-novel-class-of-immune-therapies-for-patients-with-alzheimer-s-disease-1005437178,negative,0.8318590521812439
104,10/24/2017 1:06:10 PM,A company that's taking a new approach to tackling Alzheimer's just landed a $225 million endorsement (ABBV),Business Insider,http://www.businessinsider.com/abbvie-partners-with-alector-in-225-million-alzheimers-disease-deal-2017-10,negative,0.838421642780304
105,10/24/2017 3:00:00 PM,AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting,PR Newswire,/news/stocks/abbvie-to-showcase-robust-immunology-portfolio-with-new-and-late-breaking-data-at-the-2017-acr-arhp-annual-meeting-1005448253,negative,0.9404569268226624
106,10/25/2017 2:00:00 PM,Nail psoriasis data now part of HUMIRA® label,PR Newswire,/news/stocks/nail-psoriasis-data-now-part-of-humira-label-1001648884,positive,0.9499601721763611
107,10/25/2017 2:00:00 PM,Nail psoriasis data now part of HUMIRA® label,PR Newswire,/news/stocks/nail-psoriasis-data-now-part-of-humira-label-1005570006,positive,0.9499601721763611
108,10/26/2017 2:02:00 PM,"Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies",PR Newswire,/news/stocks/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies-1005699212,negative,0.9565666913986206
109,10/27/2017 1:00:00 PM,AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain,PR Newswire,/news/stocks/abbvie-receives-u-s-fda-priority-review-for-investigational-oral-treatment-elagolix-for-the-management-of-endometriosis-with-associated-pain-1002128050,negative,0.904456615447998
110,10/27/2017 1:30:00 PM,AbbVie Increases Quarterly Dividend by 11 Percent,PR Newswire,/news/stocks/abbvie-increases-quarterly-dividend-by-11-percent-1005828078,negative,0.8778010010719299
111,10/27/2017 1:40:00 PM,AbbVie Reports Third-Quarter 2017 Financial Results,PR Newswire,/news/stocks/abbvie-reports-third-quarter-2017-financial-results-452206,positive,0.7931459546089172
112,10/27/2017 1:44:37 PM,AbbVie Gets FDA Priority Review For Elagolix; Hikes Dividend - Quick Facts ,RTTNews,/news/stocks/abbvie-gets-fda-priority-review-for-elagolix-hikes-dividend-quick-facts-1005829026,negative,0.9221318960189819
113,10/27/2017 2:09:58 PM,"AbbVie Q3 Profit Tops View, Ups Dividend; Lifts FY Forecast - Quick Facts ",RTTNews,/news/stocks/abbvie-q3-profit-tops-view-ups-dividend-lifts-fy-forecast-quick-facts-1005830921,negative,0.9403930902481079
114,10/30/2017 4:00:28 AM,"FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch ",RTTNews,/news/stocks/fda-to-rule-on-elagolix-in-q2-more-light-from-celg-s-radiance-tgtx-on-watch-1006126907,positive,0.9202567934989929
115,11/1/2017 5:00:00 PM,AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain,PR Newswire,/news/stocks/abbvie-announces-positive-phase-3-extension-study-data-for-investigational-oral-treatment-elagolix-for-management-of-endometriosis-with-associated-pain-1006469261,negative,0.9458026885986328
116,11/3/2017 1:00:00 PM,AbbVie to Present at the Jefferies 2017 London Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-jefferies-2017-london-healthcare-conference-1006728093,positive,0.921238899230957
117,11/6/2017 5:38:55 AM,"Lilly, Incyte: Baricitinib Shows Greater Improvements In Pain Control In RA ",RTTNews,/news/stocks/lilly-incyte-baricitinib-shows-greater-improvements-in-pain-control-in-ra-1007018255,negative,0.9568936228752136
118,11/15/2017 1:00:00 PM,AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-1008127602,positive,0.9050915837287903
119,11/21/2017 3:26:00 PM,"Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer...",PR Newswire,/news/stocks/phase-3-murano-study-of-venetoclax-chosen-as-late-breaking-abstract-at-the-2017-american-society-of-hematology-annual-meeting-exposition-highlighting-abbvie-s-commitment-to-helping-blood-cancer-1008944087,negative,0.8805569410324097
120,12/4/2017 2:03:00 PM,Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study,PR Newswire,/news/stocks/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasis-study-556589,negative,0.947847843170166
121,12/4/2017 2:19:51 PM,AbbVie: Risankizumab Meets Primary Endpoints In Fourth Phase 3 Psoriasis Study ,RTTNews,/news/stocks/abbvie-risankizumab-meets-primary-endpoints-in-fourth-phase-3-psoriasis-study-1010320586,negative,0.8507059216499329
122,12/5/2017 8:30:41 AM,"GALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff ",RTTNews,/news/stocks/galt-faces-big-test-today-abbv-clears-psoriasis-trial-depo-cuts-40-of-staff-1010340387,negative,0.8654345870018005
123,12/5/2017 2:00:00 PM,IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint,PR Newswire,/news/stocks/imbruvica-ibrutinib-plus-rituximab-phase-3-innovate-trial-in-rare-waldenstroem-s-macroglobulinemia-met-primary-endpoint-1010349516,negative,0.4976172149181366
124,12/9/2017 3:00:00 PM,IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients,PR Newswire,/news/stocks/imbruvica-ibrutinib-patient-reported-outcomes-data-detail-long-term-improvement-in-treatment-outcomes-and-quality-of-life-experience-in-chronic-lymphocytic-leukemia-cll-patients-1010712258,negative,0.9547985792160034
125,12/9/2017 6:03:00 PM,IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL),PR Newswire,/news/stocks/imbruvica-ibrutinib-pooled-analysis-suggests-benefit-in-progression-free-survival-pfs-at-3-5-years-in-patients-with-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-1010727315,negative,0.9383105635643005
126,12/11/2017 4:00:00 PM,"IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition",PR Newswire,/news/stocks/imbruvica-ibrutinib-data-provide-insights-into-its-potential-treatment-benefits-for-previously-treated-chronic-graft-versus-host-disease-a-serious-possibly-life-threatening-condition-1010950861,negative,0.8681902885437012
127,12/12/2017 1:30:00 PM,AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint,PR Newswire,/news/stocks/abbvie-announces-phase-3-study-of-venclexta-venclyxto-venetoclax-in-combination-with-rituxan-rituximab-meets-its-primary-endpoint-1011075980,negative,0.8191443085670471
128,12/12/2017 1:59:06 PM,Genentech: Phase 3 Data Shows Venclexta Plus Rituxan Significantly Improved PFS ,RTTNews,/news/stocks/genentech-phase-3-data-shows-venclexta-plus-rituxan-significantly-improved-pfs-1011078129,negative,0.957217812538147
129,12/19/2017 2:00:00 PM,AbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top,PR Newswire,/news/stocks/abbvie-to-present-at-the-goldman-sachs-10th-annual-healthcare-ceos-unscripted-a-view-from-the-top-1011641079,positive,0.8693503737449646
130,12/20/2017 2:00:00 PM,"AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints",PR Newswire,/news/stocks/abbvie-s-upadacitinib-shows-positive-results-as-monotherapy-in-phase-3-rheumatoid-arthritis-study-meeting-all-primary-and-key-secondary-endpoints-1011682222,negative,0.9529777765274048
131,1/8/2018 2:00:00 PM,AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis,PR Newswire,/news/stocks/abbvie-s-upadacitinib-granted-breakthrough-therapy-designation-from-the-u-s-food-and-drug-administration-for-atopic-dermatitis-1012663005,negative,0.9343817234039307
132,1/12/2018 2:00:00 PM,AbbVie to Host Fourth-Quarter 2017 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-fourth-quarter-2017-earnings-conference-call-1013027725,positive,0.9156484603881836
133,1/26/2018 1:51:00 PM,AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results,PR Newswire,/news/stocks/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results-1014124273,positive,0.8762266039848328
134,1/26/2018 5:45:11 PM,"S&P, Dow hit records on upbeat Intel, AbbVie earnings",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/URI7NJzKi1c/sp-dow-hit-records-on-upbeat-intel-abbvie-earnings-idUSKBN1FF1KJ,negative,0.8485286235809326
135,2/6/2018 3:00:00 PM,AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ - an oral therapy for the treatment of patients with hepatitis C,PR Newswire,/news/stocks/abbvie-receives-a-positive-recommendation-from-the-cadth-canadian-drug-expert-committee-for-maviret-an-oral-therapy-for-the-treatment-of-patients-with-hepatitis-c-1014996676,negative,0.9459649324417114
136,2/12/2018 2:00:00 PM,"AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting",PR Newswire,/news/stocks/abbvie-showcases-new-late-breaking-investigational-data-at-2018-american-academy-of-dermatology-aad-annual-meeting-1002078564,positive,0.887112557888031
137,2/15/2018 6:49:00 PM,AbbVie Increases Dividend and Announces New Stock Repurchase Program,PR Newswire,/news/stocks/abbvie-increases-dividend-and-announces-new-stock-repurchase-program-1015918670,negative,0.5970686674118042
138,2/15/2018 7:14:33 PM,"AbbVie to buy back $10 billion of shares, raises dividend",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/5Q42SN3WNw8/abbvie-to-buy-back-10-billion-of-shares-raises-dividend-idUSKCN1FZ2GQ,negative,0.7782459259033203
139,2/16/2018 5:20:00 PM,AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks,PR Newswire,/news/stocks/abbvie-announces-new-phase-2-data-for-upadacitinib-showing-clinical-and-endoscopic-outcomes-in-crohn-s-disease-at-52-weeks-1016035647,negative,0.7273696064949036
140,2/16/2018 9:47:00 PM,AbbVie Inc. -- Moody's says AbbVie's shareholder payouts are credit negative,Moodys,/news/bonds/abbvie-inc-moody-s-says-abbvie-s-shareholder-payouts-are-credit-negative-1016057938,neutral,0.9025008082389832
141,2/17/2018 10:00:00 PM,AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting,PR Newswire,/news/stocks/abbvie-presents-new-late-breaking-phase-2b-data-on-upadacitinib-in-atopic-dermatitis-at-the-2018-american-academy-of-dermatology-annual-meeting-1002095917,positive,0.8266267776489258
142,2/17/2018 10:50:00 PM,AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting,PR Newswire,/news/stocks/abbvie-presents-new-positive-late-breaking-data-from-two-phase-3-psoriasis-trials-of-risankizumab-at-the-2018-american-academy-of-dermatology-annual-meeting-1016168551,negative,0.811213493347168
143,2/20/2018 1:00:00 PM,AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases,PR Newswire,/news/stocks/abbvie-and-voyager-therapeutics-announce-global-strategic-collaboration-to-develop-potential-new-treatments-for-alzheimer-s-disease-and-other-tau-related-neurodegenerative-diseases-1016433543,negative,0.9211307764053345
144,2/21/2018 2:00:00 PM,Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease,PR Newswire,/news/stocks/canadians-living-with-moderate-to-severe-hidradenitis-suppurativa-are-beginning-to-have-public-access-to-humira-adalimumab-to-manage-their-disease-1016573768,negative,0.523103654384613
145,2/21/2018 2:13:09 PM,AbbVie Reports Positive Topline Results From Phase 3 Elagolix Study ,RTTNews,/news/stocks/abbvie-reports-positive-topline-results-from-phase-3-elagolix-study-1016574861,negative,0.9514127373695374
146,2/22/2018 10:17:01 AM,In The Spotlight: Inflarx ,RTTNews,/news/stocks/in-the-spotlight-inflarx-1016690602,positive,0.9314760565757751
147,2/22/2018 1:00:00 PM,Nova Scotians living with Advanced Parkinson's Disease now have public access to DUODOPA® to manage their disease,PR Newswire,/news/stocks/nova-scotians-living-with-advanced-parkinson-s-disease-now-have-public-access-to-duodopa-to-manage-their-disease-1016706482,positive,0.840063750743866
148,2/22/2018 2:00:00 PM,AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-1016712335,positive,0.9074402451515198
149,2/25/2018 5:34:41 AM,An Ear To The Pharma: 6 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-6-stocks-to-watch-this-week-1017039106,positive,0.9051325917243958
150,2/26/2018 2:00:00 PM,AbbVie to Present at the Barclays Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-barclays-global-healthcare-conference-1001790415,positive,0.9058839678764343
151,3/2/2018 12:12:11 PM,"Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts ",RTTNews,/news/stocks/biogen-abbvie-voluntarily-withdraw-worldwide-ma-for-zinbryta-quick-facts-1017686335,positive,0.7689930200576782
152,3/7/2018 11:07:23 PM,Zinbrynta Now Connected To Brain Inflammation ,RTTNews,/news/stocks/zinbrynta-now-connected-to-brain-inflammation-1018317673,positive,0.8420149683952332
153,3/13/2018 1:00:00 PM,AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids,PR Newswire,/news/stocks/abbvie-announces-positive-topline-results-from-second-phase-3-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids-1001838735,negative,0.9371870160102844
154,3/21/2018 2:00:00 PM,AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma,PR Newswire,/news/stocks/abbvie-and-the-international-myeloma-foundation-announce-partnership-to-study-the-role-of-a-genetic-mutation-in-outcomes-of-patients-with-multiple-myeloma-1018992659,negative,0.7978993058204651
155,3/22/2018 1:45:00 PM,AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer,PR Newswire,/news/stocks/abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-rova-t-for-third-line-treatment-of-patients-with-dll3-expressing-relapsed-refractory-small-cell-lung-cancer-1019063716,negative,0.8177424669265747
156,3/22/2018 2:16:37 PM,UPDATE 1-AbbVie says not to seek faster approval for lung cancer drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gEjvc9Cg3l4/update-1-abbvie-says-not-to-seek-faster-approval-for-lung-cancer-drug-idUSL3N1R44PD,positive,0.725756824016571
157,3/22/2018 8:11:00 PM,AbbVie Inc. -- Moody's: AbbVie's Rova-T results credit negative,Moodys,/news/bonds/abbvie-inc-moody-s-abbvie-s-rova-t-results-credit-negative-1019088091,neutral,0.6638233065605164
158,3/23/2018 4:47:42 AM,"ABBV Let Down By TRINITY, ODT Down 10% So Far This Month, NCNA On Watch ",RTTNews,/news/stocks/abbv-let-down-by-trinity-odt-down-10-so-far-this-month-ncna-on-watch-1019120247,neutral,0.965452253818512
159,3/26/2018 11:04:20 PM,U.S. jury orders AbbVie to pay $3 mln in AndroGel retrial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/vr3fA1imfvI/u-s-jury-orders-abbvie-to-pay-3-mln-in-androgel-retrial-idUSL8N1R86HR,neutral,0.9397159218788147
160,3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162,positive,0.7716754078865051
161,3/28/2018 4:49:00 PM,Tom's of Maine New Whole Care® Mouthwash Provides Six Benefits in One,PR Newswire,/news/stocks/tom-s-of-maine-new-whole-care-mouthwash-provides-six-benefits-in-one-1001893837,positive,0.7068018317222595
162,4/3/2018 1:54:24 PM,Will These Drugs Reach Blockbuster Status? ,RTTNews,/news/stocks/will-these-drugs-reach-blockbuster-status-1020339832,positive,0.7288854122161865
163,4/5/2018 2:26:46 PM,"Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization ",RTTNews,/news/stocks/biogen-samsung-bioepis-announce-deal-with-abbvie-for-imraldi-commercialization-1020573431,negative,0.8017106652259827
164,4/5/2018 3:29:06 PM,"BRIEF-Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/YPLl3uMbd68/brief-biogen-samsung-bioepis-to-settle-with-abbvie-over-humira-biosimilar-idUSFWN1RI0F2,positive,0.5544743537902832
165,4/5/2018 3:42:52 PM,AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/P1k7tmEpFAA/abbvie-in-deal-with-biogen-to-delay-humira-biosimilar-u-s-launch-to-2023-idUSL4N1RI3VC,neutral,0.522926390171051
166,4/5/2018 4:36:58 PM,UPDATE 1-AbbVie in deal with Samsung Bioepis to delay Humira biosimilar U.S. launch,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zr2FXzFD9uU/update-1-abbvie-in-deal-with-samsung-bioepis-to-delay-humira-biosimilar-u-s-launch-idUSL4N1RI3YO,neutral,0.41250696778297424
167,4/5/2018 6:34:19 PM,"UPDATE 2-AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5XCc_CKH04M/update-2-abbvie-samsung-bioepis-in-deal-humira-biosimilar-u-s-release-in-2023-idUSL4N1RI3YO,positive,0.575955867767334
168,4/6/2018 2:00:00 PM,AbbVie to Host First-Quarter 2018 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-first-quarter-2018-earnings-conference-call-1001911037,positive,0.9136093258857727
169,4/9/2018 2:45:00 PM,Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis,PR Newswire,/news/stocks/upadacitinib-meets-all-primary-and-ranked-secondary-endpoints-including-superiority-versus-adalimumab-in-phase-3-study-in-rheumatoid-arthritis-1020951427,negative,0.9327366352081299
170,4/10/2018 6:34:49 AM,"ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs ",RTTNews,/news/stocks/abbv-s-select-compare-hits-goals-mnlo-s-atomik-flops-vtvt-down-63-after-hrs-1021016031,neutral,0.956183671951294
171,4/10/2018 2:24:41 PM,"FDA extends review for AbbVie, Neurocrine's uterine pain drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RFyChQbyVrk/fda-extends-review-for-abbvie-neurocrines-uterine-pain-drug-idUSL3N1RN4LV,positive,0.44954216480255127
172,4/10/2018 2:31:05 PM,AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain ,RTTNews,/news/stocks/abbvie-pdufa-target-date-of-q3-for-elagolix-in-endometriosis-associated-pain-1021051064,positive,0.9246415495872498
173,4/10/2018 2:31:50 PM,BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/DkXQigD2SmU/brief-abbvie-and-neurocrine-biosciences-announce-pdufa-target-date-of-q3-2018-for-elagolix-in-endometriosis-associated-pain-idUSFWN1RN0MF,positive,0.7117245197296143
174,4/10/2018 2:38:41 PM,"UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AvUfNXfyVlc/update-1-fda-needs-more-time-to-review-abbvie-neurocrines-uterine-pain-drug-idUSL3N1RN4MG,positive,0.7557561993598938
175,4/10/2018 4:16:42 PM,"UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/c-DQEHXg0-A/update-2-fda-needs-more-time-to-review-abbvie-neurocrines-uterine-pain-drug-idUSL3N1RN4WJ,positive,0.7579873204231262
176,4/11/2018 6:55:59 AM,"AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch ",RTTNews,/news/stocks/agtc-awaits-gene-therapy-data-fda-delays-decision-on-elagolix-kpti-on-watch-1021132321,positive,0.5905052423477173
177,4/18/2018 2:00:00 PM,AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-deutsche-bank-s-43rd-annual-health-care-conference-1021495113,positive,0.872256875038147
178,4/19/2018 10:26:00 AM,"Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising",Moodys,/news/bonds/moody-s-stable-outlook-for-global-pharmaceuticals-m-a-event-risk-is-rising-1021562771,negative,0.6777340173721313
179,4/24/2018 3:10:21 PM,Modern Miracles: America's 10 Best-Selling Drugs ,RTTNews,/news/stocks/modern-miracles-america-s-10-best-selling-drugs-1022118861,positive,0.849453330039978
180,4/25/2018 2:30:00 PM,AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients,PR Newswire,/news/stocks/abbvie-s-upadacitinib-meets-primary-and-key-efficacy-endpoints-in-phase-2b-3-rheumatoid-arthritis-study-in-japanese-patients-1002295154,negative,0.9363054037094116
181,4/25/2018 2:45:00 PM,AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis,PR Newswire,/news/stocks/abbvie-submits-biologics-license-application-to-u-s-fda-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis-1022259296,negative,0.7926620841026306
182,4/26/2018 1:47:00 PM,AbbVie Reports First-Quarter 2018 Financial Results,PR Newswire,/news/stocks/abbvie-reports-first-quarter-2018-financial-results-1022396252,positive,0.8461235165596008
183,4/26/2018 1:48:08 PM,"AbbVie beats quarterly revenue estimates, raises earnings forecast",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/A0ac1uUBiFE/abbvie-beats-quarterly-revenue-estimates-raises-earnings-forecast-idUSL3N1S34VK,negative,0.9402942061424255
184,4/26/2018 1:49:55 PM,BRIEF-Abbvie Inc Reports Q1 GAAP Earnings Per Share Of $1.74,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/VJgVeMqipdk/brief-abbvie-inc-reports-q1-gaap-earnings-per-share-of-1-74-idUSB8N1HP02E,positive,0.7461807727813721
185,4/26/2018 8:22:00 PM,AbbVie Inc. -- Moody's: AbbVie's share repurchase acceleration credit negative,Moodys,/news/bonds/abbvie-inc-moody-s-abbvie-s-share-repurchase-acceleration-credit-negative-1022436260,positive,0.8843584060668945
186,4/27/2018 2:18:02 PM,AbbVie Presents New Investigational Data For Elagolix ,RTTNews,/news/stocks/abbvie-presents-new-investigational-data-for-elagolix-1022540365,positive,0.9001424908638
187,4/30/2018 5:35:00 PM,AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology,PR Newswire,/news/stocks/abbvie-and-rice-university-establish-k-c-nicolaou-research-accelerator-to-advance-therapies-in-oncology-1022904236,positive,0.6850748062133789
188,5/1/2018 1:47:00 PM,AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock,PR Newswire,/news/stocks/abbvie-commences-self-tender-offer-for-up-to-7-5-billion-of-its-common-stock-1023005494,positive,0.862928569316864
189,5/1/2018 1:50:59 PM,BRIEF-AbbVie Commences Self-Tender Offer For Up To $7.5 Bln Of Its Common Stock,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/G1KECv63Zd0/brief-abbvie-commences-self-tender-offer-for-up-to-7-5-bln-of-its-common-stock-idUSFWN1S807F,positive,0.8689297437667847
190,5/1/2018 2:45:00 PM,AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis,PR Newswire,/news/stocks/abbvie-submits-marketing-authorization-application-to-the-european-medicines-agency-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis-1023011041,negative,0.7856937646865845
191,5/1/2018 2:49:09 PM,BRIEF-Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/QTq0gNZpbMs/brief-abbvie-submits-marketing-authorization-application-to-ema-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis-idUSFWN1S8094,negative,0.829546332359314
192,5/1/2018 11:32:06 PM,BRIEF-Abbvie Estimates Complete Blackout Could Begin As Soon As 4 P.M NY Time on May 23,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AmUCM46Vi_g/brief-abbvie-estimates-complete-blackout-could-begin-as-soon-as-4-p-m-ny-time-on-may-23-idUSFWN1S80NX,positive,0.7492579221725464
193,5/2/2018 2:00:00 PM,AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-2018-bank-of-america-merrill-lynch-health-care-conference-1023132416,positive,0.9218835830688477
194,5/8/2018 2:00:00 PM,AbbVie to Present at the UBS Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-ubs-global-healthcare-conference-1023748476,positive,0.903540849685669
195,5/13/2018 5:00:00 AM,"Apon Wellbeing Ltd. wins MetLife Foundation Financial Innovation Competition powered by Verb, secures $50,000 Grant",PR Newswire,/news/stocks/apon-wellbeing-ltd-wins-metlife-foundation-financial-innovation-competition-powered-by-verb-secures-$50-000-grant-677156,negative,0.911469042301178
196,5/16/2018 10:59:00 PM,AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting,PR Newswire,/news/stocks/abbvie-to-show-progress-and-growth-in-oncology-research-at-the-american-society-of-clinical-oncology-2018-annual-meeting-1024752443,negative,0.9218494892120361
197,5/22/2018 2:00:00 PM,AbbVie to Present at the Jefferies 2018 Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-jefferies-2018-global-healthcare-conference-1025086568,positive,0.8901443481445312
198,5/24/2018 3:00:00 PM,IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint,PR Newswire,/news/stocks/imbruvica-ibrutinib-plus-gazyva-obinutuzumab-phase-3-illuminate-trial-for-first-line-therapy-of-chronic-lymphocytic-leukemia-cll-patients-met-primary-endpoint-1002070989,negative,0.8585300445556641
199,5/24/2018 3:08:17 PM,AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In PFS ,RTTNews,/news/stocks/abbvie-says-phase-3-illuminate-trial-met-primary-endpoint-of-improvement-in-pfs-1025205520,negative,0.946325421333313
200,5/29/2018 2:00:00 PM,AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-1025708168,positive,0.8807505369186401
201,5/30/2018 2:00:00 PM,AbbVie Announces Preliminary Results of Tender Offer,PR Newswire,/news/stocks/abbvie-announces-preliminary-results-of-tender-offer-1025840152,positive,0.9227160215377808
202,5/31/2018 2:00:00 PM,AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European...,PR Newswire,/news/stocks/abbvie-to-present-new-data-from-several-investigational-studies-of-venetoclax-as-monotherapy-or-in-combination-for-the-management-of-a-number-of-difficult-to-treat-blood-cancers-at-23rd-european-1025975692,positive,0.7009189128875732
203,5/31/2018 3:00:00 PM,StarfishETL Recognized for IT Management Software Excellence by FinancesOnline Directory,PR Newswire,/news/stocks/starfishetl-recognized-for-it-management-software-excellence-by-financesonline-directory-1002074012,negative,0.9260953664779663
204,6/1/2018 10:45:00 PM,"Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone",PR Newswire,/news/stocks/phase-3-imbruvica-ibrutinib-data-suggest-improved-treatment-outcomes-in-waldenstroem-s-macroglobulinemia-wm-a-rare-form-of-blood-cancer-in-combination-with-rituximab-versus-rituximab-alone-1026159475,negative,0.9535742402076721
205,6/3/2018 4:45:00 PM,Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL),PR Newswire,/news/stocks/phase-2-imbruvica-ibrutinib-plus-venclexta-venetoclax-early-data-show-high-rates-of-responses-in-patients-with-previously-untreated-chronic-lymphocytic-leukemia-cll-1026350779,negative,0.9312083721160889
206,6/4/2018 2:00:00 PM,AbbVie Announces Final Results of Tender Offer,PR Newswire,/news/stocks/abbvie-announces-final-results-of-tender-offer-1026438745,positive,0.9134983420372009
207,6/5/2018 12:58:00 AM,Arjo strengthens position within Long-Term Care in North America,PR Newswire,/news/stocks/arjo-strengthens-position-within-long-term-care-in-north-america-1002088861,negative,0.948094367980957
208,6/5/2018 2:30:00 PM,Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis,PR Newswire,/news/stocks/upadacitinib-monotherapy-meets-all-primary-and-ranked-secondary-endpoints-versus-methotrexate-in-a-phase-3-study-in-rheumatoid-arthritis-1001761731,negative,0.899581253528595
209,6/8/2018 8:55:00 PM,AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma...,PR Newswire,/news/stocks/abbvie-announces-u-s-fda-approval-of-venclexta-venetoclax-tablets-in-combination-with-rituximab-as-a-fixed-duration-treatment-for-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-1026816359,negative,0.8891146183013916
210,6/13/2018 12:38:00 AM,AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018),PR Newswire,/news/stocks/abbvie-presents-additional-outcomes-data-from-three-upadacitinib-phase-3-studies-in-rheumatoid-arthritis-at-the-annual-european-congress-of-rheumatology-eular-2018-1026892226,positive,0.7536823153495789
211,6/15/2018 12:52:00 AM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1027046789,neutral,0.5513123869895935
212,6/15/2018 8:45:00 AM,AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd...,PR Newswire,/news/stocks/abbvie-announces-new-undetectable-minimal-residual-disease-data-from-phase-3-relapsed-refractory-chronic-lymphocytic-leukemia-murano-trial-of-venetoclax-in-combination-with-rituximab-at-23rd-1027078060,positive,0.5812815427780151
213,6/19/2018 3:21:00 PM,"8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual ""Week of Possibilities""",PR Newswire,/news/stocks/8-000-abbvie-employees-volunteer-across-five-continents-during-fifth-annual-week-of-possibilities-1027201451,positive,0.8353533148765564
214,6/26/2018 2:29:21 PM,AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico ,RTTNews,/news/stocks/abbvie-extends-collaboration-with-alphabet-backed-life-sciences-company-calico-1027318314,negative,0.8553367853164673
215,6/29/2018 2:19:39 PM,Biotech Stocks Facing FDA Decision In July ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-1027330822,positive,0.7290647029876709
216,6/30/2018 1:43:50 AM,"Abbvie, Androgel partner owe $488 million in antitrust case -U.S. judge",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/p9T5Acj1GFs/abbvie-androgel-partner-owe-488-million-in-antitrust-case-u-s-judge-idUSL1N1TV2AQ,positive,0.861018180847168
217,6/30/2018 2:05:12 AM,"UPDATE 1-AbbVie, AndroGel partner owe $488 million in antitrust case -U.S. judge",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5Kf7Om2Nqkw/update-1-abbvie-androgel-partner-owe-488-million-in-antitrust-case-u-s-judge-idUSL1N1TV2B5,positive,0.7664188742637634
218,6/30/2018 3:20:48 AM,"CORRECTED-Abbvie, Androgel partner owe $448 million in antitrust case -U.S. judge",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/DUEciZYEkzk/corrected-abbvie-androgel-partner-owe-448-million-in-antitrust-case-u-s-judge-idUSL1N1TV2AQ,positive,0.7993451952934265
219,6/30/2018 3:21:07 AM,"CORRECTED-UPDATE 1-AbbVie, AndroGel partner owe $448 million in antitrust case -U.S. judge",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2EhCz8PihLY/corrected-update-1-abbvie-androgel-partner-owe-448-million-in-antitrust-case-u-s-judge-idUSL1N1TV2B5,positive,0.6380181908607483
220,6/30/2018 3:23:02 AM,"AbbVie, AndroGel partner owe $448 million in antitrust case - U.S. judge",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/6i6VdLI4P30/abbvie-androgel-partner-owe-448-million-in-antitrust-case-u-s-judge-idINKBN1JQ007,positive,0.8647746443748474
221,6/30/2018 3:37:22 AM,"UPDATE 2-AbbVie, AndroGel partner owe $448 million in antitrust case -U.S. judge",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NDYqyGnYZfg/update-2-abbvie-androgel-partner-owe-448-million-in-antitrust-case-u-s-judge-idUSL1N1TW00X,positive,0.7831019163131714
222,7/1/2018 6:45:16 AM,AbbVie Says Will Appeal $448 Mln Antitrust Judgment ,RTTNews,/news/stocks/abbvie-says-will-appeal-448-mln-antitrust-judgment-1027332826,positive,0.7033353447914124
223,7/5/2018 7:44:16 PM,U.S. judge tosses $140 mln verdict against AbbVie in AndroGel case,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TR7ib8sjb6Y/u-s-judge-tosses-140-mln-verdict-against-abbvie-in-androgel-case-idUSL1N1U114L,neutral,0.8325679898262024
224,7/5/2018 8:10:04 PM,UPDATE 1-U.S. judge tosses $140 mln verdict against AbbVie in AndroGel case,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kvYTiX1IbHc/update-1-u-s-judge-tosses-140-mln-verdict-against-abbvie-in-androgel-case-idUSL1N1U115I,neutral,0.8265865445137024
225,7/11/2018 2:09:46 PM,AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL ,RTTNews,/news/stocks/abbvie-updates-on-phase-3-study-of-ibrutinib-in-blood-cancer-dlbcl-1027358245,positive,0.8534296154975891
226,7/12/2018 7:10:49 AM,Genentech Announces Submission Of SNDA For Venclexta - Quick Facts ,RTTNews,/news/stocks/genentech-announces-submission-of-snda-for-venclexta-quick-facts-1027360631,positive,0.9137378931045532
227,7/17/2018 2:46:02 PM,Mylan signs U.S. license deal on Humira with AbbVie,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/OiJP0Qg679o/mylan-signs-u-s-license-deal-on-humira-with-abbvie-idUSL4N1UD45D,negative,0.8427572846412659
228,7/24/2018 2:40:21 PM,AbbVie Reports FDA Approval Of ORILISSA - Quick Facts ,RTTNews,/news/stocks/abbvie-reports-fda-approval-of-orilissa-quick-facts-1027393980,positive,0.545697033405304
229,7/24/2018 2:51:06 PM,A new treatment for a condition that can feel like tiny people skating on razor blades in your stomach and affects an estimated 200 million women just got approved (ABBV),Business Insider,https://www.businessinsider.com/fda-approves-abbvie-endometriosis-drug-elagolix-orilissa-2018-7,positive,0.8741006255149841
230,7/24/2018 7:46:16 PM,"AbbVie prices new endometriosis drug at $10,000 a year",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zpuNVDrs-BA/abbvie-prices-new-endometriosis-drug-at-10000-a-year-idUSL1N1UK17S,positive,0.8830704092979431
231,7/24/2018 10:00:00 PM,Citron's Left reiterates belief AbbVie shares will fall sharply,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zly1y7-i-dw/citrons-left-reiterates-belief-abbvie-shares-will-fall-sharply-idUSL1N1UK1G1,neutral,0.9700694680213928
232,7/24/2018 11:15:49 PM,UPDATE 1-Citron's Left reiterates belief AbbVie shares will fall sharply,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gYfpRh7wl40/update-1-citrons-left-reiterates-belief-abbvie-shares-will-fall-sharply-idUSL1N1UK1V2,neutral,0.9696904420852661
233,7/25/2018 3:02:27 PM,AbbVie earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/abbvie-stock-quarter-earnings-preview-q2-1027398836,positive,0.9269446134567261
234,7/27/2018 1:38:25 PM,"AbbVie tops second-quarter estimates, sets higher earnings target",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0l68_Eyj-8w/abbvie-tops-second-quarter-estimates-sets-higher-earnings-target-idUSL4N1UN3MY,negative,0.9464102983474731
235,7/27/2018 5:20:22 PM,UPDATE 1-AbbVie shares slide as Humira barely beats sales estimates,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/m3XFJKNPHAE/update-1-abbvie-shares-slide-as-humira-barely-beats-sales-estimates-idUSL4N1UN43O,neutral,0.9709270596504211
236,7/27/2018 7:12:19 PM,"UPDATE 2-AbbVie cash cow Humira barely beats sales estimates, stock slides",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Z-QC1IwMtiM/update-2-abbvie-cash-cow-humira-barely-beats-sales-estimates-stock-slides-idUSL4N1UN43O,negative,0.37985125184059143
237,8/17/2018 10:10:51 AM,New Drugs Approved In July ,RTTNews,/news/stocks/new-drugs-approved-in-july-1027466563,positive,0.6490791440010071
238,8/22/2018 2:39:48 PM,AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix ,RTTNews,/news/stocks/abbvie-announces-positive-results-from-phase-3-extension-study-on-elagolix-1027476988,negative,0.9460288286209106
239,8/23/2018 1:17:14 PM,"Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone ",RTTNews,/news/stocks/bristol-myers-fda-to-review-sbla-for-empliciti-with-pomalidomide-dexamethasone-1027480033,positive,0.6671409606933594
240,8/29/2018 3:15:10 PM,FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/DYXzNayhDVo/focus-europe-ready-to-cash-in-on-cheap-copies-of-abbvie-biotech-drug-idUSL8N1VK1CD,negative,0.8657156229019165
241,9/13/2018 4:44:00 PM,AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's sr. notes; stable outlook,Moodys,/news/bonds/abbvie-inc-moody-s-assigns-baa2-to-abbvie-s-sr-notes-stable-outlook-1027532992,negative,0.7968636751174927
242,9/18/2018 8:51:41 PM,California insurance commissioner sues AbbVie over Humira,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TG7R3JZ--ps/california-insurance-commissioner-sues-abbvie-over-humira-idUSL3N1W458S,neutral,0.9313579797744751
243,9/18/2018 9:18:26 PM,UPDATE 1-California insurance regulator sues AbbVie alleging Humira kickbacks,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/UPB86djozPE/update-1-california-insurance-regulator-sues-abbvie-alleging-humira-kickbacks-idUSL3N1W459P,neutral,0.9215220808982849
244,9/19/2018 5:27:52 PM,California Sues AbbVie Alleging Kickbacks For Humira ,RTTNews,/news/stocks/california-sues-abbvie-alleging-kickbacks-for-humira-1027548393,neutral,0.935094952583313
245,9/20/2018 1:28:42 PM,Mylan To Launch Biosimilar To Humira In Europe - Quick Facts ,RTTNews,/news/stocks/mylan-to-launch-biosimilar-to-humira-in-europe-quick-facts-1027550766,positive,0.8111785054206848
246,10/4/2018 9:19:00 AM,"Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US",Moodys,/news/bonds/moody-s-biosimilars-a-growing-challenge-biotech-drugs-with-european-market-developing-more-quickly-than-the-us-1027589140,negative,0.8536537885665894
247,10/12/2018 12:04:38 AM,Abbvie settles Humira patent disputes with Novartis unit,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/_Rm1iO3VXmE/abbvie-settles-humira-patent-disputes-with-novartis-unit-idUSKCN1ML31B,positive,0.506633996963501
248,10/12/2018 3:25:05 AM,"Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes ",RTTNews,/news/stocks/sandoz-abbvie-announce-global-resolution-of-humira-patent-disputes-1027611036,positive,0.7307688593864441
249,10/12/2018 3:30:37 AM,Abbvie settles Humira patent disputes with Novartis unit,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/S3Jr26xFzS0/abbvie-settles-humira-patent-disputes-with-novartis-unit-idINKCN1MM03Q,positive,0.506633996963501
250,10/16/2018 2:28:50 PM,"Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/D7Uaz3n9gQM/amgen-novartis-kick-off-fight-for-abbvie-blockbuster-drug-in-eu-idUSL8N1WW26J,negative,0.7335519194602966
251,10/18/2018 3:17:26 PM,AbbVie Announces Resolution Of HUMIRA Patent Disputes With Fresenius Kabi ,RTTNews,/news/stocks/abbvie-announces-resolution-of-humira-patent-disputes-with-fresenius-kabi-1027630350,neutral,0.37454259395599365
252,10/18/2018 3:45:51 PM,AbbVie settles Humira biosimilar dispute with Fresenius Kabi,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/T5WbYBezlwg/abbvie-settles-humira-biosimilar-dispute-with-fresenius-kabi-idUSL3N1WY4IE,neutral,0.46148812770843506
253,10/18/2018 3:56:07 PM,AbbVie settles Humira biosimilar dispute with Fresenius Kabi,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/McTJifXk2QY/abbvie-settles-humira-biosimilar-dispute-with-fresenius-kabi-idINKCN1MS25G,neutral,0.46148812770843506
254,10/19/2018 4:00:11 PM,AbbVie names Robert Michael chief financial officer,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9LUoIHslKuM/abbvie-names-robert-michael-chief-financial-officer-idUSL3N1WZ4XE,positive,0.9421675801277161
255,10/19/2018 4:55:44 PM,AbbVie CFO William Chase Plans To Retire In Mid-2019 ,RTTNews,/news/stocks/abbvie-cfo-william-chase-plans-to-retire-in-mid-2019-1027634394,positive,0.9122839570045471
256,10/19/2018 6:45:50 PM,"UPDATE 1-AbbVie CFO Chase stepping down, to retire by mid-year 2019",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/1I7ExZmEqug/update-1-abbvie-cfo-chase-stepping-down-to-retire-by-mid-year-2019-idUSL3N1WZ57K,positive,0.6397048234939575
257,10/19/2018 6:48:55 PM,"AbbVie CFO Chase stepping down, to retire by mid-year 2019",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/bYq3GjBhLYs/abbvie-cfo-chase-stepping-down-to-retire-by-mid-year-2019-idUSKCN1MT2FY,positive,0.6919054388999939
258,10/19/2018 8:59:06 PM,UPDATE 2-AbbVie CFO Chase to retire by mid-year 2019,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xeSRJNt_Q8Q/update-2-abbvie-cfo-chase-to-retire-by-mid-year-2019-idUSL3N1WZ57K,positive,0.8846471309661865
259,10/19/2018 9:26:37 PM,AbbVie CFO Chase to retire by mid-year 2019,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Zbbp35vnEpM/abbvie-cfo-chase-to-retire-by-mid-year-2019-idUSKCN1MT2FY,positive,0.8484611511230469
260,10/23/2018 8:43:01 AM,"ABBV ACHIEVES Goals, HealthStream's CFO Resigns, NTEC On Watch ",RTTNews,/news/stocks/abbv-achieves-goals-healthstream-s-cfo-resigns-ntec-on-watch-1027642313,neutral,0.688109278678894
261,10/23/2018 4:14:21 PM,AbbVie rheumatoid arthritis drug succeeds in late stage trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pVP-jUNNcdg/abbvie-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-idUSL2N1X30KX,negative,0.8954479098320007
262,10/23/2018 4:46:27 PM,AbbVie rheumatoid arthritis drug succeeds in late stage trial,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/YLrqUrsbqIY/abbvie-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-idINKCN1MX24S,negative,0.8954479098320007
263,10/25/2018 4:50:50 AM,Galapagos And AbbVie Restructure CF Collaboration ,RTTNews,/news/stocks/galapagos-and-abbvie-restructure-cf-collaboration-1027651973,positive,0.9287651777267456
264,10/26/2018 8:56:11 PM,"Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/82Fp5LcIPz0/abbott-abbvie-settle-u-s-case-over-tricor-marketing-for-25-mln-idUSL2N1X61H0,negative,0.4742342233657837
265,10/26/2018 9:39:15 PM,"UPDATE 1-Abbott, AbbVie to pay $25 mln to settle TriCor marketing case",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wZr-U3s9SiY/update-1-abbott-abbvie-to-pay-25-mln-to-settle-tricor-marketing-case-idUSL2N1X61K5,positive,0.8521546721458435
266,10/26/2018 11:16:01 PM,"UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/L0FT0bDriM0/update-2-abbott-abbvie-settle-tricor-marketing-case-for-25-mln-idUSL2N1X61K5,positive,0.840973973274231
267,10/27/2018 1:54:35 AM,"Abbott, AbbVie settle TriCor marketing case for $25 million",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/LBOGWyYVxhI/abbott-abbvie-settle-tricor-marketing-case-for-25-million-idINKCN1N02XY,positive,0.8910031318664551
268,10/31/2018 3:02:40 PM,Here's what Wall Street expects from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-stock-q3-earnings-preview-1027676592,positive,0.9177791476249695
269,10/31/2018 4:14:06 PM,FDA approves Novartis' copy of AbbVie bestseller Humira,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ufn-hOgVnr4/fda-approves-novartis-copy-of-abbvie-bestseller-humira-idUSL3N1XB66R,positive,0.7995054721832275
270,10/31/2018 10:49:41 PM,"AbbVie, Roche combo treatment meets main goal of leukemia trial",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/p-R_eMpK1P0/abbvie-roche-combo-treatment-meets-main-goal-of-leukemia-trial-idUSL3N1XB7BC,negative,0.6963217258453369
271,11/1/2018 6:33:24 AM,AbbVie: VENCLYXTO Plus Rituximab Gets Europe Approval To Treat CLL Patients ,RTTNews,/news/stocks/abbvie-venclyxto-plus-rituximab-gets-europe-approval-to-treat-cll-patients-1027678634,negative,0.9431431889533997
272,11/1/2018 12:08:18 PM,"CORRECTED-AbbVie, Roche combo treatment meets main goal of leukemia trial",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/BsFdCGMTrow/corrected-abbvie-roche-combo-treatment-meets-main-goal-of-leukemia-trial-idUSL3N1XB7BC,negative,0.7210319638252258
273,11/2/2018 12:50:27 PM,AbbVie lifts profit target after cancer drug powers third-quarter beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/tFebyNOjn-M/abbvie-lifts-profit-target-after-cancer-drug-powers-third-quarter-beat-idUSL3N1XD3MR,negative,0.8636168241500854
274,11/2/2018 12:52:26 PM,AbbVie lifts profit target after cancer drug powers third-quarter beat,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/LwwoSn3f0p8/abbvie-lifts-profit-target-after-cancer-drug-powers-third-quarter-beat-idUSKCN1N719Q,negative,0.8636168241500854
275,11/2/2018 1:59:37 PM,AbbVie lifts profit target after cancer drug powers quarterly beat,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/gF0zH5sMuZg/abbvie-lifts-profit-target-after-cancer-drug-powers-quarterly-beat-idUSKCN1N719Q,neutral,0.49477317929267883
276,11/2/2018 2:30:40 PM,AbbVie expects double-digit earnings growth in 2019,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/QOT9DFVQliY/abbvie-expects-double-digit-earnings-growth-in-2019-idUSKCN1N71JY,negative,0.9530660510063171
277,11/2/2018 3:08:44 PM,Humira biosimilars available at up to 80 pct discount in Europe-AbbVie,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9PF84ztDvX0/humira-biosimilars-available-at-up-to-80-pct-discount-in-europe-abbvie-idUSL3N1XD4TY,positive,0.693795382976532
278,11/2/2018 3:11:12 PM,Humira biosimilars available at up to 80 percent discount in Europe: AbbVie,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/9D1KVLkkLBI/humira-biosimilars-available-at-up-to-80-percent-discount-in-europe-abbvie-idUSKCN1N71NZ,positive,0.847869336605072
279,11/2/2018 4:20:38 PM,AbbVie sees hit to Humira sales from European competition,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/YBuYk_iztns/abbvie-sees-hit-to-humira-sales-from-european-competition-idUSKCN1N719Q,negative,0.90317302942276
280,11/15/2018 4:52:17 AM,"MNK Awaits D-Day, AMEH In Good Health, AXSM To Report ASCEND Data In Jan. ",RTTNews,/news/stocks/mnk-awaits-d-day-ameh-in-good-health-axsm-to-report-ascend-data-in-jan-1027728212,negative,0.5508719682693481
281,11/21/2018 5:47:10 PM,Roche-AbbVie cancer drug gets accelerated FDA approval,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0RjYibHtwj0/roche-abbvie-cancer-drug-gets-accelerated-fda-approval-idUSL4N1XW4GF,negative,0.8378332257270813
282,11/21/2018 6:06:48 PM,UPDATE 1-Roche-AbbVie cancer drug gets accelerated FDA approval,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kBZx5ZRk7V0/update-1-roche-abbvie-cancer-drug-gets-accelerated-fda-approval-idUSL4N1XW4GX,negative,0.791664183139801
283,11/21/2018 6:23:43 PM,CORRECTED-UPDATE 1-Roche-AbbVie cancer drug gets accelerated FDA approval,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/k-xVC-sbpE4/corrected-update-1-roche-abbvie-cancer-drug-gets-accelerated-fda-approval-idUSL4N1XW4GX,negative,0.7555274963378906
284,11/21/2018 6:24:25 PM,Roche-AbbVie cancer drug gets accelerated FDA approval,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/WgKQ1A2VuX8/roche-abbvie-cancer-drug-gets-accelerated-fda-approval-idINKCN1NQ288,negative,0.8378332257270813
285,11/30/2018 4:13:54 PM,Pfizer Reaches Global Agreement With AbbVie; To Withdraw Pending Litigation ,RTTNews,/news/stocks/pfizer-reaches-global-agreement-with-abbvie-to-withdraw-pending-litigation-1027771392,neutral,0.4190761148929596
286,12/4/2018 4:37:01 PM,JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zzaIl8PmFIc/jnj-abbvie-cancer-drug-imbruvica-succeeds-in-late-stage-trial-idUSL4N1Y949R,negative,0.9215868711471558
287,12/4/2018 5:24:32 PM,UPDATE 1-JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mRlzbOKqzWY/update-1-jnj-abbvie-cancer-drug-imbruvica-succeeds-in-late-stage-trial-idUSL4N1Y94AV,negative,0.9331817626953125
288,12/5/2018 10:46:26 PM,AbbVie halts late-stage trial for lung cancer drug Rova-T,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/j_lG1jsL9AA/abbvie-halts-late-stage-trial-for-lung-cancer-drug-rova-t-idUSL4N1YA4OG,neutral,0.8974228501319885
289,12/5/2018 11:23:31 PM,UPDATE 1-AbbVie halts late-stage trial for lung cancer drug Rova-T,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NVssIY3iwZk/update-1-abbvie-halts-late-stage-trial-for-lung-cancer-drug-rova-t-idUSL4N1YA4SN,neutral,0.9224227070808411
290,12/5/2018 11:54:07 PM,A cancer drug that AbbVie acquired in a $10 billion deal is looking more and more like a failure (ABBV),Business Insider,https://www.businessinsider.com/abbvie-stopped-a-phase-3-trial-after-its-stemcentrx-drug-flopped-2018-12,positive,0.4854748249053955
291,12/24/2018 3:43:05 PM,"Lupin, AbbVie To Develop Novel Oncology Drug To Treat Hematological Cancers ",RTTNews,/news/stocks/lupin-abbvie-to-develop-novel-oncology-drug-to-treat-hematological-cancers-1027831432,negative,0.6567715406417847
292,1/4/2019 11:40:08 PM,Abbvie to record $4 bln impairment charges on Stemcentrx assets,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/y1wrQveCcLg/abbvie-to-record-4-bln-impairment-charges-on-stemcentrx-assets-idUSL3N1Z44M4,neutral,0.9639282822608948
293,1/23/2019 3:01:34 PM,AbbVie earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/abbvie-stock-q4-earnings-preview-1027889692,positive,0.9104300737380981
294,1/25/2019 1:45:52 PM,AbbVie profit misses as Humira faces biosimilar challenge in Europe,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cSuVPzCRENM/abbvie-profit-misses-as-humira-faces-biosimilar-challenge-in-europe-idUSL3N1ZP3AO,neutral,0.9699232578277588
295,1/25/2019 2:15:01 PM,AbbVie Q4 Results Miss View; Stock Down ,RTTNews,/news/stocks/abbvie-q4-results-miss-view-stock-down-1027896291,neutral,0.9381625056266785
296,1/25/2019 3:24:25 PM,UPDATE 1-AbbVie profit misses as Humira faces biosimilar challenge in Europe,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FauU0ndCO_w/update-1-abbvie-profit-misses-as-humira-faces-biosimilar-challenge-in-europe-idUSL3N1ZP3UU,neutral,0.9732605814933777
297,1/25/2019 3:44:48 PM,AbbVie not contemplating big deals - CEO,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/m4OuVbcpc8U/abbvie-not-contemplating-big-deals-ceo-idUSL3N1ZP456,positive,0.9314274787902832
298,1/25/2019 4:19:14 PM,REFILE-UPDATE 2-AbbVie warns of steeper decline in Humira's international sales,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5xyFVh1JvfE/refile-update-2-abbvie-warns-of-steeper-decline-in-humiras-international-sales-idUSL3N1ZP3UU,neutral,0.8325874209403992
299,1/25/2019 5:05:16 PM,UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/WN9PiAI_S0g/update-3-abbvie-expects-steeper-decline-in-humiras-overseas-sales-shares-fall-idUSL3N1ZP3UU,neutral,0.9694436192512512
300,1/28/2019 3:00:56 PM,What's Making News In These Pharma And Cannabis Stocks Today? ,RTTNews,/news/stocks/what-s-making-news-in-these-pharma-and-cannabis-stocks-today-1027900991,positive,0.7741166949272156
301,2/15/2019 10:15:00 PM,AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.,Moodys,/news/bonds/abbvie-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-abbvie-inc-1027957905,positive,0.8537180423736572
302,2/20/2019 6:13:18 AM,"FDA Nod For NVO's Hemophilia A Drug, ICPT's NASH Trial Hits Goal, NVTA Abuzz ",RTTNews,/news/stocks/fda-nod-for-nvo-s-hemophilia-a-drug-icpt-s-nash-trial-hits-goal-nvta-abuzz-1027966173,negative,0.8868404626846313
303,2/22/2019 2:10:22 PM,AbbVie And Voyager Therapeutics Collaborate To Develop Vectorized Antibodies ,RTTNews,/news/stocks/abbvie-and-voyager-therapeutics-collaborate-to-develop-vectorized-antibodies-1027975435,positive,0.6931362152099609
304,3/19/2019 1:57:14 PM,AbbVie : FDA Places Partial Clinical Hold On All Clinical Trials On Venetoclax ,RTTNews,/news/stocks/abbvie-fda-places-partial-clinical-hold-on-all-clinical-trials-on-venetoclax-1028041598,neutral,0.9203352332115173
305,3/26/2019 6:28:25 AM,AbbVie Announces Approval Of SKYRIZI In Japan - Quick Facts ,RTTNews,/news/stocks/abbvie-announces-approval-of-skyrizi-in-japan-quick-facts-1028057446,positive,0.8055700659751892
306,3/26/2019 12:16:18 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1028058579,positive,0.7716754078865051
307,4/4/2019 5:16:01 AM,10 Best Selling Drugs Of 2018 ,RTTNews,/news/stocks/10-best-selling-drugs-of-2018-1028084412,positive,0.7440220713615417
308,4/23/2019 3:02:22 PM,AbbVie earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/abbvie-stock-q1-earnings-preview-1028129917,positive,0.9269446134567261
309,4/24/2019 6:03:31 AM,Plaque Psoriasis Armamentarium Gets New Addition ,RTTNews,/news/stocks/plaque-psoriasis-armamentarium-gets-new-addition-1028132263,negative,0.6228421926498413
310,4/25/2019 1:44:09 PM,AbbVie beats estimates as Humira sales fall less than feared,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/KoDMatfxy_Y/abbvie-beats-estimates-as-humira-sales-fall-less-than-feared-idUSL3N226481,neutral,0.9582662582397461
311,4/25/2019 2:48:35 PM,UPDATE 1-AbbVie beats estimates as Humira sales fall less than feared,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/GYW64X1Cf24/update-1-abbvie-beats-estimates-as-humira-sales-fall-less-than-feared-idUSL3N2273A2,neutral,0.9417150020599365
312,4/25/2019 4:04:32 PM,"AbbVie says Humira rivals from Biogen, Amgen most aggressive so far",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CZwtzCsvXk8/abbvie-says-humira-rivals-from-biogen-amgen-most-aggressive-so-far-idUSKCN1S11TS,positive,0.5537651777267456
313,4/25/2019 5:53:10 PM,"UPDATE 2-AbbVie raises profit forecast, but Humira concerns weigh on shares",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/7YDcDnWdYSk/update-2-abbvie-raises-profit-forecast-but-humira-concerns-weigh-on-shares-idUSL3N2273A2,neutral,0.6180042624473572
314,4/25/2019 5:56:38 PM,"AbbVie raises profit forecast, but Humira concerns weigh on shares",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/LlrTWXZgPfA/abbvie-raises-profit-forecast-but-humira-concerns-weigh-on-shares-idUSKCN1S11HB,neutral,0.8944675922393799
315,5/16/2019 7:34:53 AM,Roche Announces FDA Approval For Expanded Use Of Venclexta - Quick Facts ,RTTNews,/news/stocks/roche-announces-fda-approval-for-expanded-use-of-venclexta-quick-facts-1028205977,negative,0.4881311058998108
316,5/17/2019 3:00:01 PM,AbbVie halts patient enrollment after brain cancer trial misses goal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dUPPz-lsAWw/abbvie-halts-patient-enrollment-after-brain-cancer-trial-misses-goal-idUSL4N22T2ZH,neutral,0.9484708309173584
317,5/17/2019 3:18:15 PM,"UPDATE 1-AbbVie halts enrollment after brain cancer trial misses goal, shares fall",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/McmVUgv6WMI/update-1-abbvie-halts-enrollment-after-brain-cancer-trial-misses-goal-shares-fall-idUSL4N22T302,neutral,0.9662127494812012
318,5/17/2019 3:18:58 PM,"AbbVie halts enrollment after brain cancer trial misses goal, shares fall",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/2dOJmoYMJAI/abbvie-halts-enrollment-after-brain-cancer-trial-misses-goal-shares-fall-idINKCN1SN1KI,neutral,0.9495545625686646
319,5/17/2019 3:19:06 PM,"AbbVie halts enrollment after brain cancer trial misses goal, shares fall",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/rNOl5-pDpwk/abbvie-halts-enrollment-after-brain-cancer-trial-misses-goal-shares-fall-idUSKCN1SN1IV,neutral,0.9495545625686646
320,6/5/2019 11:10:17 AM,Investors Aren’t Likely to Clean up on Procter & Gamble Stock,InvestorPlace,/news/stocks/investors-clean-procter-gamble-stock-1028258521,neutral,0.6199532151222229
321,6/11/2019 7:15:22 PM,10 Smart Dividend Stocks for the Rest of the Year,InvestorPlace,/news/stocks/dividend-stocks-to-buy-1028271983,positive,0.8653878569602966
322,6/24/2019 1:05:13 PM,"3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie",InvestorPlace,/news/stocks/3-big-stock-charts-for-monday-abbv-payx-mdt-1028303885,positive,0.8924997448921204
323,6/25/2019 12:34:57 PM,AbbVie nears deal to buy Allergan for more than $60 bln - WSJ,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JLlKD3yzQoc/abbvie-nears-deal-to-buy-allergan-for-more-than-60-bln-wsj-idUSL4N23W2KI,negative,0.7088037133216858
324,6/25/2019 12:45:55 PM,AbbVie nears deal to buy Allergan for more than $60 billion: WSJ,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/rDAft66k0lg/abbvie-nears-deal-to-buy-allergan-for-more-than-60-billion-wsj-idUSKCN1TQ15X,positive,0.5708620548248291
325,6/25/2019 12:47:29 PM,UPDATE 1-AbbVie to buy Allergan in $63 bln deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/h22Cy3NR7lc/update-1-abbvie-to-buy-allergan-in-63-bln-deal-idUSL4N23W2KP,positive,0.7879425287246704
326,6/25/2019 12:55:00 PM,AbbVie to buy Allergan in $63 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/2GGhJ4gmmr0/abbvie-to-buy-allergan-in-63-billion-deal-idUSKCN1TQ15X,positive,0.9022810459136963
327,6/25/2019 12:56:56 PM,UPDATE 2-AbbVie to buy Botox-maker Allergan in $63 bln deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pJHmZy9eV28/update-2-abbvie-to-buy-botox-maker-allergan-in-63-bln-deal-idUSL4N23W2KP,positive,0.6175306439399719
328,6/25/2019 1:12:17 PM,"AbbVie To Buy Allergan In $63 Bln Cash, Stock Deal - Quick Facts ",RTTNews,/news/stocks/abbvie-to-buy-allergan-in-63-bln-cash-stock-deal-quick-facts-1028304958,positive,0.7774803638458252
329,6/25/2019 1:28:36 PM,AbbVie to buy Botox-maker Allergan in $63 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/tS7kyqPxg14/abbvie-to-buy-botox-maker-allergan-in-63-billion-deal-idUSKCN1TQ15X,positive,0.8667370676994324
330,6/25/2019 1:30:53 PM,UPDATE 3-AbbVie to buy Botox-maker Allergan in $63 bln deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/6bEnYMAEtLw/update-3-abbvie-to-buy-botox-maker-allergan-in-63-bln-deal-idUSL4N23W2KP,positive,0.6023723483085632
331,6/25/2019 1:33:00 PM,AbbVie Inc. -- Moody's affirms AbbVie's Baa2 ratings; outlook stable,Moodys,/news/bonds/abbvie-inc-moody-s-affirms-abbvie-s-baa2-ratings-outlook-stable-1028305065,negative,0.7907505035400391
332,6/25/2019 2:10:33 PM,AbbVie to buy Botox-maker Allergan in $63 billion deal,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/pW2PiilajB4/abbvie-to-buy-botox-maker-allergan-in-63-billion-deal-idINKCN1TQ1H3,positive,0.8667370676994324
333,6/25/2019 2:48:05 PM,"Allergan spikes 30% after AbbVie agrees to buy the Botox-maker for $63 billion (AGN, ABBV)",Business Insider,https://markets.businessinsider.com/news/stocks/allergan-stock-price-reaction-to-abbvie-aquisition-agreement-2019-6-1028305530,negative,0.903061032295227
334,6/25/2019 3:11:17 PM,UPDATE 4-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/bbx1tRXie2Q/update-4-abbvie-looks-beyond-humira-with-63-bln-deal-for-botox-maker-allergan-idUSL4N23W2KP,negative,0.9233264327049255
335,6/25/2019 3:12:11 PM,AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/X6HERhKZi6o/abbvie-looks-beyond-humira-with-63-billion-deal-for-botox-maker-allergan-idINKCN1TQ1H3,negative,0.6807485222816467
336,6/25/2019 3:14:20 PM,AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/eX6JRyq6-os/abbvie-looks-beyond-humira-with-63-billion-deal-for-botox-maker-allergan-idUSKCN1TQ15X,negative,0.6807485222816467
337,6/25/2019 4:44:55 PM,AbbVie-Allergan Deal: AGN Stock Soars on $63 Billion Buyout,InvestorPlace,/news/stocks/abbvie-allergan-deal-boost-agn-stock-1028307939,negative,0.8956983089447021
338,6/25/2019 4:46:38 PM,3 Healthcare Stocks to Buy With the Market Near All-Time Highs,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-with-the-market-near-all-time-highs-1028307938,negative,0.6229497790336609
339,6/25/2019 5:11:40 PM,UPDATE 5-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FCPniYV_y0Y/update-5-abbvie-looks-beyond-humira-with-63-bln-deal-for-botox-maker-allergan-idUSL4N23W2KP,negative,0.9198765158653259
340,6/25/2019 5:15:56 PM,AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/bcbN1TYIzf8/abbvie-looks-beyond-humira-with-63-bln-deal-for-botox-maker-allergan-idINKCN1TQ1H3,negative,0.8078505396842957
341,6/25/2019 7:51:21 PM,3 Biopharma Stocks to Buy for Income,InvestorPlace,/news/stocks/3-biopharma-stocks-to-buy-for-income-1028307925,positive,0.9193856716156006
342,6/25/2019 7:57:00 PM,"Allergan Finance, LLC -- Moody's reviews Allergan's Baa3 ratings for upgrade",Moodys,/news/bonds/allergan-finance-llc-moody-s-reviews-allergan-s-baa3-ratings-for-upgrade-1028307015,positive,0.905825674533844
343,6/25/2019 8:11:08 PM,"5 Top Stock Trades for Wednesday — AGN, ABBV, FDX, MSFT, BB",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-agn-abbv-fdx-msft-bb-1028307924,positive,0.936821699142456
344,6/25/2019 8:46:12 PM,Nasdaq Today: Hard to Keep Track of the Losers,InvestorPlace,/news/stocks/nasdaq-today-hard-to-keep-track-of-the-losers-1028307921,positive,0.5613378286361694
345,6/25/2019 9:05:23 PM,UPDATE 6-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/eBTg8MEKSnM/update-6-abbvie-looks-beyond-humira-with-63-bln-deal-for-botox-maker-allergan-idUSL4N23W2KP,negative,0.9242135882377625
346,6/25/2019 11:53:10 PM,UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Cykj6UVQn2U/update-7-abbvie-looks-beyond-humira-with-63-bln-deal-for-botox-maker-allergan-idUSL4N23W2KP,negative,0.922646701335907
347,6/26/2019 11:53:18 AM,"3 Big Stock Charts for Wednesday: Tyson Foods, Lennar and State Street",InvestorPlace,/news/stocks/3-big-stock-charts-for-wednesday-tsn-stt-len-1028312024,positive,0.9272056818008423
348,6/26/2019 1:42:26 PM,"Wednesday’s Vital Data: AbbVie, FedEx and Micron",InvestorPlace,/news/stocks/tuesdays-vital-data-abbvie-fedex-and-micron-1028312014,positive,0.9350108504295349
349,6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984,neutral,0.8470374941825867
350,6/27/2019 3:09:12 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028313919,positive,0.9520016312599182
351,6/28/2019 1:45:22 PM,This Pharmaceutical Company is Oversold and Starting to Recover,InvestorPlace,/news/stocks/this-pharmaceutical-company-is-oversold-and-starting-to-recover-1028318797,neutral,0.966069221496582
352,6/28/2019 2:51:02 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028317248,positive,0.9520016312599182
353,7/1/2019 10:38:04 AM,Acquisition Improves the Outlook of Pfizer Stock,InvestorPlace,/news/stocks/acquiring-array-biopharma-improves-pfizers-prospects-1028323091,negative,0.956790030002594
354,7/1/2019 4:42:43 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028321807,positive,0.9520016312599182
355,7/2/2019 3:55:47 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028325067,positive,0.9520016312599182
356,7/3/2019 3:51:16 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028328203,positive,0.9520016312599182
357,7/4/2019 4:28:57 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028330549,positive,0.9520016312599182
358,7/5/2019 2:46:12 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028332356,positive,0.9520016312599182
359,7/8/2019 3:46:37 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028335380,positive,0.9520016312599182
360,7/9/2019 4:13:01 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028339155,positive,0.9520016312599182
361,7/9/2019 5:52:32 PM,The S&P 500’s 5 Best Highest-Yielding Dividend Stocks,InvestorPlace,/news/stocks/the-sp-500s-best-highest-yielding-dividend-stocks-1028340729,positive,0.6045562624931335
362,7/10/2019 3:05:52 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028342419,positive,0.9520016312599182
363,7/11/2019 3:13:36 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028346279,positive,0.9520016312599182
364,7/12/2019 2:38:21 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028349089,positive,0.9520016312599182
365,7/15/2019 3:11:58 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028352849,positive,0.9520016312599182
366,7/16/2019 2:58:17 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028356590,positive,0.9520016312599182
367,7/17/2019 3:03:58 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028360673,positive,0.9520016312599182
368,7/18/2019 2:46:47 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028364645,positive,0.9520016312599182
369,7/19/2019 2:55:03 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028367843,positive,0.9520016312599182
370,7/22/2019 3:17:42 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028372176,positive,0.9520016312599182
371,7/23/2019 2:37:27 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028375991,positive,0.9520016312599182
372,7/23/2019 6:03:36 PM,Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings,InvestorPlace,/news/stocks/why-bristol-myers-is-down-ahead-of-its-earnings-report-1028378737,neutral,0.564351499080658
373,7/24/2019 2:12:37 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028380306,positive,0.9520016312599182
374,7/24/2019 3:02:07 PM,What Wall Street expects from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-quarter-earnings-preview-q2-1028380509,positive,0.9298630356788635
375,7/24/2019 3:13:46 PM,9 Dividend Stocks to Buy to Suit Any Investing Style,InvestorPlace,/news/stocks/9-dividend-stocks-to-buy-to-suit-any-investing-style-1028383018,positive,0.9261885285377502
376,7/25/2019 2:57:22 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028385066,positive,0.9520016312599182
377,7/26/2019 1:29:36 PM,Bristol-Myers Gets Positive CHMP Opinion For Empliciti ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-empliciti-1028388214,negative,0.9433078169822693
378,7/26/2019 1:43:46 PM,AbbVie raises 2019 profit target as quarterly sales beat estimates,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/jNP_iMv6r38/abbvie-raises-2019-profit-target-as-quarterly-sales-beat-estimates-idUSL4N24R2M8,negative,0.9360242486000061
379,7/26/2019 2:02:06 PM,AbbVie Boosts FY19 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/abbvie-boosts-fy19-adj-eps-outlook-quick-facts-1028388303,negative,0.8233383297920227
380,7/26/2019 3:04:40 PM,UPDATE 1-AbbVie raises 2019 earnings target as quarterly profit beats estimates,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/q-G9DFsLruQ/update-1-abbvie-raises-2019-earnings-target-as-quarterly-profit-beats-estimates-idUSL4N24R35Q,negative,0.941128134727478
381,7/26/2019 4:02:57 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028388721,positive,0.9520016312599182
382,7/26/2019 4:10:13 PM,AbbVie Earnings: ABBV Stock Pops on Q2 Beat,InvestorPlace,/news/stocks/abbvie-earnings-bump-abbv-stock-1028389962,positive,0.594828188419342
383,7/26/2019 4:15:46 PM,AbbVie does not expect to divest new psoriasis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/tLynmCfef8Q/abbvie-does-not-expect-to-divest-new-psoriasis-drug-idUSL4N24R3LE,positive,0.946395754814148
384,7/26/2019 5:48:38 PM,"UPDATE 2-AbbVie spotlights Allergan deal, new drugs as Humira sales wane",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/aQYN4YCJByo/update-2-abbvie-spotlights-allergan-deal-new-drugs-as-humira-sales-wane-idUSL4N24R35Q,negative,0.8160286545753479
385,7/26/2019 7:25:01 PM,"UPDATE 3-AbbVie spotlights Allergan deal, new drugs as Humira sales wane",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/XgBk8K49sHE/update-3-abbvie-spotlights-allergan-deal-new-drugs-as-humira-sales-wane-idUSL4N24R35Q,negative,0.8136796951293945
386,7/26/2019 7:26:48 PM,"AbbVie spotlights Allergan deal, new drugs as Humira sales wane",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/0gJcn-HQfwY/abbvie-spotlights-allergan-deal-new-drugs-as-humira-sales-wane-idINKCN1UL23V,negative,0.573871374130249
387,7/29/2019 1:28:28 PM,Biotech Stocks Facing FDA Decision In August 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2019-1028393221,positive,0.828368604183197
388,7/29/2019 2:35:12 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028393587,positive,0.9520016312599182
389,7/30/2019 3:15:57 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028399221,positive,0.9520016312599182
390,7/31/2019 2:56:33 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028403402,positive,0.9520016312599182
391,8/1/2019 2:54:47 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028408322,positive,0.9520016312599182
392,8/2/2019 3:41:17 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028411997,positive,0.9520016312599182
393,8/6/2019 2:58:47 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028421818,positive,0.9520016312599182
394,8/6/2019 8:32:32 PM,Stock Market Today: How Many Times Will the Fed Cut Rates? ,InvestorPlace,/news/stocks/stock-market-today-how-many-times-will-the-fed-cut-rates-1028424325,neutral,0.5237130522727966
395,8/7/2019 2:57:53 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028426525,positive,0.9520016312599182
396,8/7/2019 4:36:00 PM,"Moody's – Latest proposals to reduce drug prices extend social, financial risk for US drug industry",Moodys,/news/bonds/moody-s-latest-proposals-to-reduce-drug-prices-extend-social-financial-risk-for-us-drug-industry-1028427249,negative,0.6079421043395996
397,8/8/2019 2:53:23 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028430959,positive,0.9520016312599182
398,8/9/2019 3:01:48 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028434433,positive,0.9520016312599182
399,8/9/2019 6:59:06 PM,7 Large-Cap Stocks to Sell Right Now,InvestorPlace,/news/stocks/7-large-cap-stocks-to-sell-right-now-1028435555,positive,0.8879852294921875
400,8/12/2019 11:40:24 AM,"3M Stock Isn’t Crumbling, but It’s No Bargain Either",InvestorPlace,/news/stocks/3m-stock-next-ge-bargain-either-1028440109,positive,0.8345479965209961
401,8/12/2019 3:02:20 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028438261,positive,0.9520016312599182
402,8/13/2019 3:17:23 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028442205,positive,0.9520016312599182
403,8/14/2019 2:58:03 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028445948,positive,0.9520016312599182
404,8/15/2019 3:10:07 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028449801,positive,0.9520016312599182
405,8/16/2019 2:52:33 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028452641,positive,0.9520016312599182
406,8/16/2019 8:19:16 PM,"UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/l2s41cZzso0/update-2-abbvie-prices-new-rheumatoid-arthritis-drug-at-59000-yr-idUSL4N25C341,negative,0.8145477175712585
407,8/19/2019 3:35:22 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028456133,positive,0.9520016312599182
408,8/20/2019 3:45:59 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028459836,positive,0.9520016312599182
409,8/21/2019 4:07:47 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028463462,positive,0.9520016312599182
410,8/22/2019 4:15:02 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028466989,positive,0.9520016312599182
411,8/23/2019 3:30:22 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028469717,positive,0.9520016312599182
412,8/26/2019 2:28:12 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028473122,positive,0.9520016312599182
413,8/27/2019 2:03:12 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028476366,positive,0.9520016312599182
414,8/28/2019 1:55:33 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028480365,positive,0.9520016312599182
415,8/28/2019 9:25:51 PM,"FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RxxW8diF-60/fda-flags-serious-risks-with-hepatitis-c-drugs-from-abbvie-gilead-and-merck-idUSL3N25O3WS,neutral,0.6740937829017639
416,8/28/2019 9:45:05 PM,"UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_bVsv9h9HEc/update-1-fda-flags-risks-from-abbvie-gilead-merck-hepatitis-c-drugs-to-certain-patients-idUSL3N25O3X2,positive,0.37260955572128296
417,8/29/2019 2:02:38 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028484140,positive,0.9520016312599182
418,8/29/2019 2:59:20 PM,AbbVie terminates late-stage lung cancer trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rWB2vs8deoQ/abbvie-terminates-late-stage-lung-cancer-trial-idUSL3N25P3QL,positive,0.7994384765625
419,8/29/2019 3:10:11 PM,AbbVie Terminates Rovalpituzumab Tesirine Research And Development Program ,RTTNews,/news/stocks/abbvie-terminates-rovalpituzumab-tesirine-research-and-development-program-1028484611,positive,0.925239086151123
420,8/29/2019 3:35:41 PM,UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/f-D2B2qUtrU/update-1-abbvie-abandons-late-stage-lung-cancer-asset-rova-t-idUSL3N25P3RQ,positive,0.9043819904327393
421,8/30/2019 2:43:02 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028487643,positive,0.9520016312599182
422,9/2/2019 4:36:07 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028491334,positive,0.9520016312599182
423,9/3/2019 2:57:12 PM,"Form 8.3 - The Vanguard Group, Inc.: AbbVie plc",EQS Group,/news/stocks/form-8-3-the-vanguard-group-inc-abbvie-plc-1028493727,positive,0.9520016312599182
424,9/4/2019 11:16:29 AM,Nanogold Treatment In The Making For Prostate Cancer ,RTTNews,/news/stocks/nanogold-treatment-in-the-making-for-prostate-cancer-1028496674,positive,0.8055061101913452
425,9/10/2019 2:55:17 PM,10 Healthcare Stocks to Buy Despite the Headlines,InvestorPlace,/news/stocks/10-healthcare-stocks-to-buy-despite-the-headlines-1028514931,positive,0.49671414494514465
426,9/13/2019 12:11:03 AM,"Consumer groups, unions urge caution on $63 bln AbbVie deal for Allergan",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/htzC8xq_rEg/consumer-groups-unions-urge-caution-on-63-bln-abbvie-deal-for-allergan-idUSL2N2621NG,neutral,0.867326557636261
427,9/13/2019 12:24:57 AM,"Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/xCiyTfEAP1w/consumer-groups-unions-urge-caution-on-63-billion-abbvie-deal-for-allergan-idUSKCN1VX2VL,neutral,0.7894248366355896
428,9/16/2019 3:00:00 PM,AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's euro notes; stable outlook,Moodys,/news/bonds/abbvie-inc-moody-s-assigns-baa2-to-abbvie-s-euro-notes-stable-outlook-1028526925,negative,0.7783567309379578
429,9/26/2019 2:47:18 PM,Don’t Ignore the Johnson and Johnson Pharmaceutical Pipeline,InvestorPlace,/news/stocks/johnson-johnson-drug-pipeline-underappreciated-1028558195,positive,0.8949278593063354
430,9/27/2019 2:43:34 AM,AbbVie Receives FDA Approval Of MAVYRET ,RTTNews,/news/stocks/abbvie-receives-fda-approval-of-mavyret-1028557974,negative,0.7737035155296326
431,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645,positive,0.9301358461380005
432,9/27/2019 10:50:52 PM,"FTC requests AbbVie, Allergan for more information on $63 bln deal",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0XiM49J-LVs/ftc-requests-abbvie-allergan-for-more-information-on-63-bln-deal-idUSL3N26I482,positive,0.9333418011665344
433,9/27/2019 10:56:40 PM,"FTC requests AbbVie, Allergan for more information on $63 billion deal",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/BArIo2MhoiI/ftc-requests-abbvie-allergan-for-more-information-on-63-billion-deal-idINKBN1WC2E9,positive,0.9450604319572449
434,9/30/2019 3:56:05 AM,FTC Seeks Addl Information On AbbVie-Allergan $63 Bln Deal ,RTTNews,/news/stocks/ftc-seeks-addl-information-on-abbvie-allergan-63-bln-deal-1028561372,positive,0.9429983496665955
435,10/1/2019 11:15:40 AM,"3 Big Stock Charts for Tuesday: AbbVie, S&P Global and FleetCor Technologies",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-abbvie-sp-global-and-fleetcor-technologies-1028569364,positive,0.92848801612854
436,10/1/2019 3:08:33 PM,4 Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/4-healthcare-stocks-to-buy-now-1028569344,positive,0.8973767757415771
437,10/3/2019 3:56:03 PM,Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures?,InvestorPlace,/news/stocks/are-these-10-high-yielding-sp-500-stocks-traps-or-treasures-1028575945,positive,0.902236819267273
438,10/7/2019 6:51:22 PM,Why Johnson & Johnson Stock Is Not a Screaming Buy,InvestorPlace,/news/stocks/johnson-johnson-jnj-stock-not-screaming-buy-1028581887,positive,0.9226393103599548
439,10/11/2019 11:30:08 AM,"3 Big Stock Charts for Friday: AbbVie, Chubb and Applied Materials",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-abbvie-chubb-and-applied-materials-1028594612,positive,0.9332523941993713
440,10/14/2019 3:39:06 PM,Allergan Shareholders Oks Acquisition By AbbVie ,RTTNews,/news/stocks/allergan-shareholders-oks-acquisition-by-abbvie-1028596695,positive,0.939370334148407
441,10/24/2019 10:36:53 AM,"3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-cisco-systems-eli-lilly-colgate-palmolive-1028627304,positive,0.905576229095459
442,10/25/2019 4:27:00 PM,"Allergan Finance, LLC -- Moody's assigns Baa2 to AbbVie's exchange note offering",Moodys,/news/bonds/allergan-finance-llc-moody-s-assigns-baa2-to-abbvie-s-exchange-note-offering-1028631762,positive,0.8416592478752136
443,10/30/2019 5:13:03 PM,7 Buy-and-Hold Stocks to Play Investing’s Biggest Trends,InvestorPlace,/news/stocks/7-buy-and-hold-stocks-to-play-investings-biggest-trends-1028645322,positive,0.8700729012489319
444,10/31/2019 3:13:08 PM,3 Breakout Stocks to Buy for the Rest of 2019,InvestorPlace,/news/stocks/3-breakout-stocks-to-buy-for-the-rest-of-2019-1028649293,positive,0.910839319229126
445,11/1/2019 8:09:31 AM,Novartis: Cosentyx Shows Positive Results Vs Humira In Psoriatic Arthritis Trial ,RTTNews,/news/stocks/novartis-cosentyx-shows-positive-results-vs-humira-in-psoriatic-arthritis-trial-1028650514,negative,0.9547558426856995
446,11/1/2019 12:52:05 PM,AbbVie lifts 2019 profit forecast as Humira helps beat revenue estimates,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/IPEc6qejit0/abbvie-lifts-2019-profit-forecast-as-humira-helps-beat-revenue-estimates-idUSKBN1XB42P,negative,0.9428171515464783
447,11/1/2019 1:07:20 PM,AbbVie Boosts FY19 Adj. EPS Outlook; Boosts Dividend 10.2% - Quick Facts ,RTTNews,/news/stocks/abbvie-boosts-fy19-adj-eps-outlook-boosts-dividend-10-2-quick-facts-1028651236,negative,0.9469809532165527
448,11/1/2019 1:46:39 PM,UPDATE 1-AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SEiUYDReAtQ/update-1-abbvie-boosts-2019-profit-outlook-as-humira-helps-beat-revenue-estimates-idUSL3N27H2TX,negative,0.951400101184845
449,11/1/2019 1:51:58 PM,AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/WBBu7QIxWQ0/abbvie-boosts-2019-profit-outlook-as-humira-helps-beat-revenue-estimates-idUSKBN1XB42P,negative,0.9529246687889099
450,11/1/2019 3:00:02 PM,AbbVie says multiple parties vying for assets related to Allergan deal approval,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/O0_MJCOVrew/abbvie-says-multiple-parties-vying-for-assets-related-to-allergan-deal-approval-idUSL3N27H3AQ,positive,0.6752442717552185
451,11/1/2019 3:10:07 PM,AbbVie says multiple parties vying for assets related to Allergan deal approval,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/q8SyZKWWGRM/abbvie-says-multiple-parties-vying-for-assets-related-to-allergan-deal-approval-idUSKBN1XB4CD,positive,0.6752442717552185
452,11/1/2019 4:15:30 PM,UPDATE 2-AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/F5LSrd9NhNI/update-2-abbvie-2019-revenue-forecast-tops-wall-street-estimates-while-it-eyes-future-botox-sales-idUSL3N27H2TX,negative,0.9397816061973572
453,11/1/2019 4:16:56 PM,AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/S0Nci_ECh74/abbvie-2019-revenue-forecast-tops-wall-street-estimates-while-it-eyes-future-botox-sales-idUSKBN1XB42P,negative,0.9231184124946594
454,11/1/2019 7:09:43 PM,AbbVie Earnings: 5 Things for ABBV Stock Investors to Note,InvestorPlace,/news/stocks/abbvie-earnings-5-things-for-abbv-stock-investors-to-note-1028652565,positive,0.9040349125862122
455,11/1/2019 7:24:54 PM,"6 Top Stock Trades for Monday: BABA, PINS, CVX",InvestorPlace,/news/stocks/6-top-stock-trades-for-monday-baba-pins-cvx-1028652790,positive,0.9172887802124023
456,11/8/2019 1:45:20 PM,10 Medical Marijuana Stocks to Cure Your Portfolio,InvestorPlace,/news/stocks/10-medical-marijuana-stocks-to-cure-your-portfolio-1028440112,positive,0.8184427618980408
457,11/12/2019 6:50:33 PM,7 Biotech Stocks to Buy With Plenty of Power in the Pipeline,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-plenty-of-power-in-the-pipeline-1028682538,positive,0.8071872591972351
458,11/13/2019 7:34:42 PM,Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?,InvestorPlace,/news/stocks/should-investors-add-johnson-johnson-stock-to-their-shopping-lists-1028686949,positive,0.9315013289451599
459,11/13/2019 9:28:14 PM,Stock Market Today: General Electric Bears; Disney+ Bonanza,InvestorPlace,/news/stocks/stock-market-today-general-electric-bears-disney-bonanza-1028687253,positive,0.9298951029777527
460,11/14/2019 12:36:23 PM,"3 Big Stock Charts for Thursday: Gilead Sciences, DocuSign and Western Digital",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-gilead-sciences-docusign-and-western-digital-1028689209,positive,0.932224690914154
461,11/18/2019 1:00:58 PM,Pfizer: FDA Approves ABRILADA As Biosimilar To Humira - Quick Facts ,RTTNews,/news/stocks/pfizer-fda-approves-abrilada-as-biosimilar-to-humira-quick-facts-1028695939,negative,0.8298218846321106
462,11/26/2019 2:37:43 PM,5 Great Dividend Stocks for Young Investors,InvestorPlace,/news/stocks/5-great-dividend-stocks-for-young-investors-1028718817,positive,0.8430158495903015
463,12/11/2019 7:18:55 PM,Best ETFs for 2020: The AdvisorShares Vice ETF Is a Long-Term Winner,InvestorPlace,/news/stocks/best-etfs-for-2020-the-advisorshares-vice-etf-is-a-long-term-winner-1028756681,positive,0.7968711256980896
464,12/13/2019 4:44:51 PM,5 Cheap Dividend Stocks With High Yields And Annual Increases,InvestorPlace,/news/stocks/5-cheap-dividend-stocks-high-yields-1028762898,positive,0.6791468858718872
465,12/16/2019 1:10:58 PM,BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0nT_5KBHy-Q/beigene-drug-fails-main-goal-in-late-stage-study-against-abbvie-jj-rival-imbruvica-idUSL4N28Q2Y4,negative,0.4919700026512146
466,12/16/2019 1:44:03 PM,UPDATE 1-BeiGene drug fails comparative study against AbbVie-J&J rival Imbruvica,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lPd0YVNUq_0/update-1-beigene-drug-fails-comparative-study-against-abbvie-jj-rival-imbruvica-idUSL4N28Q2ZV,negative,0.9314455389976501
467,12/16/2019 3:53:33 PM,UPDATE 2-BeiGene cancer drug fails in study against AbbVie-J&J's Imbruvica,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FthVm1ooTpU/update-2-beigene-cancer-drug-fails-in-study-against-abbvie-jjs-imbruvica-idUSL4N28Q2ZV,negative,0.7471482157707214
468,12/17/2019 3:59:24 PM,5 Large-Cap Dividend Stocks to Buy,InvestorPlace,/news/stocks/5-large-cap-dividend-stocks-to-buy-1028769849,positive,0.8997653722763062
469,12/26/2019 9:17:26 PM,Stock Market Today: Amazon Breakout?; REIT Hate,InvestorPlace,/news/stocks/stock-market-today-amazon-breakout-reit-hate-1028785340,positive,0.938673734664917
470,12/30/2019 4:02:44 PM,5 Cheap High-Yield Dividend Stocks with Growing Dividends,InvestorPlace,/news/stocks/5-cheap-high-yield-dividend-stocks-1028788478,negative,0.590648889541626
471,12/30/2019 4:06:03 PM,7 High-Yield Dividend Stocks for Growth and Income in the 2020s,InvestorPlace,/news/stocks/7-dividend-stocks-growth-income-2020s-1028788477,positive,0.892297625541687
472,1/6/2020 3:12:34 PM,Is Amarin Stock a Top Pick for 2020?,InvestorPlace,/news/stocks/is-amarin-stock-a-top-pick-for-2020-1028796965,positive,0.8600980043411255
473,1/6/2020 5:18:24 PM,7 Investing Resolutions to Follow in 2020,InvestorPlace,/news/stocks/7-investing-resolutions-to-follow-in-2020-1028797249,positive,0.9337491393089294
474,1/8/2020 2:36:31 PM,AbbVie To Create New Global Business Upon Completion Of Allergan Acquisition ,RTTNews,/news/stocks/abbvie-to-create-new-global-business-upon-completion-of-allergan-acquisition-1028803035,negative,0.5130468010902405
475,1/10/2020 3:02:48 PM,EU clears AbbVie takeover of Allergan subject to conditions,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/usJWID8HtNk/eu-clears-abbvie-takeover-of-allergan-subject-to-conditions-idUSB5N27Y03C,positive,0.9378218054771423
476,1/10/2020 3:25:18 PM,7 High-Yield Dividend Stocks Set for Growth,InvestorPlace,/news/stocks/7-high-yield-dividend-stocks-growth-1028550794,positive,0.9129140973091125
477,1/10/2020 5:08:08 PM,7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-or-sell-as-pricing-pressures-mount-1028809866,neutral,0.7713858485221863
478,1/13/2020 3:06:56 PM,7 Great High-Yield Stocks With Payouts Over 5%,InvestorPlace,/news/stocks/great-high-yield-stocks-with-payouts-5-over-1028677919,positive,0.6121369004249573
479,1/14/2020 3:01:27 PM,AbbVie : Late-stage Plaque Psoriasis Study Meets Primary & Secondary Endpoints ,RTTNews,/news/stocks/abbvie-late-stage-plaque-psoriasis-study-meets-primary-secondary-endpoints-1028816076,positive,0.7796627283096313
480,1/14/2020 7:00:00 PM,AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.,Moodys,/news/bonds/abbvie-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-abbvie-inc-1028817181,positive,0.8537180423736572
481,1/14/2020 7:00:00 PM,"Allergan Finance, LLC -- Moody's announces completion of a periodic review of ratings of Allergan, Inc.",Moodys,/news/bonds/allergan-finance-llc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-allergan-inc-1028817178,positive,0.8196895718574524
482,1/16/2020 1:27:17 PM,"Beyond the Growing Dividend, Abbvie Stock Is a Good Buy Here",InvestorPlace,/news/stocks/growing-dividend-abbvie-stock-good-buy-1028823662,negative,0.8297058343887329
483,1/21/2020 2:22:04 PM,"Buffett Owns Teva Stock, But Should You?",InvestorPlace,/news/stocks/buffett-owns-teva-stock-but-should-you-1028832732,positive,0.9392610192298889
484,1/26/2020 8:11:00 PM,"China testing HIV drug as treatment for new coronavirus, AbbVie says",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TKU5TWTxfVQ/china-testing-hiv-drug-as-treatment-for-new-coronavirus-abbvie-says-idUSL1N29V04Y,negative,0.6661313772201538
485,1/27/2020 7:41:44 AM,"Allergan To Sell Brazikumab To AstraZeneca, Zenpep To Nestle Under AbbVie Merger ",RTTNews,/news/stocks/allergan-to-sell-brazikumab-to-astrazeneca-zenpep-to-nestle-under-abbvie-merger-1028845504,positive,0.9475051760673523
486,1/27/2020 10:20:24 AM,"AbbVie-Allergan $63 bln deal aided by Nestle, AstraZeneca buys",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/bVTNsqqjuTY/abbvie-allergan-63-bln-deal-aided-by-nestle-astrazeneca-buys-idUSL8N29W1H4,negative,0.8051882386207581
487,1/27/2020 10:32:37 AM,"AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/jFKRnTyANW0/abbvie-allergan-63-billion-deal-aided-by-nestle-astrazeneca-buys-idUSKBN1ZQ0RC,negative,0.7583162188529968
488,1/27/2020 9:26:45 PM,Stock Market Today: Beyond Meat Grows Partnerships; Coronavirus Cure?,InvestorPlace,/news/stocks/stock-market-today-beyond-meat-grows-partnerships-coronavirus-cure-1028848288,positive,0.8881845474243164
489,1/31/2020 1:19:03 PM,AbbVie Reports CHMP Positive Opinion For VENCLYXTO - Quick Facts ,RTTNews,/news/stocks/abbvie-reports-chmp-positive-opinion-for-venclyxto-quick-facts-1028863118,negative,0.9296148419380188
490,2/5/2020 3:12:55 PM,AbbVie: RINVOQ Meets Endpoints In Phase 3 Study In Psoriatic Arthritis ,RTTNews,/news/stocks/abbvie-rinvoq-meets-endpoints-in-phase-3-study-in-psoriatic-arthritis-1028877191,negative,0.7191965579986572
491,2/6/2020 3:02:20 PM,What Wall Street expects from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-stock-price-q4-earnings-preview-1028881434,positive,0.9298630356788635
492,2/6/2020 4:32:55 PM,5 Total Yield Dividend Stocks That Offer Attractive Returns,InvestorPlace,/news/stocks/high-total-yield-dividend-stocks-returns-1028882433,positive,0.5161064863204956
493,2/6/2020 4:49:53 PM,Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda,InvestorPlace,/news/stocks/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-1028882432,positive,0.7825398445129395
494,2/6/2020 10:30:20 PM,AbbVie Q4 2019 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3539307-abbvie-q4-2019-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6258180737495422
495,2/7/2020 12:46:50 PM,"AbbVie EPS beats by $0.02, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3539653-abbvie-eps-beats-0_02-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8099485039710999
496,2/7/2020 1:46:58 PM,AbbVie leans on new treatments to forecast upbeat 2020 profit,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/CaIs9Pru-eI/abbvie-leans-on-new-treatments-to-forecast-upbeat-2020-profit-idUSKBN2011KE,negative,0.7186408042907715
497,2/7/2020 1:50:52 PM,AbbVie Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q4-adjusted-earnings-beat-estimates-1028884723,negative,0.8978273868560791
498,2/7/2020 2:20:28 PM,AbbVie Issues FY20 Outlook - Quick Facts ,RTTNews,/news/stocks/abbvie-issues-fy20-outlook-quick-facts-1028884865,positive,0.925485372543335
499,2/7/2020 3:00:37 PM,UPDATE 1-AbbVie leans on new treatments to forecast upbeat 2020 profit,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sdW5-MnUsLA/update-1-abbvie-leans-on-new-treatments-to-forecast-upbeat-2020-profit-idUSL4N2A73MS,negative,0.9086217880249023
500,2/7/2020 4:11:57 PM,Stock Alert: AbbVie Ascends 5% ,RTTNews,/news/stocks/stock-alert-abbvie-ascends-5-1028885264,positive,0.5832945108413696
501,2/7/2020 5:11:04 PM,Gilead an acquisition target? Deep pockets required,Seeking Alpha,https://seekingalpha.com/news/3539763-gilead-acquisition-target-deep-pockets-required?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8995611071586609
502,2/7/2020 6:56:29 PM,AbbVie Earnings: ABBV Stock Jumps More Than 6% on Q4 Beats,InvestorPlace,/news/stocks/abbvie-earnings-boost-abbv-stock-up-1028885758,negative,0.9440661072731018
503,2/10/2020 7:32:42 PM,Allergan Earnings: AGN Stock Ticks Nearly 2% Higher on Q4 Beat,InvestorPlace,/news/stocks/allergan-earnings-bump-agn-stock-up-1028890658,negative,0.9474566578865051
504,2/13/2020 5:25:45 PM,Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation,InvestorPlace,/news/stocks/inovios-surge-on-a-coronavirus-vaccine-was-just-speculation-1028904499,positive,0.8955076336860657
505,2/18/2020 7:45:17 AM,30 Marijuana Stocks to Buy as the Future Turns Green,InvestorPlace,/news/stocks/30-marijuana-stocks-buy-future-turns-green-1028546644,positive,0.8506041765213013
506,2/18/2020 2:16:49 PM,"Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares",InvestorPlace,/news/stocks/moderna-stock-rebound-wait-for-dip-1028914534,negative,0.3802567422389984
507,2/18/2020 8:00:54 PM,30 Marijuana Stocks to Buy as the Future Turns Green,InvestorPlace,/news/stocks/marijuana-stocks-to-buy-future-turns-green-1028788743,positive,0.8506041765213013
508,2/18/2020 8:56:00 PM,"Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/6Jlc27hBkAU/consumer-groups-unions-oppose-fix-for-planned-merger-of-abbvie-and-allergan-idUSKBN20C2H1,neutral,0.8683287501335144
509,2/20/2020 6:14:57 PM,"CoolTone competitor sues Allergan over ""false"" advertising",Seeking Alpha,https://seekingalpha.com/news/3544066-cooltone-competitor-sues-allergan-over-false-advertising?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9340693950653076
510,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9021157026290894
511,2/27/2020 2:36:23 PM,Fighting The Deadly Coronavirus ,RTTNews,/news/stocks/fighting-the-deadly-coronavirus-1028945765,positive,0.888126015663147
512,2/29/2020 12:10:04 AM,AbbVie venetoclax combo trial misses endpoint,Seeking Alpha,https://seekingalpha.com/news/3547230-abbvie-venetoclax-combo-trial-misses-endpoint?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5454331636428833
513,3/5/2020 4:51:18 PM,3 Dividend Stocks to Ride out the Market Volatility,InvestorPlace,/news/stocks/3-dividend-stocks-ride-out-volatility-1028969488,positive,0.6735812425613403
514,3/6/2020 12:31:53 PM,EC OKs expanded 8-week regimen for AbbVie's hep C med Maviret,Seeking Alpha,https://seekingalpha.com/news/3549346-ec-oks-expanded-8-week-regimen-for-abbvies-hep-c-med-maviret?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8375020623207092
515,3/6/2020 1:32:58 PM,AbbVie : EU Approves Change To Marketing Authorization For Maviret ,RTTNews,/news/stocks/abbvie-eu-approves-change-to-marketing-authorization-for-maviret-1028971721,positive,0.629632830619812
516,3/6/2020 2:16:59 PM,Japan to test coronavirus drug despite risk of birth defects,Seeking Alpha,https://seekingalpha.com/news/3549396-japan-to-test-coronavirus-drug-despite-risk-of-birth-defects?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7806103825569153
517,3/6/2020 4:09:53 PM,Biotechs using AI to speed development of coronavirus drugs,Seeking Alpha,https://seekingalpha.com/news/3549446-biotechs-using-ai-to-speed-development-of-coronavirus-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8101133108139038
518,3/6/2020 6:19:57 PM,Pfizer Won’t Win the Coronavirus Pharma War,InvestorPlace,/news/stocks/pfizer-wont-win-the-coronavirus-pharma-war-1028973045,positive,0.8832708597183228
519,3/9/2020 1:03:31 PM,AbbVie HIV drug being investigated as potential treatment COVID-19,Seeking Alpha,https://seekingalpha.com/news/3549715-abbvie-hiv-drug-being-investigated-potential-treatment-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7641193270683289
520,3/9/2020 2:12:57 PM,AbbVie: Chinese Media Reports Claim HIV Medicine Effective In COVID-19 Treatment ,RTTNews,/news/stocks/abbvie-chinese-media-reports-claim-hiv-medicine-effective-in-covid-19-treatment-1028976515,negative,0.8314841389656067
521,3/10/2020 10:23:58 PM,Generic anti-malarial may treat COVID-19 - Raymond James,Seeking Alpha,https://seekingalpha.com/news/3550389-generic-anti-malarial-may-treat-covidminus-19-raymond-james?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7612016201019287
522,3/11/2020 10:10:04 AM,5 Biotech Stocks to Buy for a Strong Growth Prognosis,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-for-a-strong-growth-prognosis-1028378734,negative,0.5414467453956604
523,3/12/2020 1:03:50 PM,Roche : EC Oks Venclyxto-Gazyvaro For Adults With Chronic Lymphocytic Leukaemia ,RTTNews,/news/stocks/roche-ec-oks-venclyxto-gazyvaro-for-adults-with-chronic-lymphocytic-leukaemia-1028989286,positive,0.8606136441230774
524,3/12/2020 4:40:12 PM,First American may receive coronavirus vaccine soon - Fauci,Seeking Alpha,https://seekingalpha.com/news/3551121-first-american-may-receive-coronavirus-vaccine-soon-fauci?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8341766595840454
525,3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6742608547210693
526,3/16/2020 11:14:02 AM,U.S. stocks set to gap down at open,Seeking Alpha,https://seekingalpha.com/news/3551922-u-s-stocks-set-to-gap-down-open?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9542070627212524
527,3/16/2020 2:31:48 PM,7 Biotech Stocks to Buy and Hold in 2020,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-and-hold-in-2020-1028769847,positive,0.8950077891349792
528,3/17/2020 8:46:04 PM,AbbVie and Allergan ink agreement with FTC over divestment of certain assets,Seeking Alpha,https://seekingalpha.com/news/3552708-abbvie-and-allergan-ink-agreement-ftc-over-divestment-of-certain-assets?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8693247437477112
529,3/19/2020 3:40:53 PM,CORRECTED-Israel OKs use of generic AbbVie drug to treat coronavirus despite patent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/tdCR9R_Cil4/corrected-israel-oks-use-of-generic-abbvie-drug-to-treat-coronavirus-despite-patent-idUSL8N2BC5D6,negative,0.7504618167877197
530,3/19/2020 4:07:01 PM,UPDATE 1-Israel OKs use of generic AbbVie drug to treat coronavirus despite patent,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lezxwRo4mjA/update-1-israel-oks-use-of-generic-abbvie-drug-to-treat-coronavirus-despite-patent-idUSL8N2BC70E,negative,0.8212823867797852
531,3/19/2020 5:00:38 PM,Profit-taking pressures Moderna after Hahn comments on vaccine timeline,Seeking Alpha,https://seekingalpha.com/news/3553448-profit-taking-pressures-moderna-after-hahn-comments-on-vaccine-timeline?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9628137350082397
532,3/19/2020 5:29:02 PM,Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play,InvestorPlace,/news/stocks/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-1029014502,positive,0.8325722813606262
533,3/23/2020 10:58:56 AM,SocGen cuts view on AbbVie in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3554092-socgen-cuts-view-on-abbvie-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6225669980049133
534,3/23/2020 12:32:16 PM,AbbVie extends debt exchange offer to April 10,Seeking Alpha,https://seekingalpha.com/news/3554159-abbvie-extends-debt-exchange-offer-to-april-10?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8446556329727173
535,3/23/2020 12:47:19 PM,Roche and AbbVie's Venclexta extends survival in first-line AML,Seeking Alpha,https://seekingalpha.com/news/3554169-roche-and-abbvies-venclexta-extends-survival-in-first-line-aml?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.950039803981781
536,3/23/2020 1:33:34 PM,Genentech's Late-stage Study On Aggressive Leukemia Meets Primary Endpoints ,RTTNews,/news/stocks/genentech-s-late-stage-study-on-aggressive-leukemia-meets-primary-endpoints-1029022518,positive,0.8311663866043091
537,3/23/2020 6:45:10 PM,MEDIA-AbbVie drops patent rights for Kaletra antiviral treatment - FT,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/r2YOhJyqWJs/media-abbvie-drops-patent-rights-for-kaletra-antiviral-treatment-ft-idUSL4N2BG4UW,neutral,0.8660893440246582
538,3/24/2020 4:11:12 PM,AbbVie combo HIV med comes up short in Covid-19 study - Raymond James,Seeking Alpha,https://seekingalpha.com/news/3554732-abbvie-combo-hiv-med-comes-up-short-in-covidminus-19-study-raymond-james?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7071208953857422
539,3/24/2020 5:55:21 PM,Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet,InvestorPlace,/news/stocks/ibio-stock-could-be-worth-speculation-on-a-covid-19-vaccine-1029028361,negative,0.7425907850265503
540,3/25/2020 6:19:39 PM,Mylan waives exclusive U.S. rights to generic Kaletra; shares down 4%,Seeking Alpha,https://seekingalpha.com/news/3555159-mylan-waives-exclusive-u-s-rights-to-generic-kaletra-shares-down-4?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9625958800315857
541,3/27/2020 4:59:14 PM,The Easy Gains May Be Over for American Airlines Stock,InvestorPlace,/news/stocks/easy-gains-over-american-airlines-aal-stock-1029040380,negative,0.47719842195510864
542,4/5/2020 2:40:44 PM,Malaria drugs in high demand amid COVID-19,Seeking Alpha,https://seekingalpha.com/news/3558453-malaria-drugs-in-high-demand-amid-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.937008798122406
543,4/5/2020 6:55:44 PM,Incyte details late-stage data on ruxolitinib cream for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3558456-incyte-details-late-stage-data-on-ruxolitinib-cream-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8612488508224487
544,4/6/2020 9:16:17 AM,New Drugs Approved In The Month Of March ,RTTNews,/news/stocks/new-drugs-approved-in-the-month-of-march-1029066601,positive,0.5216236710548401
545,4/8/2020 2:03:52 PM,Ignore the Coronavirus Catalyst for ABBV Stock,InvestorPlace,/news/stocks/ignore-the-coronavirus-catalyst-for-abbv-stock-1029076383,positive,0.9230981469154358
546,4/20/2020 7:41:51 PM,Buy AbbVie Stock as the Drugmaker Diversifies Its Pipeline,InvestorPlace,/news/stocks/buy-abbvie-stock-as-the-drugmaker-diversifies-its-pipeline-1029108964,positive,0.8432252407073975
547,4/21/2020 7:56:51 PM,FDA OK new use of AbbVie's Imbruvica,Seeking Alpha,https://seekingalpha.com/news/3562765-fda-ok-new-use-of-abbvies-imbruvica?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6404172778129578
548,4/27/2020 9:55:33 AM,Dr. Reddy's Labs Launches Fenofibrate Tablets In U.S. ,RTTNews,/news/stocks/dr-reddy-s-labs-launches-fenofibrate-tablets-in-u-s-1029131633,positive,0.6226420402526855
549,4/27/2020 11:20:31 AM,Why You Can Buy AbbVie At a Massive Discount,InvestorPlace,/news/stocks/why-you-can-buy-abbvie-at-a-massive-discount-1029132501,positive,0.9177271723747253
550,4/27/2020 4:41:36 PM,Harpoon Therapeutics up 9% on launch of HPN217 study in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3564719-harpoon-therapeutics-up-9-on-launch-of-hpn217-study-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9491780996322632
551,4/28/2020 9:01:07 AM,The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors,InvestorPlace,/news/stocks/the-abbvie-buyout-is-not-a-sure-thing-for-allergan-stock-investors-1029137151,positive,0.9339045286178589
552,4/28/2020 6:26:24 PM,Buy Allergan Stock as Big Pharma’s Biggest Deal Is About to Close,InvestorPlace,/news/stocks/buy-allergan-stock-as-big-pharmas-biggest-deal-is-about-to-close-1029140376,positive,0.861431360244751
553,5/1/2020 11:45:42 AM,"AbbVie EPS beats by $0.17, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3567580-abbvie-eps-beats-0_17-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7753464579582214
554,5/1/2020 12:11:54 PM,AbbVie Q1 Humira sales up 6%; non-GAAP EPS guidance maintained,Seeking Alpha,https://seekingalpha.com/news/3567605-abbvie-q1-humira-sales-up-6-non-gaap-eps-guidance-maintained?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9540458917617798
555,5/1/2020 1:45:25 PM,Abbvie quarterly sales beat as Humira shines; maintains forecast,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/6w2pAVhBa4U/abbvie-quarterly-sales-beat-as-humira-shines-maintains-forecast-idUSL4N2CJ1PU,negative,0.9373332858085632
556,5/1/2020 1:53:21 PM,AbbVie Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q1-adjusted-earnings-beat-estimates-1029154918,negative,0.8994625210762024
557,5/1/2020 1:54:59 PM,AbbVie Confirms Standalone 2020 Adj. EPS Guidance - Quick Facts ,RTTNews,/news/stocks/abbvie-confirms-standalone-2020-adj-eps-guidance-quick-facts-1029154917,positive,0.8998158574104309
558,5/1/2020 2:52:13 PM,UPDATE 1-Abbvie stands by 2020 profit forecast as Humira fuels quarterly beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/LMAhVTgYjTQ/update-1-abbvie-stands-by-2020-profit-forecast-as-humira-fuels-quarterly-beat-idUSL4N2CJ20X,negative,0.8462029695510864
559,5/1/2020 5:37:39 PM,"UPDATE 2-AbbVie sees substantial hit to Botox from pandemic, lowers Humira growth forecast",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/A-NdKiGlPKc/update-2-abbvie-sees-substantial-hit-to-botox-from-pandemic-lowers-humira-growth-forecast-idUSL4N2CJ20X,neutral,0.7290453910827637
560,5/1/2020 7:59:43 PM,AbbVie Earnings: 5 Things for ABBV Stock Investors to Know About Q1,InvestorPlace,/news/stocks/abbvie-earnings-q1-highlights-1029156093,positive,0.9357532858848572
561,5/5/2020 9:50:25 PM,"5 Top Stock Trades for Wednesday: ATVI, SHOP, CHGG, ABT, ABBV",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-atvi-shop-chgg-abt-abbv-1029168272,positive,0.934794008731842
562,5/5/2020 11:10:56 PM,AbbVie deal for Allergan wins antitrust approval,Seeking Alpha,https://seekingalpha.com/news/3569732-abbvie-deal-for-allergan-wins-antitrust-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8192980885505676
563,5/6/2020 12:13:02 AM,AbbVie wins U.S. antitrust approval to buy Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SgVJfGQevew/abbvie-wins-u-s-antitrust-approval-to-buy-allergan-idUSASA00NVC,negative,0.6911098957061768
564,5/6/2020 12:48:03 AM,UPDATE 1-AbbVie wins U.S. antitrust approval to buy Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sImsNd11cIQ/update-1-abbvie-wins-u-s-antitrust-approval-to-buy-allergan-idUSL1N2CN2KP,negative,0.8902837634086609
565,5/6/2020 2:39:36 AM,UPDATE 2-AbbVie wins U.S. antitrust approval to buy Allergan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/jKunWSJLkE0/update-2-abbvie-wins-u-s-antitrust-approval-to-buy-allergan-idUSL1N2CN2KP,negative,0.8857348561286926
566,5/6/2020 4:34:28 AM,AbbVie wins U.S. antitrust approval to buy Allergan,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/K9V0r7PLCQQ/abbvie-wins-u-s-antitrust-approval-to-buy-allergan-idINKBN22I06G,negative,0.6911098957061768
567,5/6/2020 8:25:22 PM,Stock Market Today: Disney Halts Dividend; Worst ADP Report Ever,InvestorPlace,/news/stocks/stock-market-today-disney-halts-dividend-worst-adp-report-ever-1029173123,neutral,0.9633510112762451
568,5/7/2020 3:23:50 AM,Salesforce.com To Replace Allergan In S&P100 ,RTTNews,/news/stocks/salesforce-com-to-replace-allergan-in-s-p100-1029173329,positive,0.9322589039802551
569,5/8/2020 8:23:06 PM,AbbVie finalizes Allergan takeover,Seeking Alpha,https://seekingalpha.com/news/3572333-abbvie-finalizes-allergan-takeover?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9486947059631348
570,5/11/2020 4:20:03 PM,5 Healthcare Stocks That Are Profitable but Also Cheap,InvestorPlace,/news/stocks/5-healthcare-stocks-low-pe-ratios-ample-yields-1029188693,positive,0.8779802918434143
571,5/12/2020 10:56:55 PM,A now-bigger drugmaker becomes a top idea at JPMorgan,Seeking Alpha,https://seekingalpha.com/news/3573697-now-bigger-drugmaker-becomes-top-idea-jpmorgan?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5342851281166077
572,5/13/2020 12:29:00 PM,It’s Time to Buy AbbVie Stock Now After Its Allergan Purchase,InvestorPlace,/news/stocks/its-time-to-buy-abbvie-now-after-its-agn-stock-purchase-1029197990,positive,0.9100152850151062
573,5/13/2020 10:22:19 PM,"CytomX Therapeutics announces presentations at ASCO20 virtual scientific program, shares down 23%",Seeking Alpha,https://seekingalpha.com/news/3574233-cytomx-therapeutics-announces-presentations-asco20-virtual-scientific-program-shares-down-23?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.949080765247345
574,5/19/2020 12:07:33 PM,AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions,InvestorPlace,/news/stocks/whole-of-abbv-stock-more-than-sum-of-parts-1029214731,positive,0.9493720531463623
575,5/19/2020 12:26:18 PM,"Bitcoin the Best Cryptocurrency, but There Are Safer Blockchain Buys",InvestorPlace,/news/stocks/bitcoin-best-cryptocurrency-safer-blockchain-buys-1029215783,positive,0.9062784910202026
576,5/22/2020 3:32:23 PM,Evolus up 31% on no news,Seeking Alpha,https://seekingalpha.com/news/3577208-evolus-up-31-on-no-news?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9455456733703613
577,5/22/2020 6:09:00 PM,"Allergan Finance, LLC -- Moody's withdraws Allergan's ratings",Moodys,/news/bonds/allergan-finance-llc-moody-s-withdraws-allergan-s-ratings-1029227517,neutral,0.7598946690559387
578,5/27/2020 2:20:38 PM,"Ironwood, AbbVie To Discontinue Development Of MD-7246 - Quick Facts ",RTTNews,/news/stocks/ironwood-abbvie-to-discontinue-development-of-md-7246-quick-facts-1029237519,positive,0.7080824971199036
579,5/27/2020 2:35:44 PM,The 3 Best Stocks for Beginning Investors,InvestorPlace,/news/stocks/the-3-best-stocks-for-beginning-investors-1029238780,positive,0.8245431780815125
580,5/29/2020 4:45:50 PM,FDA OKs AbbVie med for women with fibroid-related issues,Seeking Alpha,https://seekingalpha.com/news/3578726-fda-oks-abbvie-med-for-women-fibroid-related-issues?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7764371037483215
581,5/30/2020 6:14:08 AM,FDA Oks AbbVie's Oriahnn To Treat Heavy Menstrual Bleeding Associated With Fibroids In Women ,RTTNews,/news/stocks/fda-oks-abbvie-s-oriahnn-to-treat-heavy-menstrual-bleeding-associated-with-fibroids-in-women-1029265084,negative,0.6757547855377197
582,6/2/2020 2:59:21 PM,AbbVie Stock Is a Winner in the Pharmaceutical Industry,InvestorPlace,/news/stocks/abbvie-stock-is-a-winner-in-the-pharmaceutical-industry-1029273603,negative,0.9098109602928162
583,6/2/2020 6:36:53 PM,AbbVie Stock Is More Than a Great Dividend Payer,InvestorPlace,/news/stocks/abbv-stock-1029274240,positive,0.8016200661659241
584,6/2/2020 6:43:52 PM,AbbVie Will Be in Big Trouble When Its Patent Cliff Arrives,InvestorPlace,/news/stocks/abbvie-will-be-in-big-trouble-when-its-patent-cliff-arrives-1029274239,neutral,0.9463762640953064
585,6/3/2020 9:16:46 AM,Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk,InvestorPlace,/news/stocks/abbv-stock-an-oil-yield-without-oil-1029275806,positive,0.8119696378707886
586,6/5/2020 10:13:22 AM,AbbVie to develop antibody therapy for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3580690-abbvie-to-develop-antibody-therapy-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6798668503761292
587,6/5/2020 12:48:45 PM,Abbvie strikes partnership to develop COVID-19 antibody therapy,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sUkFNb7Pvp0/abbvie-strikes-partnership-to-develop-covid-19-antibody-therapy-idUSL4N2DI2IT,negative,0.5857399106025696
588,6/6/2020 3:10:22 PM,AbbVie's Rinvoq tops Bristol-Myers' Orencia in rheumatoid arthritis study,Seeking Alpha,https://seekingalpha.com/news/3580955-abbvies-rinvoq-tops-bristol-myers-orencia-in-rheumatoid-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5877073407173157
589,6/10/2020 12:18:31 PM,AbbVie Signs Broad Collaboration Agreement With Denmark's Genmab - Quick Facts ,RTTNews,/news/stocks/abbvie-signs-broad-collaboration-agreement-with-denmark-s-genmab-quick-facts-1029295965,negative,0.9382345676422119
590,6/10/2020 12:21:25 PM,Abbvie partners with Genmab in $750 mln cancer therapy deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3t1rlXi4IA4/abbvie-partners-with-genmab-in-750-mln-cancer-therapy-deal-idUSL4N2DN2F2,negative,0.6429766416549683
591,6/10/2020 12:43:43 PM,UPDATE 1-Abbvie partners with Genmab in $750 mln cancer therapy deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AwJKsHZWcLw/update-1-abbvie-partners-with-genmab-in-750-mln-cancer-therapy-deal-idUSL4N2DN2HW,negative,0.8585332036018372
592,6/10/2020 1:38:20 PM,Abbvie partners with Genmab in $750 million cancer therapy deal,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/uHtMd4IIBTw/abbvie-partners-with-genmab-in-750-million-cancer-therapy-deal-idINKBN23H1QC,negative,0.5759232044219971
593,6/10/2020 2:06:01 PM,UPDATE 2-Abbvie to partner with Genmab in $750 mln cancer therapy deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/jIJgYQEsgfI/update-2-abbvie-to-partner-with-genmab-in-750-mln-cancer-therapy-deal-idUSL4N2DN2HW,negative,0.9039442539215088
594,6/10/2020 4:29:34 PM,UPDATE 3-Abbvie to partner with Denmark's Genmab in $750 mln cancer therapy deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SroEcgNAktQ/update-3-abbvie-to-partner-with-denmarks-genmab-in-750-mln-cancer-therapy-deal-idUSL4N2DN2HW,negative,0.9125633239746094
595,6/12/2020 7:19:47 PM,AbbVie reports additional data from successful study of Skyrizi in psoriasis,Seeking Alpha,https://seekingalpha.com/news/3582753-abbvie-reports-additional-data-from-successful-study-of-skyrizi-in-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7021007537841797
596,6/12/2020 8:52:10 PM,AbbVie thumbs down on discounted mini-tender for shares,Seeking Alpha,https://seekingalpha.com/news/3582793-abbvie-thumbs-down-on-discounted-mini-tender-for-shares?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9151603579521179
597,6/13/2020 2:06:38 PM,Roche/AbbVie's Venclexta extends survival in AML study,Seeking Alpha,https://seekingalpha.com/news/3582827-roche-abbvies-venclexta-extends-survival-in-aml-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9482188820838928
598,6/15/2020 9:34:01 PM,New kid on the block in race for NASH drug,Seeking Alpha,https://seekingalpha.com/news/3583247-new-kid-on-block-in-race-for-nash-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8193024396896362
599,6/17/2020 2:37:20 PM,AbbVie declares $1.18 dividend,Seeking Alpha,https://seekingalpha.com/news/3583833-abbvie-declares-1_18-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9288312792778015
600,6/18/2020 2:25:01 PM,"Alpine Immune, AbbVie Enter Into Option And License Deal For ALPN-101 ",RTTNews,/news/stocks/alpine-immune-abbvie-enter-into-option-and-license-deal-for-alpn-101-1029321685,negative,0.8115425109863281
601,6/18/2020 3:46:13 PM,AbbVie's Rinvoq Shows Improvement In Skin Clearance And Itch In Phase 3 Study For Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-s-rinvoq-shows-improvement-in-skin-clearance-and-itch-in-phase-3-study-for-atopic-dermatitis-1029322283,negative,0.9493337273597717
602,6/18/2020 4:04:07 PM,Stock Alert: Alpine Immune Jumps 100% After Inking Deal With AbbVie ,RTTNews,/news/stocks/stock-alert-alpine-immune-jumps-100-after-inking-deal-with-abbvie-1029322332,negative,0.9402747750282288
603,6/18/2020 8:14:11 PM,AbbVie nixes microbiome GI program collaboration with Assembly Biosciences,Seeking Alpha,https://seekingalpha.com/news/3584322-abbvie-nixes-microbiome-gi-program-collaboration-assembly-biosciences?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8181329369544983
604,6/19/2020 7:52:36 AM,"FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars ",RTTNews,/news/stocks/fda-nod-for-epzm-rare-court-rules-in-myl-s-favor-ocuphire-to-hop-onto-nasdaq-alpn-soars-1029324381,negative,0.8128530979156494
605,6/22/2020 2:24:29 PM,Allergan Files SBLA To Extend Use Of BOTOX For Patients 5 To 17 Years Old ,RTTNews,/news/stocks/allergan-files-sbla-to-extend-use-of-botox-for-patients-5-to-17-years-old-1029329268,positive,0.7659221887588501
606,6/23/2020 1:58:46 PM,AbbVie Says FDA To Review SNDA For IMBRUVICA In Combination With Rituximab - Quick Facts ,RTTNews,/news/stocks/abbvie-says-fda-to-review-snda-for-imbruvica-in-combination-with-rituximab-quick-facts-1029333238,positive,0.7209600210189819
607,6/26/2020 7:28:57 AM,AbbVie: FDA Issues Complete Response Letter To BLA For Abicipar Pegol ,RTTNews,/news/stocks/abbvie-fda-issues-complete-response-letter-to-bla-for-abicipar-pegol-1029344620,positive,0.8075204491615295
608,7/1/2020 3:09:05 PM,Best ETFs for 2020: The AdvisorShares Vice ETF Bets Big on Booze,InvestorPlace,/news/stocks/best-etfs-for-2020-the-advisorshares-vice-etf-bets-big-on-booze-1029360049,positive,0.5211629867553711
609,7/2/2020 4:32:50 PM,AbbVie Is Cheap and Pays an Attractive Yield,InvestorPlace,/news/stocks/abbvie-stock-cheap-attractive-yield-target-value-1029363918,positive,0.6760624647140503
610,7/2/2020 5:02:06 PM,"Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO",InvestorPlace,/news/stocks/keep-eye-rprx-stock-2020-1029363917,positive,0.9034902453422546
611,7/6/2020 10:40:08 AM,Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years,InvestorPlace,/news/stocks/rprx-stock-is-likely-to-reach-new-highs-coming-years-1029368649,negative,0.9159573912620544
612,7/7/2020 5:37:26 PM,AbbVie Stands to Benefit from Affluenza,InvestorPlace,/news/stocks/abbvie-stands-to-benefit-from-affluenza-1029373959,negative,0.8936930894851685
613,7/7/2020 8:46:54 PM,"4 Top Stock Trades for Wednesday: LVGO, WMT, ABBV, NVAX",InvestorPlace,/news/stocks/4-top-stock-trades-for-wednesday-lvgo-wmt-abbv-nvax-1029374390,positive,0.935929000377655
614,7/8/2020 1:01:40 PM,AbbVie Remains One of the Safest Pharma Investments You Can Make,InvestorPlace,/news/stocks/abbvie-stock-remains-one-of-the-safest-pharma-investments-you-can-make-1029377128,positive,0.7755791544914246
615,7/10/2020 3:07:26 AM,AbbVie : FDA Oks Expanded BOTOX Label For Treatment Of Pediatric Patients With Spasticity ,RTTNews,/news/stocks/abbvie-fda-oks-expanded-botox-label-for-treatment-of-pediatric-patients-with-spasticity-1029382443,negative,0.8640085458755493
616,7/10/2020 8:18:52 AM,"Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here ",RTTNews,/news/stocks/botox-keytruda-get-fda-approval-for-new-uses-bvxv-abuzz-first-droopy-eyelid-treatment-is-here-1029382741,positive,0.509865939617157
617,7/14/2020 3:37:23 PM,The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase,InvestorPlace,/news/stocks/the-7-best-pharmaceutical-stocks-that-go-beyond-the-covid-19-chase-1029393527,positive,0.8562304377555847
618,7/15/2020 11:36:51 AM,Novavax Stock Has Probably Topped Out Until Successful Clinical Trials,InvestorPlace,/news/stocks/nvax-stock-topped-out-clinical-trials-1029397795,negative,0.8751546740531921
619,7/21/2020 2:56:05 PM,Gilead To Acquire 49.9% Equity Interest In Tizona - Quick Facts ,RTTNews,/news/stocks/gilead-to-acquire-49-9-equity-interest-in-tizona-quick-facts-1029414716,positive,0.9359233379364014
620,7/21/2020 3:02:03 PM,AbbVie: RINVOQ Meets Endpoints In Second Phase 3 Study For Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-rinvoq-meets-endpoints-in-second-phase-3-study-for-atopic-dermatitis-1029414787,positive,0.6836020946502686
621,7/23/2020 6:33:09 PM,The 8 Most Reliable Blue-Chip Stocks In the Market Today,InvestorPlace,/news/stocks/the-8-most-reliable-blue-chip-stocks-in-the-market-today-1029426636,positive,0.6566005349159241
622,7/24/2020 6:06:35 PM,5 High-Yield Drug Stocks That Are Undervalued With Great Upside,InvestorPlace,/news/stocks/high-yield-drug-stocks-undervalued-cheap-huge-upside-1029429574,negative,0.55074143409729
623,7/29/2020 3:20:35 PM,AbbVie Announces Positive Late-stage Data For Atogepant In Migraine Prevention ,RTTNews,/news/stocks/abbvie-announces-positive-late-stage-data-for-atogepant-in-migraine-prevention-1029446060,negative,0.9398530721664429
624,7/30/2020 3:02:56 PM,Here's what to expect from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-quarter-earnings-preview-q2-1029451203,positive,0.9412732124328613
625,7/31/2020 1:53:23 PM,AbbVie Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q2-adjusted-earnings-beat-estimates-1029455120,negative,0.8946022391319275
626,7/31/2020 2:08:48 PM,AbbVie Issues Combined Company 2020 Earnings Guidance - Quick Facts ,RTTNews,/news/stocks/abbvie-issues-combined-company-2020-earnings-guidance-quick-facts-1029455182,positive,0.9239885807037354
627,7/31/2020 3:10:07 PM,AbbVie Earnings: ABBV Stock Drops 2% Despite Q2 Beats,InvestorPlace,/news/stocks/abbvie-earnings-abbv-stock-drops-2-despite-q2-beats-1029456371,neutral,0.9731865525245667
628,8/3/2020 2:04:59 PM,"AbbVie, Amgen, Takeda Pharma Enroll First Patients In I-SPY COVID Trial ",RTTNews,/news/stocks/abbvie-amgen-takeda-pharma-enroll-first-patients-in-i-spy-covid-trial-1029461249,positive,0.8758940100669861
629,8/4/2020 9:31:42 AM,"ALRN To Report Data In Q4, IMUC Hits New High, VYGR Pulls Out Of ABBV Deal, VNDA To Face FDA In Dec. ",RTTNews,/news/stocks/alrn-to-report-data-in-q4-imuc-hits-new-high-vygr-pulls-out-of-abbv-deal-vnda-to-face-fda-in-dec-1029465250,neutral,0.7175808548927307
630,8/4/2020 4:44:42 PM,Keytruda Powers a Stellar Q2 for Merck,InvestorPlace,/news/stocks/keytruda-powers-a-stellar-second-quarter-for-mrk-stock-1029468691,negative,0.877044141292572
631,8/5/2020 1:59:32 PM,Novavax Stock Needs Solid Results Beyond Headlines,InvestorPlace,/news/stocks/nvax-stock-needs-solid-results-beyond-headlines-1029473742,negative,0.9414753913879395
632,8/24/2020 12:13:32 PM,10 Growth Stocks That Could Seriously Double,InvestorPlace,/news/stocks/10-growth-stocks-that-could-seriously-double-1029528153,neutral,0.8835014700889587
633,8/24/2020 6:47:14 PM,The 4 Best Dividend Aristocrats to Buy Now,InvestorPlace,/news/stocks/4-best-dividend-aristocrats-to-buy-now-abt-rost-pep-vfc-1029529077,positive,0.8545804619789124
634,8/25/2020 11:30:20 AM,7 Hot Stocks to Buy Before It’s Too Late,InvestorPlace,/news/stocks/7-hot-stocks-to-buy-before-its-too-late-1029531264,positive,0.8980832695960999
635,8/25/2020 3:35:40 PM,6 Marijuana Stocks to Buy That Are Sticking In the Green,InvestorPlace,/news/stocks/6-marijuana-stocks-to-buy-that-are-sticking-in-the-green-1029532746,positive,0.8569176197052002
636,8/26/2020 9:30:05 PM,30 Dividend Stocks to Buy Now for 20 Years of Income Growth,InvestorPlace,/news/stocks/30-dividend-stocks-to-buy-for-20-years-of-income-growth-1029537832,positive,0.8688682317733765
637,8/27/2020 2:37:25 PM,UroGen Pharma: Phase 2 APOLLO Clinical Trial Did Not Meet Primary Endpoint ,RTTNews,/news/stocks/urogen-pharma-phase-2-apollo-clinical-trial-did-not-meet-primary-endpoint-1029539914,neutral,0.8436765670776367
638,9/4/2020 1:14:20 PM,AbbVie To License I-Mab's Anti-CD47 Monoclonal Antibody Lemzoparlimab ,RTTNews,/news/stocks/abbvie-to-license-i-mab-s-anti-cd47-monoclonal-antibody-lemzoparlimab-1029563086,negative,0.5749850869178772
639,9/4/2020 6:09:53 PM,Biopharma News: IMAB Stock Soars 4% on AbbVie Pact,InvestorPlace,/news/stocks/biopharma-news-boosts-imab-stock-on-abbv-deal-1029564279,negative,0.7839264273643494
640,9/5/2020 7:33:19 PM,Graybug Vision readies IPO,Seeking Alpha,https://seekingalpha.com/news/3611911-graybug-vision-readies-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9485812783241272
641,9/15/2020 5:24:16 PM,Great Yield and Packed Pipeline Signal a Buy for AbbVie,InvestorPlace,/news/stocks/great-yield-and-packed-pipeline-signal-a-buy-for-abbvie-stock-1029591781,negative,0.9228698015213013
642,9/17/2020 2:51:41 PM,6 Dividend Stocks To Buy For Stable Yield And Growth Potential,InvestorPlace,/news/stocks/6-dividend-stocks-to-buy-for-stable-yield-and-growth-potential-1029599920,positive,0.6477497220039368
643,9/21/2020 1:28:48 PM,7 Cheap Stocks to Buy Under $10,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-under-10-1029607465,positive,0.8324239253997803
644,9/21/2020 4:24:17 PM,7 Undervalued Stocks With Massive Potential,InvestorPlace,/news/stocks/7-undervalued-stocks-to-buy-massive-potential-1029608347,neutral,0.7337618470191956
645,9/25/2020 6:19:26 PM,7 Sin Stocks To Buy That Will Outperform the S&P 500,InvestorPlace,/news/stocks/7-sin-stocks-to-buy-that-will-outperform-the-sp-500-1029624209,negative,0.9204394221305847
646,9/28/2020 2:12:48 PM,AbbVie: FDA Grants Orphan Drug & Fast Track Designations For Elezanumab ,RTTNews,/news/stocks/abbvie-fda-grants-orphan-drug-fast-track-designations-for-elezanumab-1029626640,negative,0.7440634965896606
647,10/1/2020 12:23:03 PM,"AbbVie: New Brunswick, British Columbia List SKYRIZI On Its Provincial Formulary ",RTTNews,/news/stocks/abbvie-new-brunswick-british-columbia-list-skyrizi-on-its-provincial-formulary-1029639075,positive,0.9505529403686523
648,10/1/2020 1:19:34 PM,7 Dividend Stocks Perfect for a Retiree’s Portfolio,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-perfect-for-a-retirees-portfolio-1029640681,positive,0.9082668423652649
649,10/1/2020 6:43:07 PM,Best ETFs for 2020: The AdvisorShares Vice ETF Saved by SAM and TMO,InvestorPlace,/news/stocks/best-etfs-for-2020-the-advisorshares-vice-etf-sam-1029642036,positive,0.6936799883842468
650,10/6/2020 2:44:51 PM,The 7 Best New Stocks From 2020 to Buy Now,InvestorPlace,/news/stocks/the-7-best-new-stocks-from-2020-to-buy-now-1029653691,positive,0.8444294929504395
651,10/7/2020 2:22:01 PM,Allergan Aesthetics To Acquire Luminera's Dermal Filler Business - Quick Facts ,RTTNews,/news/stocks/allergan-aesthetics-to-acquire-luminera-s-dermal-filler-business-quick-facts-1029656921,positive,0.8457388281822205
652,10/8/2020 2:14:51 AM,"Regenerative medicine company Aziyo Biologics prices $50M IPO, trades Thursday",Seeking Alpha,https://seekingalpha.com/news/3620652-regenerative-medicine-company-aziyo-biologics-prices-50m-ipo-trades-thursday?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9218683838844299
653,10/15/2020 1:04:48 PM,7 Value Stocks To Buy in an Overvalued Market,InvestorPlace,/news/stocks/7-value-stocks-to-buy-in-overvalued-market-1029684752,positive,0.857827365398407
654,10/16/2020 9:16:53 AM,5 High-Yield Stocks for 5%-Plus Dividend Payouts,InvestorPlace,/news/stocks/5-high-yield-stocks-abbv-enb-pm-unm-ibm-for-5-plus-dividend-payouts-1029687693,positive,0.9269535541534424
655,10/16/2020 11:02:00 PM,JPM picks big pharma names to benefit with busy catalyst calendar ahead,Seeking Alpha,https://seekingalpha.com/news/3623038-jpm-picks-big-pharma-names-to-benefit-busy-catalyst-calendar-ahead?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6425066590309143
656,10/19/2020 7:25:21 AM,Roche: FDA Approves Venclexta Combinations For Treatment Of Acute Myeloid Leukaemia ,RTTNews,/news/stocks/roche-fda-approves-venclexta-combinations-for-treatment-of-acute-myeloid-leukaemia-1029691950,negative,0.8790503740310669
657,10/19/2020 9:51:58 AM,VENCLEXTA receives FDA full approval for acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3623102-venclexta-receives-fda-full-approval-for-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9151199460029602
658,10/19/2020 10:36:18 AM,FDA fully approves Roche's venetoclax for first-line acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3623116-fda-fully-approves-roches-venetoclax-for-first-line-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7995211482048035
659,10/19/2020 3:48:04 PM,AbbVie files applications for Rinvoq for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3623305-abbvie-files-applications-for-rinvoq-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8851150274276733
660,10/20/2020 7:59:57 AM,"ABBV Seeks Expanded Approval Of Rinvoq, APTX Cheered By PTSD Data, ENDP Snaps Up BSTC, LQDA On Watch ",RTTNews,/news/stocks/abbv-seeks-expanded-approval-of-rinvoq-aptx-cheered-by-ptsd-data-endp-snaps-up-bstc-lqda-on-watch-1029696844,negative,0.8440489172935486
661,10/20/2020 8:02:17 PM,7 Dividend Stocks To Buy For Big Returns In Your Bank Account,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-for-big-returns-in-your-bank-account-1029700734,positive,0.8990662097930908
662,10/24/2020 4:30:00 AM,Gilead solidifies leadership in COVID-19 treatments with FDA remdesivir nod,Seeking Alpha,https://seekingalpha.com/news/3625261-gilead-solidifies-leadership-in-covidminus-19-treatments-fda-remdesivir-nod?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9483959674835205
663,10/28/2020 12:50:17 PM,Allergan's presbyopia med successful in late-stage studies,Seeking Alpha,https://seekingalpha.com/news/3627213-allergans-presbyopia-med-successful-in-late-stage-studies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8829323053359985
664,10/28/2020 12:59:39 PM,7 Cutting-Edge Biotech Stocks for Tomorrow ,InvestorPlace,/news/stocks/7-cutting-edge-biotech-stocks-for-tomorrow-1029734117,positive,0.8713727593421936
665,10/29/2020 9:38:23 AM,AbbVie To Present New Analyses From Phase 3 Studies For RINVOQ - Quick Facts ,RTTNews,/news/stocks/abbvie-to-present-new-analyses-from-phase-3-studies-for-rinvoq-quick-facts-1029739140,positive,0.8093177676200867
666,10/29/2020 3:03:48 PM,Here's what Wall Street expects from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-stock-quarter-earnings-preview-q3-1029741796,positive,0.9177791476249695
667,10/29/2020 3:58:17 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3628394-notable-earnings-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
668,10/29/2020 4:47:10 PM,AbbVie Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3628435-abbvie-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6457096934318542
669,10/30/2020 11:49:33 AM,"AbbVie EPS beats by $0.06, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3629011-abbvie-eps-beats-0_06-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8262386918067932
670,10/30/2020 11:51:07 AM,AbbVie raises dividend by 10%,Seeking Alpha,https://seekingalpha.com/news/3629010-abbvie-raises-dividend-10?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5707027316093445
671,10/30/2020 12:56:16 PM,AbbVie Q3 records robust growth of >100% in Skyrizi and Rinvoq sales; non-GAAP EPS guidance raise tops consensus,Seeking Alpha,https://seekingalpha.com/news/3629075-abbvie-q3-records-robust-growth-of-100-in-skyrizi-and-rinvoq-sales-non-gaap-eps-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9543706774711609
672,10/30/2020 1:07:51 PM,AbbVie Raises FY20 Adj. EPS Outlook; Boosts Dividend 10.2% - Quick Facts ,RTTNews,/news/stocks/abbvie-raises-fy20-adj-eps-outlook-boosts-dividend-10-2-quick-facts-1029746142,negative,0.948248565196991
673,10/30/2020 1:16:31 PM,AbbVie Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q3-adjusted-earnings-beat-estimates-1029746187,negative,0.8896722197532654
674,10/30/2020 4:10:17 PM,AbbVie News: 5 Things for ABBV Investors to Know About Q3,InvestorPlace,/news/stocks/abbvie-earnings-news-q3-highlights-1029747498,positive,0.9368146061897278
675,11/2/2020 11:05:35 AM,3 Biotech Stocks With Eye-Catching Pipelines,InvestorPlace,/news/stocks/3-biotech-stocks-with-eye-catching-pipelines-1029752447,positive,0.5421434044837952
676,11/4/2020 5:12:44 PM,Healthcare rallies as Presidential vote count continues,Seeking Alpha,https://seekingalpha.com/news/3631239-healthcare-rallies-presidential-vote-count-continues?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5205023288726807
677,11/5/2020 2:19:36 PM,Genmab to launch late-stage study of epcoritamab in aggressive type of lymphoma,Seeking Alpha,https://seekingalpha.com/news/3632235-genmab-to-launch-late-stage-study-of-epcoritamab-in-aggressive-type-of-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.775263249874115
678,11/6/2020 3:34:01 PM,Drug wholesalers and J&J agree to tentative $26B deal to settle opioid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3633211-drug-wholesalers-and-j-and-j-agree-to-tentative-26b-deal-to-settle-opioid-lawsuits?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9239859580993652
679,11/6/2020 8:30:45 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3633287-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
680,11/9/2020 5:27:53 PM,7 Stable Blue-Chip Stocks for Today’s Volatile Economy,InvestorPlace,/news/stocks/blue-chip-stocks-you-can-count-on-in-todays-volatile-economy-1029783010,negative,0.6550254225730896
681,11/10/2020 1:12:45 PM,Expanded use of AbbVie's Maviret OK'd in Canada,Seeking Alpha,https://seekingalpha.com/news/3634315-expanded-use-of-abbvies-maviret-okd-in-canada?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5889528393745422
682,11/10/2020 2:56:18 PM,AbbVie: Health Canada Okays Maviret For Patients With Genotype 3 Compensated Cirrhosis ,RTTNews,/news/stocks/abbvie-health-canada-okays-maviret-for-patients-with-genotype-3-compensated-cirrhosis-1029787073,negative,0.5599972605705261
683,11/12/2020 12:16:55 PM,4 Dividend Stocks With Yields Over 5%,InvestorPlace,/news/stocks/4-dividend-stocks-yields-over-5-percent-1029796403,positive,0.8623559474945068
684,11/17/2020 10:41:52 AM,"Buffett’s Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks",InvestorPlace,/news/stocks/buffets-berkshire-hathaway-stock-buys-new-stakes-in-vaccine-makers-cut-banks-1029809986,positive,0.8204633593559265
685,11/18/2020 1:19:13 PM,AbbVie gains after BMO Capital points to positive pipeline,Seeking Alpha,https://seekingalpha.com/news/3637456-abbvie-gains-after-bmo-capital-points-to-positive-pipeline?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8845856785774231
686,11/25/2020 8:49:37 AM,Purdue Pharma pleads guilty to criminal opioid crisis charges,Seeking Alpha,https://seekingalpha.com/news/3639300-purdue-pharma-pleads-guilty-to-criminal-opioid-crisis-charges?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.708125114440918
687,12/1/2020 6:01:43 PM,4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains-1029854808,positive,0.752234935760498
688,12/2/2020 1:28:10 PM,AbbVie teams up with Frontier Medicines to tackle difficult-to-drug protein targets,Seeking Alpha,https://seekingalpha.com/news/3640780-abbvie-teams-up-frontier-medicines-to-tackle-difficult-to-drug-protein-targets?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7672075033187866
689,12/2/2020 3:01:26 PM,"AbbVie, Frontier Medicines To Collaborate On Developing Novel Therapies And E3 Degraders ",RTTNews,/news/stocks/abbvie-frontier-medicines-to-collaborate-on-developing-novel-therapies-and-e3-degraders-1029857922,negative,0.5897871255874634
690,12/3/2020 6:53:40 PM,3 Dividend Stocks for Big Total Returns in 2021,InvestorPlace,/news/stocks/3-dividend-stocks-for-big-total-returns-in-2021-abbv-jnj-mdt-1029863076,negative,0.7688309550285339
691,12/4/2020 6:30:49 AM,Reality Hits Home for Shares of Inovio Pharmaceuticals,InvestorPlace,/news/stocks/ino-stock-reality-hits-home-inovio-pharmaceuticals-1029866169,negative,0.3952213525772095
692,12/7/2020 10:01:05 AM,7 Cheap Stocks to Buy Before the Market Realizes their Worth,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-before-the-market-realizes-their-worth-abbv-t-qcom-gs-nls-f-1029868671,positive,0.8860481977462769
693,12/7/2020 10:16:02 AM,AbbVie's Imbruvica shows treatment benefit in untreated chronic lymphocytic leukemia,Seeking Alpha,https://seekingalpha.com/news/3641980-abbvies-imbruvica-shows-treatment-benefit-in-untreated-chronic-lymphocytic-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9384279251098633
694,12/7/2020 11:04:59 AM,AbbVie's Venclexta/Venclyxto combination bebeficial in chronic lymphocytic leukemia,Seeking Alpha,https://seekingalpha.com/news/3641992-abbvies-venclexta-venclyxto-combination-bebeficial-in-chronic-lymphocytic-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8770206570625305
695,12/7/2020 6:46:51 PM,7 Medical Marijuana Stocks for a Healthcare Revolution,InvestorPlace,/news/stocks/seven-medical-marijuana-stocks-for-a-healthcare-revolution-1029870666,positive,0.8611308336257935
696,12/9/2020 2:37:09 PM,AbbVie announces positive late-stage data for upadacitinib in Ulcerative Colitis,Seeking Alpha,https://seekingalpha.com/news/3642913-abbvie-announces-positive-late-stage-data-for-upadacitinib-in-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9477217197418213
697,12/9/2020 3:28:53 PM,AbbVie: Upadacitinib Meets Primary & Secondary Endpoints In First Phase3 Study On Ulcerative Colitis ,RTTNews,/news/stocks/abbvie-upadacitinib-meets-primary-secondary-endpoints-in-first-phase3-study-on-ulcerative-colitis-1029877759,negative,0.8956998586654663
698,12/10/2020 3:06:03 PM,AbbVie says Rinvoq achieved superiority versus Dupixent in atopic dermatitis study,Seeking Alpha,https://seekingalpha.com/news/3643327-abbvie-says-rinvoq-achieved-superiority-versus-dupixent-in-atopic-dermatitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9565839767456055
699,12/10/2020 3:36:49 PM,AbbVie's Upadacitinib Achieves Superiority Versus Dupilumab In Phase 3b Study On Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-s-upadacitinib-achieves-superiority-versus-dupilumab-in-phase-3b-study-on-atopic-dermatitis-1029881848,negative,0.9549251794815063
700,12/11/2020 1:42:57 PM,AbbVie: CHMP Recommends Approvals Of RINVOQ - Quick Facts ,RTTNews,/news/stocks/abbvie-chmp-recommends-approvals-of-rinvoq-quick-facts-1029885162,negative,0.7978043556213379
701,12/11/2020 8:30:29 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3643803-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
702,12/15/2020 12:58:38 PM,Roche/AbbVie's venetoclax Ok'd in Canada for first-line acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3644369-roche-abbvies-venetoclax-okd-in-canada-for-first-line-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5577602982521057
703,12/15/2020 1:47:54 PM,AbbVie: Health Canada Approves VENCLEXTA With Azacitidine Or Low Dose Cytarabine For Untreated AML ,RTTNews,/news/stocks/abbvie-health-canada-approves-venclexta-with-azacitidine-or-low-dose-cytarabine-for-untreated-aml-1029893461,negative,0.7119492888450623
704,12/15/2020 3:45:00 PM,AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.,Moodys,/news/bonds/abbvie-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-abbvie-inc-1029894424,positive,0.8537180423736572
705,12/23/2020 11:10:51 AM,5 Dividend Stocks Likely to Up Their Yield Soon,InvestorPlace,/news/stocks/5-dividend-stocks-to-buy-likely-to-up-yield-soon-abbv-leg-t-pbct-cinf-1029916866,negative,0.9177976250648499
706,12/23/2020 1:44:30 PM,AbbVie's Imbruvica wins expanded prescribing information approval from FDA,Seeking Alpha,https://seekingalpha.com/news/3646946-abbvies-imbruvica-wins-expanded-prescribing-information-approval-from-fda?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9490703344345093
707,12/23/2020 2:07:40 PM,AbbVie: FDA Approves IMBRUVICA Prescribing Information Update For Waldenström's Macroglobulinemia ,RTTNews,/news/stocks/abbvie-fda-approves-imbruvica-prescribing-information-update-for-waldenstroem-s-macroglobulinemia-1029916856,negative,0.7102634310722351
708,12/28/2020 10:31:23 AM,7 5G ETFs Sit On The Cusp of a Tech Revolution Ready to Explode in 2021,InvestorPlace,/news/stocks/7-5g-etfs-sit-on-the-cusp-of-a-tech-revolution-ready-to-explode-in-2021-1029921040,positive,0.5387457609176636
709,12/31/2020 3:20:20 PM,6 Cannabis Stocks to Buy as the U.S. Softens Its Stance,InvestorPlace,/news/stocks/6-cannabis-stocks-to-buy-as-the-u-s-softens-its-stance-1029927336,negative,0.829277515411377
710,1/4/2021 5:03:29 PM,7 Cheap Stocks to Buy in January For a Quick Buck,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-in-january-for-a-quick-buck-1029931161,positive,0.8434224724769592
711,1/5/2021 1:03:36 PM,Abbvie returns global rights to muscarinic agonist programs to Sosei,Seeking Alpha,https://seekingalpha.com/news/3648734-abbvie-returns-global-rights-to-muscarinic-agonist-programs-to-sosei?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5389576554298401
712,1/5/2021 2:06:29 PM,AbbVie's risankizumab shows positive action in patients with psoriatic arthritis,Seeking Alpha,https://seekingalpha.com/news/3648797-abbvies-risankizumab-shows-positive-action-in-patients-psoriatic-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.944969117641449
713,1/5/2021 3:26:56 PM,AbbVie Announces Positive Results From Phase 3 Studies In Adults With Active Psoriatic Arthritis ,RTTNews,/news/stocks/abbvie-announces-positive-results-from-phase-3-studies-in-adults-with-active-psoriatic-arthritis-1029934199,negative,0.9444601535797119
714,1/6/2021 7:58:20 AM,"MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301 ",RTTNews,/news/stocks/mrkr-soars-as-fda-lifts-hold-on-mt-401-rytm-sells-priority-review-voucher-mlnd-dumps-mle-301-1029936115,neutral,0.5110002756118774
715,1/6/2021 10:21:28 AM,Jim Cramer's 9 Dividend Stock Picks For Fixed Income Investors,Benzinga,/news/stocks/jim-cramer-s-9-dividend-stock-picks-for-fixed-income-investors-1029936422,positive,0.9165158271789551
716,1/7/2021 6:27:36 AM,Adamas Pharma - Starting The Year Off Right? ,RTTNews,/news/stocks/adamas-pharma-starting-the-year-off-right-1029939328,positive,0.8265392780303955
717,1/7/2021 2:05:27 PM,7 Micro-Cap Stocks That Are Worth the Risk,InvestorPlace,/news/stocks/7-micro-cap-stocks-that-are-worth-the-risk-in-2021-1029941040,positive,0.8906441926956177
718,1/7/2021 2:12:36 PM,AbbVie's risankizumab shows improvements in clinical remission and endoscopic response in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/3649613-abbvies-risankizumab-shows-improvements-in-clinical-remission-and-endoscopic-response-in?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9558259844779968
719,1/7/2021 3:34:28 PM,AbbVie : Skyrizi Shows Improvements In Clinical Responses In Two Phase 3 Studies On Crohn's Disease ,RTTNews,/news/stocks/abbvie-skyrizi-shows-improvements-in-clinical-responses-in-two-phase-3-studies-on-crohn-s-disease-1029940911,negative,0.9526259899139404
720,1/11/2021 2:37:11 PM,AbbVie rated buy at Mizuho despite patent cliff for Humira,Seeking Alpha,https://seekingalpha.com/news/3650303-abbvie-rated-buy-mizuho-despite-patent-cliff-for-humira?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9436819553375244
721,1/11/2021 4:59:22 PM,The Top 7 Pharmaceutical Stocks for the Next 10 Years ,InvestorPlace,/news/stocks/the-top-7-pharmaceutical-stocks-for-the-next-10-years-1029956488,positive,0.8569135069847107
722,1/11/2021 5:20:41 PM,7 Hot Stocks That Will Keep You Energized With 3%-Plus Yields,InvestorPlace,/news/stocks/7-hot-stocks-that-will-keep-you-energized-with-three-percent-plus-yields-1029956859,positive,0.5786494612693787
723,1/12/2021 12:32:38 PM,AbbVie in-licenses Dragonfly Therapeutics' TriNKET drug candidate,Seeking Alpha,https://seekingalpha.com/news/3650626-abbvie-in-licenses-dragonfly-therapeutics-trinket-drug-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8917405605316162
724,1/12/2021 9:28:51 PM,Allergan Aesthetics enters option to acquire a medical device company,Seeking Alpha,https://seekingalpha.com/news/3650873-allergan-aesthetics-enters-option-to-acquire-medical-device-company?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8399017453193665
725,1/13/2021 12:59:57 PM,Harpoon Therapeutics' HPN217 an orphan drug in U.S. for multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3651018-harpoon-therapeutics-hpn217-orphan-drug-in-u-s-for-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.519668459892273
726,1/13/2021 1:25:38 PM,"The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations",Benzinga,/news/stocks/the-daily-biotech-pulse-bausch-health-issues-positive-pre-announcement-acorda-streamlines-operations-1029963908,positive,0.9181804656982422
727,1/13/2021 3:41:44 PM,Evolus is up 6% after AbbVie-Cypris Medical deal,Seeking Alpha,https://seekingalpha.com/news/3651133-evolus-is-up-6-after-abbvie-cypris-medical-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.949694812297821
728,1/13/2021 7:51:59 PM,7 Pharmaceutical Stocks With Exciting Plans for 2021,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-with-exciting-plans-for-2021-1029966098,positive,0.7265651226043701
729,1/22/2021 3:31:16 PM,7 Dividend Aristocrats That Will Outlive Us All,InvestorPlace,/news/stocks/7-dividend-aristocrats-that-will-outlive-us-all-1029994855,positive,0.8277402520179749
730,1/25/2021 11:58:38 AM,3 Reasons To Invest in Pfizer Stock Despite Its Dismal Performance,InvestorPlace,/news/stocks/3-reasons-to-invest-in-pfizer-stock-despite-its-dismal-performance-1029999021,positive,0.5312947630882263
731,1/25/2021 1:43:30 PM,"Doing underway in Alector, AbbVie's study of AL002 in Alzheimer’s disease",Seeking Alpha,https://seekingalpha.com/news/3653856-doing-underway-in-alector-abbvies-study-of-al002-in-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.785422146320343
732,1/27/2021 2:41:14 PM,First Psychedelics ETF Debuts On NEO Exchange,Benzinga,/news/stocks/first-psychedelics-etf-debuts-on-neo-exchange-1030009809,positive,0.9312703609466553
733,1/27/2021 8:30:44 PM,Pfizer’s setback can hurt others with JAK inhibitors,Seeking Alpha,https://seekingalpha.com/news/3655131-pfizers-setback-can-hurt-others-with-jak-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9525027871131897
734,1/29/2021 12:02:52 AM,"Major pharma set for strong 2021, and trading at a 35% discount to market - J.P. Morgan",Seeking Alpha,https://seekingalpha.com/news/3655985-major-pharma-set-for-strong-2021-and-trading-at-a-35-discount-to-market-jp-morgan?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.795691967010498
735,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250,positive,0.8783656358718872
736,2/1/2021 3:01:40 PM,Here's what Wall Street expects from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-stock-price-quarter-earnings-preview-q4-1030027847,positive,0.931816041469574
737,2/2/2021 10:01:15 AM,7 Pharmaceutical Stocks With Compelling Pipelines,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-with-compelling-pipelines-1030031896,negative,0.9111998677253723
738,2/2/2021 5:18:57 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3657287-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.855887770652771
739,2/2/2021 5:59:53 PM,AbbVie Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3657310-abbvie-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7057066559791565
740,2/3/2021 12:39:57 PM,"AbbVie EPS beats by $0.07, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3657690-abbvie-eps-beats-0_07-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8276468515396118
741,2/3/2021 1:31:17 PM,"The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-amgen-earnings-gsk-curevac-vaccine-collaboration-mallinckrodt-fda-decision-1030037844,positive,0.940704882144928
742,2/3/2021 1:46:26 PM,EARNINGS SUMMARY: Details of AbbVie Q4 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-abbvie-q4-earnings-report-1030037922,positive,0.9159151911735535
743,2/3/2021 2:06:01 PM,"AbbVie tops Q4 forecast, guides 2021 non-GAAP EPS above consensus",Seeking Alpha,https://seekingalpha.com/news/3657745-abbvie-tops-q4-forecast-guides-2021-non-gaap-eps-above-consensus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9283361434936523
744,2/3/2021 2:17:30 PM,AbbVie Q4 Results Top Estimates; Sees FY21 Profit Above View ,RTTNews,/news/stocks/abbvie-q4-results-top-estimates-sees-fy21-profit-above-view-1030038295,negative,0.7804358005523682
745,2/3/2021 10:18:54 PM,"4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-amzn-spot-bmy-abbv-1030040762,positive,0.926028311252594
746,2/4/2021 3:00:00 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030043861,positive,0.7969076037406921
747,2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6293289065361023
748,2/6/2021 9:00:00 PM,Marijuana as medicine: the other cannabinoid pharma players,Seeking Alpha,https://seekingalpha.com/news/3659129-marijuana-as-medicine-the-other-cannabinoid-pharma-players?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9412885308265686
749,2/9/2021 2:10:28 PM,"The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement",Benzinga,/news/stocks/the-daily-biotech-pulse-dynavax-poaches-gsk-vaccine-exec-kalvista-jumps-on-data-readout-corcept-issues-negative-preannouncement-1030060223,neutral,0.8829746842384338
750,2/10/2021 1:36:25 PM,AbbVie and Caribou Biosciences strike deal for CAR-T cell products,Seeking Alpha,https://seekingalpha.com/news/3660513-abbvie-and-caribou-biosciences-strike-deal-for-car-t-cell-products?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6783213019371033
751,2/10/2021 2:06:26 PM,FDA OK's AbbVie's Botox for pediatric bladder overactivity,Seeking Alpha,https://seekingalpha.com/news/3660539-fda-oks-abbvies-botox-for-pediatric-bladder-overactivity?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6868336200714111
752,2/10/2021 2:14:51 PM,Allergan: FDA Approves BOTOX For Treating Neurogenic Detrusor Overactivity In Children ,RTTNews,/news/stocks/allergan-fda-approves-botox-for-treating-neurogenic-detrusor-overactivity-in-children-1030066574,negative,0.8840228915214539
753,2/10/2021 2:41:07 PM,"AbbVie, Caribou Biosciences Ink CAR-T Cell Products License Deal For $40 Mln Upfront Payment ",RTTNews,/news/stocks/abbvie-caribou-biosciences-ink-car-t-cell-products-license-deal-for-40-mln-upfront-payment-1030066748,positive,0.5538570880889893
754,2/14/2021 1:19:11 PM,"Cramer Gives His Opinion On Zoom, AbbVie And More",Benzinga,/news/stocks/cramer-gives-his-opinion-on-zoom-abbvie-and-more-1030080302,positive,0.9485452771186829
755,2/16/2021 2:07:45 PM,9 Safe Stocks for Your 401k,InvestorPlace,/news/stocks/9-safe-stocks-for-your-401k-1030087998,positive,0.9115642309188843
756,2/17/2021 12:46:50 PM,FDA accepts Coherus Bio's Humira biosimilar application for review,Seeking Alpha,https://seekingalpha.com/news/3662762-fda-accepts-coherus-humira-biosimilar-bla-for-review?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8504953384399414
757,2/17/2021 1:18:23 PM,Ironwood shares rise on Linzess powered fourth-quarter beat,Seeking Alpha,https://seekingalpha.com/news/3662786-ironwood-shares-rise-on-linzess-powered-fourth-quarter-beat?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7536497116088867
758,2/17/2021 4:00:37 PM,FDA Accepts Coherus Biosciences' Adalimumab Biosimilar Application For Review,Benzinga,/news/stocks/fda-accepts-coherus-biosciences-adalimumab-biosimilar-application-for-review-1030092841,positive,0.8397214412689209
759,2/17/2021 8:44:10 PM,"Q4 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q4-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030093945,positive,0.8798474073410034
760,2/18/2021 4:08:39 PM,AbbVie declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/3663520-abbvie-declares-1_30-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9302800893783569
761,2/19/2021 2:41:19 PM,"AbbVie, Evolus, and Medytox settle IP rights dispute (update)",Seeking Alpha,https://seekingalpha.com/news/3663962-abbvie-evolus-and-medytox-settle-ip-rights-dispute?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7583634257316589
762,2/19/2021 3:30:50 PM,"AbbVie, Evolus, Medytox Agree To Resolve Intellectual Property Litigation ",RTTNews,/news/stocks/abbvie-evolus-medytox-agree-to-resolve-intellectual-property-litigation-1030102107,negative,0.5995020866394043
763,2/19/2021 4:42:50 PM,"Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox",Benzinga,/news/stocks/evolus-shares-surge-after-settling-jeuveau-related-litigation-with-abbvie-medytox-1030102407,negative,0.9123321175575256
764,2/19/2021 9:05:23 PM,EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today,InvestorPlace,/news/stocks/eols-stock-the-big-news-that-has-evolus-shares-skyrocketing-today-1030103201,positive,0.5433522462844849
765,2/22/2021 2:07:58 PM,Six stocks hedge funds and mutual funds love (and 20 they don't): At the Open,Seeking Alpha,https://seekingalpha.com/news/3664311-six-stocks-hedge-funds-and-mutual-funds-love?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9283661842346191
766,2/22/2021 2:17:24 PM,AbbVie's upadacitinib successful in late-stage ulcerative colitis study,Seeking Alpha,https://seekingalpha.com/news/3664317-abbvies-upadacitinib-successful-in-late-stage-ulcerative-colitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7466448545455933
767,2/24/2021 2:32:02 PM,Evolus cut to hold from buy at Truist,Seeking Alpha,https://seekingalpha.com/news/3665489-evolus-cut-to-hold-from-buy-at-truist?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.772290825843811
768,2/25/2021 2:50:14 AM,FDA Approves AbbVie's Humira For Pediatric Ulcerative Colitis ,RTTNews,/news/stocks/fda-approves-abbvie-s-humira-for-pediatric-ulcerative-colitis-1030120914,negative,0.542605459690094
769,2/25/2021 12:39:20 PM,AbbVie's HUMIRA wins FDA approval for ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3666307-abbvies-humira-wins-fda-approval-for-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9326417446136475
770,2/25/2021 1:10:23 PM,Allergan submits AGN-190584 NDA for presbyopia treatment,Seeking Alpha,https://seekingalpha.com/news/3666358-allergan-submits-agn-190584-nda-for-presbyopia-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8450926542282104
771,2/25/2021 2:08:03 PM,"The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-goes-shopping-decision-day-for-sarepta-pfizer-moderna-unveil-vaccine-strategies-for-coronavirus-variants-1030123681,positive,0.9286142587661743
772,2/26/2021 4:02:09 PM,Delic is Bringing Psychedelics to the Mainstream,Benzinga,/news/stocks/delic-is-bringing-psychedelics-to-the-mainstream-1030129907,positive,0.864753782749176
773,3/1/2021 12:40:50 PM,AbbVie to sell Allergan Biologics to Pharmaron for $119 million,Seeking Alpha,https://seekingalpha.com/news/3667500-abbvie-to-sell-allergan-biologics-to-pharmaron-for-119-million?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9395949840545654
774,3/1/2021 4:52:26 PM,7 Safe Stocks You Can Hold Onto Forever,InvestorPlace,/news/stocks/safe-stocks-to-buy-7-safe-stocks-you-can-hold-onto-forever-1030136559,positive,0.8842860460281372
775,3/1/2021 5:30:27 PM,MORF Stock: Why Little-Known Morphic Holdings Is Up 100% Today,InvestorPlace,/news/stocks/morf-stock-why-little-known-morphic-holdings-is-up-100-today-1030137000,negative,0.9472236633300781
776,3/3/2021 10:31:49 AM,7 Great Dividend Stocks Outside the Energy Sector,InvestorPlace,/news/stocks/7-great-dividend-stocks-outside-the-energy-sector-1030144476,positive,0.8891428112983704
777,3/3/2021 2:31:53 PM,7 Blue-Chip Stocks That May Be Perfect For Retirement,InvestorPlace,/news/stocks/7-blue-chip-stocks-that-may-be-perfect-for-retirement-1030146050,positive,0.8465081453323364
778,3/9/2021 8:38:33 AM,"Corporate vaccination drives get underway, as well as mask policies",Seeking Alpha,https://seekingalpha.com/news/3670551-corporate-vaccination-drives-get-underway-as-well-as-mask-policies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6693150997161865
779,3/12/2021 1:36:15 PM,"The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-data-contrafect-secures-barda-funding-2-ipos-1030178427,positive,0.7880918979644775
780,3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6729742884635925
781,3/15/2021 4:30:50 PM,8 of the Best Index Funds With Ultra-Low Fees,InvestorPlace,/news/stocks/8-of-the-best-index-funds-with-ultra-low-fees-1030206599,negative,0.6150591373443604
782,3/15/2021 11:05:29 PM,AbbVie in talks to sell $5B women's drugs portfolio - Reuters,Seeking Alpha,https://seekingalpha.com/news/3672938-abbvie-in-talks-to-sell-5b-womens-drugs-portfolio-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9012867212295532
783,3/16/2021 9:01:29 AM,7 Blue-Chip Stocks With Strong Dividend Yields,InvestorPlace,/news/stocks/7-blue-chip-stocks-with-strong-dividend-yields-1030213281,negative,0.8644108772277832
784,3/17/2021 2:21:31 PM,AbbVie : FDA Extends Review Period For SNDA Of Upadacitinib To Q2 ,RTTNews,/news/stocks/abbvie-fda-extends-review-period-for-snda-of-upadacitinib-to-q2-1030219878,positive,0.7339040637016296
785,3/17/2021 3:59:26 PM,Abbvie shares fall following FDA review extension for RINVOQ sNDA (updated),Seeking Alpha,https://seekingalpha.com/news/3673586-abbvie-shares-fall-6-following-snda-review-extension-for-rinvoq?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9519258141517639
786,3/17/2021 9:32:52 PM,"4 Top Stock Trades for Thursday: ABBV, TLT, PDD, FIVE",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-abbv-tlt-pdd-five-1030221670,positive,0.9347846508026123
787,3/22/2021 6:14:25 PM,Abbvie veteran joins Novartis as Chief Legal Officer,Seeking Alpha,https://seekingalpha.com/news/3674921-abbvie-stock-price-higher-as-veteran-becomes-novartis-chief-legal-officer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9297305345535278
788,3/23/2021 4:46:16 PM,Drug pricing legislation introduced by Sanders weighs on pharmas,Seeking Alpha,https://seekingalpha.com/news/3675361-drug-pricing-legislation-introduced-by-sanders-weighs-on-pharmas?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8964442610740662
789,3/26/2021 9:01:09 AM,7 Value Stocks That Will Reward Investors Who Have Some Patience,InvestorPlace,/news/stocks/7-value-stocks-that-will-reward-investors-who-have-some-patience-1030249128,positive,0.8108744621276855
790,3/26/2021 7:15:40 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3676932-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
791,3/30/2021 12:46:45 PM,FDA accepts Abbvie's atogepant application for migraine,Seeking Alpha,https://seekingalpha.com/news/3677551-fda-accepts-abbvies-atogepant-application-for-migraine?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7047713994979858
792,3/30/2021 1:55:38 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1030258409,positive,0.8152946829795837
793,3/30/2021 2:23:32 PM,7 Cannabis Stocks That Offer Much More Than Just Pot,InvestorPlace,/news/stocks/7-cannabis-stocks-that-offer-much-more-than-just-pot-1030260088,positive,0.8765715956687927
794,4/1/2021 3:10:35 PM,AbbVie : Upadacitinib Improves Clinical And Radiographic Outcomes In Psoriatic Arthritis  People ,RTTNews,/news/stocks/abbvie-upadacitinib-improves-clinical-and-radiographic-outcomes-in-psoriatic-arthritis-people-1030269233,negative,0.9555115699768066
795,4/1/2021 6:29:05 PM,7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-to-prepare-your-portfolio-for-the-next-pandemic-1030270707,positive,0.9073498249053955
796,4/3/2021 2:51:53 AM,FDA extends review of Abbvie's sNDA for Rinvoq in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3678991-fda-extends-review-of-abbvie-snda-for-rinvoq-in--atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7636768221855164
797,4/3/2021 3:37:59 AM,AbbVie : FDA Extends Review Period For SNDA Of Upadacitinib For Treatment Of Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-fda-extends-review-period-for-snda-of-upadacitinib-for-treatment-of-atopic-dermatitis-1030272378,negative,0.7452088594436646
798,4/7/2021 1:11:55 PM,AbbVie submits regulatory applications for SKYRIZI in psoriatic arthritis to FDA and EMA,Seeking Alpha,https://seekingalpha.com/news/3679832-abbvie-submits-regulatory-applications-for-skyrizi-in-psoriatic-arthritis-to-fda-and-ema?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8722912073135376
799,4/7/2021 3:23:10 PM,AbbVie Seeks Approval For SKYRIZI For Treatment Of Adults With Psoriatic Arthritis ,RTTNews,/news/stocks/abbvie-seeks-approval-for-skyrizi-for-treatment-of-adults-with-psoriatic-arthritis-1030281649,negative,0.8697529435157776
800,4/19/2021 10:45:46 AM,Drugmakers go on trial for opioid epidemic in California,Seeking Alpha,https://seekingalpha.com/news/3682811-drugmakers-go-on-trial-for-opioid-epidemic-in-california?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5263085961341858
801,4/21/2021 12:25:25 PM,"Intuitive Surgical upgraded after earnings beat; Oppenheimer sizes up new Vertex – CRISPR deal, and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3683885-intuitive-surgical-upgraded-after-earnings-beat-oppenheimer-sizes-up-new-vertex-crispr-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8570231795310974
802,4/22/2021 2:21:05 PM,Canada approves AbbVie's Humira in pediatric ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3684623-canada-approves-abbvie-humira-in-pediatric-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7005218863487244
803,4/22/2021 4:29:40 PM,AbbVie's Humira Gets Approval In Canada For Treatment Of Pediatric Patients With Ulcerative Colitis ,RTTNews,/news/stocks/abbvie-s-humira-gets-approval-in-canada-for-treatment-of-pediatric-patients-with-ulcerative-colitis-1030334305,negative,0.927399218082428
804,4/22/2021 7:47:21 PM,House Democrats reintroduce bill to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3684755-house-democrats-reintroduce-bill-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6614382266998291
805,4/23/2021 12:41:23 PM,European advisory group backs AbbVie's Venclyxto combo for acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3685072-european-advisory-group-backs-abbvies-venclyxto-combo-for-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6111009120941162
806,4/23/2021 2:15:22 PM,AbbVie Announces Positive CHMP Opinion For VENCLYXTO In Acute Myeloid Leukemia ,RTTNews,/news/stocks/abbvie-announces-positive-chmp-opinion-for-venclyxto-in-acute-myeloid-leukemia-1030338539,negative,0.9424754977226257
807,4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692,positive,0.9154146313667297
808,4/26/2021 5:30:41 PM,3 Top Blue-Chip Healthcare Stocks With Healthy Dividends,InvestorPlace,/news/stocks/3-top-blue-chip-healthcare-stocks-with-healthy-dividends-1030347105,negative,0.7900867462158203
809,4/28/2021 2:29:03 PM,7 Pharmaceutical Stocks With Dividends in Hand,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-dividends-in-hand-1030359387,positive,0.926287829875946
810,4/28/2021 3:02:23 PM,What Wall Street expects from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-quarter-earnings-preview-q1-1030358252,positive,0.9298630356788635
811,4/29/2021 10:00:37 AM,7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-dividends-1030363716,negative,0.5524897575378418
812,4/29/2021 4:35:35 PM,AbbVie Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3688037-abbvie-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.38181284070014954
813,4/29/2021 4:43:04 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3688042-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
814,4/29/2021 6:10:51 PM,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,InvestorPlace,/news/stocks/7-health-focused-etfs-to-buy-now-for-the-post-covid-future-1030366420,positive,0.847977340221405
815,4/30/2021 11:43:37 AM,"AbbVie EPS beats by $0.12, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3688576-abbvie-eps-beats-0_12-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7238404750823975
816,4/30/2021 12:02:43 PM,"AbbVie posts Q1 earnings beat, raises FY profit forecast",Seeking Alpha,https://seekingalpha.com/news/3688600-abbvie-posts-q1-earnings-beat-raises-fy-profit-forecast?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9303464889526367
817,4/30/2021 1:31:19 PM,"The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-hyperphosphatemia-drug-regulatory-review-extended-phathom-pharma-data-readout-2-ipos-1030369950,positive,0.896331250667572
818,4/30/2021 1:45:41 PM,AbbVie Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q1-adjusted-earnings-beat-estimates-1030370009,negative,0.8994625210762024
819,4/30/2021 2:52:15 PM,Abbvie CEO Richard Gonzalez to testify before House committee in drug pricing probe,Seeking Alpha,https://seekingalpha.com/news/3688726-abbvie-ceo-richard-gonzales-to-testify-before-house-committee-in-drug-pricing-probe?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8994459509849548
820,4/30/2021 7:18:09 PM,7 Value Stocks You Want In Your Life,InvestorPlace,/news/stocks/7-value-stocks-you-want-in-your-life-1030371999,positive,0.9359973073005676
821,5/4/2021 2:10:21 PM,"The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data",Benzinga,/news/stocks/the-daily-biotech-pulse-vaxart-rebounds-on-strong-vaccine-data-pfizer-s-beat-and-raise-quarter-biolinerx-data-1030383815,negative,0.5902956128120422
822,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6773343086242676
823,5/5/2021 1:43:29 PM,"The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues",Benzinga,/news/stocks/the-daily-biotech-pulse-athenex-neogenomics-and-amryt-in-m-a-mix-european-nod-for-roche-s-cancer-immunotherapy-earnings-deluge-continues-1030390006,positive,0.707877516746521
824,5/6/2021 1:49:39 PM,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-keytruda-snags-another-fda-approval-moderna-slips-on-revenue-miss-chemocentryx-adcom-1030395950,neutral,0.9611167907714844
825,5/7/2021 5:13:44 PM,7 Warren Buffett Stocks to Buy for the Next Decade,InvestorPlace,/news/stocks/7-warren-buffett-stocks-to-buy-for-next-decade-1030403280,positive,0.904937207698822
826,5/10/2021 1:25:50 PM,"Soliton rallies on Allergan Aesthetics, AbbVie company, acquisition proposal of $550M",Seeking Alpha,https://seekingalpha.com/news/3693848-soliton-rallies-on-allergan-aesthetics-abbvie-company-acquisition-proposal-of-550m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6732240319252014
827,5/10/2021 3:18:32 PM,Allergan Aesthetics To Buy Soliton For $22.60/Share In Cash - Quick Facts ,RTTNews,/news/stocks/allergan-aesthetics-to-buy-soliton-for-22-60-share-in-cash-quick-facts-1030409669,positive,0.8782990574836731
828,5/10/2021 4:27:56 PM,Soliton Stock Rallies After $22.60/Share Buyout From AbbVie,Benzinga,/news/stocks/soliton-stock-rallies-after-22-60-share-buyout-from-abbvie-1030409990,negative,0.8221659064292908
829,5/10/2021 5:26:20 PM,Stocks That Hit 52-Week Highs On Monday,Benzinga,/news/stocks/stocks-that-hit-52-week-highs-on-monday-1030410156,positive,0.6719298958778381
830,5/11/2021 1:54:31 PM,"The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-pfizer-biontech-covid-19-vaccine-for-adolescents-lilly-strikes-r-d-collaboration-vaccine-stocks-novavax-inovio-sink-on-earnings-1030414147,positive,0.846595048904419
831,5/13/2021 4:19:14 PM,"With Abbvie acquisition, Cantor downgrades Soliton to neutral",Seeking Alpha,https://seekingalpha.com/news/3696048-with-abbvie-acquisition-cantor-downgrades-soliton-to-neutral?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4844023585319519
832,5/14/2021 8:21:19 PM,A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies (Updated),Benzinga,/news/stocks/a-complete-list-of-nyse-and-nasdaq-listed-cannabis-companies-1030431808,positive,0.9436577558517456
833,5/15/2021 10:45:29 PM,The 'new momentum' stocks to watch: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3696874-the-new-momentum-stocks-to-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.905489444732666
834,5/18/2021 1:44:45 PM,"The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO",Benzinga,/news/stocks/the-daily-biotech-pulse-spero-secures-niaid-funding-glaxosmithkline-releases-covid-19-data-biontech-gets-new-cfo-1030440714,positive,0.7303595542907715
835,5/18/2021 3:26:18 PM,"House report alleges drastic drug price hikes, anticompetitive practices by Abbvie (updated)",Seeking Alpha,https://seekingalpha.com/news/3697847-house-report-alleges-drastic-drug-price-hikes-anticompetitive-practices-by-abbvie?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7925257086753845
836,5/18/2021 6:39:22 PM,"Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q1-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030442901,positive,0.8799788951873779
837,5/19/2021 1:30:16 PM,"The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics",Benzinga,/news/stocks/the-daily-biotech-pulse-iovance-to-delay-regulatory-filing-for-cancer-therapy-departures-at-passage-bio-positive-readout-for-silence-therapeutics-1030445806,positive,0.6067515015602112
838,5/19/2021 6:48:06 PM,7 Best Long-Term Dividend Stocks for Your Retirement Portfolio,InvestorPlace,/news/stocks/7-best-long-term-dividend-stocks-for-your-retirement-portfolio-1030448260,positive,0.918212354183197
839,5/20/2021 12:27:47 PM,OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today,InvestorPlace,/news/stocks/obsv-stock-the-big-clinical-trial-news-boosting-obseva-today-1030451512,negative,0.9427408576011658
840,5/20/2021 5:51:41 PM,JNJ highlights potential of IMBRUVICA as a first-line treatment for leukemia,Seeking Alpha,https://seekingalpha.com/news/3698811-jnj-highlights-potential-of-imbruvica-as-a-first-line-treatment-for-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8827682733535767
841,5/24/2021 6:14:22 PM,Abivax reports strong phase 2 data on ulcerative colitis candidate; shares up 12%,Seeking Alpha,https://seekingalpha.com/news/3699576-abivax-reports-strong-phase-2-data-on-ulcerative-colitis-candidate-shares-up-12?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9496645331382751
842,5/24/2021 7:45:04 PM,3 Top Stock Trades for the New Week,InvestorPlace,/news/stocks/3-top-stock-trades-for-the-new-week-1030255526,positive,0.9133531451225281
843,5/25/2021 12:55:12 PM,AbbVie's Venclyxto combo OK'd in Europe for treatment of acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3699828-abbvies-venclyxto-combo-okd-in-europe-for-treatment-of-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5872623324394226
844,5/25/2021 3:02:38 PM,Roche : EU Oks Venclyxto-based Combinations For Adults With Newly Diagnosed Acute Myeloid Leukaemia ,RTTNews,/news/stocks/roche-eu-oks-venclyxto-based-combinations-for-adults-with-newly-diagnosed-acute-myeloid-leukaemia-1030462636,positive,0.7525855898857117
845,5/27/2021 2:23:09 PM,"The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-vir-glaxosmithkline-covid-19-antibody-treatment-approved-zosano-spikes-on-long-term-migraine-drug-data-decision-day-for-eton-2-ipos-1030471204,negative,0.7420997619628906
846,5/27/2021 4:53:01 PM,Balancing Portfolio Risk And Reward: Asset Allocation for New Graduates,InvestorPlace,/news/stocks/balancing-portfolio-risk-and-reward-asset-allocation-for-new-graduates-1030472888,positive,0.8794659376144409
847,6/1/2021 11:31:09 PM,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-june-pdufa-dates-1030484849,positive,0.9476439952850342
848,6/2/2021 5:20:03 PM,AbbVie Announces Positive Results From Late-stage Study Of Crohn's Disease Treatment ,RTTNews,/news/stocks/abbvie-announces-positive-results-from-late-stage-study-of-crohn-s-disease-treatment-1030488138,negative,0.8597401976585388
849,6/7/2021 11:36:05 AM,Health Canada approves AbbVie's RINVOQ for treatment of psoriatic arthritis,Seeking Alpha,https://seekingalpha.com/news/3703596-health-canada-approves-abbvies-rinvoq-for-treatment-of-psoriatic-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7164660096168518
850,6/7/2021 1:53:31 PM,AbbVie Says Health Canada OKs RINVOQ For Adults With Active Psoriatic Arthritis ,RTTNews,/news/stocks/abbvie-says-health-canada-oks-rinvoq-for-adults-with-active-psoriatic-arthritis-1030499172,positive,0.7583927512168884
851,6/7/2021 2:52:10 PM,"The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck",Benzinga,/news/stocks/the-week-ahead-in-biotech-biogen-alexion-and-vertex-fda-decisions-multiple-conference-presentations-on-the-deck-1030499585,positive,0.9329092502593994
852,6/7/2021 4:06:16 PM,AbbVie posts encouraging data from mid-stage Imbruvica/Venclexta combo study,Seeking Alpha,https://seekingalpha.com/news/3703774-abbvie-posts-encouraging-data-from-mid-stage-imbruvicavenclexta-combo-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9532211422920227
853,6/7/2021 5:30:00 PM,CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic ...,PR Newswire,/news/stocks/captivate-study-shows-an-imbruvica-ibrutinib-plus-venclexta-venclyxto-venetoclax-chemotherapy-free-combination-has-potential-to-provide-remission-after-fixed-duration-treatment-for-chronic-1030500368,negative,0.9129218459129333
854,6/8/2021 2:45:00 PM,Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign,PR Newswire,/news/stocks/allergan-aesthetics-and-botox-cosmetic-onabotulinumtoxina-put-real-stories-at-the-forefront-in-new-campaign-1030503476,positive,0.8698079586029053
855,6/9/2021 11:14:19 AM,AbbVie in pact with Caraway Therapeutics for neurodegenerative disorders,Seeking Alpha,https://seekingalpha.com/news/3704452-abbvie-in-pact-with-caraway-therapeutics-for-neurodegenerative-disorders?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6677483916282654
856,6/11/2021 7:03:00 AM,New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment,PR Newswire,/news/stocks/new-data-shows-abbvie-s-venclyxto-venclexta-fixed-duration-combination-demonstrates-sustained-progression-free-survival-in-chronic-lymphocytic-leukemia-patients-after-three-years-off-treatment-1030514444,negative,0.9526767134666443
857,6/11/2021 7:19:38 AM,"AbbVie, Roche's Venclexta combo shows sustained benefit in blood cancers",Seeking Alpha,https://seekingalpha.com/news/3705524-abbvie-roches-venclexta-combo-shows-sustained-benefit-in-blood-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9436712265014648
858,6/11/2021 7:37:30 AM,AbbVie: 4-year Follow-up Analysis Of Phase 3 Venetoclax Trial Continues To Show Longer PFS In CLL ,RTTNews,/news/stocks/abbvie-4-year-follow-up-analysis-of-phase-3-venetoclax-trial-continues-to-show-longer-pfs-in-cll-1030514493,negative,0.8832140564918518
859,6/12/2021 1:02:00 PM,IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leu...,PR Newswire,/news/stocks/imbruvica-ibrutinib-plus-venclexta-venclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leu-1030517327,negative,0.9592869877815247
860,6/14/2021 8:26:35 AM,JNJ/AbbVie's Imbruvica + Venclexta show promising progression-free survival in late-stage blood cancer study,Seeking Alpha,https://seekingalpha.com/news/3705857-jnjabbvies-imbruvicavenclexta-show-promising-progression-free-survival-in-blood-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9435179829597473
861,6/16/2021 1:28:40 PM,Zhongchao up 5% as it partners AbbVie's Chinese subsidiary for medical education services,Seeking Alpha,https://seekingalpha.com/news/3706856-zhongchao-teams-up-with-abbvies-chinese-subsidiary-for-medical-education-services?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9517596960067749
862,6/16/2021 6:30:10 PM,"Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today",Benzinga,/news/stocks/why-kindred-biosciences-aprea-catabasis-and-inhibikase-are-moving-today-1030529318,positive,0.9361140727996826
863,6/18/2021 12:29:00 AM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1030534047,neutral,0.5513123869895935
864,6/18/2021 6:06:42 AM,AbbVie declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/3707530-abbvie-inc-declares-1_30-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9302800893783569
865,6/18/2021 3:59:06 PM,Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight,Seeking Alpha,https://seekingalpha.com/news/3707699-bristols-up-to-3b-deal-with-eisai-puts-antibody-drug-conjugates-in-the-spotlight?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.664600670337677
866,6/18/2021 7:30:24 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3707786-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
867,6/20/2021 4:04:37 PM,"The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-incyte-ascendis-fda-decisions-liver-congress-presentations-and-4-ipos-1030537312,positive,0.9417259097099304
868,6/21/2021 3:43:05 PM,Supreme Court declines to hear Abbvie challenge over AndroGel patent,Seeking Alpha,https://seekingalpha.com/news/3708266-supreme-court-declines-to-hear-abbvie-challenge-over-androgel-patent?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8060967326164246
869,6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8699349761009216
870,6/23/2021 7:26:26 PM,7 Overlooked Blue-Chip Stocks to Buy for Eagle-Eyed Investors,InvestorPlace,/news/stocks/7-overlooked-blue-chip-stocks-to-buy-for-eagle-eyed-investors-1030548621,positive,0.8373008966445923
871,6/23/2021 9:05:00 PM,Abbvie subsidiary facing patent infringement case over proposed ADHD generic drug,Seeking Alpha,https://seekingalpha.com/news/3709374-abbvie-subsidiary-facing-patent-infringement-case-over-proposed-adhd-generic-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9414336681365967
872,6/24/2021 7:42:17 AM,Biotech Stocks Facing FDA Decision In July 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2021-1030549382,positive,0.818015456199646
873,6/24/2021 2:00:00 PM,AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma,PR Newswire,/news/stocks/abbvie-exercises-right-to-acquire-teneoone-and-lead-asset-tnb-383b-for-the-potential-treatment-of-relapsed-or-refractory-multiple-myeloma-1030550861,positive,0.6300565600395203
874,6/24/2021 2:18:17 PM,AbbVie Exercises Right To Buy TeneoOne And Lead Asset TNB-383B ,RTTNews,/news/stocks/abbvie-exercises-right-to-buy-teneoone-and-lead-asset-tnb-383b-1030550933,positive,0.9039791226387024
875,6/25/2021 8:29:49 AM,EMA advisory group backs approval of AbbVie's RINVOQ in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3710023-ema-advisory-group-backs-approval-of-abbvies-rinvoq-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8289130926132202
876,6/25/2021 8:30:00 AM,CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis,PR Newswire,/news/stocks/chmp-recommends-approval-of-rinvoq-upadacitinib-for-the-treatment-of-atopic-dermatitis-1030553834,negative,0.7757601737976074
877,6/25/2021 8:53:23 AM,AbbVie's RINVOQ Gets Positive CHMP Opinion For Atopic Dermatitis Treatment ,RTTNews,/news/stocks/abbvie-s-rinvoq-gets-positive-chmp-opinion-for-atopic-dermatitis-treatment-1030553865,negative,0.943341851234436
878,6/25/2021 11:50:45 AM,3 High-Yield Stocks With Secure Payouts,InvestorPlace,/news/stocks/3-high-yield-dividend-stocks-with-secure-payouts-1030554651,positive,0.7198594212532043
879,6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577,negative,0.7482125759124756
880,6/25/2021 2:30:00 PM,AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.,PR Newswire,/news/stocks/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-u-s-1030554817,positive,0.8522453308105469
881,6/25/2021 2:54:47 PM,FDA Won't Meet PDUFA Dates For AbbVie' RINVOQ In Psoriatic Arthritis & Ankylosing Spondylitis ,RTTNews,/news/stocks/fda-won-t-meet-pdufa-dates-for-abbvie-rinvoq-in-psoriatic-arthritis-ankylosing-spondylitis-1030554910,positive,0.6235476732254028
882,6/28/2021 2:45:00 PM,AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO),PR Newswire,/news/stocks/abbvie-gastroenterology-pipeline-to-be-featured-at-the-16th-congress-of-european-crohn-s-and-colitis-organisation-ecco-1030558895,positive,0.8865072727203369
883,6/29/2021 12:21:52 PM,AbbVie's upadacitinib successful in late-stage ulcerative colitis maintenance study,Seeking Alpha,https://seekingalpha.com/news/3710897-abbvies-upadacitinib-successful-in-late-stage-ulcerative-colitis-maintenance-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8974445462226868
884,6/29/2021 2:00:00 PM,Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients,PR Newswire,/news/stocks/upadacitinib-rinvoq-met-the-primary-and-all-secondary-endpoints-in-the-52-week-phase-3-maintenance-study-in-ulcerative-colitis-patients-1030562570,negative,0.9319294095039368
885,6/29/2021 2:18:10 PM,AbbVie Says Phase 3 Ulcerative Colitis Maintenance Study Met Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/abbvie-says-phase-3-ulcerative-colitis-maintenance-study-met-primary-endpoint-quick-facts-1030562634,negative,0.8129263520240784
886,6/29/2021 4:30:14 PM,"Jury trial against drugmakers, drug distributors over opioids begins in N.Y. (updated)",Seeking Alpha,https://seekingalpha.com/news/3711050-jury-trial-against-drugmakers-drug-distributors-over-opioids-begins-in-ny?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.835198700428009
887,6/29/2021 9:24:57 PM,"New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid",Benzinga,/news/stocks/new-york-takes-drugmakers-drug-retailers-to-legal-trial-over-opioid-1030564453,positive,0.8192856907844543
888,6/30/2021 12:55:23 PM,"Altimmune price targets lowered, Tilray’s next move predicted at BofA - in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3711337-altimmune-price-targets-lowered-tilrays-next-move-predicted-at-bofa-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8291890621185303
889,7/1/2021 2:28:17 PM,"Vertex initiated at Raymond James, Altimmune price target lowered, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3711844-vertex-initiated-at-raymond-james-altimmune-price-target-lowered-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6252794861793518
890,7/7/2021 10:49:38 AM,Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year,Seeking Alpha,https://seekingalpha.com/news/3713185-mid-size-pharmaceutical-firms-lead-bigger-rivals-in-acquisitions-this-year?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6112593412399292
891,7/7/2021 2:00:00 PM,AbbVie to Host Second-Quarter 2021 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-second-quarter-2021-earnings-conference-call-1030585491,positive,0.9099504947662354
892,7/8/2021 2:42:54 PM,Fifteen states reach agreement with Purdue over bankruptcy plan - NYT,Seeking Alpha,https://seekingalpha.com/news/3713666-fifteen-states-reach-agreement-with-purdue-over-bankruptcy-plan-nyt?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8544976711273193
893,7/8/2021 4:27:00 PM,Stay Away From Low-Growth Organon,InvestorPlace,/news/stocks/low-growth-weak-catalysts-ogn-stock-unattractive-1030590811,positive,0.9079623818397522
894,7/8/2021 7:38:27 PM,"House Oversight report says pharmas spend more on buybacks, dividends than R&D",Seeking Alpha,https://seekingalpha.com/news/3713778-house-oversight-report-says-pharmas-spend-more-on-buybacks-dividends-than-research-development?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8492424488067627
895,7/9/2021 8:02:53 PM,7 Super-Safe Dividend Stock Performers to Buy,InvestorPlace,/news/stocks/7-super-safe-dividend-stocks-to-buy-1030594111,positive,0.8698828220367432
896,7/11/2021 1:00:00 PM,"Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714139-biotech-ma-may-heat-up-with-potential-targets-horizon-therapeutics-arrowhead-pharma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8715733885765076
897,7/13/2021 2:05:06 PM,"The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data",Benzinga,/news/stocks/the-daily-biotech-pulse-equillium-issues-positive-regulatory-update-biogen-in-licenses-multiple-sclerosis-drug-aridis-releases-covid-19-antibody-cocktail-data-1030601329,positive,0.7802436947822571
898,7/15/2021 12:07:52 PM,AbbVie among firms fined for price gouging in U.K.,Seeking Alpha,https://seekingalpha.com/news/3715445-abbvie-among-firms-fined-for-price-gauging-in-uk?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9337075352668762
899,7/16/2021 12:39:41 PM,AbbVie provides regulatory update on RINVOQ sNDA,Seeking Alpha,https://seekingalpha.com/news/3715934-abbvie-provides-regulatory-update-on-rinvoq-snda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9403525590896606
900,7/16/2021 2:09:18 PM,Lilly and Incyte provide update on FDA regulatory timeline for baricitinib,Seeking Alpha,https://seekingalpha.com/news/3715993-lilly-and-incyte-provide-update-on-fda-regulatory-timeline-for-baricitinib?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9406559467315674
901,7/16/2021 2:30:00 PM,AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.,PR Newswire,/news/stocks/abbvie-provides-update-regarding-rinvoq-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-the-u-s-1030615119,positive,0.832988977432251
902,7/16/2021 2:49:33 PM,AbbVie : FDA Didn't Meet PDUFA Action Date For SNDA Of RINVOQ On Atopic Dermatitis Treatment ,RTTNews,/news/stocks/abbvie-fda-didn-t-meet-pdufa-action-date-for-snda-of-rinvoq-on-atopic-dermatitis-treatment-1030615155,neutral,0.8146650791168213
903,7/16/2021 4:10:20 PM,7 Best Dividend Stocks to Buy to Juice Your Portfolio Yield,InvestorPlace,/news/stocks/7-best-dividend-stocks-to-buy-to-juice-your-portfolio-yield-1030615780,positive,0.8995172381401062
904,7/16/2021 4:33:50 PM,Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis ,RTTNews,/news/stocks/lilly-fda-delays-review-of-baricitinib-snda-on-atopic-dermatitis-1030615528,neutral,0.9322182536125183
905,7/19/2021 4:40:06 PM,3 High-Yield Dividend Aristocrats To Buy Now,InvestorPlace,/news/stocks/3-high-yield-dividend-stocks-aristocrats-to-buy-now-1030621331,positive,0.9055553078651428
906,7/20/2021 2:30:00 PM,"Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting",PR Newswire,/news/stocks/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-2021-ascrs-american-society-of-cataract-and-refractive-surgery-annual-meeting-1030624969,positive,0.8260093927383423
907,7/20/2021 2:46:02 PM,Drug distributors agree to settle over $1B claims linked to opioid crisis in New York,Seeking Alpha,https://seekingalpha.com/news/3716928-drug-distributors-agree-to-settle-over-1b-claims-linked-to-opioid-crisis-in-new-york?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8267201781272888
908,7/21/2021 7:00:00 AM,Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS),PR Newswire,/news/stocks/venetoclax-venclexta-granted-us-fda-breakthrough-therapy-designation-btd-in-higher-risk-myelodysplastic-syndrome-mds-1030628709,negative,0.9367148876190186
909,7/21/2021 7:12:41 AM,AbbVie: Venetoclax Gets FDA's Breakthrough Therapy Designation In Higher Risk MDS ,RTTNews,/news/stocks/abbvie-venetoclax-gets-fda-s-breakthrough-therapy-designation-in-higher-risk-mds-1030628721,negative,0.919594407081604
910,7/21/2021 7:05:56 PM,"Johnson & Johnson, drug distributors enter $26B opioid settlement",Seeking Alpha,https://seekingalpha.com/news/3717632-johnson-johnson-drug-distributors-enter-26b-opioid-settlement?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6555246710777283
911,7/22/2021 6:49:00 PM,Caribou Biosciences upsizes $255M initial public offering,Seeking Alpha,https://seekingalpha.com/news/3718229-caribou-biosciences-upsizes-225m-initial-public-offering?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8761433959007263
912,7/22/2021 8:40:28 PM,The 10 Best Dividend Income Growers in the S&P 500,InvestorPlace,/news/stocks/the-10-best-dividend-income-growers-in-the-sp-500-1030636942,negative,0.7578825354576111
913,7/23/2021 4:51:02 PM,FDA approves AbbVie's skin treatment Dalvance for pediatric indication,Seeking Alpha,https://seekingalpha.com/news/3718676-fda-approves-abbvies-skin-treatment-dalvance-for-pediatric-indication?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5416560769081116
914,7/23/2021 6:37:00 PM,DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients,PR Newswire,/news/stocks/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structure-infections-in-pediatric-patients-1030639767,negative,0.9395595192909241
915,7/24/2021 6:33:09 AM,FDA Approves AbbVie's Dalvance To Treat Acute Bacterial Skin & Skin Structure Infections In Children ,RTTNews,/news/stocks/fda-approves-abbvie-s-dalvance-to-treat-acute-bacterial-skin-skin-structure-infections-in-children-1030640331,negative,0.691986083984375
916,7/24/2021 8:00:00 PM,AAIC 2021: What to look for at Alzheimer's biggest annual conference,Seeking Alpha,https://seekingalpha.com/news/3718755-aaic-2021-what-to-look-for-biggest-annual-alzheimers-conference?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9385380744934082
917,7/25/2021 3:26:31 PM,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-july-25-31-big-pharma-earnings-iterum-fda-decision-alzheimer-s-conference-ipos-and-more-1030641744,positive,0.9177685976028442
918,7/25/2021 5:31:00 PM,"New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition",PR Newswire,/news/stocks/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye-condition-1030641814,negative,0.8143572211265564
919,7/26/2021 6:00:21 AM,AbbVie's AGN-190584 shows promising action in late-stage presbyopia study,Seeking Alpha,https://seekingalpha.com/news/3718840-abbvies-agn-190584-shows-promising-action-in-late-stage-presbyopia-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9463993906974792
920,7/27/2021 12:47:47 PM,AbbVie extends collaboration with Calico with focus on age-related diseases,Seeking Alpha,https://seekingalpha.com/news/3719615-abbvie-extends-collaboration-with-calico-with-focus-on-age-related-diseases?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.770764172077179
921,7/27/2021 2:30:00 PM,AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases,PR Newswire,/news/stocks/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases-1030650074,negative,0.7943345308303833
922,7/27/2021 3:36:52 PM,"AbbVie, Calico Again Extend Collaboration Focused On Aging And Age-Related Diseases ",RTTNews,/news/stocks/abbvie-calico-again-extend-collaboration-focused-on-aging-and-age-related-diseases-1030651126,negative,0.8379762172698975
923,7/28/2021 3:02:27 PM,Here's what Wall Street expects from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-q2-earnings-preview-1030656675,positive,0.9177791476249695
924,7/29/2021 1:11:21 PM,FDA OKs expanded labelling for Allergan's Botox to treat upper limb spasticity,Seeking Alpha,https://seekingalpha.com/news/3721522-fda-oks-expanded-labelling-for-allergans-botox-to-treat-upper-limb-spasticity?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9168150424957275
925,7/29/2021 2:08:42 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3721613-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
926,7/29/2021 2:18:48 PM,"The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210,neutral,0.9680227041244507
927,7/29/2021 2:30:00 PM,FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity,PR Newswire,/news/stocks/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity-1030662334,negative,0.9154375195503235
928,7/29/2021 2:54:04 PM,AbbVie : FDA Oks Expanded BOTOX Label To Include Eight New Muscles To Treat Upper Limb Spasticity ,RTTNews,/news/stocks/abbvie-fda-oks-expanded-botox-label-to-include-eight-new-muscles-to-treat-upper-limb-spasticity-1030662474,negative,0.9048709273338318
929,7/30/2021 11:45:38 AM,"AbbVie EPS beats by $0.08, beats on revenue, raises FY21 Non-GAAP guidance",Seeking Alpha,https://seekingalpha.com/news/3722262-abbvie-eps-beats-by-008-beats-on-revenue-raises-fy-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9414646029472351
930,7/30/2021 12:15:31 PM,AbbVie tops Q2 forecast; non-GAAP EPS outlook for FY21 raised,Seeking Alpha,https://seekingalpha.com/news/3722307-abbvie-tops-q2-forecast-non-gaap-eps-outlook-for-fy21-raised?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8902750611305237
931,7/30/2021 1:44:00 PM,AbbVie Reports Second-Quarter 2021 Financial Results,PR Newswire,/news/stocks/abbvie-reports-second-quarter-2021-financial-results-1030667822,positive,0.6682677865028381
932,7/30/2021 1:53:58 PM,"The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-erytech-jumps-on-fast-track-designation-glaxosmithkline-fda-nod-alnylam-s-clinical-collaboration-4-ipos-1030667906,negative,0.7937849164009094
933,7/30/2021 1:58:52 PM,AbbVie Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q2-adjusted-earnings-beat-estimates-1030667871,negative,0.8946022391319275
934,7/30/2021 2:15:59 PM,AbbVie Lifts FY Adj. Profit View ,RTTNews,/news/stocks/abbvie-lifts-fy-adj-profit-view-1030668022,positive,0.6369588375091553
935,7/30/2021 3:51:52 PM,"AbbVie to advance beta-amyloid Alzheimer's candidate, abandons tau asset",Seeking Alpha,https://seekingalpha.com/news/3722486-abbvie-to-advance-beta-amyloid-alzheimers-candidate-abandon-tau-asset?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8751493692398071
936,8/2/2021 2:10:19 PM,€398M Irish tax decision on Takeda upheld on Shire/AbbVie break fee,Seeking Alpha,https://seekingalpha.com/news/3722980-398m-euro-irish-tax-decision-takeda-upheld-shire-abbvie-break-fee?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8379158973693848
937,8/3/2021 5:38:43 AM,Abbott's Subsidiaries Agree To Pay $160 Mln To Settle Alleged False Claims To Medicare ,RTTNews,/news/stocks/abbott-s-subsidiaries-agree-to-pay-160-mln-to-settle-alleged-false-claims-to-medicare-1030679527,negative,0.8173002004623413
938,8/4/2021 6:01:00 PM,JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Ad...,PR Newswire,/news/stocks/jama-dermatology-publishes-data-showing-rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-ad-1030690447,negative,0.9587884545326233
939,8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.935555636882782
940,8/7/2021 6:34:16 PM,UBS highlights 20 top dividend stocks in tough times for yield: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3727237-ubs-highlights-top-divident-stocks-in-tough-times-for-yield?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8619096279144287
941,8/9/2021 8:35:09 AM,Mission Therapeutics earns $20M milestone from AbbVie under Alzheimer’s disease collaboration,Seeking Alpha,https://seekingalpha.com/news/3727290-mission-therapeutics-earns-20m-milestone-from-abbvie-under-alzheimers-disease-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8552497625350952
942,8/9/2021 1:07:41 PM,AbbVie Returns Eye Drug Candidate To Molecular Partners,Benzinga,/news/stocks/abbvie-returns-eye-drug-candidate-to-molecular-partners-1030708104,negative,0.5203808546066284
943,8/9/2021 2:45:00 PM,SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis,PR Newswire,/news/stocks/skyrizi-risankizumab-rzaa-now-available-in-the-u-s-as-a-single-150-mg-injection-for-adults-with-moderate-to-severe-plaque-psoriasis-1030708617,negative,0.6450225114822388
944,8/9/2021 2:58:41 PM,AbbVie Launches SKYRIZI As Single-dose 150 Mg Injection - Quick Facts ,RTTNews,/news/stocks/abbvie-launches-skyrizi-as-single-dose-150-mg-injection-quick-facts-1030708832,positive,0.8132211565971375
945,8/17/2021 7:04:09 PM,7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire,InvestorPlace,/news/stocks/7-buffett-stocks-to-buy-and-sell-if-you-want-to-be-like-berkshire-1030739695,positive,0.9384809136390686
946,8/18/2021 1:37:56 PM,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",Benzinga,/news/stocks/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-for-priority-review-fda-nod-for-glaxosmithkline-1030741574,negative,0.5053824782371521
947,8/18/2021 11:28:00 PM,New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-12-week-results-from-study-evaluating-atogepant-for-the-preventive-treatment-of-migraine-1030743573,positive,0.7292009592056274
948,8/19/2021 1:37:27 PM,"The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck",Benzinga,/news/stocks/the-daily-biotech-pulse-coherus-soars-on-lung-cancer-data-illumina-closes-on-grail-buy-without-regulatory-clearance-adagene-strikes-collaboration-with-merck-1030745371,neutral,0.7770193219184875
949,8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7850372195243835
950,8/24/2021 2:00:00 PM,European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis,PR Newswire,/news/stocks/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-the-european-union-for-the-treatment-of-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-1030754717,negative,0.8869273066520691
951,8/24/2021 2:09:21 PM,"The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-cara-s-korsuva-greenlighted-by-fda-clinical-trial-disappointments-for-novartis-theravance-vertex-inks-crispr-licensing-deal-1030754775,positive,0.5257502198219299
952,8/24/2021 2:18:04 PM,AbbVie Announces EC Approval Of RINVOQ In Treatment Of Moderate To Severe Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-announces-ec-approval-of-rinvoq-in-treatment-of-moderate-to-severe-atopic-dermatitis-1030754801,negative,0.852007269859314
953,8/24/2021 7:45:47 PM,7 S&P 500 Stocks to Buy for Growth and Value,InvestorPlace,/news/stocks/7-sp-500-stocks-to-buy-for-growth-and-value-1030755966,positive,0.8494846224784851
954,8/26/2021 2:09:14 PM,"The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-early-approval-for-ascendis-pediatric-growth-hormone-deficiency-treatment-redhill-biopharma-spikes-on-positive-covid-19-drug-data-renovorx-ipo-1030760636,negative,0.7406299114227295
955,8/30/2021 8:43:24 AM,Biotech Stocks Facing FDA Decision In September 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2021-1030766032,positive,0.7743737697601318
956,8/31/2021 5:41:24 PM,7 Dividend Aristocrat Stocks to Buy in September for Gains and Stability,InvestorPlace,/news/stocks/7-dividend-aristocrat-stocks-to-buy-in-september-for-gains-and-stability-1030770935,positive,0.7393564581871033
957,8/31/2021 8:00:15 PM,Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-september-pdufa-dates-1030770967,positive,0.9473286271095276
958,9/1/2021 8:01:55 PM,ABBV Stock: The FDA Blow That Just Sent AbbVie Tumbling on Wednesday,InvestorPlace,/news/stocks/abbv-stock-the-fda-blow-that-just-sent-abbvie-tumbling-on-wednesday-1030774378,neutral,0.7397889494895935
959,9/1/2021 9:24:37 PM,"4 Top Stock Trades for Thursday: Ethereum, ABBV, CHWY, LCID",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-ethereum-abbv-chwy-lcid-1030774760,positive,0.9350295066833496
960,9/2/2021 2:19:58 PM,"The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab",Benzinga,/news/stocks/the-daily-biotech-pulse-assembly-bio-halts-hbv-study-moderna-initiates-submission-for-covid-19-booster-dose-fda-nod-for-beigene-tiziana-out-licenses-foralumab-1030776427,positive,0.808341920375824
961,9/2/2021 5:34:14 PM,7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In ,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-before-3-5-trillion-floods-in-1030777655,positive,0.8197962045669556
962,9/4/2021 10:04:26 PM,"The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More",Benzinga,/news/stocks/the-latest-barron-s-picks-and-pans-include-general-electric-netflix-reddit-and-more-1030780802,positive,0.9478982090950012
963,9/7/2021 2:24:49 PM,Vertex slides as Morgan Stanley cuts rating on competitive threat from AbbVie,Seeking Alpha,https://seekingalpha.com/news/3737567-vertex-slides-as-morgan-stanley-cuts-rating-on-competitive-threat-from-abbvie?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9323988556861877
964,9/8/2021 12:04:15 PM,Alector slides as two top executives plan to leave,Seeking Alpha,https://seekingalpha.com/news/3737855-alector-slides-as-two-top-executives-plan-to-leave?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8758047223091125
965,9/8/2021 3:10:00 PM,AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress,PR Newswire,/news/stocks/abbvie-to-present-data-from-its-migraine-portfolio-at-the-2021-international-headache-congress-1030787356,positive,0.8788583278656006
966,9/9/2021 1:00:00 PM,Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet,PR Newswire,/news/stocks/clinical-trial-of-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-s-lymphoma-b-nhl-published-in-the-lancet-1030789586,negative,0.5286357402801514
967,9/10/2021 3:00:00 PM,AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021,PR Newswire,/news/stocks/abbvie-to-highlight-its-leadership-in-movement-disorders-at-the-international-parkinson-and-movement-disorder-society-virtual-congress-2021-1030792655,negative,0.6310160756111145
968,9/10/2021 4:27:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1030792896,neutral,0.5513123869895935
969,9/13/2021 10:00:07 AM,7 S&P 500 Dividend Stocks To Buy Yielding 4%  ,InvestorPlace,/news/stocks/7-sp-500-dividend-stocks-to-buy-yielding-4-1030795279,positive,0.8440023064613342
970,9/13/2021 12:30:00 PM,AbbVie and REGENXBIO Announce Eye Care Collaboration,PR Newswire,/news/stocks/abbvie-and-regenxbio-announce-eye-care-collaboration-1030795317,positive,0.9225761890411377
971,9/13/2021 1:41:09 PM,AbbVie Inks Eye Care Deal With REGENXBIO ,RTTNews,/news/stocks/abbvie-inks-eye-care-deal-with-regenxbio-1030795560,negative,0.5720356106758118
972,9/13/2021 2:39:25 PM,"AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration",Benzinga,/news/stocks/abbvie-regenxbio-ink-1-75b-retinal-gene-therapy-collaboration-1030795792,positive,0.7333252429962158
973,9/13/2021 4:57:10 PM,Why Regenxbio Shares Are Trading Higher Today,Benzinga,/news/stocks/why-regenxbio-shares-are-trading-higher-today-1030796163,negative,0.5266830921173096
974,9/16/2021 2:00:00 PM,AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis,PR Newswire,/news/stocks/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-1030804385,negative,0.7362872958183289
975,9/16/2021 3:47:10 PM,AbbVie Files For FDA And EMA Approval Of Upadacitinib For Ulcerative Colitis ,RTTNews,/news/stocks/abbvie-files-for-fda-and-ema-approval-of-upadacitinib-for-ulcerative-colitis-1030804866,positive,0.5168232321739197
976,9/17/2021 11:56:31 AM,ANI Pharmaceuticals launches generic version of AbbVie's Bystolic,Seeking Alpha,https://seekingalpha.com/news/3740767-ani-pharmaceuticals-launches-generic-version-of-abbvies-bystolic?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7737421989440918
977,9/20/2021 3:10:00 PM,AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease,PR Newswire,/news/stocks/abbvie-submits-regulatory-application-to-fda-for-risankizumab-rzaa-skyrizi-for-the-treatment-of-patients-16-years-and-older-with-moderate-to-severe-crohn-s-disease-1030810065,negative,0.8395792841911316
978,9/20/2021 3:58:04 PM,AbbVie Seeks Approval For SKYRIZI Based On Data From Three Phase 3 Studies ,RTTNews,/news/stocks/abbvie-seeks-approval-for-skyrizi-based-on-data-from-three-phase-3-studies-1030810218,negative,0.7282294631004333
979,9/20/2021 6:32:57 PM,AbbVie Is Worth 28% More Based on Impressive Dividends,InvestorPlace,/news/stocks/abbv-stock-is-worth-28-more-based-on-impressive-dividends-1030810950,positive,0.7342685461044312
980,9/22/2021 11:13:42 AM,Incyte trades lower on safety warning in FDA approval for Opzelura,Seeking Alpha,https://seekingalpha.com/news/3742134-incyte-trades-lower-on-safety-warning-in-fda-approval-for-opzelura?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9539995789527893
981,9/22/2021 1:01:09 PM,3 Cheap Healthcare Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cheap-healthcare-stocks-to-buy-right-now-1030815956,positive,0.9108651280403137
982,9/23/2021 2:45:00 PM,AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress,PR Newswire,/news/stocks/abbvie-presents-new-data-analyses-for-growing-dermatology-portfolio-at-the-30th-european-academy-of-dermatology-and-venereology-eadv-congress-1030818866,positive,0.8277745842933655
983,9/24/2021 1:35:37 PM,"Biotech's big fall catalysts to watch out for, from Evercore",Seeking Alpha,https://seekingalpha.com/news/3743858-biotechs-big-fall-catalysts-to-watch-out-for-from-evercore?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.754619300365448
984,9/25/2021 6:58:09 PM,"Barron's Latest Picks And Pans: Healthcare Roundtable Picks, Dividend Aristocrats And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-healthcare-roundtable-picks-dividend-aristocrats-and-more-1030823039,positive,0.935904860496521
985,9/27/2021 2:30:00 PM,"Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals",PR Newswire,/news/stocks/americans-are-frustrated-by-unexpected-blurry-near-vision-issues-a-new-survey-reveals-1030825522,neutral,0.967832088470459
986,9/28/2021 7:30:23 PM,7 Biotech Stocks Entering the Golden Boom Phase,InvestorPlace,/news/stocks/7-biotech-stocks-entering-the-golden-boom-phase-1030829968,positive,0.7444129586219788
987,9/29/2021 12:42:00 AM,"FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine",PR Newswire,/news/stocks/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine-1030829267,negative,0.8691498637199402
988,9/29/2021 3:35:39 AM,FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine ,RTTNews,/news/stocks/fda-approves-abbvie-s-qulipta-for-preventive-treatment-of-migraine-1030829318,negative,0.805422842502594
989,9/29/2021 2:13:41 PM,"The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-abbvie-s-migraine-drug-ok-d-by-fda-amicus-spins-off-gene-therapy-business-geovax-in-licenses-cancer-drug-1030831016,positive,0.9129316210746765
990,9/30/2021 11:13:47 AM,Meet members of the 2021 IPO class: Healthcare - 1,Seeking Alpha,https://seekingalpha.com/news/3746473-meet-members-of-the-2021-ipo-class-healthcare-1?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9424605965614319
991,9/30/2021 12:58:37 PM,Sanofi says mid-stage trial for atopic dermatitis therapy met primary endpoints,Seeking Alpha,https://seekingalpha.com/news/3746561-sanofi-says-mid-stage-trial-for-atopic-dermatitis-therapy-met-primary-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6636936068534851
992,9/30/2021 1:43:13 PM,"The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-confirms-acceleron-purchase-regeneron-touts-covid-19-antibody-cocktail-data-takeda-in-licenses-huntington-s-disease-drug-1030833761,positive,0.8744046688079834
993,9/30/2021 2:30:00 PM,AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress,PR Newswire,/news/stocks/abbvie-presents-new-analyses-evaluating-rinvoq-upadacitinib-in-atopic-dermatitis-across-patient-characteristics-and-body-regions-at-eadv-virtual-congress-1030834003,positive,0.8514903783798218
994,9/30/2021 3:36:48 PM,AbbVie: New Analysis Show RINVOQ's Potential To Alleviate Itch And Rash In Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-new-analysis-show-rinvoq-s-potential-to-alleviate-itch-and-rash-in-atopic-dermatitis-1030834322,negative,0.9398584365844727
995,9/30/2021 3:45:00 PM,AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress,PR Newswire,/news/stocks/abbvie-presents-late-breaking-data-on-risankizumab-skyrizi-in-psoriatic-arthritis-at-the-30th-european-academy-of-dermatology-and-venereology-eadv-congress-1030834344,positive,0.8342210054397583
996,10/3/2021 12:06:00 AM,AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021,PR Newswire,/news/stocks/abbvie-to-showcase-new-data-at-the-united-european-gastroenterology-ueg-week-virtual-2021-1030838777,positive,0.8732936978340149
997,10/4/2021 4:27:26 PM,REGENXBIO posts biggest intraday loss in over a year after data from wet AMD trial,Seeking Alpha,https://seekingalpha.com/news/3748236-regenxbio-posts-biggest-intraday-loss-in-over-a-year-after-data-from-wet-amd-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9681655168533325
998,10/5/2021 2:00:00 PM,AbbVie to Host Third-Quarter 2021 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-third-quarter-2021-earnings-conference-call-1030843520,positive,0.9064642786979675
999,10/7/2021 2:15:00 PM,AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis,PR Newswire,/news/stocks/abbvie-s-rinvoq-upadacitinib-met-primary-and-all-ranked-secondary-endpoints-in-phase-3-study-in-ankylosing-spondylitis-1030850082,negative,0.9260411858558655
1000,10/7/2021 2:16:00 PM,AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis,PR Newswire,/news/stocks/abbvie-s-upadacitinib-rinvoq-met-primary-and-most-ranked-secondary-endpoints-in-phase-3-study-for-non-radiographic-axial-spondyloarthritis-1030850084,negative,0.9353053569793701
1001,10/7/2021 2:33:50 PM,AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies - Quick Facts ,RTTNews,/news/stocks/abbvie-rinvoq-meets-primary-endpoints-in-phase-3-studies-quick-facts-1030850152,negative,0.7101197838783264
1002,10/11/2021 12:43:40 PM,ChemoCentryx appoints rheumatologist Rita I. Jain as chief medical officer,Seeking Alpha,https://seekingalpha.com/news/3751206-chemocentryx-appoints-rheumatologist-rita-i-jain-as-chief-medical-officer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9209420680999756
1003,10/11/2021 2:42:00 PM,Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness,PR Newswire,/news/stocks/allergan-aesthetics-launches-series-of-initiatives-to-support-breast-cancer-awareness-1030856055,negative,0.7827863097190857
1004,10/11/2021 5:07:09 PM,"Cannabis Movers & Shakers: Clairvoyant Therapeutics, Eaze, Leafly, Chalice Brands",Benzinga,/news/stocks/cannabis-movers-shakers-clairvoyant-therapeutics-eaze-leafly-chalice-brands-1030856480,positive,0.9382358193397522
1005,10/11/2021 8:21:09 PM,"Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program",Benzinga,/news/stocks/psyched-seattle-decriminalizes-psychedelics-psilocybin-increases-emotions-from-music-novamind-s-palliative-care-program-1030856857,positive,0.8207285404205322
1006,10/15/2021 2:35:00 PM,AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU),PR Newswire,/news/stocks/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-active-psoriatic-arthritis-in-the-european-union-eu-1030869488,negative,0.9307770729064941
1007,10/15/2021 2:53:38 PM,AbbVie's Risankizumab Gets CHMP Positive Opinion For Active Psoriatic Arthritis Treatment ,RTTNews,/news/stocks/abbvie-s-risankizumab-gets-chmp-positive-opinion-for-active-psoriatic-arthritis-treatment-1030869555,negative,0.9499505758285522
1008,10/18/2021 10:30:00 AM,7 Blue Chips to Shield Your Portfolio From Market Downturn,InvestorPlace,/news/stocks/7-blue-chips-to-shield-your-portfolio-from-market-downturn-1030873107,positive,0.88576340675354
1009,10/18/2021 4:59:58 PM,Progenity continues rise following patents on ingestible therapeutics; shares up 32%,Seeking Alpha,https://seekingalpha.com/news/3754178-progenity-continues-rise-following-patents-on-ingestible-therapeutics-shares-up-32?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9532865285873413
1010,10/19/2021 3:53:53 PM,FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira ,RTTNews,/news/stocks/fda-oks-cyltezo-as-first-interchangeable-biosimilar-to-humira-1030877900,negative,0.8527949452400208
1011,10/19/2021 9:10:23 PM,3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat,Benzinga,/news/stocks/3-biopharma-stocks-to-watch-following-johnson-johnson-s-earnings-beat-1030878749,positive,0.8914384841918945
1012,10/20/2021 12:36:29 PM,7 A-Rated Dividend Stocks to Buy for Q4,InvestorPlace,/news/stocks/7-a-rated-dividend-stocks-to-buy-for-q4-1030881776,positive,0.9155215620994568
1013,10/21/2021 8:15:30 PM,Progenity Has Seven Quarters Left to Reverse Its Burn Rate,InvestorPlace,/news/stocks/prog-stock-could-rise-from-cash-burn-cost-cutting-at-progenity-1030887136,positive,0.6786702275276184
1014,10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741,positive,0.9414970874786377
1015,10/25/2021 6:20:54 PM,Eli Lilly Q3 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3757607-eli-lilly-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7560358643531799
1016,10/26/2021 2:20:38 PM,The 7 Best Stocks to Buy to Profit From the Rich,InvestorPlace,/news/stocks/skip-jealousy-7-best-stocks-to-buy-profit-from-rich-1030900693,positive,0.7997937798500061
1017,10/26/2021 2:30:00 PM,"Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia",PR Newswire,/news/stocks/allergan-an-abbvie-company-to-present-new-data-on-investigational-agn-190584-for-the-treatment-of-presbyopia-1030899607,positive,0.7536851763725281
1018,10/27/2021 3:02:25 PM,AbbVie earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/abbvie-stock-quarter-earnings-preview-q3-1030905365,positive,0.9269446134567261
1019,10/28/2021 12:59:34 PM,AbbVie posts encouraging data from late-stage ABBV-951 Parkinson's disease trial,Seeking Alpha,https://seekingalpha.com/news/3760028-abbvie-posts-encouraging-data-from-late-stage-abbv-951-parkinsons-disease-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9494510293006897
1020,10/28/2021 2:15:00 PM,AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with A...,PR Newswire,/news/stocks/abbvie-announces-abbv-951-foslevodopa-foscarbidopa-showed-improvement-in-controlling-motor-fluctuations-compared-to-oral-levodopa-carbidopa-medication-in-pivotal-phase-3-trial-in-patients-with-a-1030910193,negative,0.9556576609611511
1021,10/28/2021 2:53:47 PM,AbbVie: Phase 3 Trial Of ABBV-951 Shows Improvement In Motor Fluctuations In Parkinson's Disease ,RTTNews,/news/stocks/abbvie-phase-3-trial-of-abbv-951-shows-improvement-in-motor-fluctuations-in-parkinson-s-disease-1030910403,negative,0.9497995972633362
1022,10/28/2021 3:21:51 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3760147-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
1023,10/28/2021 9:56:30 PM,"FDA Restricts Sale, Approves New Labeling Of Breast Implants",Benzinga,/news/stocks/fda-restricts-sale-approves-new-labeling-of-breast-implants-1030911878,positive,0.6530255079269409
1024,10/29/2021 11:43:59 AM,"AbbVie EPS beats by $0.11, beats on revenue, raises guidance",Seeking Alpha,https://seekingalpha.com/news/3760741-abbvie-eps-beats-0_11-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9040260910987854
1025,10/29/2021 11:47:00 AM,"AbbVie hikes dividend by ~9% to $1.41 per share, stock yields 5.2%",Seeking Alpha,https://seekingalpha.com/news/3760740-abbvie-raises-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7613878846168518
1026,10/29/2021 12:03:31 PM,AbbVie's cariprazine meets main goal in late-stage major depressive disorder study,Seeking Alpha,https://seekingalpha.com/news/3760765-abbvies-cariprazine-meets-main-goal-in-late-stage-major-depressive-disorder-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7527263760566711
1027,10/29/2021 12:17:57 PM,AbbVie sets better-than-expected 2021 guidance despite slowdown in topline growth,Seeking Alpha,https://seekingalpha.com/news/3760782-abbvie-sets-better-than-expected-2021-guidance-despite-slowdown-in-topline-growth?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9497636556625366
1028,10/29/2021 1:40:00 PM,AbbVie Reports Third-Quarter 2021 Financial Results,PR Newswire,/news/stocks/abbvie-reports-third-quarter-2021-financial-results-1030914937,positive,0.7102482318878174
1029,10/29/2021 1:48:56 PM,AbbVie Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/abbvie-q3-adjusted-earnings-beat-estimates-1030914969,negative,0.8896722197532654
1030,10/29/2021 1:50:00 PM,AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder,PR Newswire,/news/stocks/abbvie-s-cariprazine-vraylar-met-primary-endpoint-in-phase-3-study-as-an-adjunctive-treatment-for-major-depressive-disorder-1030914976,negative,0.7997897267341614
1031,10/29/2021 2:05:03 PM,AbbVie Raises FY21 Outlook; Boosts Dividend 8.5% - Quick Facts ,RTTNews,/news/stocks/abbvie-raises-fy21-outlook-boosts-dividend-8-5-quick-facts-1030915024,negative,0.9481886625289917
1032,10/29/2021 2:14:43 PM,Aurinia Pharma may be worth $45-$53/share in a potential sale - analyst,Seeking Alpha,https://seekingalpha.com/news/3760897-aurinia-pharma-may-be-worth-45-53share-in-a-potential-sale-analyst?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9303962588310242
1033,10/29/2021 2:35:52 PM,AbbVie Says Cariprazine Met Primary Endpoint In Phase 3 Study For Major Depressive Disorder ,RTTNews,/news/stocks/abbvie-says-cariprazine-met-primary-endpoint-in-phase-3-study-for-major-depressive-disorder-1030915197,positive,0.5567565560340881
1034,10/29/2021 5:53:42 PM,FDA approves AbbVie's Vuity eye drops for age-related farsightedness,Seeking Alpha,https://seekingalpha.com/news/3760991-fda-approves-abbvies-vuity-eye-drops-for-age-related-farsightednes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8202469944953918
1035,10/29/2021 11:31:00 PM,"U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)",PR Newswire,/news/stocks/u-s-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-1-25-the-first-and-only-eye-drop-to-treat-presbyopia-age-related-blurry-near-vision-1030916583,negative,0.9341734647750854
1036,10/30/2021 11:27:37 AM,FDA Approves Allergan's VUITY As First Eye Drop To Treat Presbyopia ,RTTNews,/news/stocks/fda-approves-allergan-s-vuity-as-first-eye-drop-to-treat-presbyopia-1030916819,negative,0.5875371098518372
1037,11/1/2021 1:31:00 PM,AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021,PR Newswire,/news/stocks/abbvie-highlights-innovative-research-from-its-rheumatology-portfolio-at-acr-convergence-2021-1030921385,negative,0.7544534802436829
1038,11/1/2021 2:01:23 PM,Aurinia Pharma drops after GlaxoSmithKline denies report on potential bid,Seeking Alpha,https://seekingalpha.com/news/3761428-aurinia-pharma-drops-after-glaxosmithkline-denies-report-on-potential-bid?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9460808038711548
1039,11/1/2021 2:17:54 PM,"ANI Pharma surges 44% following strong earnings, expanded approval; hits 52-week high",Seeking Alpha,https://seekingalpha.com/news/3761439-ani-pharma-surges-44-following-strong-earnings-expanded-approval-hits-52-week-high?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9454042911529541
1040,11/2/2021 12:21:00 PM,California Judge Rules For Drugmakers In Major Opioid Litigation,Benzinga,/news/stocks/california-judge-rules-for-drugmakers-in-major-opioid-litigation-1030925651,positive,0.6099182963371277
1041,11/3/2021 2:38:24 PM,7 Dividend Aristocrat Stocks That Should Grace Your Portfolio,InvestorPlace,/news/stocks/7-dividend-aristocrat-stocks-that-should-grace-your-portfolio-1030933089,positive,0.9271454215049744
1042,11/4/2021 2:05:00 PM,AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting,PR Newswire,/news/stocks/abbvie-to-highlight-new-advances-in-blood-cancer-research-and-expanding-oncology-pipeline-at-63rd-ash-annual-meeting-1030937447,negative,0.7741832137107849
1043,11/5/2021 3:03:43 PM,New AbbVie Skyrizi data shows improvements in psoriatic arthritis,Seeking Alpha,https://seekingalpha.com/news/3766197-new-abbvie-skyrizi-data-shows-improvements-in-psoriatric-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9407548904418945
1044,11/5/2021 3:06:00 PM,AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021,PR Newswire,/news/stocks/abbvie-presents-integrated-efficacy-and-safety-data-from-two-phase-3-trials-on-risankizumab-skyrizi-in-psoriatic-arthritis-at-acr-convergence-2021-1030942942,positive,0.5440911650657654
1045,11/5/2021 3:25:52 PM,AbbVie Says Phase 3 Data On Risankizumab Shows Greater Improvements In Psoriatic Arthritis Signs ,RTTNews,/news/stocks/abbvie-says-phase-3-data-on-risankizumab-shows-greater-improvements-in-psoriatic-arthritis-signs-1030942981,negative,0.9571885466575623
1046,11/6/2021 8:21:10 PM,"Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-alleghany-blade-air-mobility-gene-therapy-picks-and-more-1030944140,positive,0.9395705461502075
1047,11/8/2021 2:30:00 PM,"Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting",PR Newswire,/news/stocks/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at-the-aao-american-academy-of-ophthalmology-2021-annual-meeting-1030949049,positive,0.8336284756660461
1048,11/8/2021 6:16:24 PM,Galapagos rises as analysts highlight a major catalyst ahead,Seeking Alpha,https://seekingalpha.com/news/3767006-galapagos-rises-as-analysts-highlight-a-major-catalyst-ahead?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7532625794410706
1049,11/9/2021 2:31:00 PM,AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis,PR Newswire,/news/stocks/abbvie-to-present-new-long-term-analysis-evaluating-the-sustainability-of-response-to-rinvoq-upadacitinib-among-patients-with-rheumatoid-arthritis-1030953806,negative,0.65491783618927
1050,11/9/2021 2:39:45 PM,New AbbVie data on Rinvoq shows efficacy in psoriatic arthritis and axial involvement,Seeking Alpha,https://seekingalpha.com/news/3767734-new-abbvie-data-on-rinvoq-shows-efficacy-in-psoriatic-arthritis-and-axial-involvement?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5689791440963745
1051,11/9/2021 2:45:00 PM,AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021,PR Newswire,/news/stocks/abbvie-presents-new-efficacy-data-on-upadacitinib-rinvoq-in-people-with-active-psoriatic-arthritis-and-axial-involvement-at-acr-convergence-2021-1030953839,negative,0.6716750264167786
1052,11/9/2021 3:27:05 PM,AbbVie Presents Positive Data On Upadacitinib In Active Psoriatic Arthritis And Axial Involvement ,RTTNews,/news/stocks/abbvie-presents-positive-data-on-upadacitinib-in-active-psoriatic-arthritis-and-axial-involvement-1030954443,negative,0.9517303109169006
1053,11/10/2021 2:30:00 PM,"AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025",PR Newswire,/news/stocks/abbvie-university-of-chicago-extend-research-collaboration-to-support-preclinical-oncology-research-through-2025-1030959434,negative,0.8149950504302979
1054,11/15/2021 2:30:00 PM,Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day,PR Newswire,/news/stocks/allergan-aesthetics-celebrates-third-annual-botox-cosmetic-onabotulinumtoxina-day-1030976299,positive,0.5476278066635132
1055,11/15/2021 9:47:35 PM,"Warren Buffett's Berkshire Hathaway adds Royalty Pharma, exits Merck",Seeking Alpha,https://seekingalpha.com/news/3770994-warren-buffetts-berkshire-hathaway-adds-royalty-pharma-exits-merck?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9137044548988342
1056,11/16/2021 11:00:42 AM,Merck Is a Dividend Play Ready to Get Back in Gear,InvestorPlace,/news/stocks/mrk-stock-dividend-play-ready-get-back-in-gear-1030979591,positive,0.7099084854125977
1057,11/17/2021 7:50:04 AM,European Commission approves AbbVie's SKYRIZI for psoriatic arthritis in adults,Seeking Alpha,https://seekingalpha.com/news/3771728-european-commission-approves-abbvies-skyrizi-for-psoriatic-arthritis-in-adults?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6864808201789856
1058,11/17/2021 8:05:00 AM,AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis,PR Newswire,/news/stocks/abbvie-expands-immunology-portfolio-in-the-european-union-with-the-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-adults-with-active-psoriatic-arthritis-1030983069,negative,0.8254136443138123
1059,11/17/2021 8:57:28 AM,AbbVie: SKYRIZI Gets EU Approval To Treat Adults With Active Psoriatic Arthritis ,RTTNews,/news/stocks/abbvie-skyrizi-gets-eu-approval-to-treat-adults-with-active-psoriatic-arthritis-1030983147,negative,0.9342333078384399
1060,11/17/2021 1:53:04 PM,"The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment",Benzinga,/news/stocks/the-daily-biotech-pulse-atea-sinks-on-termination-of-roche-contract-pfizer-cfo-to-retire-gsk-vir-bag-1b-contract-to-supply-covid-antibody-treatment-1030984023,positive,0.5760539174079895
1061,11/18/2021 2:37:11 PM,AbbVie Brings VENCLEXTA Plus Obinutuzumab To Chronic Lymphocytic Leukemia Patients In Quebec ,RTTNews,/news/stocks/abbvie-brings-venclexta-plus-obinutuzumab-to-chronic-lymphocytic-leukemia-patients-in-quebec-1030988105,negative,0.587235689163208
1062,11/18/2021 3:00:00 PM,New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission,PR Newswire,/news/stocks/new-literature-review-highlights-economic-benefits-associated-with-achieving-rheumatoid-arthritis-remission-1030988247,negative,0.8980699181556702
1063,11/19/2021 11:29:05 AM,7 Dividend Stocks to Buy for 2022 and Hold Forever,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-for-2022-and-hold-forever-1030881013,positive,0.94387286901474
1064,11/19/2021 2:00:00 PM,Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting,PR Newswire,/news/stocks/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2021-american-society-for-dermatologic-surgery-virtual-meeting-1030991390,positive,0.8243354558944702
1065,11/19/2021 3:35:59 PM,Piper Sandler downgrades Vertex to neutral on slowing cystic fibrosis growth,Seeking Alpha,https://seekingalpha.com/news/3772915-piper-sandler-downgrades-vertex-to-neutral-on-slowing-cystic-fibrosis-growth?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6592352986335754
1066,11/22/2021 11:09:31 AM,7 High-Yield Stock Gems for Income-Obsessed Investors,InvestorPlace,/news/stocks/seven-high-yield-stock-gems-for-income-obsessed-investors-1030901222,positive,0.9080877900123596
1067,11/23/2021 3:33:18 PM,AbbVie upgraded to buy at Societe Generale; sees 48% upside,Seeking Alpha,https://seekingalpha.com/news/3773845-societe-generale-upgrades-abbvie-to-buy-sees-48-upside?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8325985670089722
1068,11/23/2021 4:09:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-23-2021-1030998378,neutral,0.6060854196548462
1069,11/30/2021 1:11:38 PM,AbbVie submits risankizumab application to EMA in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/3775306-abbvie-submits-risankizumab-application-to-ema-in-crohns-disease?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.927959144115448
1070,11/30/2021 2:05:00 PM,AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA),PR Newswire,/news/stocks/abbvie-submits-application-for-risankizumab-skyrizi-in-moderate-to-severe-crohn-s-disease-to-european-medicines-agency-ema-1031011970,negative,0.5860413312911987
1071,12/2/2021 4:06:41 PM,Aurinia Pharmaceuticals gains amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/3776494-aurinia-pharmaceuticals-gains-on-takeover-speculation?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9189054369926453
1072,12/2/2021 6:02:11 PM,Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-december-pdufa-dates-1031020805,positive,0.9439957737922668
1073,12/3/2021 9:43:36 PM,AbbVie updates U.S. labeling info for RINVOQ in rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3777094-abbvie-updates-us-labeling-info-for-rinvoq-in-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9334484338760376
1074,12/3/2021 10:15:00 PM,AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.,PR Newswire,/news/stocks/abbvie-provides-update-on-rinvoq-upadacitinib-for-the-treatment-of-rheumatoid-arthritis-in-the-u-s-1031024006,positive,0.822492778301239
1075,12/6/2021 12:07:24 PM,"The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-6-dec-11-daré-fda-decision-adcom-tryst-for-reata-multiple-conference-presentations-and-more-1031025543,positive,0.9361634850502014
1076,12/6/2021 2:06:53 PM,AbbVie’s Rinvoq achieves primary endpoint in late-stage Crohn’s Disease trial,Seeking Alpha,https://seekingalpha.com/news/3777241-abbvie-rinvoq-achieves-primary-endpoint-in-late-stage-crohns-disease-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8420740962028503
1077,12/6/2021 2:30:00 PM,Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease,PR Newswire,/news/stocks/upadacitinib-rinvoq-achieved-primary-and-key-secondary-endpoints-in-first-phase-3-induction-study-in-patients-with-crohn-s-disease-1031026068,negative,0.926045298576355
1078,12/6/2021 2:50:02 PM,AbbVie's Upadacitinib Achieves Primary & Secondary Endpoints In Phase 3 Study On Crohn's Disease ,RTTNews,/news/stocks/abbvie-s-upadacitinib-achieves-primary-secondary-endpoints-in-phase-3-study-on-crohn-s-disease-1031026110,negative,0.9300193190574646
1079,12/7/2021 11:00:16 AM,7 Stocks to Watch as the Omicron Variant Becomes the Market’s New Wildcard,InvestorPlace,/news/stocks/7-stocks-to-watch-as-the-omicron-variant-becomes-the-markets-new-wildcard-1031028496,negative,0.5960684418678284
1080,12/8/2021 5:37:40 PM,AbbVie division Allergan in $200M settlement with New York over role in opioid crisis,Seeking Alpha,https://seekingalpha.com/news/3778370-abbvie-division-allergan-in-200m-settlement-with-new-york-over-role-in-opioid-crisis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8521217703819275
1081,12/8/2021 7:29:54 PM,Biosimilar Player Alvotech To Go Public Via $2.5B Oaktree SPAC Merger,Benzinga,/news/stocks/biosimilar-player-alvotech-to-go-public-via-2-5b-oaktree-spac-merger-1031033390,positive,0.8044466376304626
1082,12/9/2021 1:38:59 PM,"AbbVie is Wells Fargo's top pick in large biotech, pharma sectors; sees 35% upside",Seeking Alpha,https://seekingalpha.com/news/3778670-abbvie-is-wells-fargo-top-pick-in-large-biotech-pharma-sectors-sees-35-upside?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8829697966575623
1083,12/9/2021 3:00:00 PM,"VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available",PR Newswire,/news/stocks/vuity-pilocarpine-hci-ophthalmic-solution-1-25-the-first-and-only-fda-approved-eye-drop-to-treat-age-related-blurry-near-vision-presbyopia-is-now-available-1031035722,negative,0.8107231855392456
1084,12/9/2021 3:19:37 PM,Allergan Announces Availability Of FDA-Approved Eye Drop VUITY - Quick Facts ,RTTNews,/news/stocks/allergan-announces-availability-of-fda-approved-eye-drop-vuity-quick-facts-1031035849,positive,0.5650014281272888
1085,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,neutral,0.5978407859802246
1086,12/9/2021 5:06:46 PM,Where AbbVie Stands With Analysts,Benzinga,/news/stocks/where-abbvie-stands-with-analysts-1031036367,positive,0.8949053883552551
1087,12/10/2021 1:50:11 PM,"The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-sings-metabolic-disorder-drug-pact-moderna-reports-positive-flu-vaccine-data-halozyme-to-buy-back-shares-1031038565,positive,0.6495084166526794
1088,12/13/2021 7:57:17 AM,"AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch ",RTTNews,/news/stocks/astrazeneca-elated-on-calquence-data-imgn-s-imgn632-appears-to-be-promising-in-aml-xrtx-on-watch-1031040799,negative,0.9492062330245972
1089,12/13/2021 7:32:25 PM,Why does Pfizer's $6.7B acquisition of Arena Pharmaceuticals make sense? Etrasimod,Seeking Alpha,https://seekingalpha.com/news/3779629-why-does-pfizer-67b-acquisition-of-arena-pharmaceuticals-make-sense-etrasimod?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.917937159538269
1090,12/14/2021 1:43:32 PM,"AbbVie, Endo under investigation in Texas over sales practices for hormone blockers",Seeking Alpha,https://seekingalpha.com/news/3779885-abbvie-endo-under-investigation-in-texas-over-sales-practices-for-hormone-blockers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9291568994522095
1091,12/14/2021 3:29:40 PM,Genentech's Polivy Combination Reduces Risk Of Disease Worsening Or Death By 27% In DLBCL ,RTTNews,/news/stocks/genentech-s-polivy-combination-reduces-risk-of-disease-worsening-or-death-by-27-in-dlbcl-1031043790,negative,0.9397051930427551
1092,12/14/2021 9:55:45 PM,Idera says AbbVie has discontinued enrollment in its study for tilsotolimod combo,Seeking Alpha,https://seekingalpha.com/news/3780144-idera-says-abbvie-has-discontinued-enrollment-in-its-study-for-tilsotolimod-combo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8784255385398865
1093,12/15/2021 12:18:00 AM,RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis,PR Newswire,/news/stocks/rinvoq-upadacitinib-receives-u-s-fda-approval-for-active-psoriatic-arthritis-1031046554,negative,0.9418200850486755
1094,12/15/2021 1:59:28 AM,FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis ,RTTNews,/news/stocks/fda-approves-abbvie-s-rinvoq-to-treat-active-psoriatic-arthritis-1031044741,negative,0.7703279852867126
1095,12/15/2021 7:42:41 AM,AbbVie's Rinvoq receives FDA approval for active psoriatic arthritis,Seeking Alpha,https://seekingalpha.com/news/3780196-abbvies-rinvoq-receives-fda-approval-for-active-psoriatic-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9341334700584412
1096,12/16/2021 2:57:00 PM,Allergan Aesthetics Completes Acquisition of Soliton,PR Newswire,/news/stocks/allergan-aesthetics-completes-acquisition-of-soliton-1031050358,positive,0.8560677766799927
1097,12/17/2021 4:17:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-17-2021-1031053650,neutral,0.5951845049858093
1098,12/17/2021 9:25:40 PM,Abbvie seeks U.S. International Trade Commission help to block Humira biosimilar,Seeking Alpha,https://seekingalpha.com/news/3781450-abbvie-seeks-us-international-trade-commission-help-to-block-humira-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7197697758674622
1099,12/17/2021 10:31:30 PM,"4 Top Stock Trades for Monday: AMC, GM, ABBV, SBUX",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-amc-gm-abbv-sbux-1031054337,positive,0.9379370808601379
1100,12/20/2021 6:36:56 PM,AbbVie regains despite FDA approval for Humira biosimilar,Seeking Alpha,https://seekingalpha.com/news/3781914-abbvie-regains-despite-fda-approval-for-humira-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6849310398101807
1101,12/20/2021 10:24:30 PM,CytomX Therapeutics falls 28% on interim mid-stage results on cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3782151-cytomx-therapeutics-falls-28-on-interim-mid-stage-results-on-cancer-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9725542068481445
1102,12/21/2021 11:00:30 AM,7 Best-Looking Stock Charts Going Into Christmas,InvestorPlace,/news/stocks/7-best-looking-stock-charts-going-into-christmas-1031058677,positive,0.8963985443115234
1103,12/21/2021 1:53:12 PM,CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate,Benzinga,/news/stocks/cytomx-posts-interim-data-from-phase-2-trial-of-cd71-targeting-cancer-candidate-1031059001,positive,0.9124030470848083
1104,12/21/2021 2:11:20 PM,"The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail",Benzinga,/news/stocks/the-daily-biotech-pulse-aldeyra-sinks-on-dry-eye-disease-readout-sanofi-goes-shopping-regulatory-setback-for-aquestive-aridis-touts-pan-coronavirus-antibody-cocktail-1031059051,positive,0.6017129421234131
1105,12/22/2021 11:00:21 AM,3 of the Best Biotech Stocks for 2022 to Buy Now,InvestorPlace,/news/stocks/3-of-the-best-biotech-stocks-for-2022-to-buy-now-1031061336,positive,0.7894664406776428
1106,12/22/2021 6:50:31 PM,BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today,InvestorPlace,/news/stocks/bad-etf-the-top-sin-stock-holdings-in-the-new-anti-esg-fund-that-debuts-today-1031062665,positive,0.9194077253341675
1107,12/23/2021 12:01:46 AM,"ETF BAD Debuts With A Focus On Cannabis Stocks, Gambling And Alcohol",Benzinga,/news/stocks/etf-bad-debuts-with-a-focus-on-cannabis-stocks-gambling-and-alcohol-1031062884,positive,0.9337550401687622
1108,12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755,positive,0.7226237654685974
1109,12/30/2021 7:42:41 PM,Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock,InvestorPlace,/news/stocks/best-stocks-for-2022-why-abbvie-abbv-stock-looks-like-high-dividend-growth-stock-1031071815,positive,0.5186933279037476
1110,1/3/2022 6:47:55 PM,7 of the Best High-Yield Dividend Stocks for 2022 to Buy Now,InvestorPlace,/news/stocks/7-of-the-best-high-yield-dividend-stocks-for-2022-to-buy-now-1031074735,positive,0.7906323671340942
1111,1/4/2022 2:15:00 PM,AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer,PR Newswire,/news/stocks/abbvie-announces-u-s-fda-granted-breakthrough-therapy-designation-btd-to-telisotuzumab-vedotin-teliso-v-for-previously-treated-non-small-cell-lung-cancer-1031076055,negative,0.9413684606552124
1112,1/4/2022 2:39:19 PM,AbbVie: Teliso-V Gets Breakthrough Therapy Designation ,RTTNews,/news/stocks/abbvie-teliso-v-gets-breakthrough-therapy-designation-1031076114,negative,0.8712912201881409
1113,1/5/2022 5:17:46 PM,Aspira Women’s Health reports Q4 updates; partners Axia on genetics platform,Seeking Alpha,https://seekingalpha.com/news/3785502-aspira-womens-health-reports-q4-updates-partners-axia-on-genetics-platform?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9310899972915649
1114,1/5/2022 8:04:11 PM,Analyst Ratings For AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1031080117,positive,0.9059829115867615
1115,1/5/2022 8:28:12 PM,AbbVie hits 52-week high in today's trading session,Seeking Alpha,https://seekingalpha.com/news/3785561-abbvie-hits-52-week-high-in-todays-trading-session?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8771985173225403
1116,1/6/2022 11:00:29 AM,4 EV Charging Stocks to Buy Ahead of Biden’s National Network,InvestorPlace,/news/stocks/4-ev-charging-stocks-chpt-evgo-beem-vlta-to-buy-ahead-of-bidens-national-network-1031081068,positive,0.7941417098045349
1117,1/6/2022 6:37:19 PM,10 Warren Buffett Stocks That Belong on Your 2022 Watchlist,InvestorPlace,/news/stocks/10-warren-buffett-stocks-that-belong-on-your-2022-watchlist-1031082348,positive,0.937095582485199
1118,1/7/2022 2:30:04 PM,AbbVie submits applications for Rinvoq in U.S. and Europe for axial spondyloarthritis,Seeking Alpha,https://seekingalpha.com/news/3786211-abbvie-submits-applications-for-rinvoq-in-us-and-europe-for-axial-spondyloarthritis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8307464718818665
1119,1/7/2022 3:00:00 PM,AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA),PR Newswire,/news/stocks/abbvie-submits-applications-for-upadacitinib-rinvoq-in-non-radiographic-axial-spondyloarthritis-to-u-s-food-and-drug-administration-fda-and-european-medicines-agency-ema-1031087358,positive,0.5964081883430481
1120,1/7/2022 3:38:19 PM,AbbVie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA ,RTTNews,/news/stocks/abbvie-submits-applications-for-upadacitinib-in-non-radiographic-axial-spondyloarthritis-to-fda-1031087758,positive,0.811743438243866
1121,1/11/2022 1:45:00 PM,ACELYRIN Appoints Melanie Gloria as Chief Operating Officer,PR Newswire,/news/stocks/acelyrin-appoints-melanie-gloria-as-chief-operating-officer-1031093657,positive,0.9282802939414978
1122,1/11/2022 2:22:36 PM,"AbbVie reaffirms more than $15B in Rinvoq, Skyrizi sales in 2025",Seeking Alpha,https://seekingalpha.com/news/3787095-abbvie-reaffirms-more-than-15b-in-rinvoq-skyrizi-sales-in-2025?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6649593114852905
1123,1/11/2022 2:45:00 PM,AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025,PR Newswire,/news/stocks/abbvie-confirms-guidance-of-greater-than-15-billion-in-combined-risk-adjusted-sales-for-rinvoq-and-skyrizi-in-2025-1031093962,negative,0.7595801949501038
1124,1/11/2022 2:54:29 PM,"AbbVie Confirms Outlook Of Over $15 Bln In Combined Risk-Adj. Sales For Rinvoq, Skyrizi In 2025 ",RTTNews,/news/stocks/abbvie-confirms-outlook-of-over-15-bln-in-combined-risk-adj-sales-for-rinvoq-skyrizi-in-2025-1031093978,negative,0.9030005931854248
1125,1/11/2022 6:33:26 PM,Diabetes meds 3 of the 4 highest TV DTC ad spends through 2021,Seeking Alpha,https://seekingalpha.com/news/3787218-diabetes-meds-3-of-the-4-highest-tv-dtc-ad-spends-through-2021?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.556958794593811
1126,1/12/2022 3:52:31 PM,AbbVie’s guidance for Skyrizi and Rinvoq lifts remaining overhang - Morgan Stanley,Seeking Alpha,https://seekingalpha.com/news/3787560-abbvies-guidance-for-skyrizi-and-rinvoq-lifts-remaining-overhang-morgan-stanley?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8678873181343079
1127,1/13/2022 8:52:18 AM,Calls grow to treat COVID like an 'endemic' illness,Seeking Alpha,https://seekingalpha.com/news/3787737-calls-grow-to-treat-covid-like-an-endemic-illness?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5648321509361267
1128,1/14/2022 7:10:00 PM,"U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis",PR Newswire,/news/stocks/u-s-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis-1031104012,negative,0.9112608432769775
1129,1/14/2022 7:40:32 PM,AbbVie gains on FDA approval for RINVOQ in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3788396-abbvie-gains-on-fda-approval-for-rinvoq-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9437136054039001
1130,1/14/2022 9:14:03 PM,Pfizer granted FDA approval for CIBINQO in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3788420-pfizer-granted-fda-approval-for-cibinqo-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9392638802528381
1131,1/18/2022 7:27:13 PM,7 of the Top-Rated Pharmaceutical Stocks for Q1,InvestorPlace,/news/stocks/7-of-the-top-rated-pharmaceutical-stocks-for-q1-1031110217,positive,0.8801546692848206
1132,1/19/2022 11:00:09 AM,3 Dividend Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-and-hold-forever-abbv-kr-cvx-1031111966,positive,0.9479490518569946
1133,1/19/2022 4:54:28 PM,3 Healthcare Stocks Ignoring the Market Mayhem,InvestorPlace,/news/stocks/3-healthcare-stocks-ignoring-the-market-mayhem-1031113540,neutral,0.6080146431922913
1134,1/20/2022 5:40:12 PM,Vertex upgraded to outperform at BMO on bullish outlook for rare kidney disease candidate,Seeking Alpha,https://seekingalpha.com/news/3789931-vertex-upgraded-to-outperform-at-bmo-on-bullish-outlook-for-rare-kidney-disease-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9038508534431458
1135,1/20/2022 6:13:32 PM,Evolus on the rise after Truist upgraded on prospects for wrinkles treatment,Seeking Alpha,https://seekingalpha.com/news/3789962-evolus-on-the-rise-after-truist-upgraded-on-prospects-for-wrinkles-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8719810843467712
1136,1/20/2022 7:29:04 PM,3 Dividend Aristocrats Yielding Over 4%,InvestorPlace,/news/stocks/3-dividend-aristocrats-yielding-over-4-1031117369,positive,0.8441977500915527
1137,1/21/2022 10:06:57 PM,AbbVie announces FDA approval for Skyrizi in psoriatic arthritis,Seeking Alpha,https://seekingalpha.com/news/3790465-abbvie-announces-fda-approval-for-skyrizi-in-psoriatic-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7285289168357849
1138,1/21/2022 10:30:00 PM,U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis,PR Newswire,/news/stocks/u-s-fda-approves-second-indication-for-skyrizi-risankizumab-rzaa-to-treat-adults-with-active-psoriatic-arthritis-1031119973,negative,0.9301140904426575
1139,1/24/2022 2:00:00 PM,Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA),PR Newswire,/news/stocks/allergan-aesthetics-announces-open-casting-call-for-botox-cosmetic-onabotulinumtoxina-1031122476,positive,0.5340948700904846
1140,1/24/2022 7:17:18 PM,Analyst Ratings For AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1031123703,positive,0.9059829115867615
1141,1/27/2022 3:56:38 PM,Galapagos at a six-month high after naming former J&J science chief as CEO,Seeking Alpha,https://seekingalpha.com/news/3792569-galapagos-at-a-six-month-high-after-naming-former-jj-science-chief-as-ceo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7416487336158752
1142,1/28/2022 4:07:22 PM,"U.S. Int'l Trade Commission investigating Teva, Alvotech biosimilars of AbbVie's Humira",Seeking Alpha,https://seekingalpha.com/news/3793136-us-intl-trade-commission-investigating-teva-alvotech-biosimilars-of-abbvie-humira?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6337432861328125
1143,1/28/2022 4:25:01 PM,"What Jim Cramer Thinks About Canopy Growth, Vista Outdoor And 8 Other Stocks",Benzinga,/news/stocks/what-jim-cramer-thinks-about-canopy-growth-vista-outdoor-and-8-other-stocks-1031139769,positive,0.9446668028831482
1144,1/28/2022 6:15:32 PM,7 Technology Stocks Reporting Earnings the Week of January 31,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-1028709625,positive,0.5936208367347717
1145,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,positive,0.9110234379768372
1146,1/31/2022 9:09:29 PM,Inventiva gets €4M milestone payment from AbbVie in cedirogant trial to treat psoriasis,Seeking Alpha,https://seekingalpha.com/news/3793724-inventiva-gets-4m-milestone-payment-from-abbvie-in-cedirogant-trial-to-treat-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9127675890922546
1147,2/1/2022 12:38:41 PM,Will AbbVie's upbeat earnings pattern continue in Q4?,Seeking Alpha,https://seekingalpha.com/news/3793957-will-abbvies-upbeat-earnings-pattern-continue-in-q4?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7697925567626953
1148,2/1/2022 2:28:49 PM,"The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program",Benzinga,/news/stocks/the-daily-biotech-pulse-immunitybio-reports-positive-readout-valneva-starts-late-stage-chikungunya-vaccine-study-sio-gene-shelves-parkinson-s-program-1031149041,positive,0.7992680072784424
1149,2/1/2022 2:45:00 PM,AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO),PR Newswire,/news/stocks/abbvie-showcases-its-leadership-in-research-in-inflammatory-bowel-diseases-with-new-analyses-to-be-presented-at-the-17th-congress-of-european-crohn-s-and-colitis-organization-ecco-1031149111,negative,0.8188638091087341
1150,2/1/2022 3:01:13 PM,What Wall Street expects from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-stock-price-quarter-earnings-preview-q4-1031149301,positive,0.9298630356788635
1151,2/1/2022 3:47:07 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3794149-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.855887770652771
1152,2/2/2022 12:45:23 PM,"AbbVie Non-GAAP EPS of $3.31 beats by $0.03, revenue of $14.89B misses by $70M",Seeking Alpha,https://seekingalpha.com/news/3794781-abbvie-non-gaap-eps-of-3_31-beats-0_03-revenue-of-14_89b-misses-70m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6020980477333069
1153,2/2/2022 1:32:57 PM,AbbVie beats Q4 non-GAAP EPS forecast; 2022 guidance tops consensus,Seeking Alpha,https://seekingalpha.com/news/3794824-abbvie-beats-q4-non-gaap-eps-forecast-2022-guidance-tops-consensus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9260801672935486
1154,2/2/2022 1:33:38 PM,"The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales",Benzinga,/news/stocks/the-daily-biotech-pulse-logicbio-genome-editing-therapy-study-placed-on-clinical-hold-gilead-q4-disappoints-on-slowing-veklury-sales-1031153587,neutral,0.9577975273132324
1155,2/2/2022 1:43:00 PM,AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results,PR Newswire,/news/stocks/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results-1031153588,positive,0.8742037415504456
1156,2/2/2022 1:50:37 PM,"AbbVie Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/abbvie-q4-profit-increases-beats-estimates-1031153611,negative,0.928683340549469
1157,2/2/2022 2:00:21 PM,AbbVie Guides FY22 Adj. EPS Above Estimates - Quick Facts ,RTTNews,/news/stocks/abbvie-guides-fy22-adj-eps-above-estimates-quick-facts-1031153630,positive,0.7684424519538879
1158,2/2/2022 9:34:46 PM,"5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV",InvestorPlace,/news/stocks/5-top-stock-trades-for-thursday-amd-nvda-fb-qcom-abbv-1031155846,positive,0.9396387338638306
1159,2/3/2022 7:58:59 PM,Vertex downgraded to sector perform at RBC due to valuation,Seeking Alpha,https://seekingalpha.com/news/3795664-vertex-downgraded-to-sector-perform-at-rbc-due-to-valuation?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7985761761665344
1160,2/3/2022 10:42:21 PM,Viatris gets FDA nod for 1st generic version of AbbVie's dry eye therapy Restasis,Seeking Alpha,https://seekingalpha.com/news/3795887-viatris-gets-fda-nod-for-1st-generic-version-of-abbvies-dry-eye-therapy-restasis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9124302268028259
1161,2/4/2022 1:06:39 PM,"CNBC's Final Trades: Ranpak, AbbVie, Texas Instruments And This Financial Stock",Benzinga,/news/stocks/cnbc-s-final-trades-ranpak-abbvie-texas-instruments-and-this-financial-stock-1031162272,positive,0.9405965805053711
1162,2/8/2022 1:32:04 PM,AbbVie's JUVÉDERM VOLBELLA gets FDA nod for expanded use for undereye hollows,Seeking Alpha,https://seekingalpha.com/news/3797157-abbvies-juvderm-volbella-gets-fda-nod-for-expanded-use-for-undereye-hollows?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9168000817298889
1163,2/8/2022 2:00:00 PM,FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows,PR Newswire,/news/stocks/fda-approves-juvéderm-volbella-xc-for-undereye-hollows-1031171438,negative,0.7845315933227539
1164,2/8/2022 2:12:22 PM,Allergan Aesthetics: FDA Approves JUVÉDERM VOLBELLA XC For Improvement Of Infraorbital Hollows ,RTTNews,/news/stocks/allergan-aesthetics-fda-approves-juvéderm-volbella-xc-for-improvement-of-infraorbital-hollows-1031171557,negative,0.9338821768760681
1165,2/8/2022 5:23:23 PM,Can Teva Pharmaceutical's Q4 results bring positive surprise?,Seeking Alpha,https://seekingalpha.com/news/3797380-can-teva-pharmaceuticals-q4-results-bring-positive-surprise?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6302435994148254
1166,2/9/2022 2:04:58 PM,"AbbVie hit a 52-week high yesterday, and is set to surpass it today",Seeking Alpha,https://seekingalpha.com/news/3797823-abbvie-hit-a-52-week-high-yesterday-and-is-set-to-surpass-it-today?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9191990494728088
1167,2/10/2022 12:45:19 PM,AbbVie inks reimbursement agreements for Venclexta combo for blood cancer in Canada,Seeking Alpha,https://seekingalpha.com/news/3798501-abbvies-inks-reimbursement-agreements-for-venclexta-combo-for-blood-cancer-in-canada?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7614017724990845
1168,2/10/2022 2:49:15 PM,Healis Therapeutics acquires botulinum toxin patent from AbbVie for use in depression,Seeking Alpha,https://seekingalpha.com/news/3798624-healis-therapeutics-acquires-botulinum-toxin-patent-from-abbvie-for-use-in-depression?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.579733669757843
1169,2/10/2022 3:00:00 PM,Healis Therapeutics acquires ownership of key botulinum toxin patent,PR Newswire,/news/stocks/healis-therapeutics-acquires-ownership-of-key-botulinum-toxin-patent-1031182242,positive,0.7782310247421265
1170,2/14/2022 7:29:44 PM,7 Dividend Aristocrats That Could Outpace This Volatile Market,InvestorPlace,/news/stocks/7-dividend-aristocrats-that-could-outpace-this-volatile-market-1031192576,positive,0.8186362981796265
1171,2/14/2022 9:23:15 PM,"4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-se-abbv-td-car-1031192795,positive,0.9367202520370483
1172,2/14/2022 9:35:53 PM,"Buffett's Berkshire Hathaway adds Activision Blizzard stake, exists Teva",Seeking Alpha,https://seekingalpha.com/news/3799802-buffetts-berkshire-hathaway-adds-activision-blizzard-stake-exists-teva?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9212615489959717
1173,2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8565000891685486
1174,2/17/2022 4:58:07 PM,AbbVie declares $1.41 dividend,Seeking Alpha,https://seekingalpha.com/news/3801536-abbvie-inc-declares-1_41-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9414845108985901
1175,2/17/2022 5:33:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1031205871,neutral,0.5513123869895935
1176,2/18/2022 11:51:50 AM,"Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices",Benzinga,/news/stocks/coherus-biosciences-q4-sales-fall-34-on-lower-udenyca-volume-prices-1031208112,neutral,0.9749013781547546
1177,2/18/2022 1:58:27 PM,7 Value Stocks to Buy in This Pricey Market,InvestorPlace,/news/stocks/7-value-stocks-to-buy-in-this-pricey-market-1031208678,positive,0.9119290113449097
1178,2/21/2022 4:12:25 PM,Growth stocks rule in Goldman screen of biggest retail investor buys and sells,Seeking Alpha,https://seekingalpha.com/news/3802227-growth-stocks-rule-in-goldman-screen-of-biggest-retail-investors-buys-and-sells?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8495696187019348
1179,2/22/2022 12:52:46 PM,Karyopharm slips as medical chief steps down,Seeking Alpha,https://seekingalpha.com/news/3802386-kpti-stock-slips-as-medical-chief-steps-down?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9363846182823181
1180,2/22/2022 1:47:22 PM,AbbVie submits Vraylar sNDA for adjunctive treatment of depression,Seeking Alpha,https://seekingalpha.com/news/3802439-abbvie-submits-vraylar-snda-for-adjunctive-treatment-of-depression?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6774815917015076
1181,2/22/2022 1:50:57 PM,AbbVie seeks FDA approval for fourth indication of cariprazine,Seeking Alpha,https://seekingalpha.com/news/3802446-abbvie-stock-in-focus-on-fda-filing-for-anti-depressant-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8217918276786804
1182,2/22/2022 2:15:00 PM,AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder,PR Newswire,/news/stocks/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-for-cariprazine-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder-1031215841,negative,0.8363819122314453
1183,2/22/2022 7:57:48 PM,7 New ETFs To Consider if You Want To Play Today’s Top Trends,InvestorPlace,/news/stocks/7-new-etfs-to-consider-if-you-want-to-play-todays-top-trends-1031217554,positive,0.9149611592292786
1184,2/23/2022 5:37:51 PM,7 High-Yield Blue-Chip Stocks Suitable for Any Retiree,InvestorPlace,/news/stocks/7-high-yield-blue-chip-stocks-suitable-for-any-retiree-1031222596,positive,0.8893870711326599
1185,2/24/2022 2:00:00 PM,Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease,PR Newswire,/news/stocks/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-and-endoscopic-outcomes-in-patients-with-crohn-s-disease-1031226417,negative,0.9562128782272339
1186,2/24/2022 2:28:39 PM,ABBV: Phase 3 Study Confirms Upadacitinib Improved Clinical & Endoscopic Outcomes In Crohn's Disease ,RTTNews,/news/stocks/abbv-phase-3-study-confirms-upadacitinib-improved-clinical-endoscopic-outcomes-in-crohn-s-disease-1031226661,negative,0.9558719396591187
1187,2/24/2022 3:59:51 PM,AbbVie's Rinvoq demonstrates efficacy in second late-stage Crohn's study,Seeking Alpha,https://seekingalpha.com/news/3805240-abbvie-rinvoq-demonstrates-efficacy-in-second-late-stage-crohns-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9323595762252808
1188,2/24/2022 5:22:00 PM,"Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting",PR Newswire,/news/stocks/allergan-an-abbvie-company-to-present-data-from-its-leading-portfolio-of-eye-care-treatments-at-the-2022-american-glaucoma-society-ags-annual-meeting-1031227790,positive,0.8018073439598083
1189,2/28/2022 1:54:07 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031237950,positive,0.7998325824737549
1190,2/28/2022 2:00:00 PM,AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD),PR Newswire,/news/stocks/abbvie-seeks-new-indication-for-imbruvica-ibrutinib-in-pediatric-patients-with-chronic-graft-versus-host-disease-cgvhd-1031237934,negative,0.8771581649780273
1191,2/28/2022 2:29:46 PM,AbbVie submits sNDA for Imbruvica in pediatric indication,Seeking Alpha,https://seekingalpha.com/news/3806885-abbvie-submits-snda-for-imbruvica-in-pediatric-indication?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9165005087852478
1192,2/28/2022 3:14:07 PM,Where AbbVie Stands With Analysts,Benzinga,/news/stocks/where-abbvie-stands-with-analysts-1031238557,positive,0.8949053883552551
1193,2/28/2022 4:27:22 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-28-2022-1031238799,neutral,0.538459300994873
1194,2/28/2022 5:54:01 PM,AbbVie downgraded to neutral at UBS based on current valuation,Seeking Alpha,https://seekingalpha.com/news/3806985-abbvie-downgraded-to-neutral-at-ubs-based-on-current-valuation?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5508800745010376
1195,2/28/2022 10:15:00 PM,AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S.,PR Newswire,/news/stocks/abbvie-provides-update-regarding-skyrizi-risankizumab-rzaa-for-the-treatment-of-moderate-to-severe-crohn-s-disease-in-the-u-s-1031239912,positive,0.8895828723907471
1196,3/1/2022 1:51:14 PM,"The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution",Benzinga,/news/stocks/the-daily-biotech-pulse-legend-biotech-cti-biopharma-receive-fda-approvals-abbvie-announces-delay-in-skyrizi-review-editas-gains-on-crispr-patent-resolution-1031242590,positive,0.7575392723083496
1197,3/1/2022 2:00:00 PM,"AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio",PR Newswire,/news/stocks/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio-1031242624,positive,0.8098206520080566
1198,3/1/2022 2:11:04 PM,"AbbVie acquires Syndesi, expanding neuroscience portfolio, in up to $1B deal",Seeking Alpha,https://seekingalpha.com/news/3807671-abbvie-acquires-syndesi-expanding-neuroscience-portfolio-in-up-to-1b-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5761101841926575
1199,3/1/2022 10:19:38 PM,Regenxbio stock unchanged after hours despite bottom and top line beats,Seeking Alpha,https://seekingalpha.com/news/3808198-regenxbio-stock-unchanged-after-hours-despite-bottom-top-line-beats?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4651689827442169
1200,3/2/2022 12:54:28 PM,Harpoon wins FDA’s Fast Track designation for multiple myeloma therapy,Seeking Alpha,https://seekingalpha.com/news/3808369-harpoon-wins-fdas-fast-track-designation-for-multiple-myeloma-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9019381403923035
1201,3/2/2022 2:12:17 PM,Harpoon Therapeutics: HPN217 Receives FDA Fast Track Designation ,RTTNews,/news/stocks/harpoon-therapeutics-hpn217-receives-fda-fast-track-designation-1031247531,positive,0.6271873116493225
1202,3/2/2022 7:34:18 PM,Executives Sell More Than $47M Of 5 Stocks,Benzinga,/news/stocks/executives-sell-more-than-47m-of-5-stocks-1031248804,positive,0.9067370295524597
1203,3/2/2022 7:49:41 PM,Regenxbio gains the most in five months on the launch of “5x25 strategy”,Seeking Alpha,https://seekingalpha.com/news/3808610-rgnx-stock-gains-on-the-launch-of-5x25-strategy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9218020439147949
1204,3/2/2022 7:54:23 PM,Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock,Benzinga,/news/stocks/jefferies-raises-price-target-on-this-small-cap-stand-out-biotech-stock-1031248857,negative,0.6062159538269043
1205,3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946,positive,0.8909978270530701
1206,3/3/2022 6:43:20 PM,Companies warn sanctions can disrupt medical supplies to Russia - Reuters,Seeking Alpha,https://seekingalpha.com/news/3809259-companies-warn-sanctions-can-disrupt-medical-supplies-to-russia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9393597841262817
1207,3/8/2022 10:09:40 PM,AbbVie grants Alvotech license to Humira patents in litigation resolution,Seeking Alpha,https://seekingalpha.com/news/3810868-abbvie-grants-alvotech-license-to-humira-patents-in-litigation-resolution?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7729660868644714
1208,3/8/2022 10:32:00 PM,AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech,PR Newswire,/news/stocks/abbvie-resolves-humira-adalimumab-u-s-litigation-with-alvotech-1031264211,positive,0.4505673050880432
1209,3/9/2022 2:54:54 AM,AbbVie Resolves All U.S. HUMIRA Litigation With Alvotech ,RTTNews,/news/stocks/abbvie-resolves-all-u-s-humira-litigation-with-alvotech-1031264483,positive,0.8987246751785278
1210,3/9/2022 11:40:07 AM,8 Strong Uptrend Stocks to Buy on the Next Dip,InvestorPlace,/news/stocks/8-strong-uptrend-stocks-to-buy-on-the-next-dip-1031265802,negative,0.8061011433601379
1211,3/9/2022 12:33:39 PM,AbbVie settles Humira patent dispute with Alvotech,Seeking Alpha,https://seekingalpha.com/news/3811034-abbvie-settles-humira-patent-dispute-with-alvotech?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6086289286613464
1212,3/9/2022 1:52:45 PM,"The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-begins-late-stage-pediatric-covid-pill-study-midatech-and-j-j-unit-expand-r-d-collaboration-abbvie-alvotech-settle-humira-dispute-1031266063,negative,0.6761938333511353
1213,3/9/2022 2:25:52 PM,"AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar",Benzinga,/news/stocks/abbvie-alvotech-resolve-us-patent-dispute-related-to-humira-biosimilar-1031266276,positive,0.4447286128997803
1214,3/9/2022 3:28:13 PM,7 Dividend Stocks to Finance Your Golden Years,InvestorPlace,/news/stocks/7-dividend-stocks-to-finance-your-golden-years-1031266985,positive,0.8461456298828125
1215,3/10/2022 12:35:12 PM,7 Drug Stocks to Consider After the Viatris Plunge,InvestorPlace,/news/stocks/7-drug-stocks-to-consider-after-the-viatris-plunge-abbv-bmy-gsk-vtrs-jnj-teva-pfe-nvs-mrk-1031269941,positive,0.926745593547821
1216,3/10/2022 2:05:42 PM,AbbVie to seek label expansion of migraine therapy after main goal met in late-stage study,Seeking Alpha,https://seekingalpha.com/news/3812144-abbvie-meets-main-goal-for-migraine-therapy-in-late-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8979988694190979
1217,3/10/2022 2:15:00 PM,AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine,PR Newswire,/news/stocks/abbvie-announces-positive-phase-3-atogepant-qulipta-data-for-the-preventive-treatment-of-chronic-migraine-1031270114,negative,0.9428339600563049
1218,3/10/2022 2:53:41 PM,AbbVie: Phase 3 Study With Atogepant In Adult Patients With Chronic Migraine Meets Primary Endpoint ,RTTNews,/news/stocks/abbvie-phase-3-study-with-atogepant-in-adult-patients-with-chronic-migraine-meets-primary-endpoint-1031270314,positive,0.5620145201683044
1219,3/11/2022 8:00:00 AM,AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases,PR Newswire,/news/stocks/abbvie-and-gedeon-richter-announce-collaboration-in-neuropsychiatric-diseases-1031272892,negative,0.5399148464202881
1220,3/11/2022 8:18:39 AM,"AbbVie, Gedeon To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases Treatment ",RTTNews,/news/stocks/abbvie-gedeon-to-develop-dopamine-receptor-modulators-for-neuropsychiatric-diseases-treatment-1031272938,positive,0.606239378452301
1221,3/11/2022 11:23:54 AM,"AbbVie, Gedeon Richter team up to develop therapies for neuropsychiatric diseases",Seeking Alpha,https://seekingalpha.com/news/3812608-abbvie-gedeon-richter-team-up-to-develop-therapies-for-neuropsychiatric-diseases?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5082094669342041
1222,3/15/2022 12:29:44 PM,AbbVie working with Scripps Research to develop COVID-19 antiviral treatments,Seeking Alpha,https://seekingalpha.com/news/3813552-abbvie-working-with-scripps-research-to-develop-covid-19-antiviral-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7092908620834351
1223,3/15/2022 1:00:00 PM,AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19,PR Newswire,/news/stocks/abbvie-and-scripps-research-announce-collaboration-to-develop-antiviral-treatments-for-covid-19-1031280908,negative,0.8971622586250305
1224,3/15/2022 1:27:06 PM,"AbbVie, Scripps Join Hands To Develop Direct-acting Antiviral Treatments For Covid-19 ",RTTNews,/news/stocks/abbvie-scripps-join-hands-to-develop-direct-acting-antiviral-treatments-for-covid-19-1031281113,negative,0.7094247341156006
1225,3/15/2022 1:45:00 PM,"Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours",PR Newswire,/news/stocks/now-available-over-the-counter-lastacaft-provides-eye-allergy-itch-relief-in-minutes-that-lasts-through-16-hours-1031281218,positive,0.7345378994941711
1226,3/15/2022 5:02:42 PM,3 Top Stock Trades for This Week,InvestorPlace,/news/stocks/3-top-stock-trades-for-this-week-1031282462,positive,0.9186509847640991
1227,3/15/2022 6:46:18 PM,AbbVie hits new 52-week high thanks to recent dealmaking,Seeking Alpha,https://seekingalpha.com/news/3813771-abbvie-hits-new-52-week-high?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9349282383918762
1228,3/15/2022 8:13:26 PM,AbbVie hits new 52-week high thanks to recent dealmaking,Seeking Alpha,https://seekingalpha.com/news/3813771-abbvie-hits-new-52-week-high-thanks-to-recent-dealmaking?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9349282383918762
1229,3/16/2022 10:29:00 PM,RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis,PR Newswire,/news/stocks/rinvoq-upadacitinib-receives-fda-approval-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-1031286768,negative,0.9389216899871826
1230,3/17/2022 9:52:57 AM,AbbVie Rinvoq gets US FDA approval to treat ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3814446-abbvie-rinvoq-gets-us-fda-approval-to-treat-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9200969934463501
1231,3/17/2022 11:52:39 AM,AbbVie price target raised at BofA after Rinvoq approval for ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3814515-abbvie-price-target-raised-at-bofa-after-rinvoq-approval-for-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8643791675567627
1232,3/17/2022 12:53:34 PM,"The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data",Benzinga,/news/stocks/the-daily-biotech-pulse-abbvie-s-rinvoq-gets-label-expansion-astrazeneca-covid-antibody-cocktail-authorized-by-uk-regulator-stealth-touts-positive-data-1031288399,negative,0.8934017419815063
1233,3/18/2022 5:00:40 PM,Biotech ETF XBI is on pace for best week in 21-months after it touched near 2-year low,Seeking Alpha,https://seekingalpha.com/news/3815061-biotech-etf-xbi-is-on-pace-for-best-week-in-21-months-after-it-touched-near-2-year-low?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9294695854187012
1234,3/18/2022 6:38:55 PM,3 Dividend Growth Stocks to Buy During This Market Correction,InvestorPlace,/news/stocks/3-dividend-growth-stocks-to-buy-during-this-market-correction-1031292571,positive,0.8936126232147217
1235,3/21/2022 1:30:00 PM,AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting,PR Newswire,/news/stocks/abbvie-and-allergan-aesthetics-to-present-new-research-across-dermatology-portfolio-at-2022-aad-annual-meeting-1031294931,positive,0.8707649111747742
1236,3/21/2022 4:27:54 PM,Oaktree Acquisition Corp. II started at outperform at Northland ahead of Alvotech merger,Seeking Alpha,https://seekingalpha.com/news/3815545-oaktree-acquisition-corp-ii-started-at-outperform-at-northland-ahead-of-alvotech-merger?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8927307724952698
1237,3/21/2022 8:52:27 PM,"Teva, AbbVie unit reach $107M opioid settlement with Rhode Island",Seeking Alpha,https://seekingalpha.com/news/3815782-teva-abbvie-unit-reach-107m-opioid-settlement-with-rhode-island?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9226720929145813
1238,3/22/2022 2:38:25 PM,AbbVie draws cautious remarks from Jefferies on upcoming cystic fibrosis readout,Seeking Alpha,https://seekingalpha.com/news/3816040-abbv-stock-lower-after-cautious-remarks-from-jefferies-on-cystic-fibrosis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.649196207523346
1239,3/23/2022 6:22:35 PM,All The Stocks That Moved Wednesday From CNBC's 'Fast Money: Halftime Report',Benzinga,/news/stocks/all-the-stocks-that-moved-wednesday-from-cnbc-s-fast-money-halftime-report-1031302400,positive,0.7525022625923157
1240,3/24/2022 7:26:51 PM,This high dividend-yielding ETF has outperformed the S&P 500 by over 10% in 2022,Seeking Alpha,https://seekingalpha.com/news/3817158-this-high-dividend-yielding-etf-has-outperformed-the-sp-500-by-over-10-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9544948935508728
1241,3/25/2022 3:02:12 PM,3 Profitable Passive Income Stocks to Buy for Your Retirement Years,InvestorPlace,/news/stocks/3-profitable-passive-income-stocks-to-buy-for-your-retirement-years-1031308548,positive,0.9400347471237183
1242,3/29/2022 2:00:00 PM,AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting,PR Newswire,/news/stocks/abbvie-to-showcase-breadth-of-neuroscience-portfolio-and-pipeline-at-american-academy-of-neurology-aan-2022-annual-meeting-1031314991,positive,0.5575335025787354
1243,3/30/2022 10:11:11 AM,7 Blue-Chip Stocks With Dividends to Add to Your Buy List,InvestorPlace,/news/stocks/7-blue-chip-stocks-with-dividends-to-add-to-your-buy-list-pfejpmintcpeplmt-abbv-cvx-1031318198,positive,0.9334786534309387
1244,3/30/2022 3:39:18 PM,"Florida reaches opioid settlement with Teva, CVS, Allergan, Endo worth ~$860M",Seeking Alpha,https://seekingalpha.com/news/3818931-florida-reaches-opioid-settlement-with-teva-cvs-allergan-endo-worth-860m?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8454621434211731
1245,3/30/2022 9:38:30 PM,"CVS Health, Teva Settle Florida State's Opioid-Related Claims: Report",Benzinga,/news/stocks/cvs-health-teva-settle-florida-state-s-opioid-related-claims-report-1031320117,positive,0.7778938412666321
1246,4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374,positive,0.9468021392822266
1247,4/4/2022 9:09:14 PM,"West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters",Benzinga,/news/stocks/west-virginia-says-j-j-teva-abbvie-caused-tsunami-of-opioid-addiction-reuters-1031331125,positive,0.6891766786575317
1248,4/5/2022 10:59:46 AM,7 Biotech Stocks to Buy With Key Catalysts for April,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-key-catalysts-for-april-1031332726,positive,0.7184770703315735
1249,4/5/2022 1:10:02 PM,Teva upgraded at Barclays; prospects for Humira biosimilar cited,Seeking Alpha,https://seekingalpha.com/news/3820743-teva-stock-gains-on-barclays-upgrade?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7195670008659363
1250,4/5/2022 2:30:00 PM,"Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with A...",PR Newswire,/news/stocks/allergan-an-abbvie-company-announces-positive-topline-phase-3-results-evaluating-investigational-twice-daily-administration-of-vuity-pilocarpine-hci-ophthalmic-solution-1-25-in-adults-with-a-1031333083,negative,0.944819986820221
1251,4/5/2022 2:59:28 PM,Allergan Reveals Positive Phase 3 Results Of VUITY In Adults With Age-Related Blurry Near Vision ,RTTNews,/news/stocks/allergan-reveals-positive-phase-3-results-of-vuity-in-adults-with-age-related-blurry-near-vision-1031333266,negative,0.9530823826789856
1252,4/5/2022 3:32:39 PM,3 Vanguard ETFs to Buy Now,InvestorPlace,/news/stocks/3-vanguard-etfs-to-buy-now-1031333971,positive,0.9078019857406616
1253,4/5/2022 10:17:17 PM,7 Safe Stocks to Buy to Guard Against a Recession,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-to-guard-against-a-recession-1031334812,positive,0.8407782912254333
1254,4/6/2022 4:16:37 PM,AbbVie wins Bullish views at Morgan Stanley on diversification plans amid threat to Humira,Seeking Alpha,https://seekingalpha.com/news/3821266-abbv-stock-gains-as-morgan-stanley-issues-overweight-rating?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7991955280303955
1255,4/6/2022 7:07:36 PM,Analyst Ratings For AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1031337652,positive,0.9059829115867615
1256,4/8/2022 11:35:39 AM,"Best Stocks for 2022: Up 20% This Year, AbbVie Is Doing Great",InvestorPlace,/news/stocks/best-stocks-for-2022-up-20-this-year-abbv-stock-is-doing-great-1031342773,negative,0.9464345574378967
1257,4/8/2022 8:52:36 PM,10 Stocks That Have Moved Over 20% Since The Indices Plummeted,Benzinga,/news/stocks/10-stocks-that-have-moved-over-20-since-the-indices-plummeted-1031343762,neutral,0.8974549174308777
1258,4/8/2022 11:01:00 PM,"ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV",PR Newswire,/news/stocks/rosen-a-leading-law-firm-encourages-abbvie-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-abbv-1031343922,positive,0.8154852986335754
1259,4/9/2022 4:00:14 PM,Healthcare stocks outperform as investors look for safety,Seeking Alpha,https://seekingalpha.com/news/3822171-healthcare-stocks-outperform-as-investors-look-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9504939317703247
1260,4/11/2022 2:25:59 PM,Beigene's Brukinsa bests Imbruvica in overall response in leukemia trial,Seeking Alpha,https://seekingalpha.com/news/3822346-beigene-brukinsa-bests-imbruvica-in-overall-response-in-leukemia-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9112858772277832
1261,4/11/2022 5:09:04 PM,Walgreens goes to trial in Florida over its role in opioid crisis,Seeking Alpha,https://seekingalpha.com/news/3822414-wba-stock-in-focus-as-company-goes-to-trial-in-florida-over-opioid-crisis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7779765129089355
1262,4/12/2022 12:53:27 PM,AbbVie myelofibrosis candidate navitoclax shows improvement in mid-stage trial,Seeking Alpha,https://seekingalpha.com/news/3822654-abbvie-myelofibrosis-candidate-navitoclax-shows-improvement-in-mid-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.955564558506012
1263,4/12/2022 2:00:00 PM,AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis,PR Newswire,/news/stocks/abbvie-presents-positive-investigational-navitoclax-combination-data-in-phase-2-refine-study-suggesting-anti-fibrosis-activity-for-patients-with-myelofibrosis-1031349415,negative,0.9513522982597351
1264,4/12/2022 2:34:26 PM,AbbVie : Phase 2 Study Of Navitoclax Combination Shows Anti-Fibrosis Activity In Rare Blood Cancer ,RTTNews,/news/stocks/abbvie-phase-2-study-of-navitoclax-combination-shows-anti-fibrosis-activity-in-rare-blood-cancer-1031349605,negative,0.613865077495575
1265,4/12/2022 8:42:11 PM,"4 Top Stock Trades for Wednesday: WMT, SMH, DAL, ABBV",InvestorPlace,/news/stocks/4-top-stock-trades-for-wednesday-wmt-smh-dal-abbv-1031351154,positive,0.9310643672943115
1266,4/13/2022 2:00:00 PM,BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval,PR Newswire,/news/stocks/botox-cosmetic-onabotulinumtoxina-celebrates-20-years-since-first-u-s-fda-approval-1031353155,positive,0.7717497944831848
1267,4/13/2022 2:05:29 PM,AbbVie Vice Chairman & President to step down,Seeking Alpha,https://seekingalpha.com/news/3823083-abbvie-vice-chairman-president-to-step-down?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8069387674331665
1268,4/13/2022 2:44:38 PM,Vertex price target raised at UBS calling company top pick in large cap biotech,Seeking Alpha,https://seekingalpha.com/news/3823100-vertex-price-target-raised-at-ubs-calling-company-top-pick-in-large-cap-biotech?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8940551280975342
1269,4/13/2022 4:04:38 PM,AbbVie down 6% following departure of president though presents buying opportunity,Seeking Alpha,https://seekingalpha.com/news/3823128-abbvie-down-6-following-departure-of-president-though-presents-buying-opportunity?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9705612063407898
1270,4/14/2022 12:53:00 AM,AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL),PR Newswire,/news/stocks/abbvie-and-genmab-announce-topline-results-for-epcoritamab-duobody-cd3xcd20-from-phase-1-2-trial-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-lbcl-1031354884,negative,0.8037109971046448
1271,4/14/2022 3:45:30 AM,AbbVie Announces Positive Results For Epcoritamab From Phase 1/2 Trial In Blood Cancer ,RTTNews,/news/stocks/abbvie-announces-positive-results-for-epcoritamab-from-phase-1-2-trial-in-blood-cancer-1031354914,negative,0.9461613893508911
1272,4/14/2022 7:46:37 AM,Sandoz Launches Generic Version Of Eyedrop In U.S. For Patients With Ocular Hypertension ,RTTNews,/news/stocks/sandoz-launches-generic-version-of-eyedrop-in-u-s-for-patients-with-ocular-hypertension-1031355673,negative,0.5286862254142761
1273,4/14/2022 9:00:18 AM,Novartis' Sandoz launches generic version of AbbVie’s eye drop Combigan in US,Seeking Alpha,https://seekingalpha.com/news/3823318-novartis-sandoz-launches-generic-version-of-abbvies-eye-drop-combigan-in-us?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5619678497314453
1274,4/14/2022 2:00:00 PM,AbbVie to Host First-Quarter 2022 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-first-quarter-2022-earnings-conference-call-1031356507,positive,0.9121084809303284
1275,4/14/2022 2:15:55 PM,28 Biggest Movers From Yesterday,Benzinga,/news/stocks/28-biggest-movers-from-yesterday-1031356637,positive,0.734295129776001
1276,4/14/2022 3:35:45 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regeneron-s-covid-19-therapy-decision-pushed-protagonist-s-rusfertide-breakthrough-tag-update-and-more-1031357104,positive,0.9389084577560425
1277,4/18/2022 6:11:00 PM,"ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV",PR Newswire,/news/stocks/rosen-a-top-ranked-firm-encourages-abbvie-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-abbv-1031361406,positive,0.5871427059173584
1278,4/19/2022 2:30:00 PM,"Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting",PR Newswire,/news/stocks/allergan-an-abbvie-company-to-present-new-data-from-its-eye-care-portfolio-at-the-2022-american-society-of-cataract-and-refractive-surgery-ascrs-annual-meeting-1031363896,positive,0.8693659901618958
1279,4/19/2022 3:19:35 PM,AbbVie falls as partner Johnson & Johnson cites pressure on Imbruvica sales,Seeking Alpha,https://seekingalpha.com/news/3824338-abbv-stock-falls-as-johnson--johnson-as-imbruvica-sales-drop?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9588532447814941
1280,4/20/2022 6:37:29 AM,AbbVie discontinues alliance with BioArctic on alpha-synuclein portfolio,Seeking Alpha,https://seekingalpha.com/news/3824564-abbvie-discontinues-alliance-with-bioarctic-on-alpha-synuclein-portfolio?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8412700891494751
1281,4/20/2022 9:03:27 AM,"Alabama reaches $276M settlement with J&J, McKesson, Endo over opioid claims - Waff",Seeking Alpha,https://seekingalpha.com/news/3824600-alabama-reaches-276m-settlement-with-jj-mckesson-endo-over-opioid-claims-waff?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.47748932242393494
1282,4/20/2022 9:29:32 AM,AbbVie Walks Away From Alpha-synuclein Collaboration With BioArctic ,RTTNews,/news/stocks/abbvie-walks-away-from-alpha-synuclein-collaboration-with-bioarctic-1031367100,positive,0.5410422682762146
1283,4/20/2022 12:27:38 PM,AbbVie expands research collaboration with Dragonfly Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3824689-abbvie-expands-research-collaboration-with-dragonfly-therapeutics?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9328290820121765
1284,4/20/2022 2:00:00 PM,Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases,PR Newswire,/news/stocks/dragonfly-therapeutics-announces-multi-target-expansion-of-its-research-collaboration-with-abbvie-to-develop-novel-therapeutic-candidates-for-immune-mediated-diseases-1031367711,negative,0.9203029870986938
1285,4/20/2022 2:22:12 PM,Dragonfly Therapeutics Expands Collaboration With AbbVie To Develop Novel Immunotherapies ,RTTNews,/news/stocks/dragonfly-therapeutics-expands-collaboration-with-abbvie-to-develop-novel-immunotherapies-1031367885,negative,0.8868229985237122
1286,4/20/2022 9:51:56 PM,"JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters",Benzinga,/news/stocks/jnj-mckesson-endo-settle-275m-opioid-claims-with-alabama-reuters-1031369258,positive,0.9004384279251099
1287,4/22/2022 3:20:39 PM,Ironwood Pharmaceuticals initiated at overweight at Piper on cash flow from Linzess,Seeking Alpha,https://seekingalpha.com/news/3825789-ironwood-pharmaceuticals-initiated-at-overweight-at-piper-on-cash-flow-from-linzess?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6600497364997864
1288,4/25/2022 8:10:02 PM,Analyst Ratings for AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1031381216,positive,0.9059829115867615
1289,4/25/2022 9:38:00 PM,TOP RANKED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV,PR Newswire,/news/stocks/top-ranked-rosen-law-firm-encourages-abbvie-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action-abbv-1031381346,positive,0.81837397813797
1290,4/25/2022 10:11:22 PM,"San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters",Benzinga,/news/stocks/san-francisco-to-start-opioid-epidemic-trial-against-teva-walgreen-reuters-1031381415,positive,0.8948363661766052
1291,4/26/2022 10:16:16 AM,3 Dividend Stocks for Value Investors Seeking Regular Income,InvestorPlace,/news/stocks/dividend-stocks-investors-seeking-income-1031384022,positive,0.9316470623016357
1292,4/26/2022 10:30:18 AM,What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks,InvestorPlace,/news/stocks/recession-stocks-to-buy-that-will-do-well-in-a-recession-our-7-top-picks-mcd-tgt-wmt-pg-abbv-mgn-nrg-1031384084,positive,0.6847883462905884
1293,4/26/2022 11:36:17 AM,7 Retirement Stocks to Buy to Sleep Soundly at Night,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-to-sleep-soundly-at-night-kmb-lmt-mrk-abbv-dlr-gis-pg-1031384356,positive,0.8780571818351746
1294,4/27/2022 11:42:25 AM,"AbbVie's Vraylar gets approval in Canada to treat bipolar 1, schizophrenia in adults",Seeking Alpha,https://seekingalpha.com/news/3827492-abbvies-vraylar-gets-approval-in-canada-to-treat-bipolar-1-schizophrenia-in-adults?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9325909614562988
1295,4/27/2022 3:04:58 PM,AbbVie: Health Canada Approves VRAYLAR - Quick Facts ,RTTNews,/news/stocks/abbvie-health-canada-approves-vraylar-quick-facts-1031391726,positive,0.6716422438621521
1296,4/28/2022 1:11:40 PM,"Abbvie, Plexium team up to develop therapies for neurological disorders",Seeking Alpha,https://seekingalpha.com/news/3828606-abbvie-plexium-team-up-to-develop-therapies-for-neurological-disorders?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6170589327812195
1297,4/28/2022 2:30:00 PM,"Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting",PR Newswire,/news/stocks/allergan-an-abbvie-company-to-present-new-data-from-its-leading-portfolio-of-eye-care-treatments-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting-1031397170,positive,0.7460013628005981
1298,4/28/2022 2:49:21 PM,7 A-Rated Dividend Stocks to Buy Forever,InvestorPlace,/news/stocks/7-a-rated-dividend-stocks-to-buy-forever-1031398153,positive,0.9069212675094604
1299,4/28/2022 2:52:43 PM,"The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-seeks-fda-approval-for-covid-19-shot-for-children-2-6-tax-disclosure-for-amgen-fast-track-tags-for-sqz-biotech-timber-pharma-candidates-1031397312,positive,0.7427427768707275
1300,4/28/2022 2:55:37 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3828682-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
1301,4/28/2022 3:01:13 PM,AbbVie earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/abbvie-stock-q1-earnings-preview-1031397419,positive,0.9104300737380981
1302,4/28/2022 4:13:59 PM,All eyes on AbbVie Q1 results amid challenges to Humira's dominance,Seeking Alpha,https://seekingalpha.com/news/3828723-all-eyes-on-abbvie-q1-results-amid-challenges-to-humiras-dominance?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4180147051811218
1303,4/29/2022 11:44:09 AM,"AbbVie Non-GAAP EPS of $3.16 beats by $0.02, revenue of $13.54B misses by $70M",Seeking Alpha,https://seekingalpha.com/news/3829310-abbvie-non-gaap-eps-of-3_16-beats-0_02-revenue-of-13_54b-misses-70m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5589028596878052
1304,4/29/2022 12:42:23 PM,"AbbVie down 4% premarket after lowering full-year guidance, quarterly revenue miss",Seeking Alpha,https://seekingalpha.com/news/3829360-abbvie-down-5-premarket-after-lowering-full-year-guidance-quarterly-revenue-miss?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9745388031005859
1305,4/29/2022 1:43:00 PM,AbbVie Reports First-Quarter 2022 Financial Results,PR Newswire,/news/stocks/abbvie-reports-first-quarter-2022-financial-results-1031402207,positive,0.8918559551239014
1306,4/29/2022 2:02:47 PM,AbbVie Trims FY22 Adj. EPS Outlook - Update ,RTTNews,/news/stocks/abbvie-trims-fy22-adj-eps-outlook-update-1031402298,positive,0.8647462129592896
1307,4/29/2022 2:03:10 PM,AbbVie Q1 Income Rises,RTTNews,/news/stocks/abbvie-q1-income-rises-1031402296,neutral,0.4472053050994873
1308,4/29/2022 2:27:23 PM,Why Is AbbVie Stock Down Today?,InvestorPlace,/news/stocks/why-is-abbvie-stock-down-today-1031402948,neutral,0.8665536642074585
1309,4/29/2022 2:47:31 PM,Why Is GTY Technology (GTYH) Stock Up 100% Today?,InvestorPlace,/news/stocks/why-is-gty-technology-gtyh-stock-up-100-today-1031403050,negative,0.859582781791687
1310,4/29/2022 3:00:32 PM,"The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approves-bristol-myers-oral-heart-disease-drug-european-approval-for-merck-s-keytruda-genocea-restructures-zymeworks-takeover-bid-1031402592,negative,0.6426587700843811
1311,4/29/2022 4:50:00 PM,AbbVie Shares Hurt On Reduced Earnings Outlook ,RTTNews,/news/stocks/abbvie-shares-hurt-on-reduced-earnings-outlook-1031403028,neutral,0.9692730903625488
1312,4/29/2022 6:27:17 PM,48 Stocks Moving In Friday's Mid-Day Session,Benzinga,/news/stocks/48-stocks-moving-in-friday-s-mid-day-session-1031403301,positive,0.7196979522705078
1313,4/29/2022 7:09:29 PM,AbbVie announces FDA approval of Rinvoq for new arthritic indication,Seeking Alpha,https://seekingalpha.com/news/3829620-abbv-stock-slips-despite-fda-approval-of-rinvoq-for-new-arthritic-indication?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.779668390750885
1314,4/29/2022 8:44:00 PM,RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis,PR Newswire,/news/stocks/rinvoq-upadacitinib-approved-by-u-s-fda-as-an-oral-treatment-for-adults-with-active-ankylosing-spondylitis-1031403499,negative,0.9108421802520752
1315,4/30/2022 6:27:33 AM,FDA Approves AbbVie's Rinvoq To Treatment Active Ankylosing Spondylitis ,RTTNews,/news/stocks/fda-approves-abbvie-s-rinvoq-to-treatment-active-ankylosing-spondylitis-1031403844,negative,0.7842313051223755
1316,5/2/2022 11:46:47 AM,70 Biggest Movers From Friday,Benzinga,/news/stocks/70-biggest-movers-from-friday-1031407807,positive,0.7708724141120911
1317,5/2/2022 1:16:21 PM,Gilead to develop Dragonfly natural killer cell engager immunotherapy; $300M upfront,Seeking Alpha,https://seekingalpha.com/news/3829992-gilead-to-develop-dragonfly-natural-killer-cell-engager-immunotherapy-300m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7901163697242737
1318,5/2/2022 8:51:00 PM,"Rosen, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV",PR Newswire,/news/stocks/rosen-a-leading-law-firm-encourages-abbvie-inc-investors-with-losses-exceeding-100k-to-secure-counsel-before-important-deadline-in-securities-class-action-abbv-1031410109,positive,0.6858137845993042
1319,5/2/2022 9:49:38 PM,Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer,Benzinga,/news/stocks/here-s-why-this-analyst-is-on-sidelines-despite-european-approval-of-myovant-s-relugolix-for-prostate-cancer-1031410194,positive,0.5220879912376404
1320,5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.786922812461853
1321,5/3/2022 4:45:54 PM,Vertex upgraded at Morgan Stanley as AbbVie fails in cystic fibrosis study,Seeking Alpha,https://seekingalpha.com/news/3831225-vrtx-stock-rebounds-as-morgan-stanley-upgrades-on-abbvie-setback?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5455621480941772
1322,5/6/2022 11:33:52 AM,7 Defensive Dividend Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/7-defensive-healthcare-stocks-to-buy-now-1031430769,positive,0.8179723024368286
1323,5/10/2022 6:06:29 PM,"Teva, Allergan ready to pay $5B to settle thousands of opioid lawsuits - Bloomberg Law",Seeking Alpha,https://seekingalpha.com/news/3836148-teva-allergan-abbvier-ready-to-pay-5b-to-settle-thousands-of-opioid-lawsuits-bloomberg-law?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8096034526824951
1324,5/10/2022 9:03:06 PM,"4 Top Stock Trades for Wednesday: TSLA, PANW, SOFI, ABBV",InvestorPlace,/news/stocks/4-top-stock-trades-for-wednesday-tsla-panw-sofi-abbv-1031444314,positive,0.9395002722740173
1325,5/10/2022 11:30:19 PM,6 Undervalued Stocks You Should Buy For the Long Term,InvestorPlace,/news/stocks/6-undervalued-stocks-you-should-buy-for-the-long-term-1031444322,positive,0.8774169683456421
1326,5/11/2022 1:58:44 PM,AbbVie's Rinvoq demonstrates remission at one year in Crohn's patients,Seeking Alpha,https://seekingalpha.com/news/3836825-abbvie-rinvoq-demonstrates-remission-at-one-year-in-crohns-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5914818048477173
1327,5/11/2022 2:45:00 PM,Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease,PR Newswire,/news/stocks/upadacitinib-rinvoq-achieved-clinical-remission-and-endoscopic-response-at-one-year-in-phase-3-maintenance-study-in-patients-with-crohn-s-disease-1031448101,negative,0.9246206879615784
1328,5/11/2022 3:22:00 PM,AbbVie Announces Positive Topline Results From U-ENDURE Phase 3 Study Evaluating Upadacitinib ,RTTNews,/news/stocks/abbvie-announces-positive-topline-results-from-u-endure-phase-3-study-evaluating-upadacitinib-1031448760,negative,0.9470548033714294
1329,5/11/2022 10:26:59 PM,The Top 10 Stocks Helping Warren Buffett Beat the Market,InvestorPlace,/news/stocks/the-top-10-stocks-helping-warren-buffett-beat-the-market-1031450438,negative,0.558830738067627
1330,5/12/2022 2:30:00 PM,"AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education",PR Newswire,/news/stocks/abbvie-awards-45-scholarships-to-u-s-students-living-with-chronic-immune-mediated-diseases-in-their-pursuit-of-higher-education-1031453461,negative,0.7650302648544312
1331,5/12/2022 5:39:00 PM,AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses,PR Newswire,/news/stocks/abbvie-to-showcase-oncology-portfolio-and-pipeline-during-the-2022-asco-and-eha-annual-congresses-1031454576,positive,0.7071282863616943
1332,5/14/2022 7:12:00 PM,"ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV",PR Newswire,/news/stocks/rosen-a-top-ranked-firm-encourages-abbvie-inc-investors-with-losses-exceeding-100k-to-secure-counsel-before-important-deadline-in-securities-class-action-abbv-1031460214,negative,0.5204007625579834
1333,5/16/2022 10:00:57 AM,7 Retirement Stocks for Steady Long-Term Income Growth,InvestorPlace,/news/stocks/7-retirement-stocks-for-steady-long-term-income-growth-1031463769,negative,0.7566248774528503
1334,5/16/2022 11:00:18 AM,The 5 Best Dividend Stocks to Buy Now,InvestorPlace,/news/stocks/the-5-best-dividend-stocks-to-buy-now-1031464022,positive,0.877388060092926
1335,5/16/2022 1:30:00 PM,AbbVie and Cugene Announce Collaboration in Autoimmune Diseases,PR Newswire,/news/stocks/abbvie-and-cugene-announce-collaboration-in-autoimmune-diseases-1031464071,negative,0.5160133242607117
1336,5/16/2022 1:52:52 PM,"AbbVie Receives Option To License Certain IL-2 Muteins, Including CUG252, From Cugene ",RTTNews,/news/stocks/abbvie-receives-option-to-license-certain-il-2-muteins-including-cug252-from-cugene-1031464169,positive,0.6420708894729614
1337,5/16/2022 2:00:00 PM,AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®,PR Newswire,/news/stocks/abbvie-to-showcase-depth-of-gastroenterology-portfolio-and-pipeline-at-digestive-disease-week-1031464221,positive,0.7031062245368958
1338,5/16/2022 2:59:52 PM,AbbVie expands autoimmune disease treatment options with Cugene collaboration,Seeking Alpha,https://seekingalpha.com/news/3839284-abbvie-expands-autoimmune-disease-treatment-options-with-cugene-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8467394709587097
1339,5/16/2022 10:31:40 PM,"Berkshire Hathaway takes 2.5% stake in Citi in Q1, exits Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/3839678-berkshire-hathaway-takes-25-stake-in-citi-in-q1-exits-wells-fargo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9384966492652893
1340,5/17/2022 12:39:47 PM,Idera halts melanoma trial for cancer candidate after early positive results,Seeking Alpha,https://seekingalpha.com/news/3839915-idra-stock-surges-on-positive-results-for-melanoma-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6378729343414307
1341,5/18/2022 10:16:18 PM,7 Best Value Stocks to Buy if You Need Some Market Stability in Your Life ,InvestorPlace,/news/stocks/7-best-value-stocks-to-buy-if-you-need-some-market-stability-in-your-life-1031473820,positive,0.9113149642944336
1342,5/19/2022 4:00:44 PM,6 Stocks to Buy to Hedge Your Portfolio in a Down Market,InvestorPlace,/news/stocks/6-stocks-to-buy-to-hedge-your-portfolio-with-stable-dividends-and-low-pes-1031476521,positive,0.9005402326583862
1343,5/20/2022 1:03:05 PM,AbbVie submits NDA for Parkinson's disease treatment,Seeking Alpha,https://seekingalpha.com/news/3841341-abbvie-submits-nda-for-parkinsons-disease-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9059329032897949
1344,5/20/2022 2:15:00 PM,AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease,PR Newswire,/news/stocks/abbvie-submits-new-drug-application-to-u-s-fda-for-investigational-abbv-951-foscarbidopa-foslevodopa-for-the-treatment-of-advanced-parkinson-s-disease-1031478452,negative,0.8314374089241028
1345,5/20/2022 2:43:46 PM,AbbVie Submits NDA For ABBV-951 To FDA For Treatment Of Advanced Parkinson's Disease ,RTTNews,/news/stocks/abbvie-submits-nda-for-abbv-951-to-fda-for-treatment-of-advanced-parkinson-s-disease-1031478555,negative,0.4998754560947418
1346,5/21/2022 11:31:40 AM,7 Retirement Stocks to Buy for Any Market Conditions,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-for-any-market-conditions-1031479718,positive,0.9313405156135559
1347,5/21/2022 3:00:44 PM,7 Quality Dividend Stocks to Buy on the Dip,InvestorPlace,/news/stocks/7-quality-dividend-stocks-to-buy-on-the-dip-1031479756,positive,0.9070187211036682
1348,5/22/2022 9:58:01 PM,"The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-22-28-verrica-bristol-myers-squibb-fda-decisions-medtronic-earnings-conference-presentations-more-1031480317,positive,0.9357399940490723
1349,5/23/2022 8:00:00 AM,CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis,PR Newswire,/news/stocks/chmp-recommends-european-commission-approval-of-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-ulcerative-colitis-1031480813,negative,0.7914243340492249
1350,5/23/2022 8:27:47 AM,AbbVie:CHMP Recommends European Commission Approval Of Upadacitinib For Ulcerative Colitis Treatment ,RTTNews,/news/stocks/abbvie-chmp-recommends-european-commission-approval-of-upadacitinib-for-ulcerative-colitis-treatment-1031480868,negative,0.8636164665222168
1351,5/23/2022 10:20:12 AM,AbbVie's Rinvoq gets EMA panel nod for expanded use in ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3841602-abbvies-rinvoq-gets-ema-panel-nod-for-expanded-use-in-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8683506846427917
1352,5/23/2022 2:00:00 PM,AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting,PR Newswire,/news/stocks/abbvie-presents-positive-data-from-phase-3-study-of-cariprazine-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder-at-2022-apa-annual-meeting-1031481655,negative,0.8987507820129395
1353,5/23/2022 3:05:03 PM,What 8 Analyst Ratings Have To Say About AbbVie,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-abbvie-1031482048,positive,0.9406131505966187
1354,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320,positive,0.527824878692627
1355,5/24/2022 2:00:00 PM,AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress,PR Newswire,/news/stocks/abbvie-showcases-its-leadership-in-rheumatology-research-with-new-data-across-multiple-inflammatory-joint-diseases-at-the-eular-2022-congress-1031484603,negative,0.8869986534118652
1356,5/24/2022 2:24:47 PM,"The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-inmune-bio-s-planned-alzheimer-s-trial-on-fda-hold-caladrius-stops-enrollment-in-heart-disease-study-biomx-restructures-1031484881,neutral,0.7328180074691772
1357,5/24/2022 6:55:00 PM,"ABBV LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV",PR Newswire,/news/stocks/abbv-loss-alert-rosen-trusted-national-trial-counsel-encourages-abbvie-inc-investors-with-losses-to-secure-counsel-before-important-june-6-deadline-in-securities-class-action-abbv-1031485948,positive,0.8313974142074585
1358,5/25/2022 1:11:44 PM,7 Retirement Stocks to Buy to Turbocharge Your Savings,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-to-turbocharge-your-savings-2-1031488560,positive,0.9142357110977173
1359,5/25/2022 4:58:45 PM,AbbVie trails Lilly despite a 30% bigger ex-Humira business - Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3842736-abbvie-stock-gains-as-wells-fargo-backs-ex-humira-business?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5263083577156067
1360,5/26/2022 2:41:13 PM,7 Ideal Dividend Stocks to Buy for a Rich Retirement,InvestorPlace,/news/stocks/7-ideal-dividend-stocks-to-buy-for-a-rich-retirement-1031491415,positive,0.8249520063400269
1361,5/26/2022 2:41:14 PM,"GCOW, the dividend ETF that's +10% in 2022 while the broader markets plunge",Seeking Alpha,https://seekingalpha.com/news/3843134-gcow-the-dividend-etf-thats-10-on-the-year-is-getting-noticed?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8514460921287537
1362,5/26/2022 10:00:22 PM,7 High-Yield Retirement Stocks to Buy for Your Nest Egg,InvestorPlace,/news/stocks/7-high-yield-retirement-stocks-to-buy-for-your-nest-egg-1031492120,positive,0.9213324189186096
1363,5/27/2022 9:00:00 AM,The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease,PR Newswire,/news/stocks/the-lancet-publishes-results-from-phase-3-induction-and-maintenance-programs-evaluating-risankizumab-skyrizi-in-crohn-s-disease-1031492689,positive,0.8854286670684814
1364,5/27/2022 9:15:00 AM,The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis,PR Newswire,/news/stocks/the-lancet-publishes-results-from-phase-3-induction-and-maintenance-programs-evaluating-upadacitinib-rinvoq-in-ulcerative-colitis-1031492718,positive,0.8806596398353577
1365,5/30/2022 10:15:54 AM,The 3 Best Performing ETFs Money Can Buy in 2022,InvestorPlace,/news/stocks/the-3-best-performing-etfs-money-can-buy-in-2022-1031495787,positive,0.6743149161338806
1366,5/30/2022 8:03:18 PM,"The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-30-june-4-fda-decision-for-eton-s-partnered-epilepsy-drug-asco-conference-gets-underway-and-more-1031496572,positive,0.689422607421875
1367,5/31/2022 2:49:12 PM,7 Safe Dividend Stocks With High Yields to Buy Now,InvestorPlace,/news/stocks/7-safe-dividend-stocks-with-high-yields-to-buy-now-1031498852,positive,0.810308039188385
1368,5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9459705948829651
1369,6/1/2022 3:35:34 PM,AbbVie JAK inhibitor meets main goal in late-stage trials for arthritic disorders,Seeking Alpha,https://seekingalpha.com/news/3844461-abbvie-rinvoq-meets-main-goal-in-late-stage-trials-for-arthritic-disorders?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.629422664642334
1370,6/1/2022 4:35:00 PM,AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022,PR Newswire,/news/stocks/abbvie-presents-positive-results-from-phase-3-select-axis-2-trials-of-upadacitinib-rinvoq-in-patients-with-axial-spondyloarthritis-at-eular-2022-1031502400,negative,0.9490708112716675
1371,6/2/2022 3:52:44 AM,AbbVie Presents Positive Results From Phase 3 Trials Of Upadacitinib In Axial Spondyloarthritis ,RTTNews,/news/stocks/abbvie-presents-positive-results-from-phase-3-trials-of-upadacitinib-in-axial-spondyloarthritis-1031503763,negative,0.9509837627410889
1372,6/2/2022 5:56:00 AM,"ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV",PR Newswire,/news/stocks/rosen-a-leading-longstanding-and-top-ranked-firm-encourages-abbvie-inc-investors-with-losses-to-secure-counsel-before-important-june-6-deadline-in-securities-class-action-abbv-1031503848,negative,0.5711374878883362
1373,6/6/2022 10:48:57 AM,Curis gains over 20% as majority of patients respond to blood cancer drug,Seeking Alpha,https://seekingalpha.com/news/3845814-cris-stock-gains-as-majority-of-patients-respond-to-blood-cancer-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9540715217590332
1374,6/7/2022 2:00:00 PM,AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting,PR Newswire,/news/stocks/abbvie-to-present-extensive-data-from-its-migraine-portfolio-at-the-2022-american-headache-society-ahs-annual-scientific-meeting-1031513108,positive,0.866182804107666
1375,6/10/2022 7:05:00 AM,New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment,PR Newswire,/news/stocks/new-data-demonstrates-abbvie-s-venclyxto-venclexta-combination-sustained-progression-free-survival-in-chronic-lymphocytic-leukemia-patients-after-four-years-off-treatment-1031521160,negative,0.955815851688385
1376,6/10/2022 7:39:15 AM,AbbVie : Data Shows Venclyxto/Venclexta Combination Sustained PFS In Chronic Lymphocytic Leukemia ,RTTNews,/news/stocks/abbvie-data-shows-venclyxto-venclexta-combination-sustained-pfs-in-chronic-lymphocytic-leukemia-1031521182,negative,0.6574615836143494
1377,6/10/2022 9:15:00 AM,AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients,PR Newswire,/news/stocks/abbvie-presents-investigational-navitoclax-preliminary-data-in-jak-inhibitor-naïve-myelofibrosis-patients-1031521315,positive,0.8243533372879028
1378,6/10/2022 10:11:09 AM,3 Dividend Stocks to Buy Now for 20 Years of Income Growth,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-now-for-20-years-of-income-growth-1031521688,positive,0.870885968208313
1379,6/10/2022 11:13:29 AM,"AbbVie navitoclax, Jakafi combo shows promise in trial to treat rare bone marrow cancer",Seeking Alpha,https://seekingalpha.com/news/3847598-abbvie-navitoclax-jakafi-combo-shows-promise-in-trial-to-treat-rare-bone-marrow-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9031885862350464
1380,6/10/2022 1:50:31 PM,AbbVie presents 5-year follow-up data for its CLL combination treatment developed with Roche,Seeking Alpha,https://seekingalpha.com/news/3847680-abbvie-presents-5-year-follow-up-data-for-its-cll-combination-treatment-developed-with-roche?utm_source=businessinsider&utm_medium=referral,negative,0.5547595620155334
1381,6/10/2022 2:57:48 PM,7 Great ETFs to Buy Now for Momentum in Q2,InvestorPlace,/news/stocks/7-great-etfs-to-buy-now-for-momentum-in-q2-1031522477,negative,0.6736835837364197
1382,6/11/2022 10:43:20 AM,7 Dividend Stocks to Buy for Your Grandkids,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-for-your-grandkids-1031523169,positive,0.9282500743865967
1383,6/11/2022 2:45:00 PM,AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hemat...,PR Newswire,/news/stocks/abbvie-announces-late-breaking-results-from-phase-2-trial-of-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-lbcl-at-the-european-hemat-1031523299,negative,0.7540909647941589
1384,6/11/2022 7:24:32 PM,AbbVie : Phase 2 Trial Of Epcoritamab Shows Clinically Meaningful Efficacy In Large B-cell Lymphoma ,RTTNews,/news/stocks/abbvie-phase-2-trial-of-epcoritamab-shows-clinically-meaningful-efficacy-in-large-b-cell-lymphoma-1031523327,negative,0.9467670321464539
1385,6/11/2022 8:43:43 PM,"With bluebird bio's success, what are other gene therapies companies to pay attention to?",Seeking Alpha,https://seekingalpha.com/news/3847855-with-bluebird-bios-success-what-are-other-gene-therapies-companies-to-pay-attention-to?utm_source=businessinsider&utm_medium=referral,positive,0.9216489195823669
1386,6/13/2022 1:12:08 PM,AbbVie's Allergan Aesthetics in deal with Sirona Biochem for skin care treatments,Seeking Alpha,https://seekingalpha.com/news/3847998-abbvie-allergan-aesthetics-in-deal-with-sirona-biochem-for-skin-care-treatments?utm_source=businessinsider&utm_medium=referral,negative,0.7985867857933044
1387,6/13/2022 4:11:11 PM,Consistent Clinical Results Indicate Upside for AbbVie Stock,InvestorPlace,/news/stocks/consistent-clinical-results-indicate-upside-for-abbv-stock-1031525755,negative,0.9393349885940552
1388,6/17/2022 12:22:47 PM,AbbVie wins FDA approval for Skyrizi in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/3849551-abbvie-wins-fda-approval-for-skyrizi-in-crohns-disease?utm_source=businessinsider&utm_medium=referral,negative,0.8805835247039795
1389,6/17/2022 2:00:00 PM,SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults,PR Newswire,/news/stocks/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohn-s-disease-in-adults-1031535286,negative,0.9315040707588196
1390,6/17/2022 2:21:22 PM,AbbVie: FDA Approves SKYRIZI In Treatment Of Crohn's Disease ,RTTNews,/news/stocks/abbvie-fda-approves-skyrizi-in-treatment-of-crohn-s-disease-1031535352,negative,0.8676102757453918
1391,6/17/2022 3:00:00 PM,Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry,PR Newswire,/news/stocks/allergan-aesthetics-publishes-the-future-of-aesthetics-global-trends-report-providing-unrivalled-insight-into-future-of-industry-1031535483,positive,0.5189403295516968
1392,6/17/2022 5:15:48 PM,"The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease",Benzinga,/news/stocks/the-daily-biotech-pulse-addex-terminates-parkinson-s-study-expanded-use-of-rhythm-s-obesity-drug-fda-approval-for-abbvie-s-skyrizi-in-crohn-s-disease-1031535854,negative,0.6887987852096558
1393,6/21/2022 2:00:00 PM,AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine,PR Newswire,/news/stocks/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-for-atogepant-qulipta-to-support-label-expansion-for-the-preventive-treatment-of-migraine-1031539789,negative,0.9192546010017395
1394,6/21/2022 2:15:16 PM,AbbVie Files SNDA For Atogepant For Label Expansion ,RTTNews,/news/stocks/abbvie-files-snda-for-atogepant-for-label-expansion-1031539917,positive,0.929006040096283
1395,6/21/2022 11:38:14 PM,Recap of Tuesday's Biotech Catalysts - End of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031541740,positive,0.9340888261795044
1396,6/22/2022 11:28:34 AM,AbbVie ends partnership with Morphic for integrin therapeutics,Seeking Alpha,https://seekingalpha.com/news/3850664-abbvie-ends-partnership-with-morphic-for-integrin-therapeutics?utm_source=businessinsider&utm_medium=referral,negative,0.6007761359214783
1397,6/22/2022 12:15:20 PM,Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money,InvestorPlace,/news/stocks/economic-hurricane-ahead-7-profitable-places-to-hide-your-money-1031543188,positive,0.8941921591758728
1398,6/22/2022 1:21:27 PM,Canada approves use of AbbVie's antiviral Maviret in children with chronic hepatitis C,Seeking Alpha,https://seekingalpha.com/news/3850755-canada-approves-use-of-abbvies-antiviral-maviret-in-children-with-chronic-hepatitis-c?utm_source=businessinsider&utm_medium=referral,positive,0.6120214462280273
1399,6/22/2022 2:15:46 PM,AbbVie: Health Canada Approves Label Extension For MAVIRET To Include Use In Paediatric Patients ,RTTNews,/news/stocks/abbvie-health-canada-approves-label-extension-for-maviret-to-include-use-in-paediatric-patients-1031543068,negative,0.8569576144218445
1400,6/23/2022 6:24:23 PM,AbbVie tapped priority review voucher to expand Rinvoq into ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3851333-abbvie-taps-priority-review-voucher-to-expand-rinvoq-into-ulcerative-colitis?utm_source=businessinsider&utm_medium=referral,negative,0.8514575362205505
1401,6/23/2022 7:47:08 PM,AbbVie declares $1.41 dividend,Seeking Alpha,https://seekingalpha.com/news/3851349-abbvie-inc-declares-1_41-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9414845108985901
1402,6/23/2022 9:43:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1031547278,neutral,0.5513123869895935
1403,6/24/2022 12:19:14 PM,EMA advisors recommend indication extension for AbbVie's Rinvoq,Seeking Alpha,https://seekingalpha.com/news/3851486-ema-advisors-recommend-indication-extension-for-abbvie-rinvoq?utm_source=businessinsider&utm_medium=referral,positive,0.6304870843887329
1404,6/24/2022 2:00:00 PM,New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer,PR Newswire,/news/stocks/new-survey-offers-perspective-on-mental-and-emotional-journey-for-patients-diagnosed-with-slow-growing-blood-cancer-1031548545,positive,0.792725145816803
1405,6/27/2022 8:00:00 AM,CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis,PR Newswire,/news/stocks/chmp-recommends-approval-of-upadacitinib-rinvoq-for-the-treatment-of-adults-with-active-non-radiographic-axial-spondyloarthritis-1031550736,negative,0.8193217515945435
1406,6/27/2022 8:45:19 AM,AbbVie: Europe's CHMP Recommends To Approve Upadacitinib To Treat Active Nr-axSpA Patients ,RTTNews,/news/stocks/abbvie-europe-s-chmp-recommends-to-approve-upadacitinib-to-treat-active-nr-axspa-patients-1031550817,negative,0.8834401369094849
1407,6/27/2022 2:00:00 PM,"Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities",PR Newswire,/news/stocks/approximately-15-000-abbvie-employees-to-volunteer-globally-to-support-local-communities-in-annual-week-of-possibilities-1031551522,negative,0.5750882625579834
1408,6/27/2022 4:10:57 PM,AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding,InvestorPlace,/news/stocks/abbv-stocks-healthy-yield-makes-it-a-high-conviction-holding-1031552481,negative,0.8126968145370483
1409,6/28/2022 9:08:38 AM,"AmerisourceBergen, McKesson, Cardinal to pay Oklahoma $250M to resolve opioid claims",Seeking Alpha,https://seekingalpha.com/news/3852297-amerisourcebergen-mckesson-cardinal-to-pay-oklahoma-250m-to-resolve-opioid-claims?utm_source=businessinsider&utm_medium=referral,negative,0.6288767457008362
1410,6/28/2022 1:33:05 PM,AbbVie names new CFO,Seeking Alpha,https://seekingalpha.com/news/3852455-abbv-stock-in-focus-as-company-names-new-cfo?utm_source=businessinsider&utm_medium=referral,positive,0.9157155156135559
1411,7/2/2022 6:00:00 PM,"As amyloid-targeting therapies for Alzheimer's fail, where might success lie?",Seeking Alpha,https://seekingalpha.com/news/3853361-as-amyloid-targeting-therapies-for-alzheimers-fail-where-might-success-lie?utm_source=businessinsider&utm_medium=referral,positive,0.8673624992370605
1412,7/5/2022 9:47:06 AM,US judge rules in favor of drug distributors in West Virginia county opioid suit - AP,Seeking Alpha,https://seekingalpha.com/news/3854023-us-judge-rules-in-favor-of-drug-distributors-in-west-virginia-county-opioid-suit-ap?utm_source=businessinsider&utm_medium=referral,positive,0.5534666776657104
1413,7/6/2022 12:27:40 PM,Applied Molecular crashes 38% after mid-stage data for ulcerative colitis therapy,Seeking Alpha,https://seekingalpha.com/news/3854540-amti-stock-crashes-after-mid-stage-data-for-ulcerative-colitis-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.5381349325180054
1414,7/6/2022 8:54:32 PM,"AbbVie lowers Q2 and FY 2022 guidance on acquired R&D assets, milestones expense",Seeking Alpha,https://seekingalpha.com/news/3854809-abbvie-lowers-q2-and-fy-2022-guidance-on-acquired-research-development-assets-milestones-expense?utm_source=businessinsider&utm_medium=referral,neutral,0.901332437992096
1415,7/7/2022 10:39:16 AM,Best Stocks for 2022: AbbVie Is a Recession-Resistant Dividend King,InvestorPlace,/news/stocks/best-stocks-for-2022-abbv-stock-1031572601,positive,0.6148743629455566
1416,7/7/2022 12:43:06 PM,CytomX downgraded at several Street firms following breast cancer therapy results,Seeking Alpha,https://seekingalpha.com/news/3854968-cytomx-downgraded-at-several-street-firms-following-breast-cancer-therapy-results?utm_source=businessinsider&utm_medium=referral,neutral,0.9528310298919678
1417,7/7/2022 3:02:20 PM,AbbVie in crosshairs of Senator Wyden interim report on pharma tax practices,Seeking Alpha,https://seekingalpha.com/news/3855045-abbvie-in-crosshairs-of-senator-wyden-interim-report-on-pharma-tax-practices?utm_source=businessinsider&utm_medium=referral,positive,0.9231782555580139
1418,7/8/2022 11:47:49 AM,AbbVie ends partnership with Alector for Alzheimer’s candidate,Seeking Alpha,https://seekingalpha.com/news/3855314-alec-stock-on-watch-as-abbvie-ends-partnership-for-alzheimers-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.8031442761421204
1419,7/8/2022 2:00:00 PM,AbbVie to Host Second-Quarter 2022 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-second-quarter-2022-earnings-conference-call-1031575346,positive,0.9160057902336121
1420,7/8/2022 2:41:41 PM,What 7 Analyst Ratings Have To Say About AbbVie,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-abbvie-1031575496,positive,0.9406120777130127
1421,7/8/2022 4:54:34 PM,AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector,Benzinga,/news/stocks/abbvie-dumps-an-early-alzheimer-s-candidate-developing-in-collaboration-with-alector-1031575865,neutral,0.6105767488479614
1422,7/11/2022 2:59:34 PM,7 Overlooked Blue-Chip Stocks to Add to Your Buy List,InvestorPlace,/news/stocks/7-overlooked-blue-chip-stocks-to-add-to-your-buy-list-1031578750,positive,0.9194825887680054
1423,7/12/2022 3:14:02 PM,"Teva, AbbVie reach $54M opioid deal with San Francisco",Seeking Alpha,https://seekingalpha.com/news/3856106-teva-abbvie-reaches-54m-opioid-deal-with-san-francisco?utm_source=businessinsider&utm_medium=referral,negative,0.9041810035705566
1424,7/14/2022 8:16:27 PM,Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study,Seeking Alpha,https://seekingalpha.com/news/3856987-oncternal-to-collaborate-with-an-abbvie-company-for-its-phase-3-lymphoma-study?utm_source=businessinsider&utm_medium=referral,negative,0.5411360859870911
1425,7/17/2022 10:50:02 AM,"Best Stocks for 2022: After Two Quarters, Who Holds The Lead?",InvestorPlace,/news/stocks/best-stocks-for-2022-after-two-quarters-who-holds-lead-1031591864,positive,0.9161376357078552
1426,7/18/2022 8:00:00 AM,AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine,PR Newswire,/news/stocks/abbvie-submits-marketing-authorization-application-to-ema-for-atogepant-for-the-preventive-treatment-of-migraine-1031593009,negative,0.74174964427948
1427,7/18/2022 8:30:27 AM,AbbVie: EMA's CHMP To Review Marketing Authorization Application For Migraine Drug Atogepant ,RTTNews,/news/stocks/abbvie-ema-s-chmp-to-review-marketing-authorization-application-for-migraine-drug-atogepant-1031593050,positive,0.7857827544212341
1428,7/18/2022 10:13:19 AM,AbbVie files for EU approval of atogepant to prevent migraine,Seeking Alpha,https://seekingalpha.com/news/3857427-abbvie-files-for-eu-approval-of-atogepant-to-prevent-migraine?utm_source=businessinsider&utm_medium=referral,negative,0.85655677318573
1429,7/18/2022 10:57:31 AM,Top sticky stocks most immune to big earnings misses and beats,Seeking Alpha,https://seekingalpha.com/news/3857382-top-sticky-stocks-most-immune-to-big-earnings-misses-and-beats?utm_source=businessinsider&utm_medium=referral,neutral,0.6961941719055176
1430,7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral,negative,0.9346281290054321
1431,7/18/2022 7:07:59 PM,$192 Price Target Makes AbbVie Stock a Notable Healthcare Pick,InvestorPlace,/news/stocks/192-price-target-makes-abbv-stock-a-notable-healthcare-pick-1031594848,negative,0.5894898772239685
1432,7/19/2022 12:07:45 AM,Recap of Monday's Biotech Catalysts - End of the Day Summary,Benzinga,/news/stocks/recap-of-monday-s-biotech-catalysts---end-of-the-day-summary-1031595191,positive,0.9351576566696167
1433,7/20/2022 10:15:47 AM,7 Best Income Stocks to Buy Now,InvestorPlace,/news/stocks/best-income-stocks-1031600382,positive,0.9180880188941956
1434,7/20/2022 12:54:40 PM,"AbbVie to inject $60M in iSTAR, gets option to acquire eye care device maker",Seeking Alpha,https://seekingalpha.com/news/3858498-abbvie-to-inject-60m-in-istar-gets-option-to-acquire-eye-care-device-maker?utm_source=businessinsider&utm_medium=referral,negative,0.7973380088806152
1435,7/20/2022 1:00:00 PM,AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma,PR Newswire,/news/stocks/abbvie-and-istar-medical-announce-strategic-alliance-for-the-treatment-of-glaucoma-1031600471,negative,0.9127558469772339
1436,7/20/2022 2:28:31 PM,AbbVie To Collaborate With ISTAR Medical; To Pay $60 Mln To Further Develop MINIject ,RTTNews,/news/stocks/abbvie-to-collaborate-with-istar-medical-to-pay-60-mln-to-further-develop-miniject-1031600903,negative,0.8705146908760071
1437,7/20/2022 11:59:56 PM,Recap of Wednesday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-wednesday-s-biotech-catalysts---end-of-the-day-summary-1031602618,positive,0.9346833229064941
1438,7/21/2022 9:40:47 AM,Novartis Humira biosimilar's high concentration dosage gets FDA review,Seeking Alpha,https://seekingalpha.com/news/3858914-novartis-humira-biosimilars-high-concentration-dosage-gets-fda-review?utm_source=businessinsider&utm_medium=referral,negative,0.7493067979812622
1439,7/21/2022 4:14:27 PM,"Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners",Benzinga,/news/stocks/daily-biotech-pulse-liver-disease-focused-gene-therapy-pact-assembly-bio-stops-hbv-infection-trial-x4-pharma-looks-for-partners-1031605137,positive,0.845745325088501
1440,7/22/2022 4:37:37 PM,"Earnings week ahead: Alphabet, Amazon, Coca-Cola, Microsoft, Ford, Exxon and more",Seeking Alpha,https://seekingalpha.com/news/3859698-earnings-week-ahead-coca-cola-microsoft-ford-exxon-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.919938862323761
1441,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral,positive,0.8448383808135986
1442,7/24/2022 1:35:33 PM,7 Value Stocks Trading at a Massive Discount Right Now,InvestorPlace,/news/stocks/value-stocks-trading-at-a-discount-1031609407,positive,0.8535559773445129
1443,7/24/2022 10:37:06 PM,"Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earnings Pick Up Pace",Benzinga,/news/stocks/apple-meta-pfizer-among-key-companies-reporting-in-the-week-ahead-as-earning-picks-up-pace-1031609526,negative,0.8915560245513916
1444,7/25/2022 2:00:00 PM,AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference,PR Newswire,/news/stocks/abbvie-and-allergan-aesthetics-to-present-new-data-from-leading-neurotoxin-portfolio-at-toxins-2022-conference-1031611273,positive,0.8530691862106323
1445,7/26/2022 8:00:00 AM,European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis,PR Newswire,/news/stocks/european-commission-approves-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-ulcerative-colitis-1031614176,negative,0.7591235041618347
1446,7/26/2022 8:41:16 AM,European Commission Approves AbbVie's Rinvoq To Treat Moderate To Severe Ulcerative Colitis ,RTTNews,/news/stocks/european-commission-approves-abbvie-s-rinvoq-to-treat-moderate-to-severe-ulcerative-colitis-1031614231,negative,0.7865228056907654
1447,7/26/2022 2:23:05 PM,"Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate",Benzinga,/news/stocks/daily-biotech-pulse-eu-approval-for-abbvie-s-ulcerative-colitis-treatment-angion-biomedica-evaluates-alternatives-clinical-hold-for-immuron-s-bacterial-infection-candidate-1031615201,negative,0.6602172255516052
1448,7/27/2022 12:24:04 AM,Recap Of Tuesday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031617287,positive,0.9340888261795044
1449,7/27/2022 2:22:20 PM,7 Blue-Chip Stocks to Buy on the Dip,InvestorPlace,/news/stocks/blue-chip-stocks-to-buy-on-the-dip-1031621244,positive,0.687315821647644
1450,7/27/2022 2:45:00 PM,AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease,PR Newswire,/news/stocks/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-crohn-s-disease-1031620436,positive,0.5282193422317505
1451,7/27/2022 3:20:23 PM,"AbbVie Submits Regulatory Applications To FDA, EMA For Upadacitinib For Crohn's Disease In Adults ",RTTNews,/news/stocks/abbvie-submits-regulatory-applications-to-fda-ema-for-upadacitinib-for-crohn-s-disease-in-adults-1031620978,positive,0.8127936720848083
1452,7/27/2022 5:48:54 PM,"Abbott, Merck under Wyden scrutiny for not providing offshore taxable income info",Seeking Alpha,https://seekingalpha.com/news/3861579-abbott-merck-under-wyden-scrutiny-for-not-providing-offshore-taxable-income-info?utm_source=businessinsider&utm_medium=referral,neutral,0.9057963490486145
1453,7/28/2022 1:00:38 AM,Recap of Wednesday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-wednesday-s-biotech-catalysts---end-of-the-day-summary-1031622768,positive,0.9346833229064941
1454,7/28/2022 3:01:13 PM,Here's what to expect from AbbVie's earnings,Markets Insider Automation,/news/stocks/abbvie-q2-quarterly-earnings-preview-1031625919,positive,0.9412732124328613
1455,7/28/2022 3:24:06 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3862494-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8830810189247131
1456,7/28/2022 3:38:21 PM,All eyes on AbbVie Q2 results amid challenges to rheumatoid arthritis drug Humira,Seeking Alpha,https://seekingalpha.com/news/3862498-all-eyes-on-abbvie-q2-results-amid-challenges-to-rheumatoid-arthritis-drug-humira?utm_source=businessinsider&utm_medium=referral,neutral,0.5423700213432312
1457,7/28/2022 3:58:17 PM,"AbbVie asks FDA, EMA to approve Rinvoq for Crohn's disease",Seeking Alpha,https://seekingalpha.com/news/3862507-abbvie-asks-fda-ema-to-approve-rinvoq-for-crohns-disease?utm_source=businessinsider&utm_medium=referral,negative,0.6551957130432129
1458,7/28/2022 4:37:49 PM,"Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate",Benzinga,/news/stocks/daily-biotech-pulse-gsk-s-kidney-disease-drug-approved-for-children-tonix-pharma-to-launch-monkeypox-vaccine-study-in-kenya-positive-effect-of-cyclerion-s-schizophrenia-candidate-1031626482,negative,0.864479124546051
1459,7/29/2022 8:00:00 AM,RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis,PR Newswire,/news/stocks/rinvoq-upadacitinib-approved-by-european-commission-as-an-oral-treatment-for-adults-with-active-non-radiographic-axial-spondyloarthritis-1031628930,negative,0.9244365096092224
1460,7/29/2022 9:41:07 AM,AbbVie: RINVOQ Approved In EU To Treat Adults With Active Non-Radiographic Axial Spondyloarthritis ,RTTNews,/news/stocks/abbvie-rinvoq-approved-in-eu-to-treat-adults-with-active-non-radiographic-axial-spondyloarthritis-1031629123,negative,0.7985266447067261
1461,7/29/2022 10:28:14 AM,AbbVie Rinvoq wins another approval in EU for spinal arthritis subtype,Seeking Alpha,https://seekingalpha.com/news/3863024-abbvie-rinvoq-wins-another-approval-in-eu-for-spinal-arthritis-subtype?utm_source=businessinsider&utm_medium=referral,negative,0.9496064782142639
1462,7/29/2022 11:43:18 AM,"AbbVie Non-GAAP EPS of $3.37 beats by $0.06, revenue of $14.58B misses by $60M, cuts FY22 EPS guidance",Seeking Alpha,https://seekingalpha.com/news/3863083-abbvie-non-gaap-eps-of-337-beats-by-006-revenue-of-1458b-misses-by-60m-cuts-fy22-eps-guidance?utm_source=businessinsider&utm_medium=referral,neutral,0.5720475316047668
1463,7/29/2022 1:03:10 PM,AbbVie stock dips while Q2 revenue soars on back of blockbuster Humira; sets aside ~$2B for opioid claims,Seeking Alpha,https://seekingalpha.com/news/3863160-abbvie-q2-revenue-soars-on-back-of-blockbuster-humira-sets-aside-2b-for-opioid-claims?utm_source=businessinsider&utm_medium=referral,neutral,0.9450862407684326
1464,7/29/2022 1:41:00 PM,AbbVie Reports Second-Quarter 2022 Financial Results,PR Newswire,/news/stocks/abbvie-reports-second-quarter-2022-financial-results-1031629763,positive,0.8445644974708557
1465,7/29/2022 1:52:41 PM,"AbbVie Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/abbvie-q2-profit-increases-beats-estimates-1031629785,negative,0.9299664497375488
1466,7/29/2022 2:03:00 PM,AbbVie Confirms FY22 Adj. EPS Outlook - Update ,RTTNews,/news/stocks/abbvie-confirms-fy22-adj-eps-outlook-update-1031629838,positive,0.9121693968772888
1467,7/29/2022 3:39:24 PM,ABBV Stock Slips as AbbVie Faces Opioid Lawsuits,InvestorPlace,/news/stocks/abbv-stock-slips-as-abbvie-faces-opioid-lawsuits-1031630551,neutral,0.961124062538147
1468,7/29/2022 4:27:45 PM,"Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update",Benzinga,/news/stocks/daily-biotech-pulse-bausch-health-to-appeal-xifaxan-patent-decision-bristol-myers-drug-combo-fails-in-kidney-cancer-trial-sarepta-s-duchenne-candidate-update-1031630398,neutral,0.49885427951812744
1469,7/29/2022 6:37:42 PM,Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh,Seeking Alpha,https://seekingalpha.com/news/3863368-ironwood-pharma-falls-7-as-linzess-q2-sales-of-drug-from-abbvie-weigh?utm_source=businessinsider&utm_medium=referral,neutral,0.9674408435821533
1470,7/29/2022 11:24:17 PM,Recap Of Friday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031631044,positive,0.9370302557945251
1471,8/1/2022 2:56:58 PM,AbbVie downgraded to neutral at Atlantic on weakness in some franchises,Seeking Alpha,https://seekingalpha.com/news/3863757-abbvie-downgraded-to-neutral-at-atlantic-on-weakness-in-some-franchises?utm_source=businessinsider&utm_medium=referral,neutral,0.9314184784889221
1472,8/1/2022 4:26:05 PM,Amgen disputes IRS over $10.7B tax bill - WSJ,Seeking Alpha,https://seekingalpha.com/news/3863813-amgen-disputes-irs-over-107b-tax-bill-wsj?utm_source=businessinsider&utm_medium=referral,neutral,0.8537505269050598
1473,8/1/2022 9:08:45 PM,6 Analysts Have This to Say About AbbVie,Benzinga,/news/stocks/6-analysts-have-this-to-say-about-abbvie-1031636582,positive,0.9250975847244263
1474,8/2/2022 10:08:40 AM,AbbVie to pay $40M upfront to Sosei under pact to develop drugs for neurological diseases,Seeking Alpha,https://seekingalpha.com/news/3864442-abbvie-to-pay-40m-upfront-to-sosei-under-pact-to-develop-drugs-for-neurological-diseases?utm_source=businessinsider&utm_medium=referral,negative,0.7381477952003479
1475,8/2/2022 2:28:00 PM,"Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study",Benzinga,/news/stocks/biotech-daily-trial-setback-for-eliem-therapeutics-allarity-drops-work-on-cancer-monotherapies-axcella-aces-long-covid-study-1031639615,neutral,0.9367731809616089
1476,8/3/2022 1:31:46 PM,AbbVie gets FDA approval for JUVÉDERM to improve jawline definition,Seeking Alpha,https://seekingalpha.com/news/3865740-abbvie-gets-fda-approval-for-juvderm-to-improve-jawline-definition?utm_source=businessinsider&utm_medium=referral,negative,0.8940855860710144
1477,8/3/2022 2:45:00 PM,FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition,PR Newswire,/news/stocks/fda-approves-juvéderm-volux-xc-for-improvement-of-jawline-definition-1031645192,negative,0.9173769950866699
1478,8/3/2022 3:06:46 PM,Allegan Aesthetics Of AbbVie Gets FDA Approval For Juvederm Volux XC For Jawline Treatment ,RTTNews,/news/stocks/allegan-aesthetics-of-abbvie-gets-fda-approval-for-juvederm-volux-xc-for-jawline-treatment-1031645840,negative,0.8970053791999817
1479,8/3/2022 8:42:38 PM,7 Cheap Biotech Stocks to Buy Now,InvestorPlace,/news/stocks/cheap-biotech-stocks-1031647456,positive,0.8731281161308289
1480,8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral,positive,0.5326845645904541
1481,8/9/2022 1:38:04 AM,The 3 Best Vanguard Funds to Buy in August,InvestorPlace,/news/stocks/best-vanguard-funds-1031663161,positive,0.8945893049240112
1482,8/9/2022 2:23:25 PM,7 Blue-Chip Stocks That Will Survive 2022,InvestorPlace,/news/stocks/blue-chip-stocks-that-will-survive-2022-1031666249,positive,0.7984703183174133
1483,8/9/2022 4:17:42 PM,Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication,Seeking Alpha,https://seekingalpha.com/news/3869892-myovant-sciences-upgraded-to-outperform-at-svb-following-additional-myfembree-indication?utm_source=businessinsider&utm_medium=referral,negative,0.9474297165870667
1484,8/11/2022 9:11:59 PM,"This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside",Benzinga,/news/stocks/this-nasal-spray-for-eye-disease-stock-is-attractive-has-potential-160-upside-1031677079,negative,0.8374460339546204
1485,8/11/2022 9:42:59 PM,Amgen under fire from Sen. Wyden over tax practices - Reuters,Seeking Alpha,https://seekingalpha.com/news/3872054-amgen-under-fire-from-sen-wyden-over-tax-practices-reuters?utm_source=businessinsider&utm_medium=referral,neutral,0.9343113303184509
1486,8/13/2022 8:00:00 PM,"AbbVie, Roche, Regeneron could significantly benefit as AMD market expected to soar",Seeking Alpha,https://seekingalpha.com/news/3872108-abbvie-roche-regeneron-could-significantly-benefit-as-amd-market-expected-to-soar?utm_source=businessinsider&utm_medium=referral,negative,0.9175599217414856
1487,8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.8447362780570984
1488,8/16/2022 9:57:56 PM,AbbVie to discontinue phase 1 trial for I-Mab's anti-CD47 therapy for treatment of cancers,Seeking Alpha,https://seekingalpha.com/news/3873896-abbvie-to-discontinue-phase-1-trial-for-i-mabs-anti-cd47-therapy-for-treatment-of-cancers?utm_source=businessinsider&utm_medium=referral,positive,0.4921106696128845
1489,8/17/2022 12:08:27 PM,"Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod",Seeking Alpha,https://seekingalpha.com/news/3874070-organon-samsung-bioepis-humira-biosimilar-hadlima-high-concentration-dosage-gets-fda-nod?utm_source=businessinsider&utm_medium=referral,negative,0.9092172384262085
1490,8/17/2022 2:45:00 PM,Experience the JUVÉDERM® Difference with Allergan Aesthetics,PR Newswire,/news/stocks/experience-the-juvéderm-difference-with-allergan-aesthetics-1031689995,positive,0.8322232365608215
1491,8/17/2022 4:19:19 PM,AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate,Benzinga,/news/stocks/abbvie-calls-off-early-stage-trial-for-i-mab-s-cd47-targeted-blood-cancer-candidate-1031690411,neutral,0.9048791527748108
1492,8/17/2022 6:03:21 PM,"Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session",Benzinga,/news/stocks/why-blue-water-vaccines-is-trading-higher-by-around-80-here-are-61-stocks-moving-in-wednesday-s-mid-day-session-1031690751,positive,0.9122395515441895
1493,8/17/2022 9:24:44 PM,This Analyst Cuts I-Mab's Price Target By 43%,Benzinga,/news/stocks/this-analyst-cuts-i-mab-s-price-target-by-43-1031691099,positive,0.5389982461929321
1494,8/18/2022 9:19:51 AM,Junshi Biosciences gets Chinese regulator review of expanded approval of Humira biosimilar,Seeking Alpha,https://seekingalpha.com/news/3874474-junshi-biosciences-gets-chinese-regulator-review-of-expanded-approval-of-humira-biosimilar?utm_source=businessinsider&utm_medium=referral,negative,0.7265489101409912
1495,8/18/2022 10:59:45 AM,This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday,Benzinga,/news/stocks/this-healthcare-stock-dipped-over-30-here-are-83-biggest-movers-from-yesterday-1031692216,neutral,0.8815073370933533
1496,8/22/2022 4:58:46 AM,Five-Star Financial Blogger Zvi Bar is Bullish on These 2 Stocks,TipRanks,/news/stocks/five-star-financial-blogger-zvi-bar-is-bullish-on-these-2-stocks-1031697544,negative,0.6469536423683167
1497,8/23/2022 11:45:10 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/7-top-rated-large-cap-stocks-to-buy-and-hold-2-1031700256,positive,0.8808764219284058
1498,8/24/2022 5:07:34 PM,Expert Ratings for AbbVie,Benzinga,/news/stocks/expert-ratings-for-abbvie-1031703702,positive,0.7884920835494995
1499,8/25/2022 1:21:00 AM,Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib),PR Newswire,/news/stocks/children-with-chronic-graft-versus-host-disease-cgvhd-may-now-be-prescribed-imbruvica-ibrutinib-1031704417,positive,0.8775002956390381
1500,8/25/2022 2:51:45 AM,FDA Oks AbbVie' Imbruvica For Treatment Of Pediatric Patients With Chronic Graft Versus Host Disease ,RTTNews,/news/stocks/fda-oks-abbvie-imbruvica-for-treatment-of-pediatric-patients-with-chronic-graft-versus-host-disease-1031704443,negative,0.5769851207733154
1501,8/25/2022 9:38:03 AM,"AbbVie, J&J Imbruvica gets FDA nod to treat graft-versus-host disease in kids",Seeking Alpha,https://seekingalpha.com/news/3876504-abbvie-jj-imbruvica-gets-fda-nod-to-treat-graft-versus-host-disease-in-kids?utm_source=businessinsider&utm_medium=referral,negative,0.8829074501991272
1502,8/29/2022 2:00:00 PM,AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress,PR Newswire,/news/stocks/abbvie-showcases-new-analyses-and-real-world-data-across-multiple-immune-mediated-skin-diseases-at-the-european-academy-of-dermatology-and-venereology-eadv-2022-congress-1031710589,positive,0.7805790901184082
1503,8/30/2022 2:00:00 PM,Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report,PR Newswire,/news/stocks/allergan-aesthetics-publishes-the-future-of-aesthetics-global-trends-report-1031713152,positive,0.9107087850570679
1504,8/31/2022 6:40:38 AM,"U.S. Politicians Bought PG, ABBV & SBUX Stocks in August",TipRanks,/news/stocks/u-s-politicians-bought-pg-abbv-sbux-stocks-in-august-1031715263,positive,0.8653671741485596
1505,8/31/2022 3:00:00 PM,SkinMedica® Launches Firm & Tone Lotion for Body,PR Newswire,/news/stocks/skinmedica-launches-firm-tone-lotion-for-body-1031716214,positive,0.6127694845199585
1506,9/5/2022 10:02:10 AM,Alvotech filing for Humira biosimilar approval hit a snag as FDA cites manufacturing issues,Seeking Alpha,https://seekingalpha.com/news/3880232-alvotech-filing-for-humira-biosimilar-approval-hit-a-snag-as-fda-cites-manufacturing-issues?utm_source=businessinsider&utm_medium=referral,neutral,0.9581551551818848
1507,9/6/2022 12:41:40 PM,"AbbVie, Ironwood constipation therapy Linzess meets main goal of phase 3 trial in children",Seeking Alpha,https://seekingalpha.com/news/3880392-abbvie-ironwood-constipation-therapy-linzess-meets-main-goal-of-phase-3-trial-in-children?utm_source=businessinsider&utm_medium=referral,negative,0.7310637831687927
1508,9/6/2022 3:26:38 PM,Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients,Benzinga,/news/stocks/ironwood-s-constipation-drug-shows-efficacy-in-pediatric-patients-1031726476,negative,0.9374255537986755
1509,9/7/2022 2:00:00 PM,AbbVie to Present at the Morgan Stanley Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-1031728852,positive,0.9129487872123718
1510,9/7/2022 2:45:00 PM,Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®,PR Newswire,/news/stocks/allergan-aesthetics-celebrates-100-million-syringes-of-juvéderm-1031729118,positive,0.5347741842269897
1511,9/8/2022 1:52:19 AM,3 Safe Dividend Stocks to Buy in September,InvestorPlace,/news/stocks/safe-dividend-stocks-1031588958,positive,0.9068034291267395
1512,9/8/2022 10:00:00 AM,AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022,PR Newswire,/news/stocks/abbvie-to-present-data-from-its-robust-migraine-portfolio-at-the-migraine-trust-international-symposium-2022-1031731177,positive,0.8267791867256165
1513,9/8/2022 10:30:00 AM,"New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients",PR Newswire,/news/stocks/new-measure-ad-analyses-evaluate-clinical-psychosocial-and-economic-burdens-in-atopic-dermatitis-patients-1031731218,positive,0.793521523475647
1514,9/8/2022 11:25:42 AM,Revance climbs 14% as FDA approves facial injectable for frown lines,Seeking Alpha,https://seekingalpha.com/news/3881146-rvnc-stock-climbs-as-fda-approves-facial-injectable-for-frown-lines?utm_source=businessinsider&utm_medium=referral,negative,0.9437578916549683
1515,9/8/2022 12:18:48 PM,"Exxon (XOM), AbbVie (ABBV): Befriend These 2 Dividend Aristocrat Stocks",TipRanks,/news/stocks/exxon-xom-abbvie-abbv-befriend-these-2-dividend-aristocrat-stocks-1031731888,positive,0.8197166323661804
1516,9/8/2022 1:51:11 PM,Why Is Revance Therapeutics (RVNC) Stock Soaring Today?,InvestorPlace,/news/stocks/why-is-revance-therapeutics-rvnc-stock-soaring-today-1031732379,neutral,0.537503182888031
1517,9/8/2022 4:14:39 PM,7 S&P 500 Stocks to Buy With Superior Fundamentals,InvestorPlace,/news/stocks/7-sp-500-stocks-to-buy-with-superior-fundamentals-1031732880,negative,0.8411650061607361
1518,9/8/2022 5:12:07 PM,Revance nears eleven-month high as Botox rival gets FDA approval,Seeking Alpha,https://seekingalpha.com/news/3881326-rvnc-stock-nears-eleven-month-high-as-botox-rival-gets-fda-approval?utm_source=businessinsider&utm_medium=referral,negative,0.8941159248352051
1519,9/8/2022 9:01:53 PM,"FDA warns about skin cancer, various lymphomas in scar tissue around breast implants",Seeking Alpha,https://seekingalpha.com/news/3881442-fda-warns-about-skin-cancer-various-lymphomas-in-scar-tissue-around-breast-implants?utm_source=businessinsider&utm_medium=referral,neutral,0.7986806035041809
1520,9/9/2022 2:30:12 PM,AbbVie declares $1.41 dividend,Seeking Alpha,https://seekingalpha.com/news/3881660-abbvie-inc-declares-1_41-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9414845108985901
1521,9/9/2022 4:26:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1031734892,neutral,0.5513123869895935
1522,9/10/2022 9:20:00 AM,New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100,PR Newswire,/news/stocks/new-late-breaking-results-from-phase-3-trials-of-skyrizi-risankizumab-evaluating-long-term-effect-on-skin-and-joint-symptoms-in-patients-with-psoriatic-arthritis-at-week-100-1031735625,negative,0.6971830129623413
1523,9/12/2022 1:37:05 PM,Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-jumps-8-as-fda-approves-psoriasis-treatment-1031737488,negative,0.9333906769752502
1524,9/13/2022 2:45:00 PM,"Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories",PR Newswire,/news/stocks/allergan-aesthetics-and-botox-cosmetic-onabotulinumtoxina-reveal-new-see-yourself-campaign-cast-spotlighting-25-real-people-and-their-stories-1031739894,positive,0.8411755561828613
1525,9/14/2022 5:15:00 PM,"AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship ""Thriving Student Awards""",PR Newswire,/news/stocks/abbvie-announces-public-voting-open-for-30th-annual-cystic-fibrosis-scholarship-thriving-student-awards-1031743337,positive,0.8600949048995972
1526,9/15/2022 8:00:00 AM,AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress,PR Newswire,/news/stocks/abbvie-to-present-data-from-growing-neuroscience-and-movement-disorders-portfolio-at-2022-mds-international-congress-1031744410,positive,0.8382705450057983
1527,9/15/2022 7:00:16 PM,7 Top-Rated Biotech Stocks to Buy for Q4,InvestorPlace,/news/stocks/7-top-rated-biotech-stocks-to-buy-for-q4-1031746729,positive,0.8415942192077637
1528,9/16/2022 1:47:23 PM,EMA panel recommends extending use of AbbVie's Skyrizi drug to treat Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/3883431-ema-panel-recommends-extending-use-of-abbvies-skyrizi-drug-to-treat-crohns-disease?utm_source=businessinsider&utm_medium=referral,positive,0.7313327789306641
1529,9/17/2022 8:00:18 PM,"BioNTech, Moderna, Pfizer led biopharma revenue growth from 2020-2021",Seeking Alpha,https://seekingalpha.com/news/3883566-biontech-moderna-pfizer-led-biopharma-revenue-growth-from-2020-2021?utm_source=businessinsider&utm_medium=referral,negative,0.9150789380073547
1530,9/19/2022 2:28:30 AM,The 7 Best Market Sectors for Q4,InvestorPlace,/news/stocks/best-market-sectors-1031594318,positive,0.9104395508766174
1531,9/19/2022 8:00:00 AM,AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease,PR Newswire,/news/stocks/abbvie-secures-positive-chmp-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-moderate-to-severe-crohn-s-disease-1031749782,negative,0.9262874126434326
1532,9/19/2022 9:22:04 AM,AbbVie Receives CHMP Positive Opinion For Skyrizi For Moderate To Severe Crohn's Disease ,RTTNews,/news/stocks/abbvie-receives-chmp-positive-opinion-for-skyrizi-for-moderate-to-severe-crohn-s-disease-1031749910,negative,0.9394646883010864
1533,9/19/2022 10:25:54 AM,Morgan Stanley's quant screen chooses dividend stocks to own and avoid,Seeking Alpha,https://seekingalpha.com/news/3883594-morgan-stanleys-quant-screen-chooses-best-dividend-stocks-to-own-and-avoid?utm_source=businessinsider&utm_medium=referral,positive,0.9515529274940491
1534,9/21/2022 12:22:55 PM,Sesen Bio in merger deal with immunotherapy company Carisma Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3884772-sesn-stock-on-watch-after-merger-deal-with-carisma-therapeutics?utm_source=businessinsider&utm_medium=referral,positive,0.4977312982082367
1535,9/21/2022 1:11:21 PM,Evolus concludes certain royalty payments related to settlement of IP rights dispute,Seeking Alpha,https://seekingalpha.com/news/3884805-evolus-concludes-certain-royalty-payments-related-to-settlement-of-ip-rights-dispute?utm_source=businessinsider&utm_medium=referral,positive,0.8590148091316223
1536,9/22/2022 2:00:00 PM,The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery,PR Newswire,/news/stocks/the-forces-of-beauty-report-from-the-dream-initiative-reveals-demand-for-new-standards-of-beauty-and-imagery-1031759037,positive,0.6690820455551147
1537,9/25/2022 6:00:00 PM,The prostate cancer therapy market will soar. Here are the companies that could benefit.,Seeking Alpha,https://seekingalpha.com/news/3885824-the-prostate-cancer-therapy-market-will-soar-here-are-the-companies-that-could-benefit?utm_source=businessinsider&utm_medium=referral,positive,0.9147647023200989
1538,9/27/2022 2:00:38 PM,7 Profitable Places to Hide Your Money as We Enter a Bear Market,InvestorPlace,/news/stocks/7-profitable-places-to-hide-your-money-during-a-bear-market-1031459868,positive,0.9188072085380554
1539,9/27/2022 6:32:56 PM,Investors are pouring money into healthcare and other defensive sectors as market tanks,Seeking Alpha,https://seekingalpha.com/news/3886489-investors-are-pouring-money-into-healthcare-stocks-and-other-defensive-stocks-as-market-tanks?utm_source=businessinsider&utm_medium=referral,positive,0.8531034588813782
1540,9/29/2022 1:00:00 PM,AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022,PR Newswire,/news/stocks/abbvie-highlights-robust-gastroenterology-portfolio-with-new-data-in-crohn-s-disease-and-ulcerative-colitis-at-the-ueg-week-2022-1031772424,negative,0.9283440709114075
1541,9/30/2022 2:28:54 PM,Tilray To Crater Over 30%? Here Are 5 Other Price Target Changes For Friday,Benzinga,/news/stocks/tilray-to-crater-over-30-here-are-5-other-price-target-changes-for-friday-1031775550,positive,0.9221644401550293
1542,9/30/2022 2:31:55 PM,7 Analysts Have This to Say About AbbVie,Benzinga,/news/stocks/7-analysts-have-this-to-say-about-abbvie-1031775552,positive,0.9263938069343567
1543,9/30/2022 5:25:33 PM,AbbVie pares losses as SVB Leerink retracts guidance claims,Seeking Alpha,https://seekingalpha.com/news/3887563-abbv-stock-pares-losses-as-svb-leerink-retracts-guidance-claims?utm_source=businessinsider&utm_medium=referral,neutral,0.9529955387115479
1544,9/30/2022 8:11:00 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK), AbbVie (ABBV) and Intercept Pharma (ICPT)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-merck-company-mrk-abbvie-abbv-and-intercept-pharma-icpt-1031776731,neutral,0.9366409778594971
1545,10/4/2022 2:00:00 PM,AbbVie to Host Third-Quarter 2022 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-third-quarter-2022-earnings-conference-call-1031781336,positive,0.9129770994186401
1546,10/4/2022 8:09:04 PM,Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4,InvestorPlace,/news/stocks/best-stocks-2022-these-3-factors-can-send-sonic-automotive-sah-stock-soaring-in-q4-1031782939,negative,0.9230084419250488
1547,10/4/2022 9:39:06 PM,3 Cheap Stocks to Buy for Their High Cash Flow and Dividends,InvestorPlace,/news/stocks/3-cheap-stocks-to-buy-for-their-high-cash-flow-and-dividends-1031783125,positive,0.837051272392273
1548,10/5/2022 6:15:52 PM,Best Stocks 2022: What’s Not to Like About AbbVie (ABBV) Stock?,InvestorPlace,/news/stocks/best-stocks-2022-whats-not-to-like-about-abbvie-abbv-stock-1031785559,positive,0.88181471824646
1549,10/5/2022 8:50:43 PM,"AbbVie sees acquired IPR&D, milestone expenses negatively impacting Q3 results by $0.02",Seeking Alpha,https://seekingalpha.com/news/3889033-abbvie-sees-acquired-iprd-milestone-expenses-negatively-impacting-q3-results-by-002?utm_source=businessinsider&utm_medium=referral,neutral,0.9715963006019592
1550,10/7/2022 12:46:19 PM,7 Growth Stocks to Buy and Hold for the Next 10 Years,InvestorPlace,/news/stocks/growth-stocks-to-buy-and-hold-1031789979,positive,0.9068271517753601
1551,10/7/2022 7:00:24 PM,"Catalyst watch: DraftKings, PepsiCo, Asana, AbbVie and Walgreens in focus",Seeking Alpha,https://seekingalpha.com/news/3889745-catalyst-watch-draftkings-pepsico-asasa-abbvie-and-walgreens-in-focus?utm_source=businessinsider&utm_medium=referral,positive,0.8857030868530273
1552,10/7/2022 8:05:00 PM,Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting,PR Newswire,/news/stocks/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2022-american-society-for-dermatologic-surgery-meeting-1031790703,positive,0.782076358795166
1553,10/10/2022 10:15:48 AM,These 7 Biotech Stocks Are Set to Boom in 2023,InvestorPlace,/news/stocks/7-biotech-stocks-set-to-boom-2023-1031792647,negative,0.8603333234786987
1554,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral,positive,0.5134317874908447
1555,10/11/2022 8:15:17 PM,4 Dividend Stocks Yielding 4%+,InvestorPlace,/news/stocks/4-dividend-stocks-yielding-4-1031797274,positive,0.851168692111969
1556,10/12/2022 11:57:47 AM,BeiGene Brukinsa shows better survival benefit vs Imbruvica in blood cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3890655-beigene-brukinsa-shows-better-survival-benefit-vs-imbruvica-in-blood-cancer-patients-in-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9531958699226379
1557,10/13/2022 5:28:57 PM,BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential,Seeking Alpha,https://seekingalpha.com/news/3891157-beigene-upgraded-to-buy-at-guggenheim-on-improved-confidence-in-brukinsa-potential?utm_source=businessinsider&utm_medium=referral,negative,0.9556883573532104
1558,10/17/2022 3:00:00 PM,AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire,PR Newswire,/news/stocks/abbvie-vice-chairman-of-external-affairs-and-chief-legal-officer-laura-j-schumacher-to-retire-1031810064,positive,0.9398692846298218
1559,10/19/2022 2:10:46 PM,Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Verve Therapeutics (VERV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-and-verve-therapeutics-verv-1031817951,positive,0.9069204926490784
1560,10/20/2022 1:36:54 PM,AbbVie to acquire DJS Antibodies for $255M to bolster immunology pipeline,Seeking Alpha,https://seekingalpha.com/news/3893196-abbvie-to-acquire-djs-antibodies-for-255m-to-bolster-immunology-pipeline?utm_source=businessinsider&utm_medium=referral,negative,0.8283438682556152
1561,10/20/2022 3:00:00 PM,"AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline",PR Newswire,/news/stocks/abbvie-acquires-djs-antibodies-further-strengthening-immunology-pipeline-1031821221,negative,0.9275311231613159
1562,10/20/2022 3:37:39 PM,AbbVie: SKYRIZI Gets Health Canada Approval To Treat Moderately To Severely Active Crohn's Disease ,RTTNews,/news/stocks/abbvie-skyrizi-gets-health-canada-approval-to-treat-moderately-to-severely-active-crohn-s-disease-1031821483,negative,0.93263179063797
1563,10/20/2022 3:59:53 PM,AbbVie To Buy UK-based Biotechnology Company DJS Antibodies For About $255 Mln ,RTTNews,/news/stocks/abbvie-to-buy-uk-based-biotechnology-company-djs-antibodies-for-about-255-mln-1031821551,positive,0.8971828818321228
1564,10/21/2022 5:16:55 PM,"Earnings week ahead: Apple, Alphabet, Amazon, Meta, Boeing and more",Seeking Alpha,https://seekingalpha.com/news/3893730-earnings-week-ahead-apple-alphabet-amazon-meta-boeing-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9336963295936584
1565,10/21/2022 6:00:33 PM,"Catalyst Watch: Tech heavyweights report, Mobileye IPO and Twitter-Tesla-Musk drama redux",Seeking Alpha,https://seekingalpha.com/news/3893787-catalyst-watch-tech-heavyweights-report-mobileye-ipo-and-twitter-tesla-musk-drama-redux?utm_source=businessinsider&utm_medium=referral,positive,0.8056232929229736
1566,10/21/2022 6:26:19 PM,"Catalyst Watch: Tech heavyweights report, Mobileye IPO and Twitter-Tesla-Musk drama redux",Seeking Alpha,https://seekingalpha.com/news/3893799-catalyst-watch-tech-heavyweights-report-mobileye-ipo-and-twitter-tesla-musk-drama-redux?utm_source=businessinsider&utm_medium=referral,positive,0.8056232929229736
1567,10/21/2022 7:04:03 PM,"Catalyst Watch: Tech heavyweights report, Mobileye IPO and Twitter-Tesla-Musk drama redux",Seeking Alpha,https://seekingalpha.com/news/3893812-catalyst-watch-tech-heavyweights-report-mobileye-ipo-and-twitter-tesla-musk-drama-redux?utm_source=businessinsider&utm_medium=referral,positive,0.8056232929229736
1568,10/21/2022 8:59:12 PM,AbbVie's Rinvoq approved for type of spondyloarthritis,Seeking Alpha,https://seekingalpha.com/news/3893859-abbvie-rinvoq-approved-for-type-of-spondyloarthritis?utm_source=businessinsider&utm_medium=referral,positive,0.7641429305076599
1569,10/21/2022 10:42:00 PM,RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval,PR Newswire,/news/stocks/rinvoq-upadacitinib-receives-its-sixth-u-s-fda-approval-1031825362,negative,0.9186751842498779
1570,10/21/2022 11:33:47 PM,FDA Approves AbbVie's Rinvoq For Treatment Of Active Non-radiographic Axial Spondyloarthritis ,RTTNews,/news/stocks/fda-approves-abbvie-s-rinvoq-for-treatment-of-active-non-radiographic-axial-spondyloarthritis-1031825413,negative,0.8879313468933105
1571,10/22/2022 8:00:00 PM,"J&J, Alkermes, AbbVie, others set to benefit from expanding schizophrenia drug market",Seeking Alpha,https://seekingalpha.com/news/3893816-johnson-johnson-alkermes-abbvie-others-set-to-benefit-from-expanding-schizophrenia-drug-market?utm_source=businessinsider&utm_medium=referral,negative,0.7288205027580261
1572,10/24/2022 1:00:00 PM,AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting,PR Newswire,/news/stocks/abbvie-to-present-data-from-extensive-portfolio-at-american-college-of-gastroenterology-annual-scientific-meeting-1031827976,positive,0.9255427122116089
1573,10/27/2022 1:40:59 PM,Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-and-abbvie-abbv-1031843968,positive,0.9116554856300354
1574,10/27/2022 2:20:06 PM,All eyes on AbbVie Q3 results amid biosimilar competition to rheumatoid arthritis drug Humira,Seeking Alpha,https://seekingalpha.com/news/3896556-all-eyes-on-abbvie-q3-results-amid-biosimilar-competition-to-rheumatoid-arthritis-drug-humira?utm_source=businessinsider&utm_medium=referral,neutral,0.5592252016067505
1575,10/27/2022 3:01:13 PM,AbbVie earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/abbvie-stock-price-q3-earnings-preview-1031843576,positive,0.9104300737380981
1576,10/27/2022 3:05:22 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3896582-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8830810189247131
1577,10/27/2022 3:54:30 PM,Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’,InvestorPlace,/news/stocks/midterm-elections-2022-3-stocks-to-avoid-like-the-plague-for-a-blue-wave-1031844449,positive,0.8777721524238586
1578,10/27/2022 5:58:16 PM,Steal Some Yield and Bet on Clinical Clout With ABBV Stock,InvestorPlace,/news/stocks/steal-some-yield-and-bet-on-clinical-clout-with-abbv-stock-1031844850,positive,0.8762657642364502
1579,10/28/2022 11:45:44 AM,"AbbVie Non-GAAP EPS of $3.66 beats by $0.10, revenue of $14.81B misses by $130M, raises dividend by 5%",Seeking Alpha,https://seekingalpha.com/news/3897177-abbvie-non-gaap-eps-of-3_66-beats-0_10-revenue-of-14_81b-misses-130m?utm_source=businessinsider&utm_medium=referral,negative,0.9351403117179871
1580,10/28/2022 11:47:37 AM,AbbVie raises dividend by 5% to $1.48,Seeking Alpha,https://seekingalpha.com/news/3897178-abbvie-inc-declares-missing-dividend?utm_source=businessinsider&utm_medium=referral,negative,0.9237673878669739
1581,10/28/2022 12:57:57 PM,AbbVie falls as Humira international decline continues in Q3; narrows FY22 outlook,Seeking Alpha,https://seekingalpha.com/news/3897229-abbvie-stock-falls-as-humira-international-decline-continues-in-q3-narrows-fy22-outlook?utm_source=businessinsider&utm_medium=referral,neutral,0.9742423892021179
1582,10/28/2022 1:29:04 PM,"Genmab files for approval of blood cancer drug in US, AbbVie gets review in EU",Seeking Alpha,https://seekingalpha.com/news/3897259-genmab-files-for-approval-of-blood-cancer-drug-in-us-abbvie-gets-review-in-eu?utm_source=businessinsider&utm_medium=referral,positive,0.7828578352928162
1583,10/28/2022 1:44:00 PM,AbbVie Reports Third-Quarter 2022 Financial Results,PR Newswire,/news/stocks/abbvie-reports-third-quarter-2022-financial-results-1031848066,positive,0.8531758785247803
1584,10/28/2022 1:58:39 PM,"AbbVie Q3 Profit Increases, beats estimates",RTTNews,/news/stocks/abbvie-q3-profit-increases-beats-estimates-1031848113,negative,0.9223978519439697
1585,10/28/2022 2:45:00 PM,AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma...,PR Newswire,/news/stocks/abbvie-announces-submissions-of-regulatory-applications-for-epcoritamab-duobody-cd3xcd20-for-the-treatment-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-and-large-b-cell-lymphoma-1031848338,negative,0.620657742023468
1586,10/28/2022 3:27:31 PM,AbbVie Says EMA Validates MAA For Epcoritamab To Treat Relapsed/refractory Diffuse Large B-cell ,RTTNews,/news/stocks/abbvie-says-ema-validates-maa-for-epcoritamab-to-treat-relapsed-refractory-diffuse-large-b-cell-1031848556,negative,0.9162782430648804
1587,10/28/2022 6:17:24 PM,The 7 Most Popular Dividend Stocks Ranked from Biggest to Smallest,InvestorPlace,/news/stocks/7-most-popular-dividend-stocks-ranked-by-market-cap-1031849289,positive,0.7724806070327759
1588,10/31/2022 9:11:31 AM,Inventiva stock dips as AbbVie abandons cedirogant program for autoimmune disease,Seeking Alpha,https://seekingalpha.com/news/3897598-inventiva-stock-dips-as-abbvie-abandons-cedirogant-program-for-autoimmune-disease?utm_source=businessinsider&utm_medium=referral,neutral,0.9629589319229126
1589,10/31/2022 2:12:40 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-abbvie-abbv-1031854099,positive,0.5588529706001282
1590,10/31/2022 3:01:12 PM,Expert Ratings for AbbVie,Benzinga,/news/stocks/expert-ratings-for-abbvie-1031854009,positive,0.7884920835494995
1591,10/31/2022 6:45:22 PM,Where AbbVie Stands With Analysts,Benzinga,/news/stocks/where-abbvie-stands-with-analysts-1031854806,positive,0.8949053883552551
1592,11/1/2022 7:09:43 AM,Morgan Stanley Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-buy-rating-for-abbvie-abbv-1031857231,positive,0.8453507423400879
1593,11/1/2022 7:10:37 AM,AbbVie (ABBV) Receives a Hold from Barclays,TipRanks,/news/stocks/abbvie-abbv-receives-a-hold-from-barclays-1031857219,positive,0.8720769882202148
1594,11/1/2022 7:10:41 AM,Atlantic Equities Sticks to Its Hold Rating for AbbVie (ABBV),TipRanks,/news/stocks/atlantic-equities-sticks-to-its-hold-rating-for-abbvie-abbv-1031857218,positive,0.8299558758735657
1595,11/1/2022 7:13:40 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM), AbbVie (ABBV) and Teladoc (TDOC)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-insmed-insm-abbvie-abbv-and-teladoc-tdoc-1031857191,neutral,0.8483077883720398
1596,11/2/2022 4:45:36 AM,SVB Securities Issues a Sell Rating on AbbVie (ABBV),TipRanks,/news/stocks/svb-securities-issues-a-sell-rating-on-abbvie-abbv-1031860934,positive,0.907318651676178
1597,11/2/2022 1:00:00 PM,Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day,PR Newswire,/news/stocks/allergan-aesthetics-celebrates-fourth-annual-botox-cosmetic-onabotulinumtoxina-day-1031863646,positive,0.4994677007198334
1598,11/3/2022 1:00:00 PM,Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness,PR Newswire,/news/stocks/allergan-aesthetics-reaffirms-commitment-to-breast-health-advocacy-with-yearlong-program-for-breast-cancer-awareness-1031870016,negative,0.7253423929214478
1599,11/3/2022 4:30:26 PM,"Cancer drugs launch prices soaring, straining Medicare, report finds",Seeking Alpha,https://seekingalpha.com/news/3901117-cancer-drugs-launch-prices-soaring-straining-medicare-report-finds?utm_source=businessinsider&utm_medium=referral,neutral,0.5917294025421143
1600,11/6/2022 5:00:24 PM,"Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report",Seeking Alpha,https://seekingalpha.com/news/3902378-off-patent-drugs-make-up-91-of-prescriptions-18-of-spending?utm_source=businessinsider&utm_medium=referral,positive,0.8645551800727844
1601,11/7/2022 5:51:25 PM,AbbVie candidate for postoperative atrial fibrillation fails in mid-stage trial,Seeking Alpha,https://seekingalpha.com/news/3902823-abbvie-candidate-for-postoperative-atrial-fibrillation-fails-in-mid-stage-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.805193305015564
1602,11/7/2022 6:31:00 PM,AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery...,PR Newswire,/news/stocks/abbvie-announces-late-breaking-results-from-phase-2-exploratory-nova-trial-of-novel-investigational-neurotoxin-agn-151607-for-the-prevention-of-postoperative-atrial-fibrillation-in-cardiac-surgery-1031882520,negative,0.8027844429016113
1603,11/8/2022 2:29:09 AM,AbbVie : Phase 2 Trial Of AGN-151607 In POAF In Cardiac Surgery Patients Fails To Meet Main Goal ,RTTNews,/news/stocks/abbvie-phase-2-trial-of-agn-151607-in-poaf-in-cardiac-surgery-patients-fails-to-meet-main-goal-1031883612,neutral,0.9579959511756897
1604,11/8/2022 5:49:43 PM,"AbbVie downgraded to hold at Societe Generale on weakness in blood cancer, aesthetics",Seeking Alpha,https://seekingalpha.com/news/3903734-abbvie-downgraded-to-hold-at-societe-generale-on-weakness-in-blood-cancer-aesthetics?utm_source=businessinsider&utm_medium=referral,neutral,0.7252192497253418
1605,11/8/2022 7:04:04 PM,The 7 Best Pharma Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-best-pharma-stocks-to-buy-now-1031893081,positive,0.8310678601264954
1606,11/8/2022 9:06:00 PM,AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022,PR Newswire,/news/stocks/abbvie-presents-data-from-extensive-portfolio-at-the-american-college-of-rheumatology-convergence-2022-1031888246,positive,0.9116823673248291
1607,11/9/2022 2:00:00 PM,AbbVie to Present at the Wolfe Research Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-wolfe-research-healthcare-conference-1031891877,positive,0.9114879965782166
1608,11/9/2022 8:31:37 PM,Alector hits 52-week after Q3 results as analysts focus on pipeline,Seeking Alpha,https://seekingalpha.com/news/3904869-alec-stock-hits-52-week-after-q3-results-as-analysts-focus-on-pipeline?utm_source=businessinsider&utm_medium=referral,positive,0.5474311113357544
1609,11/10/2022 5:59:49 PM,7 No-Brainer Dividend Stocks to Buy for 2023 and Beyond,InvestorPlace,/news/stocks/7-no-brainer-dividend-stocks-to-buy-for-2023-and-beyond-1031899929,positive,0.9155628085136414
1610,11/13/2022 1:49:00 PM,The 7 Best Stocks for Retirement,TipRanks,/news/stocks/the-7-best-stocks-for-retirement-1031905794,positive,0.8411735892295837
1611,11/14/2022 12:09:58 PM,"Alvotech, Cipla's biosimilar to Humira gets approval in Australia",Seeking Alpha,https://seekingalpha.com/news/3906947-alvotech-ciplas-biosimilar-to-humira-gets-approval-in-australia?utm_source=businessinsider&utm_medium=referral,negative,0.9190951585769653
1612,11/15/2022 2:37:53 AM,The Top Dividend Stocks to Prepare for Retirement – And How to Choose Them,TipRanks,/news/stocks/the-top-dividend-stocks-to-prepare-for-retirement-–-and-how-to-choose-them-1031912167,positive,0.9443628191947937
1613,11/16/2022 11:12:51 AM,AbbVie to pay $54.4M to resolve lawsuit linked to Alzheimer's drug Namenda,Seeking Alpha,https://seekingalpha.com/news/3908475-abbvie-to-pay-544m-to-resolve-lawsuit-linked-to-alzheimers-drug-namenda?utm_source=businessinsider&utm_medium=referral,neutral,0.5830521583557129
1614,11/16/2022 2:17:17 PM,AbbVie's migraine med Ubrelvy approved in Canada,Seeking Alpha,https://seekingalpha.com/news/3908598-abbvie-migraine-med-ubrelvy-approved-in-canada?utm_source=businessinsider&utm_medium=referral,negative,0.6783355474472046
1615,11/17/2022 2:45:00 PM,Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet,PR Newswire,/news/stocks/fourth-annual-botox-cosmetic-onabotulinumtoxina-day-most-successful-one-yet-1031922250,negative,0.6879592537879944
1616,11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925,neutral,0.5206902027130127
1617,11/18/2022 6:03:08 PM,What 8 Analyst Ratings Have To Say About AbbVie,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-abbvie-1031925915,positive,0.9406131505966187
1618,11/18/2022 8:02:51 PM,Analyst Ratings for AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1031926148,positive,0.9059829115867615
1619,11/18/2022 8:31:14 PM,Credit Suisse Says AbbVie's Humira Patent Cliff Could Provide Momentum to Boost Growth,Benzinga,/news/stocks/credit-suisse-says-abbvie-s-humira-patent-cliff-could-provide-momentum-to-boost-growth-1031926200,negative,0.9521933197975159
1620,11/18/2022 9:01:09 PM,Where AbbVie Stands With Analysts,Benzinga,/news/stocks/where-abbvie-stands-with-analysts-1031926253,positive,0.8949053883552551
1621,11/21/2022 2:00:00 PM,U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma,PR Newswire,/news/stocks/u-s-fda-accepts-for-priority-review-the-biologics-license-application-for-epcoritamab-duobody-cd3xcd20-for-the-treatment-of-relapsed-refractory-large-b-cell-lymphoma-1031928321,negative,0.6721742749214172
1622,11/21/2022 2:20:07 PM,AbbVie: FDA To Review BLA For Epcoritamab - Quick Facts ,RTTNews,/news/stocks/abbvie-fda-to-review-bla-for-epcoritamab-quick-facts-1031928460,positive,0.7314385771751404
1623,11/22/2022 3:00:00 PM,AbbVie to Present at the Piper Sandler Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-piper-sandler-healthcare-conference-1031931342,positive,0.9073634743690491
1624,11/22/2022 9:45:00 PM,AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting,PR Newswire,/news/stocks/abbvie-highlights-blood-cancer-data-from-its-growing-oncology-pipeline-at-the-64th-ash-annual-meeting-1031932422,positive,0.6447592377662659
1625,11/23/2022 8:00:00 AM,AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease,PR Newswire,/news/stocks/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-active-crohn-s-disease-1031933113,negative,0.8435476422309875
1626,11/23/2022 8:21:52 AM,AbbVie: SKYRIZI (risankizumab) Gets EU Approval To Treat Moderate To Severe Active Crohn's Disease ,RTTNews,/news/stocks/abbvie-skyrizi-risankizumab-gets-eu-approval-to-treat-moderate-to-severe-active-crohn-s-disease-1031933155,negative,0.9460497498512268
1627,11/23/2022 2:00:00 PM,AbbVie to Present at the Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-evercore-isi-healthconx-conference-1031933866,positive,0.9185717701911926
1628,11/28/2022 11:01:37 AM,AbbVie’s (NYSE:ABBV) Loss Could be CVS’s (NYSE:CVS) Gain,TipRanks,/news/stocks/abbvie-s-nyse-abbv-loss-could-be-cvs-s-nyse-cvs-gain-1031939592,positive,0.7636610865592957
1629,11/29/2022 2:35:43 PM,BMO Capital Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/bmo-capital-sticks-to-its-buy-rating-for-abbvie-abbv-1031942521,positive,0.8168556094169617
1630,11/30/2022 5:43:47 PM,3 Dividend Stocks to Buy in Case the Santa Rally Doesn’t Come,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-in-case-the-santa-rally-doesnt-come-1031945904,positive,0.9058138728141785
1631,12/1/2022 1:47:05 PM,AbbVie Announces Provincial Reimbursement For RINVOQ For Rheumatoid Treatment ,RTTNews,/news/stocks/abbvie-announces-provincial-reimbursement-for-rinvoq-for-rheumatoid-treatment-1031947552,negative,0.882441520690918
1632,12/6/2022 8:00:00 AM,AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress,PR Newswire,/news/stocks/abbvie-to-showcase-migraine-portfolio-and-pipeline-during-the-16th-european-headache-federation-congress-1031954479,negative,0.5390728116035461
1633,12/6/2022 2:00:00 PM,AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline,PR Newswire,/news/stocks/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline-1031955177,negative,0.9220808148384094
1634,12/6/2022 2:06:46 PM,AbbVie gets option to license private biotech HotSpot's drug discovery program,Seeking Alpha,https://seekingalpha.com/news/3914299-abbvie-gets-option-to-license-private-biotech-hotspots-drug-discovery-program?utm_source=businessinsider&utm_medium=referral,negative,0.7042856812477112
1635,12/6/2022 2:26:01 PM,AbbVie Signs License Agreement With HotSpot For Use Of IRF5 In Autoimmune Diseases ,RTTNews,/news/stocks/abbvie-signs-license-agreement-with-hotspot-for-use-of-irf5-in-autoimmune-diseases-1031955282,negative,0.929013192653656
1636,12/6/2022 3:04:42 PM,8 Analysts Have This to Say About AbbVie,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-abbvie-1031955524,positive,0.9225807785987854
1637,12/6/2022 4:30:59 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbbVie (ABBV) and Mirati Therapeutics (MRTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-abbvie-abbv-and-mirati-therapeutics-mrtx-1031956241,positive,0.9200422167778015
1638,12/6/2022 6:29:22 PM,Karuna Therapeutics drops 12% after CEO change,Seeking Alpha,https://seekingalpha.com/news/3914476-karuna-therapeutics-drops-12-after-ceo-change?utm_source=businessinsider&utm_medium=referral,neutral,0.9636831283569336
1639,12/7/2022 10:35:06 AM,"Alvotech, STADA launch Humira biosimilar in certain European countries",Seeking Alpha,https://seekingalpha.com/news/3914767-alvotech-stada-launch-humira-biosimilar-in-european-countries?utm_source=businessinsider&utm_medium=referral,positive,0.8231791257858276
1640,12/10/2022 5:15:00 PM,AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science,PR Newswire,/news/stocks/abbvie-presents-data-at-the-64th-american-society-of-hematology-ash-annual-meeting-adds-to-robust-imbruvica-ibrutinib-science-1031963819,negative,0.8592424392700195
1641,12/10/2022 9:00:00 PM,AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients,PR Newswire,/news/stocks/abbvie-presents-data-at-the-64th-american-society-of-hematology-ash-annual-meeting-for-investigational-navitoclax-in-combination-with-ruxolitinib-for-jak-inhibitor-naïve-myelofibrosis-patients-1031963841,negative,0.4981100857257843
1642,12/11/2022 3:46:33 AM,AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients ,RTTNews,/news/stocks/abbvie-presents-data-for-navitoclax-combination-for-jak-inhibitor-naïve-myelofibrosis-patients-1031963871,negative,0.6231943964958191
1643,12/11/2022 11:30:00 PM,AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas,PR Newswire,/news/stocks/abbvie-presents-data-at-the-64th-american-society-of-hematology-ash-annual-meeting-evaluating-epcoritamab-duobody-cd3xcd20-across-b-cell-lymphomas-1031964230,positive,0.7510258555412292
1644,12/12/2022 4:52:14 PM,Harpoon adds 122% on updated Phase 1 data for multiple myeloma therapy,Seeking Alpha,https://seekingalpha.com/news/3916194-harp-stock-jumps-on-updated-phase-1-data-for-multiple-myeloma-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.7789832949638367
1645,12/12/2022 6:59:00 PM,AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year,PR Newswire,/news/stocks/abbvie-named-to-dow-jones-sustainability-world-index-for-10th-straight-year-1031967422,negative,0.4895278513431549
1646,12/12/2022 9:00:51 PM,Pfizer expects 5 new molecular entity launches in 2023,Seeking Alpha,https://seekingalpha.com/news/3916285-pfizer-expects-5-new-molecular-entity-launches-in-2023?utm_source=businessinsider&utm_medium=referral,positive,0.838889479637146
1647,12/13/2022 6:50:12 PM,BeiGene says Brukinsa bests J&J's Imbruvica in progression-free survival for leukemia,Seeking Alpha,https://seekingalpha.com/news/3916643-beigene-says-brukinsa-bests-johnson-johnson-imbruvica-in-progression-free-survival-for-leukemia?utm_source=businessinsider&utm_medium=referral,negative,0.9209824204444885
1648,12/13/2022 7:53:05 PM,The 7 Best Investment Funds to Navigate a Possible Recession,InvestorPlace,/news/stocks/the-7-best-investment-funds-to-navigate-possible-recession-1031970170,positive,0.6435859203338623
1649,12/14/2022 2:19:46 AM,7 Best Bargain Stocks to Buy in 2023,InvestorPlace,/news/stocks/best-bargain-stocks-1031571060,positive,0.9031808972358704
1650,12/14/2022 11:03:03 AM,"Exicure says development collaborations with AbbVie, Ipsen terminated",Seeking Alpha,https://seekingalpha.com/news/3916831-exicure-says-development-collaborations-with-abbvie-ipsen-terminated?utm_source=businessinsider&utm_medium=referral,positive,0.6184791326522827
1651,12/14/2022 4:51:43 PM,Fresenius Kabi becomes latest drugmaker to win approval of biosimilar of AbbVie's Humira,Seeking Alpha,https://seekingalpha.com/news/3916989-fresenius-kabi-becomes-latest-drugmaker-to-win-approval-of-biosimilar-of-abbvie-humira?utm_source=businessinsider&utm_medium=referral,negative,0.8937796354293823
1652,12/15/2022 12:27:25 AM,SPAC Priveterra to merge with Botox alternative developer AEON Biopharma,Seeking Alpha,https://seekingalpha.com/news/3917371-spac-priveterra-to-merge-with-botox-alternative-developer-aeon-biopharma?utm_source=businessinsider&utm_medium=referral,positive,0.9169899821281433
1653,12/15/2022 1:03:13 PM,AbCellera stock rises on team up with AbbVie to discover antibody therapies,Seeking Alpha,https://seekingalpha.com/news/3917499-abcellera-stock-rises-on-team-up-with-abbvie-to-discover-antibody-therapies?utm_source=businessinsider&utm_medium=referral,negative,0.8576645851135254
1654,12/15/2022 7:06:04 PM,AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3917735-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral,neutral,0.6609663367271423
1655,12/16/2022 11:25:27 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/large-cap-stocks-to-buy-and-hold-1031827937,positive,0.8808764219284058
1656,12/16/2022 1:30:00 PM,AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age,PR Newswire,/news/stocks/abbvie-submits-supplemental-new-drug-application-to-u-s-fda-to-support-new-indication-of-linzess-linaclotide-for-functional-constipation-in-children-and-adolescents-6-to-17-years-of-age-1031977149,negative,0.8305611610412598
1657,12/16/2022 2:03:25 PM,"AbbVie Submits SNDA For Linaclotide For Treatment Of Children, Adolescents ",RTTNews,/news/stocks/abbvie-submits-snda-for-linaclotide-for-treatment-of-children-adolescents-1031977223,positive,0.7178542017936707
1658,12/16/2022 3:44:21 PM,AbbVie submits sNDA for Linzess for constipation in children,Seeking Alpha,https://seekingalpha.com/news/3918074-abbvie-submits-snda-for-linzess-for-constipation-in-children?utm_source=businessinsider&utm_medium=referral,positive,0.8095558285713196
1659,12/16/2022 11:55:59 PM,AbbVie's Vraylar wins approval as adjunctive therapy for depression,Seeking Alpha,https://seekingalpha.com/news/3918239-abbvie-vraylar-wins-approval-as-adjunctive-therapy-for-depression?utm_source=businessinsider&utm_medium=referral,negative,0.9471578598022461
1660,12/17/2022 12:39:00 AM,U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder,PR Newswire,/news/stocks/u-s-fda-approves-vraylar-cariprazine-as-an-adjunctive-treatment-for-major-depressive-disorder-1031978306,negative,0.8950051069259644
1661,12/18/2022 11:21:17 PM,The 7 Hottest Biotech Stocks to Own in 2023 and Beyond,InvestorPlace,/news/stocks/the-7-hottest-biotech-stocks-to-own-in-2023-and-beyond-1031978854,positive,0.8848919868469238
1662,12/19/2022 3:15:13 PM,AbbVie (ABBV) Receives a Buy from BMO Capital,TipRanks,/news/stocks/abbvie-abbv-receives-a-buy-from-bmo-capital-1031980365,positive,0.6892908811569214
1663,12/21/2022 1:35:15 PM,Genmab files for approval of blood cancer therapy epcoritamab in Japan,Seeking Alpha,https://seekingalpha.com/news/3919375-genmab-files-for-approval-of-blood-cancer-therapy-epcoritamab-in-japan?utm_source=businessinsider&utm_medium=referral,negative,0.7537564635276794
1664,12/21/2022 8:58:39 PM,"CVS, Walgreens, Teva in opioid agreements with Washington attorney general",Seeking Alpha,https://seekingalpha.com/news/3919597-cvs-walgreens-teva-in-opioid-agreements-with-washington-attorney-general?utm_source=businessinsider&utm_medium=referral,negative,0.5860823392868042
1665,12/22/2022 10:37:45 AM,Alvotech filing for Humira interchangeable biosimilar gets FDA action date,Seeking Alpha,https://seekingalpha.com/news/3919727-alvotech-filing-for-humira-interchangeable-biosimilar-gets-fda-action-date?utm_source=businessinsider&utm_medium=referral,negative,0.6618983149528503
1666,12/25/2022 5:00:44 PM,Goldman Sachs highlights key healthcare themes for 2023,Seeking Alpha,https://seekingalpha.com/news/3920634-goldman-sachs-micro-over-macro-healthcare-themes-2023?utm_source=businessinsider&utm_medium=referral,positive,0.7464402914047241
1667,12/28/2022 6:28:17 PM,Our Predictions for the Top 7 Dividend Stocks for 2023,InvestorPlace,/news/stocks/7-dividend-stock-predictions-for-2023-1031992715,positive,0.9378817081451416
1668,12/30/2022 5:45:22 PM,Merck is best performing large U.S. pharma of 2022,Seeking Alpha,https://seekingalpha.com/news/3921306-merck-is-best-performing-large-us-pharma-of-2022?utm_source=businessinsider&utm_medium=referral,negative,0.9400242567062378
1669,1/1/2023 7:00:00 PM,"Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab",Seeking Alpha,https://seekingalpha.com/news/3920793-abbvie-vertex-genmab-among-accurate-stock-picks-at-sa-for-2022?utm_source=businessinsider&utm_medium=referral,negative,0.6699269413948059
1670,1/3/2023 2:00:00 PM,AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference-1031997664,positive,0.8769705891609192
1671,1/4/2023 5:55:05 PM,"Walgreens, CVS, Walmart in opioid settlements with Oklahoma",Seeking Alpha,https://seekingalpha.com/news/3922054-walgreens-cvs-walmart-in-opioid-settlements-with-oklahoma?utm_source=businessinsider&utm_medium=referral,neutral,0.7925224900245667
1672,1/4/2023 6:55:55 PM,7 Safe Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/safe-stocks-to-buy-and-hold-1031612420,positive,0.9261383414268494
1673,1/5/2023 2:00:00 PM,AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-fourth-quarter-2022-earnings-conference-call-1032001929,positive,0.9113327860832214
1674,1/6/2023 2:00:00 PM,AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets,PR Newswire,/news/stocks/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets-1032004133,negative,0.870381772518158
1675,1/6/2023 2:01:54 PM,Immunome up 25% on collaboration with AbbVie with for novel cancer drug targets,Seeking Alpha,https://seekingalpha.com/news/3922641-immunome-up-25-on-collaboration-with-abbvie-with-for-novel-cancer-drug-targets?utm_source=businessinsider&utm_medium=referral,negative,0.9544990062713623
1676,1/6/2023 2:33:25 PM,"AbbVie, Immunome Collaborate To Discover Multiple Novel Oncology Targets ",RTTNews,/news/stocks/abbvie-immunome-collaborate-to-discover-multiple-novel-oncology-targets-1032004213,positive,0.5255841612815857
1677,1/6/2023 6:30:04 PM,"Catalyst watch: ICR Conference, JPMorgan Healthcare Conference, CPI, major bank reports",Seeking Alpha,https://seekingalpha.com/news/3922727-catalyst-watch-icr-conference-jpmorgan-healthcare-conference-cpi-major-banks-report?utm_source=businessinsider&utm_medium=referral,positive,0.9261020421981812
1678,1/6/2023 11:18:22 PM,"AbbVie expects IPR&D and milestones expense to impact Q4, full-year 2022 results",Seeking Alpha,https://seekingalpha.com/news/3922802-abbvie-expects-iprd-and-milestones-expense-to-impact-q4-full-year-2022-results?utm_source=businessinsider&utm_medium=referral,neutral,0.955206573009491
1679,1/8/2023 5:33:53 PM,The 7 Most Undervalued Value Stocks to Buy Now   ,InvestorPlace,/news/stocks/undervalued-value-stocks-1031662465,positive,0.7967768311500549
1680,1/8/2023 6:30:38 PM,The 7 Best Dividend Stocks to Buy for Your Grandkids in 2023,InvestorPlace,/news/stocks/best-dividend-stocks-for-grandkids-1031647375,positive,0.8839948177337646
1681,1/9/2023 12:27:42 PM,AbbVie's migraine prevention therapy Qulipta gets approval in Canada,Seeking Alpha,https://seekingalpha.com/news/3922895-abbvies-migraine-prevention-drug-qulipta-gets-approval-in-canada?utm_source=businessinsider&utm_medium=referral,negative,0.9465751647949219
1682,1/9/2023 1:35:13 PM,AbbVie's Qulipta Approved In Canada For Preventive Treatment Of Episodic Migraine In Adults ,RTTNews,/news/stocks/abbvie-s-qulipta-approved-in-canada-for-preventive-treatment-of-episodic-migraine-in-adults-1032006818,negative,0.8541299700737
1683,1/10/2023 11:34:49 AM,7 Warren Buffet Stocks to Buy and Hold for the Next Decade,InvestorPlace,/news/stocks/warren-buffett-stocks-to-buy-and-hold-1031558120,positive,0.9174212217330933
1684,1/10/2023 1:32:45 PM,AbbVie seeks mRNA technology in pact with Anima Biotech,Seeking Alpha,https://seekingalpha.com/news/3923304-abbvie-seeks-mrna-technology-in-pact-with-anima-biotech?utm_source=businessinsider&utm_medium=referral,negative,0.6454262137413025
1685,1/10/2023 2:00:00 PM,AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets,PR Newswire,/news/stocks/abbvie-and-anima-biotech-announce-collaboration-for-the-discovery-and-development-of-mrna-biology-modulators-against-oncology-and-immunology-targets-1032009331,negative,0.8022406697273254
1686,1/10/2023 2:39:54 PM,"AbbVie, Anima Biotech Collaborate To Develop MRNA Modulators In Oncology, Immunology Targets ",RTTNews,/news/stocks/abbvie-anima-biotech-collaborate-to-develop-mrna-modulators-in-oncology-immunology-targets-1032009488,positive,0.743549644947052
1687,1/10/2023 11:41:30 PM,"AbbVie sees Rinvoq, Skyrizi combined sales eclipsing Humira peak sales",Seeking Alpha,https://seekingalpha.com/news/3923532-abbvie-sees-rinvoq-skyrizi-combined-sales-eclipsing-humira-peak-sales?utm_source=businessinsider&utm_medium=referral,negative,0.6573830842971802
1688,1/11/2023 2:40:32 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-abbvie-abbv-and-establishment-labs-holdings-esta-1032012560,positive,0.9047911167144775
1689,1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral,positive,0.9117305874824524
1690,1/15/2023 5:00:03 PM,Drugmakers welcome new year with 450 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/3924676-pfizer-abbvie-gsk-eli-lilly-among-drugmakers-to-raise-prices?utm_source=businessinsider&utm_medium=referral,negative,0.8843089938163757
1691,1/16/2023 12:15:26 PM,AbbVie and Lilly leave U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3924704-abbvie-and-lilly-leave-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral,neutral,0.6320776343345642
1692,1/16/2023 3:33:24 PM,Sirona Biochem ends agreement for TFC-1067 with Rodan + Fields,Seeking Alpha,https://seekingalpha.com/news/3924733-sirona-biochem-ends-agreement-for-tfc-1067-with-rodan-fields?utm_source=businessinsider&utm_medium=referral,negative,0.8203302025794983
1693,1/17/2023 1:00:04 AM,"BioMed X, AbbVie extend partnership to focus on immunology research",Seeking Alpha,https://seekingalpha.com/news/3924792-biomed-x-abbvie-extend-partnership-to-focus-on-immunology-research?utm_source=businessinsider&utm_medium=referral,negative,0.860048770904541
1694,1/17/2023 3:42:53 AM,BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering ,RTTNews,/news/stocks/biomed-x-extends-research-collaboration-with-abbvie-on-immunology-and-tissue-engineering-1032021142,negative,0.8210911750793457
1695,1/17/2023 2:00:00 PM,SkinMedica® Launches Even & Correct,PR Newswire,/news/stocks/skinmedica-launches-even-correct-1032022325,negative,0.5192335247993469
1696,1/18/2023 2:00:00 PM,JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE,PR Newswire,/news/stocks/juvéderm-volux-xc-for-improvement-of-jawline-definition-now-available-nationwide-1032025278,positive,0.8325139880180359
1697,1/18/2023 4:55:10 PM,"AbbVie's Allergan unit launches new, long-lasting Juvederm dermal filler",Seeking Alpha,https://seekingalpha.com/news/3925501-abbvie-allergan-unit-launches-new-long-lasting-juvederm-dermal-filler?utm_source=businessinsider&utm_medium=referral,negative,0.6422401666641235
1698,1/18/2023 8:44:49 PM,7 Biotech Stocks That Will Make You Rich in 10 Years,InvestorPlace,/news/stocks/7-biotech-stocks-that-will-make-you-rich-in-10-years-1032026652,positive,0.8400203585624695
1699,1/19/2023 5:13:34 PM,Alpine Immune wins bullish views at Morgan Stanley on lead program,Seeking Alpha,https://seekingalpha.com/news/3925993-alpn-stock-wins-bullish-views-morgan-stanley-lead-program?utm_source=businessinsider&utm_medium=referral,negative,0.8394452929496765
1700,1/19/2023 10:05:01 PM,BeiGene's Brukinsa gains approval for two additional types of leukemia,Seeking Alpha,https://seekingalpha.com/news/3926154-beigene-brukinsa-gains-approval-for-two-additional-types-of-leukemia?utm_source=businessinsider&utm_medium=referral,negative,0.9115498065948486
1701,1/20/2023 4:55:22 PM,7 Stocks Every Smart Investor Should Own in 2023,InvestorPlace,/news/stocks/7-stocks-every-smart-investor-should-own-in-2023-1032031313,positive,0.9292073249816895
1702,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.9066245555877686
1703,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,negative,0.8150349855422974
1704,1/23/2023 12:15:10 PM,Morphic says Johnson & Johnson unit ended research collaboration,Seeking Alpha,https://seekingalpha.com/news/3926626-morf-stock-slips-johnson--johnson-unit-end-research-deal?utm_source=businessinsider&utm_medium=referral,positive,0.8502250909805298
1705,1/24/2023 10:02:09 AM,"Alvotech, Bioventure get approval for Humira biosimilar in Saudi Arabia",Seeking Alpha,https://seekingalpha.com/news/3927020-alvotech-bioventure-get-approval-for-humira-biosimilar-in-saudi-arabia?utm_source=businessinsider&utm_medium=referral,negative,0.8509032726287842
1706,1/25/2023 3:32:10 PM,180 Life Sciences up 12% on tumor necrosis factor as target for Dupuytren’s disease,Seeking Alpha,https://seekingalpha.com/news/3927796-180-life-sciences-up-14-on-tumor-necrosis-factor-as-target-for-dupuytrens-disease?utm_source=businessinsider&utm_medium=referral,negative,0.938054084777832
1707,1/25/2023 5:42:00 PM,Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023,PR Newswire,/news/stocks/allergan-aesthetics-takes-a-360-approach-to-non-surgical-aesthetic-treatments-to-improve-patient-outcomes-with-expert-led-medical-education-symposium-at-imcas-2023-1032041146,positive,0.5283321142196655
1708,1/25/2023 10:20:18 PM,3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later,InvestorPlace,/news/stocks/3-gene-editing-stocks-to-buy-now-or-youll-be-kicking-yourself-later-1032041864,positive,0.8379383683204651
1709,1/27/2023 4:25:22 AM,SVB Securities Remains a Sell on AbbVie (ABBV),TipRanks,/news/stocks/svb-securities-remains-a-sell-on-abbvie-abbv-1032045359,positive,0.9468420743942261
1710,1/27/2023 12:52:31 PM,J&J pulls Imbruvica combo filing in EU as EMA cites potential 'serious side effects',Seeking Alpha,https://seekingalpha.com/news/3928895-jj-pulls-imbruvica-combo-filing-in-eu-as-ema-cites-potential-serious-side-effects?utm_source=businessinsider&utm_medium=referral,neutral,0.9580039381980896
1711,1/27/2023 2:48:06 PM,5 Cheapest Health Care Stocks You Should Think About,Benzinga,/news/stocks/5-cheapest-health-care-stocks-you-should-think-about-1032046780,positive,0.8687607645988464
1712,1/28/2023 6:12:08 PM,7 Dividend Stocks to Buy Now or You’ll Be Kicking Yourself Later,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-now-or-youll-be-kicking-yourself-later-1032047967,positive,0.7315204739570618
1713,1/29/2023 5:00:25 PM,AbbVie’s global bestseller to face knockoffs starting this week,Seeking Alpha,https://seekingalpha.com/news/3929211-abbvies-global-bestseller-to-face-knockoffs-starting-this-week?utm_source=businessinsider&utm_medium=referral,neutral,0.4311627745628357
1714,1/31/2023 11:40:30 AM,Amgen's biosimilar of AbbVie's Humira enters US market,Seeking Alpha,https://seekingalpha.com/news/3929723-amgens-biosimilar-to-humira-enters-us-market?utm_source=businessinsider&utm_medium=referral,positive,0.6708455085754395
1715,1/31/2023 12:47:06 PM,These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts,Benzinga,/news/stocks/these-3-healthcare-stocks-with-over-3-dividend-yields-are-recommended-by-benzinga-s-most-accurate-analysts-1032053714,positive,0.7530388832092285
1716,2/1/2023 2:05:33 PM,BMO Capital Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/bmo-capital-sticks-to-its-buy-rating-for-abbvie-abbv-1032059189,positive,0.8168556094169617
1717,2/1/2023 2:06:55 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), GlaxoSmithKline (GSK) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-glaxosmithkline-gsk-and-abbvie-abbv-1032059161,positive,0.9150770306587219
1718,2/2/2023 4:28:18 PM,The 3 Most Undervalued Penny Stocks to Buy in February 2023,InvestorPlace,/news/stocks/undervalued-penny-stocks-to-buy-in-february-2023-1032063578,positive,0.7138308882713318
1719,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral,neutral,0.9276774525642395
1720,2/3/2023 7:30:12 PM,"Catalyst watch: Google talks AI, Nordstrom drama and Canada Goose event",Seeking Alpha,https://seekingalpha.com/news/3931946-catalyst-watch-google-talks-ai-nordstrom-drama-and-canada-goose-event?utm_source=businessinsider&utm_medium=referral,positive,0.948539137840271
1721,2/3/2023 9:37:59 PM,"Earnings week ahead: PepsiCo, Disney, BP, Chipotle and more",Seeking Alpha,https://seekingalpha.com/news/3932028-earnings-week-ahead-pepsico-disney-bp-chipotle-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9127805829048157
1722,2/5/2023 5:00:57 PM,Drug price inflation continues upward momentum at 3.8% – report,Seeking Alpha,https://seekingalpha.com/news/3932101-drug-price-inflation-continues-upward-momentum-at-38-report?utm_source=businessinsider&utm_medium=referral,negative,0.9158604145050049
1723,2/6/2023 12:03:10 PM,AbbVie pins hopes on newer drugs and deals to face Humira knockoffs – WSJ,Seeking Alpha,https://seekingalpha.com/news/3932220-abbvie-pins-hopes-on-newer-drugs-and-deals-to-face-humira-knockoffs?utm_source=businessinsider&utm_medium=referral,negative,0.9318223595619202
1724,2/6/2023 12:10:37 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032070049,negative,0.5521676540374756
1725,2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral,positive,0.6935389041900635
1726,2/6/2023 6:15:50 PM,How to Score Profits In Every Trade With Minimal Risk,InvestorPlace,/news/stocks/how-to-score-profits-in-every-trade-with-minimal-risk-1032071173,positive,0.9093331098556519
1727,2/8/2023 3:01:13 PM,AbbVie earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/abbvie-q4-quarterly-earnings-preview-1032078696,positive,0.9269446134567261
1728,2/8/2023 3:17:16 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3933579-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8825733065605164
1729,2/8/2023 4:30:06 PM,AbbVie Q4 results in focus with eye on new drugs as Humira challengers enter US doors,Seeking Alpha,https://seekingalpha.com/news/3933605-abbvie-q4-results-in-focus-with-eye-on-new-drugs-as-humira-challengers-enter-us-doors?utm_source=businessinsider&utm_medium=referral,negative,0.8027873039245605
1730,2/9/2023 12:30:52 PM,"Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-teva-pharmaceutical-teva-vertex-pharmaceuticals-vrtx-and-abbvie-abbv-1032082776,positive,0.9071211218833923
1731,2/9/2023 12:45:41 PM,"AbbVie Non-GAAP EPS of $3.60 beats by $0.02, revenue of $15.12B misses by $180M, initiates FY outlook",Seeking Alpha,https://seekingalpha.com/news/3934166-abbvie-non-gaap-eps-of-360-beats-by-002-revenue-of-1512b-misses-by-180m-initiates-fy-outlook?utm_source=businessinsider&utm_medium=referral,negative,0.62453293800354
1732,2/9/2023 1:22:32 PM,AbbVie sets outlook below consensus amid generic threat to best selling drug,Seeking Alpha,https://seekingalpha.com/news/3934202-abbvie-sets-outlook-below-consensus-amid-generic-threat-humira?utm_source=businessinsider&utm_medium=referral,neutral,0.9538064002990723
1733,2/9/2023 1:44:00 PM,AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results,PR Newswire,/news/stocks/abbvie-reports-full-year-and-fourth-quarter-2022-financial-results-1032082785,positive,0.8983466029167175
1734,2/9/2023 1:47:26 PM,"AbbVie Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/abbvie-q4-profit-decreases-but-beats-estimates-1032082798,neutral,0.9705538153648376
1735,2/9/2023 5:38:02 PM,AbbVie gains after revising estimates for Humira sales erosion,Seeking Alpha,https://seekingalpha.com/news/3934365-abbvie-gains-after-revising-estimates-for-humira-sales-erosion?utm_source=businessinsider&utm_medium=referral,negative,0.9080122709274292
1736,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,positive,0.5336910486221313
1737,2/10/2023 12:30:21 PM,"Analysts Are Bullish on Top Healthcare Stocks: AstraZeneca (AZN), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-astrazeneca-azn-abbvie-abbv-1032086245,negative,0.7236570715904236
1738,2/10/2023 4:00:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-10-2023-1032086625,neutral,0.5272051692008972
1739,2/10/2023 4:25:18 PM,Atlantic Equities Remains a Hold on AbbVie (ABBV),TipRanks,/news/stocks/atlantic-equities-remains-a-hold-on-abbvie-abbv-1032086836,positive,0.6773468255996704
1740,2/10/2023 4:30:53 PM,Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tenet-healthcare-thc-and-abbvie-abbv-1032086878,positive,0.9140446186065674
1741,2/10/2023 7:01:37 PM,Where AbbVie Stands With Analysts,Benzinga,/news/stocks/where-abbvie-stands-with-analysts-1032087051,positive,0.8949053883552551
1742,2/13/2023 12:55:43 PM,"AbbVie, Ironwood Linzess gets FDA priority review to treat functional constipation in children",Seeking Alpha,https://seekingalpha.com/news/3935136-abbvie-ironwood-linzess-gets-fda-priority-review-to-treat-functional-constipation-in-children?utm_source=businessinsider&utm_medium=referral,negative,0.9068682789802551
1743,2/13/2023 7:18:57 PM,"OmniAb initiated with a buy at H.C. Wainwright on antibody collaborations, partnerships",Seeking Alpha,https://seekingalpha.com/news/3935341-omniab-initiated-with-a-buy-at-hc-wainwright-on-antibody-collaborations-partnerships?utm_source=businessinsider&utm_medium=referral,positive,0.7189428806304932
1744,2/13/2023 10:42:16 PM,The 7 Most Undervalued Dividend Aristocrats to Buy,InvestorPlace,/news/stocks/the-7-most-undervalued-dividend-aristocrats-to-buy-1032092498,negative,0.5109917521476746
1745,2/14/2023 11:10:32 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tenet Healthcare (THC) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-tenet-healthcare-thc-and-abbvie-abbv-1032094214,neutral,0.8095172643661499
1746,2/14/2023 4:47:32 PM,MoonLake wins bullish view at Cantor on skin disease candidate,Seeking Alpha,https://seekingalpha.com/news/3935820-mnlk-stock-wins-bullish-view-cantor-skin-disease-candidate?utm_source=businessinsider&utm_medium=referral,negative,0.5019634366035461
1747,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,positive,0.4218192398548126
1748,2/15/2023 7:09:07 PM,3 ETFs Investors Can Buy to Weather a Recession,TipRanks,/news/stocks/3-etfs-investors-can-buy-to-weather-a-recession-1032100105,positive,0.854220449924469
1749,2/15/2023 8:49:23 PM,3 Defensive Growth Stocks to Load Up on in Q1,InvestorPlace,/news/stocks/mcd-abbv-noc-3-defensive-growth-stocks-to-load-up-on-in-q1-1032100197,negative,0.8161535263061523
1750,2/16/2023 5:44:38 PM,AbbVie declares $1.48 dividend,Seeking Alpha,https://seekingalpha.com/news/3937314-abbvie-inc-declares-1_48-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9382003545761108
1751,2/16/2023 5:45:17 PM,Beauty Health falls amid new short report from The Bear Cave,Seeking Alpha,https://seekingalpha.com/news/3937320-beauty-health-falls-amid-new-short-report-from-the-bear-cave?utm_source=businessinsider&utm_medium=referral,neutral,0.9025330543518066
1752,2/16/2023 6:41:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1032103669,neutral,0.5513123869895935
1753,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral,negative,0.9136704802513123
1754,2/22/2023 4:00:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-22-2023-1032116274,neutral,0.5363326668739319
1755,2/22/2023 7:21:40 PM,AbbVie sued in Netherlands for breaching human rights over Humira pricing,Seeking Alpha,https://seekingalpha.com/news/3939351-abbvie-sued-in-netherlands-for-breaching-human-rights-over-humira-pricing?utm_source=businessinsider&utm_medium=referral,neutral,0.8990124464035034
1756,2/23/2023 10:59:00 AM,AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need,PR Newswire,/news/stocks/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need-1032118871,negative,0.9091770052909851
1757,2/23/2023 11:01:00 AM,AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need,PR Newswire,/news/stocks/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need-1032118884,negative,0.9091770052909851
1758,2/23/2023 11:13:40 AM,"AbbVie, Capsida expand team up to develop genetic therapies for eye diseases",Seeking Alpha,https://seekingalpha.com/news/3939743-abbvie-capsida-expand-team-up-to-develop-genetic-therapies-for-eye-diseases?utm_source=businessinsider&utm_medium=referral,negative,0.6866612434387207
1759,2/23/2023 11:30:24 AM,7 Dividend Yield Monsters Poised to Soar,InvestorPlace,/news/stocks/7-high-yield-dividend-stocks-that-are-monsters-poised-to-soar-1032119206,negative,0.6373535394668579
1760,2/23/2023 1:45:09 PM,180 Life Sciences stock dips as recruitment in trial for Frozen shoulder closes amid challenges,Seeking Alpha,https://seekingalpha.com/news/3939921-180lifesciencesstock-dips-as-recruitment-in-trial-for-frozen-shoulder-closes-amid-challenges?utm_source=businessinsider&utm_medium=referral,neutral,0.9646171927452087
1761,2/23/2023 2:49:46 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-healthcare-stocks-delivering-high-dividend-yields-1032119875,positive,0.7092065811157227
1762,2/26/2023 2:45:56 PM,7 Mega-Cap Stocks to Buy for the Long Haul,InvestorPlace,/news/stocks/7-mega-cap-stocks-to-buy-for-the-long-haul-1032125500,positive,0.8480883240699768
1763,2/27/2023 8:00:00 AM,AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease,PR Newswire,/news/stocks/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-crohn-s-disease-1032126753,negative,0.9431732892990112
1764,2/27/2023 8:33:17 AM,AbbVie Gets Positive CHMP Opinion For Upadacitinib For Treatment Of Adults With Crohn's Disease ,RTTNews,/news/stocks/abbvie-gets-positive-chmp-opinion-for-upadacitinib-for-treatment-of-adults-with-crohn-s-disease-1032126817,negative,0.9502795338630676
1765,2/27/2023 10:48:26 AM,AbbVie wins EU nod for Rinvoq in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/3941008-abbvie-wins-eu-nod-rinvoq-crohns-disease?utm_source=businessinsider&utm_medium=referral,negative,0.8263248801231384
1766,2/27/2023 12:00:00 PM,AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO),PR Newswire,/news/stocks/abbvie-highlights-robust-gastroenterology-portfolio-with-new-analyses-and-data-in-inflammatory-bowel-diseases-at-the-18th-congress-of-european-crohn-s-and-colitis-organisation-ecco-1032127167,negative,0.9276502132415771
1767,2/27/2023 1:42:26 PM,3 High-Yield Dividend Stocks to Buy and Hold Forever ,InvestorPlace,/news/stocks/3-high-yield-dividend-stocks-to-buy-and-hold-forever-1032127715,positive,0.9395121335983276
1768,2/28/2023 11:30:12 AM,Stocks most and least liked by hedge funds and mutual funds -  Goldman,Seeking Alpha,https://seekingalpha.com/news/3941168-stocks-most-and-least-liked-by-hedge-funds-and-mutual-funds-goldman?utm_source=businessinsider&utm_medium=referral,positive,0.8097005486488342
1769,2/28/2023 2:51:00 PM,AbbVie to Present at the Cowen 43rd Annual Health Care Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-cowen-43rd-annual-health-care-conference-1032131570,positive,0.9023640155792236
1770,3/1/2023 4:00:51 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-1-2023-1032136808,positive,0.5188173055648804
1771,3/1/2023 7:28:42 PM,3 Top Defensive Stocks to Own for a Focus on Quality,InvestorPlace,/news/stocks/3-top-defensive-stocks-to-own-for-a-focus-on-quality-1032137567,positive,0.8808692693710327
1772,3/1/2023 8:57:46 PM,"AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says",Benzinga,/news/stocks/abbvie-can-write-diversified-growth-story-without-humira-rest-of-the-business-has-strength-analyst-says-1032137626,negative,0.7829598188400269
1773,3/1/2023 9:00:49 PM,8 Analysts Have This to Say About AbbVie,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-abbvie-1032137625,positive,0.9225807785987854
1774,3/3/2023 12:20:56 PM,Viatris joins AbbVie and Lilly in protesting against U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3943792-viatris-joins-abbvie-and-lilly-in-protesting-against-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral,neutral,0.7959650754928589
1775,3/4/2023 6:45:00 PM,Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines,Seeking Alpha,https://seekingalpha.com/news/3944195-pharma-research-developmeny-funding-soared-to-a-new-record-in-2022-as-oncology-candidates-dominate-pipelines?utm_source=businessinsider&utm_medium=referral,negative,0.9410833716392517
1776,3/6/2023 9:51:35 PM,7 Dividend Kings to Buy for an Uncertain Market Environment,InvestorPlace,/news/stocks/7-dividend-kings-to-buy-for-an-uncertain-market-environment-1032148499,positive,0.6553321480751038
1777,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral,negative,0.533659815788269
1778,3/8/2023 1:34:07 AM,Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason,Benzinga,/news/stocks/health-care-etfs-have-lost-in-the-last-month---these-top-pharma-stocks-are-the-reason-1032151775,neutral,0.9652082920074463
1779,3/8/2023 11:41:29 AM,Sleep-at-night stocks for those hedging or risk averse,Seeking Alpha,https://seekingalpha.com/news/3945026-sleep-at-night-stocks-for-those-hedging-or-risk-averse?utm_source=businessinsider&utm_medium=referral,positive,0.7829471826553345
1780,3/8/2023 1:25:08 PM,Morgan Stanley Sticks to Their Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-buy-rating-for-abbvie-abbv-1032153500,positive,0.8486794233322144
1781,3/8/2023 2:00:00 PM,AbbVie to Present at the Barclays Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-barclays-global-healthcare-conference-1032153372,positive,0.9058839678764343
1782,3/8/2023 2:45:00 PM,BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs,PR Newswire,/news/stocks/botox-cosmetic-onabotulinumtoxina-partners-with-ifundwomen-to-help-close-the-confidence-gap-for-women-entrepreneurs-1032153564,negative,0.8600308299064636
1783,3/9/2023 9:31:14 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and TScan Therapeutics (TCRX),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-and-tscan-therapeutics-tcrx-1032156123,neutral,0.9477642178535461
1784,3/9/2023 6:55:10 PM,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,Seeking Alpha,https://seekingalpha.com/news/3946094-biden-budget-to-save-160b-by-allowing-medicare-to-negotiate-prices-for-more-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.8639830946922302
1785,3/10/2023 12:54:37 PM,Endo launches 1st generic of Allergan's ulcer bacterial infection drug Pylera,Seeking Alpha,https://seekingalpha.com/news/3946417-endo-launches-1st-generic-of-allergans-ulcer-bacterial-infection-drug-pylera?utm_source=businessinsider&utm_medium=referral,negative,0.5130304098129272
1786,3/12/2023 2:00:00 PM,Biosimilars expected to save $180B over next five years as more gain approval,Seeking Alpha,https://seekingalpha.com/news/3946583-biosimilars-expected-to-save-180b-over-next-five-years-as-more-gain-approval?utm_source=businessinsider&utm_medium=referral,negative,0.8129683136940002
1787,3/13/2023 12:07:25 PM,"Pfizer, AbbVie, BMS among firms at risk of U.S. drug price negotiations - report",Seeking Alpha,https://seekingalpha.com/news/3946793-pfizer-abbvie-bristol-myers-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.6864007115364075
1788,3/13/2023 1:03:00 PM,AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting,PR Newswire,/news/stocks/abbvie-showcases-strength-of-dermatology-portfolio-with-new-data-presented-at-the-2023-aad-annual-meeting-1032163024,negative,0.7363872528076172
1789,3/15/2023 1:03:00 PM,AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema,PR Newswire,/news/stocks/abbvie-partners-with-award-winning-redglass-pictures-on-new-film-shedding-light-on-the-hidden-struggles-of-those-living-with-eczema-1032169171,negative,0.5110923051834106
1790,3/15/2023 1:10:29 PM,"AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation",Seeking Alpha,https://seekingalpha.com/news/3947647-abbvie-gilead-seagen-among-firms-fined-for-raising-prices-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,neutral,0.6228245496749878
1791,3/16/2023 12:34:23 PM,Organon draws bullish views at Raymond James on Humira biosimilar launch,Seeking Alpha,https://seekingalpha.com/news/3948150-organon-draws-bullish-views-raymond-james-humira-biosimilar-launch?utm_source=businessinsider&utm_medium=referral,positive,0.7328687310218811
1792,3/16/2023 6:15:32 PM,Medicare publishes initial guidance on drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3948265-medicare-publishes-initial-guidance-on-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.9513846635818481
1793,3/18/2023 3:03:00 PM,AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor T...,PR Newswire,/news/stocks/abbvie-announces-late-breaking-results-of-study-evaluating-52-week-efficacy-and-safety-of-skyrizi-risankizumab-in-plaque-psoriasis-patients-with-a-prior-suboptimal-response-to-il-17-inhibitor-t-1032177071,negative,0.7660921812057495
1794,3/19/2023 4:00:30 PM,Pfizer CEO pockets $33M for 2022 after 36% pay hike,Seeking Alpha,https://seekingalpha.com/news/3948694-pfizer-ceo-pockets-33m-for-2022-after-36-percent-pay-hike?utm_source=businessinsider&utm_medium=referral,positive,0.5718112587928772
1795,3/20/2023 10:45:56 AM,Takeda hits main goals in mid-stage trial for plaque psoriasis therapy,Seeking Alpha,https://seekingalpha.com/news/3948751-takeda-hits-main-goals-mid-stage-trial-plaque-psoriasis-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8746462464332581
1796,3/22/2023 8:40:44 AM,Novartis Humira biosimilar's high concentration gets FDA approval,Seeking Alpha,https://seekingalpha.com/news/3949786-novartis-humira-biosimilars-high-concentration-form-gets-fda-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9143567681312561
1797,3/22/2023 1:04:32 PM,AbbVie lower as FDA rejects Parkinson's therapy,Seeking Alpha,https://seekingalpha.com/news/3949901-abbv-stock-lower-as-fda-rejects-parkinsons-therapy?utm_source=businessinsider&utm_medium=referral,neutral,0.8384076356887817
1798,3/22/2023 1:45:00 PM,AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application,PR Newswire,/news/stocks/abbvie-provides-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa-new-drug-application-1032184776,positive,0.9148598313331604
1799,3/22/2023 2:01:27 PM,AbbVie: FDA Requests Additional Information Related To NDA Review Of ABBV-951 ,RTTNews,/news/stocks/abbvie-fda-requests-additional-information-related-to-nda-review-of-abbv-951-1032184854,positive,0.9217373132705688
1800,3/23/2023 1:02:17 PM,AbbVie gains as Skyrizi succeeds in Phase 3 trial for ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3950354-abbvie-gains-skyrizi-succeeds-ulcerative-colitis?utm_source=businessinsider&utm_medium=referral,negative,0.9499377608299255
1801,3/23/2023 1:30:00 PM,Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis,PR Newswire,/news/stocks/risankizumab-skyrizi-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-study-in-patients-with-ulcerative-colitis-1032187666,negative,0.9330897331237793
1802,3/23/2023 1:57:02 PM,AbbVie: Phase 3 Induction Study With Risankizumab Meets Endpoints ,RTTNews,/news/stocks/abbvie-phase-3-induction-study-with-risankizumab-meets-endpoints-1032187804,positive,0.8138642907142639
1803,3/23/2023 2:00:00 PM,AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus,PR Newswire,/news/stocks/abbvie-advances-upadacitinib-rinvoq-to-phase-3-clinical-trials-in-systemic-lupus-erythematosus-1032187810,negative,0.8572554588317871
1804,3/23/2023 2:23:28 PM,AbbVie moves Rinvoq into phase 3 for lupus,Seeking Alpha,https://seekingalpha.com/news/3950417-abbvie-moves-rinvoq-phase-3-lupus?utm_source=businessinsider&utm_medium=referral,positive,0.9045009016990662
1805,3/23/2023 9:57:53 PM,"J&J, AbbVie's Imbruvica gets expanded blood cancer indication in Canada",Seeking Alpha,https://seekingalpha.com/news/3950766-johnson-johnson-abbvie-imbruvica-expanded-blood-cancer-indication-canada?utm_source=businessinsider&utm_medium=referral,negative,0.8477422595024109
1806,3/24/2023 10:25:44 AM,Morgan Stanley Reaffirms Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-abbvie-abbv-1032190390,positive,0.8407372236251831
1807,3/28/2023 3:39:52 PM,"CytomX slumps ~15% amid FY22 miss, AbbVie pulls plug on CX-2029 studies",Seeking Alpha,https://seekingalpha.com/news/3951925-cytomx-stock-slumps--fy22-miss-abbvie-pulls-plug-cx-2029-studies?utm_source=businessinsider&utm_medium=referral,neutral,0.9615961313247681
1808,3/29/2023 1:18:46 AM,DIV ETF Yields 7.3% and Pays Monthly. Here are the Pros and Cons,TipRanks,/news/stocks/div-etf-yields-7-3-and-pays-monthly-here-are-the-pros-and-cons-1032198634,positive,0.8933655619621277
1809,3/29/2023 3:00:00 PM,"Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023",PR Newswire,/news/stocks/allergan-aesthetics-to-showcase-360-approach-to-clinical-practice-aesthetic-products-and-patients-with-expert-led-symposia-at-amwc-2023-1032200424,positive,0.6628105044364929
1810,3/30/2023 10:59:00 PM,Investing Your Tax Return? Check Out This 11.8%-Yielding ETF,TipRanks,/news/stocks/investing-your-tax-return-check-out-this-11-8--yielding-etf-1032201784,positive,0.9212412238121033
1811,3/31/2023 3:51:38 AM,PFE vs. ABBV: Which Pharmaceutical Stock is Better?,TipRanks,/news/stocks/pfe-vs-abbv-which-pharmaceutical-stock-is-better-1032205251,positive,0.8005634546279907
1812,4/1/2023 8:00:21 PM,Antibody-drug conjugates key to Pfizer's Seagen acquisition,Seeking Alpha,https://seekingalpha.com/news/3953370-antibody-drug-conjugates-key-pfizer-seagen-acquisition?utm_source=businessinsider&utm_medium=referral,positive,0.8750739097595215
1813,4/3/2023 2:00:00 PM,CoolSculpting® Elite Announces First Ever CoolMonth,PR Newswire,/news/stocks/coolsculpting-elite-announces-first-ever-coolmonth-1032210465,positive,0.7429819703102112
1814,4/3/2023 7:58:32 PM,3 Dividend ETFs to Consider Buying with Your Tax Return,TipRanks,/news/stocks/3-dividend-etfs-to-consider-buying-with-your-tax-return-1032211936,positive,0.9275018572807312
1815,4/4/2023 8:35:28 AM,Novartis Humira biosimilar's high concentration gets approval in EU,Seeking Alpha,https://seekingalpha.com/news/3954067-novartis-humira-biosimilars-high-concentration-gets-eu-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9276140928268433
1816,4/4/2023 2:00:00 PM,AbbVie to Host First-Quarter 2023 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-first-quarter-2023-earnings-conference-call-1032213431,positive,0.9129507541656494
1817,4/5/2023 3:56:43 PM,AbbVie downgraded to hold at Argus on Humira competition in US,Seeking Alpha,https://seekingalpha.com/news/3954728-abbvie-downgraded-hold-argus-humira-competition-us?utm_source=businessinsider&utm_medium=referral,neutral,0.7839371562004089
1818,4/5/2023 5:00:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-5-2023-1032217169,positive,0.5246401429176331
1819,4/5/2023 8:51:06 PM,AbbVie 2023 EPS guidance range below consensus,Seeking Alpha,https://seekingalpha.com/news/3954812-abbvie-2023-eps-guidance-range-below-consensus?utm_source=businessinsider&utm_medium=referral,positive,0.7927271127700806
1820,4/5/2023 11:00:21 PM,The Latest Analyst Ratings for AbbVie,Benzinga,/news/stocks/the-latest-analyst-ratings-for-abbvie-1032217780,positive,0.9348931312561035
1821,4/6/2023 7:50:24 AM,"Analysts’ Top Healthcare Picks: Johnson & Johnson (JNJ), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-top-healthcare-picks-johnson-johnson-jnj-abbvie-abbv-1032218380,negative,0.7094581127166748
1822,4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.9218350052833557
1823,4/12/2023 5:00:00 PM,AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year,PR Newswire,/news/stocks/abbvie-invites-college-students-living-with-cystic-fibrosis-to-apply-for-the-abbvie-cf-scholarship-for-the-2023-2024-academic-school-year-1032227772,positive,0.8133438229560852
1824,4/15/2023 1:38:31 PM,3 Dividend Stocks to Buy for a Recession-Proof Portfolio,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-for-a-recession-proof-portfolio-1032234092,positive,0.834452748298645
1825,4/17/2023 8:00:00 AM,AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease,PR Newswire,/news/stocks/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-moderately-to-severely-active-crohn-s-disease-1032235393,negative,0.8816161751747131
1826,4/17/2023 8:53:33 AM,European Commission Approves AbbVie's Rinvoq To Treat Severely Active Crohn's Disease ,RTTNews,/news/stocks/european-commission-approves-abbvie-s-rinvoq-to-treat-severely-active-crohn-s-disease-1032235465,negative,0.7561218738555908
1827,4/17/2023 11:06:34 AM,AbbVie wins EU nod for Rinvoq in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/3956839-abbvie-stock-wins-eu-nod-for-rinvoq-in-crohns-disease?utm_source=businessinsider&utm_medium=referral,negative,0.8263248801231384
1828,4/18/2023 1:41:00 AM,U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine,PR Newswire,/news/stocks/u-s-fda-approves-qulipta-atogepant-for-adults-with-chronic-migraine-1032237658,negative,0.9005857706069946
1829,4/18/2023 3:02:44 AM,FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine In Adults ,RTTNews,/news/stocks/fda-approves-abbvie-s-qulipta-for-preventive-treatment-of-migraine-in-adults-1032237697,negative,0.8159473538398743
1830,4/18/2023 9:26:19 AM,AbbVie gets reimbursement for Vraylar for schizophrenia in Québec,Seeking Alpha,https://seekingalpha.com/news/3957210-abbvie-gets-reimbursement-for-vraylar-for-schizophrenia-in-qubec?utm_source=businessinsider&utm_medium=referral,negative,0.9215826988220215
1831,4/18/2023 4:04:00 PM,Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS,PR Newswire,/news/stocks/allergan-aesthetics-celebrates-the-journeys-of-women-surgeons-with-limitless-1032240103,positive,0.8162426948547363
1832,4/19/2023 1:24:40 AM,COWZ ETF: A Cash Cow for Your Portfolio,TipRanks,/news/stocks/cowz-etf-a-cash-cow-for-your-portfolio-1032241273,positive,0.9224590063095093
1833,4/19/2023 9:55:09 AM,Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-hold-rating-on-abbvie-abbv-1032242814,positive,0.9210310578346252
1834,4/21/2023 6:01:00 AM,AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 ...,PR Newswire,/news/stocks/abbvie-announces-late-breaking-results-from-phase-3-trial-evaluating-atogepant-qulipta-for-the-preventive-treatment-of-episodic-migraine-among-patients-with-prior-treatment-failure-at-the-2023-1032248513,negative,0.7849011421203613
1835,4/21/2023 10:02:53 AM,"AbbVie's migraine preventing drug Qulipta shows benefit in treatment failure patients, meets trial goals",Seeking Alpha,https://seekingalpha.com/news/3958577-abbvies-migraine-preventing-drug-qulipta-meets-phase-3-goals?utm_source=businessinsider&utm_medium=referral,negative,0.9326208233833313
1836,4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9372532963752747
1837,4/21/2023 7:00:36 PM,"Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut",Seeking Alpha,https://seekingalpha.com/news/3958768-catalyst-watch-earnings-blitz-mobileye-lockup-expiration-and-the-new-one-day-vix-debut?utm_source=businessinsider&utm_medium=referral,positive,0.9063062071800232
1838,4/22/2023 8:00:00 PM,Ulcerative colitis market set to hit $9.6B by 2031,Seeking Alpha,https://seekingalpha.com/news/3958777-ulcerative-colitis-market-set-to-hit-96b-by-2031?utm_source=businessinsider&utm_medium=referral,negative,0.7096775770187378
1839,4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral,positive,0.9020150899887085
1840,4/25/2023 12:32:15 PM,Enanta Pharma sells portion of Mavyret royalties for $200M,Seeking Alpha,https://seekingalpha.com/news/3959652-enanta-pharma-sells-portion-mavyret-royalties-200m?utm_source=businessinsider&utm_medium=referral,positive,0.9285538196563721
1841,4/25/2023 5:40:12 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Bluebird Bio (BLUE) and Avidity Biosciences (RNA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-bluebird-bio-blue-and-avidity-biosciences-rna-1032259607,neutral,0.917183518409729
1842,4/26/2023 3:01:13 PM,Here's what Wall Street expects from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-quarter-earnings-preview-q1-1032263704,positive,0.9177791476249695
1843,4/26/2023 3:07:35 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3960517-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8825733065605164
1844,4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.8721349239349365
1845,4/27/2023 11:34:43 AM,"AbbVie Non-GAAP EPS of $2.46 misses by $0.03, revenue of $12.23B in-line",Seeking Alpha,https://seekingalpha.com/news/3961251-abbvie-non-gaap-eps-of-2_46-misses-0_03-revenue-of-12_23b-in-line?utm_source=businessinsider&utm_medium=referral,positive,0.6907872557640076
1846,4/27/2023 12:32:55 PM,AbbVie falls as key drugs underperform amid Humira patent cliff,Seeking Alpha,https://seekingalpha.com/news/3961308-abbvie-falls-key-drugs-underperform-amid-humira-patent-cliff?utm_source=businessinsider&utm_medium=referral,neutral,0.9420436024665833
1847,4/27/2023 12:33:26 PM,"GMDA, TIGO and INAB among pre-market losers",Seeking Alpha,https://seekingalpha.com/news/3961310-gmda-tigo-and-inab-among-pre-market-losers?utm_source=businessinsider&utm_medium=referral,positive,0.9201926589012146
1848,4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050,negative,0.7996723055839539
1849,4/27/2023 1:32:00 PM,AbbVie Reports First-Quarter 2023 Financial Results,PR Newswire,/news/stocks/abbvie-reports-first-quarter-2023-financial-results-1032268262,positive,0.8833460807800293
1850,4/27/2023 2:04:10 PM,"AbbVie Q1 Profit Drops, Inline With Estimates",RTTNews,/news/stocks/abbvie-q1-profit-drops-inline-with-estimates-1032268403,neutral,0.9739859700202942
1851,4/27/2023 3:09:09 PM,Vertex gains as AbbVie ends cystic fibrosis development program,Seeking Alpha,https://seekingalpha.com/news/3961447-vertex-gains-as-abbvie-ends-cystic-fibrosis-development-program?utm_source=businessinsider&utm_medium=referral,negative,0.7121264338493347
1852,4/27/2023 5:06:41 PM,Elevance Health upgraded at Morgan Stanley on BioPlus business,Seeking Alpha,https://seekingalpha.com/news/3961501-elevance-stock--upgraded-at-morgan-stanley-on-bioplus-business?utm_source=businessinsider&utm_medium=referral,positive,0.8529893755912781
1853,4/27/2023 6:48:47 PM,Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session,Benzinga,/news/stocks/why-netgear-shares-are-trading-lower-by-18-here-are-other-stocks-moving-in-thursday-s-mid-day-session-1032269841,neutral,0.8025427460670471
1854,4/27/2023 8:52:22 PM,"Amgen 2023 revenue, earnings outlook include consensus estimates",Seeking Alpha,https://seekingalpha.com/news/3961737-amgen-2023-revenue-earnings-outlook-consensus-estimates?utm_source=businessinsider&utm_medium=referral,positive,0.9054314494132996
1855,4/27/2023 9:25:17 PM,"Why did AbbVie stock fall today? Lower than expected EPS, sales",Seeking Alpha,https://seekingalpha.com/news/3961791-why-did-abbvie-stock-fall-today-lower-than-expected-eps-sales?utm_source=businessinsider&utm_medium=referral,neutral,0.9501186609268188
1856,4/28/2023 8:25:41 AM,Barclays Reaffirms Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-abbvie-abbv-1032272678,positive,0.8249869346618652
1857,4/28/2023 9:35:05 AM,Goldman Sachs Reaffirms Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/goldman-sachs-reaffirms-their-hold-rating-on-abbvie-abbv-1032272920,positive,0.861198365688324
1858,4/28/2023 9:50:05 AM,Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-exelixis-exel-and-abbvie-abbv-1032272970,positive,0.9051567316055298
1859,4/29/2023 8:00:00 PM,"Pfizer, GSK, AbbVie among pharmas set to rise with May catalysts",Seeking Alpha,https://seekingalpha.com/news/3962345-pfizer-gsk-abbvie-among-pharmas-rise-may-catalysts?utm_source=businessinsider&utm_medium=referral,negative,0.9250966310501099
1860,4/30/2023 6:48:26 PM,7 High-Yield Dividend Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/7-high-yield-dividend-stocks-to-buy-and-hold-forever-1032276200,positive,0.9397075772285461
1861,5/1/2023 12:33:59 PM,Morgan Stanley's Wilson screens for stocks as earnings stabilize but data disappoints,Seeking Alpha,https://seekingalpha.com/news/3962504-norgan-stanleys-wilson-screens-for-stocks-as-earnigns-stabilize-but-data-disappoints?utm_source=businessinsider&utm_medium=referral,neutral,0.6267549991607666
1862,5/1/2023 2:55:45 PM,SVB Securities Reaffirms Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/svb-securities-reaffirms-their-hold-rating-on-abbvie-abbv-1032278583,positive,0.8321705460548401
1863,5/1/2023 3:15:09 PM,SVB Securities Reaffirms Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/svb-securities-reaffirms-their-hold-rating-on-abbvie-abbv-1032278694,positive,0.8321705460548401
1864,5/1/2023 5:29:00 PM,"Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report",Seeking Alpha,https://seekingalpha.com/news/3962788-abbvie-bristol-myers-competed-with-merck-in-sale-of-prometheus-report?utm_source=businessinsider&utm_medium=referral,negative,0.8889114856719971
1865,5/2/2023 2:00:00 PM,AbbVie to Present at the Bank of America Securities Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-bank-of-america-securities-healthcare-conference-1032281925,positive,0.9339443445205688
1866,5/4/2023 10:30:58 AM,7 Stock Upgrades and Downgrades Alerts You Cannot Ignore,InvestorPlace,/news/stocks/7-stock-upgrades-and-downgrades-alerts-you-cannot-ignore-1032291797,positive,0.7048253417015076
1867,5/4/2023 7:36:19 PM,Vertex assumed Overweight at Piper Sandler despite recent rally,Seeking Alpha,https://seekingalpha.com/news/3965917-vertex-stock-draws-bullish-view-piper-sandler?utm_source=businessinsider&utm_medium=referral,positive,0.5357123017311096
1868,5/4/2023 8:41:35 PM,7 Dividend-Paying Large-Cap Stocks to Buy in May,InvestorPlace,/news/stocks/7-dividend-paying-large-cap-stocks-to-buy-in-may-2-1032294293,positive,0.8960413336753845
1869,5/6/2023 3:00:34 AM,XLV: 5 Reasons to Put This Healthcare ETF on Your Radar,TipRanks,/news/stocks/xlv-5-reasons-to-put-this-healthcare-etf-on-your-radar-1032298857,positive,0.9032704830169678
1870,5/6/2023 1:30:00 PM,AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®,PR Newswire,/news/stocks/abbvie-releases-new-data-demonstrating-breadth-of-its-gastroenterology-portfolio-at-2023-digestive-disease-week-1032298983,positive,0.7538326382637024
1871,5/9/2023 12:17:23 AM,7 Dividend Stocks That Will Pay You Through Any Market Turmoil,InvestorPlace,/news/stocks/7-dividend-stocks-that-will-pay-you-through-any-market-turmoil-1032303954,positive,0.930162787437439
1872,5/9/2023 11:59:35 AM,AbbVie's Rinvoq gets approval in Canada for expanded use in axial spondyloarthritis,Seeking Alpha,https://seekingalpha.com/news/3967901-abbvie-rinvoq-gets-approval-in-canada-for-expanded-use?utm_source=businessinsider&utm_medium=referral,negative,0.9315859079360962
1873,5/9/2023 12:56:49 PM,Big pharma maps legal strategy against U.S. drug pricing regulation – Reuters,Seeking Alpha,https://seekingalpha.com/news/3967966-big-pharma-maps-legal-strategy-against-drug-pricing-regulation?utm_source=businessinsider&utm_medium=referral,positive,0.9252361059188843
1874,5/9/2023 2:12:56 PM,AbbVie Says Health Canada Approves RINVOQ To Treat Adults With Active Nr-axSpA ,RTTNews,/news/stocks/abbvie-says-health-canada-approves-rinvoq-to-treat-adults-with-active-nr-axspa-1032306524,negative,0.8956521153450012
1875,5/9/2023 3:16:56 PM,Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/check-out-3-health-care-stocks-with-over-3-dividend-yields-from-wall-street-s-most-accurate-analysts-1032307234,positive,0.7954005599021912
1876,5/9/2023 9:16:44 PM,Why Enanta Shares Are Plunging Today,Benzinga,/news/stocks/why-enanta-shares-are-plunging-today-1032308453,neutral,0.8304384350776672
1877,5/10/2023 8:27:21 PM,This Analyst Likes Evolus As 'Top Play In Aesthetics',Benzinga,/news/stocks/this-analyst-likes-evolus-as-top-play-in-aesthetics-1032313891,positive,0.6264578104019165
1878,5/10/2023 8:33:44 PM,Is ChatGPT A Better Financial Advisor? We're Going To Find Out,Benzinga,/news/etf/is-chatgpt-a-better-financial-advisor-we-re-going-to-find-out-1032313893,positive,0.8116571307182312
1879,5/13/2023 8:00:00 PM,Cancer therapies spending set to surge through end of decade,Seeking Alpha,https://seekingalpha.com/news/3971001-cancer-therapies-spending-set-surge-through-end-decade?utm_source=businessinsider&utm_medium=referral,negative,0.9407323002815247
1880,5/15/2023 2:45:00 PM,SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval,PR Newswire,/news/stocks/skinvive-by-juvéderm-receives-u-s-fda-approval-1032327375,negative,0.9330026507377625
1881,5/15/2023 3:03:56 PM,Allergan Aesthetics Says FDA Approves SKINVIVE By JUVEDERM ,RTTNews,/news/stocks/allergan-aesthetics-says-fda-approves-skinvive-by-juvederm-1032327511,positive,0.7000001072883606
1882,5/16/2023 12:59:31 AM,"Steven Cohen's Point72 adds AT&T, Intel; exits Airbnb, Tesla",Seeking Alpha,https://seekingalpha.com/news/3971835-steven-cohens-point72-adds-att-intel-exits-airbnb-tesla?utm_source=businessinsider&utm_medium=referral,positive,0.8812435269355774
1883,5/16/2023 12:52:10 PM,AstraZeneca to exit leading U.S. drug industry group PhRMA,Seeking Alpha,https://seekingalpha.com/news/3972045-astrazeneca-stock-exits-leading-us-drug-lobby-phrma?utm_source=businessinsider&utm_medium=referral,positive,0.6984096169471741
1884,5/16/2023 4:33:21 PM,"Famed Short Seller Muddy Waters Targets Chinook Therapeutics, Points To Drug Data Questions",Benzinga,/news/stocks/famed-short-seller-muddy-waters-targets-chinook-therapeutics-points-to-drug-data-questions-1032331778,positive,0.8954986929893494
1885,5/16/2023 6:30:14 PM,Pfizer bond offering to fund Seagen deal said to be among largest on record,Seeking Alpha,https://seekingalpha.com/news/3972277-pfizer-bond-offering-fund-seagen-deal-among-largest?utm_source=businessinsider&utm_medium=referral,negative,0.520749032497406
1886,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral,neutral,0.7930806875228882
1887,5/18/2023 4:45:43 PM,AbbVie gains Crohn's disease indication for Rinvoq in US,Seeking Alpha,https://seekingalpha.com/news/3973141-abbvie-gains-crohns-disease-indication-rinvoq-us?utm_source=businessinsider&utm_medium=referral,positive,0.7744700312614441
1888,5/18/2023 6:25:00 PM,U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults,PR Newswire,/news/stocks/u-s-fda-approves-rinvoq-upadacitinib-as-a-once-daily-pill-for-moderately-to-severely-active-crohn-s-disease-in-adults-1032338078,negative,0.9069890975952148
1889,5/19/2023 5:06:45 AM,FDA Approves AbbVie's Rinvoq As Once-Daily Pill For Crohn's Disease In Adults ,RTTNews,/news/stocks/fda-approves-abbvie-s-rinvoq-as-once-daily-pill-for-crohn-s-disease-in-adults-1032338681,negative,0.5505818724632263
1890,5/19/2023 9:50:13 AM,Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Medtronic (MDT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-and-medtronic-mdt-1032339346,positive,0.9085791707038879
1891,5/19/2023 4:59:30 PM,"AbbVie, Genmab granted FDA nod for lymphoma therapy",Seeking Alpha,https://seekingalpha.com/news/3973543-abbvie-genmab-win-fda-nod-lymphoma-therapy-epkinly?utm_source=businessinsider&utm_medium=referral,negative,0.9119819402694702
1892,5/19/2023 6:34:00 PM,EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),PR Newswire,/news/stocks/epkinly-epcoritamab-bysp-approved-by-u-s-fda-as-the-first-and-only-bispecific-antibody-to-treat-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-1032340260,negative,0.8391698002815247
1893,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.7357143759727478
1894,5/22/2023 12:58:00 AM,HDV: This Dividend ETF Proves That High Yield Isn’t Always Best,TipRanks,/news/stocks/hdv-this-dividend-etf-proves-that-high-yield-isn-t-always-best-1032341360,positive,0.7474883198738098
1895,5/24/2023 2:35:39 PM,Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-buy-these-3-health-care-stocks-with-over-3-dividend-yields-1032348428,negative,0.5285109281539917
1896,5/24/2023 3:00:00 PM,AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress,PR Newswire,/news/stocks/abbvie-presents-long-term-data-further-supporting-the-efficacy-and-safety-profile-of-rinvoq-upadacitinib-across-multiple-rheumatic-diseases-at-the-eular-2023-congress-1032348537,negative,0.9026128053665161
1897,5/25/2023 2:45:00 PM,New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-results-from-phase-3-induction-and-maintenance-programs-evaluating-upadacitinib-rinvoq-in-crohn-s-disease-1032351598,positive,0.8730571269989014
1898,5/26/2023 10:38:37 AM,Elon Musk's Neuralink gets FDA nod to start human trial of brain implant,Seeking Alpha,https://seekingalpha.com/news/3975338-elon-musks-neuralink-gets-fda-nod-to-start-human-trial-of-brain-implant?utm_source=businessinsider&utm_medium=referral,negative,0.5858262777328491
1899,5/30/2023 2:23:37 PM,Vertex initiated at outperform at William Blair on cystic fibrosis growth,Seeking Alpha,https://seekingalpha.com/news/3975829-vertex-initiated-outperform-william-blair-cystic-fibrosis-growth?utm_source=businessinsider&utm_medium=referral,negative,0.452208012342453
1900,5/31/2023 8:30:00 AM,Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus,PR Newswire,/news/stocks/phase-2-study-of-upadacitinib-rinvoq-alone-or-as-a-combination-therapy-meets-primary-and-key-secondary-endpoints-in-patients-with-systemic-lupus-erythematosus-1032359927,negative,0.5762423872947693
1901,5/31/2023 9:24:54 AM,AbbVie Says  Upadacitinib 30 Mg Meets Primary Goals In SLE Patients In Mid-stage Study ,RTTNews,/news/stocks/abbvie-says-upadacitinib-30-mg-meets-primary-goals-in-sle-patients-in-mid-stage-study-1032360046,negative,0.8612972497940063
1902,5/31/2023 11:09:43 AM,AbbVie meets key goals for Rinvoq in mid-stage SLE trial,Seeking Alpha,https://seekingalpha.com/news/3976121-abbvie-stock-meets-key-goals-rinvoq-sle-trial?utm_source=businessinsider&utm_medium=referral,negative,0.8320115804672241
1903,6/1/2023 10:48:48 AM,AstraZeneca halts AbbVie-partnered bowel disease drug program,Seeking Alpha,https://seekingalpha.com/news/3976506-astrazeneca-stock-halts-abbvie-partnered-drug-program?utm_source=businessinsider&utm_medium=referral,neutral,0.8591462969779968
1904,6/1/2023 1:22:19 PM,"Coherus, Mark Cuban’s generic drug firm unveil cheapest Humira version",Seeking Alpha,https://seekingalpha.com/news/3976595-coherus-mark-cubans-firm-unveil-cheapest-humira-version?utm_source=businessinsider&utm_medium=referral,negative,0.49993467330932617
1905,6/1/2023 1:23:14 PM,Mark Cuban online pharmacy to offer AbbVie Humira biosimilar,Seeking Alpha,https://seekingalpha.com/news/3976594-mark-cuban-online-pharmacy-offer-abbvie-humira-biosimilar?utm_source=businessinsider&utm_medium=referral,positive,0.861520528793335
1906,6/1/2023 2:43:36 PM,Pfizer posts promising Phase 3 data for AbbVie-partnered antibiotic,Seeking Alpha,https://seekingalpha.com/news/3976637-pfizer-stock-posts-data-for-abbvie-partnered-antibiotic?utm_source=businessinsider&utm_medium=referral,negative,0.9472237825393677
1907,6/1/2023 6:17:38 PM,"AbbVie, Amgen hit 52-week lows as Coherus unveils cheapest Humira version",Seeking Alpha,https://seekingalpha.com/news/3976787-abbvie-stock-amgen-stock-slump-coherus-cheapest-humira?utm_source=businessinsider&utm_medium=referral,neutral,0.7989323735237122
1908,6/1/2023 8:03:53 PM,Why Is AbbVie Stock Trading Down Today?,Benzinga,/news/stocks/why-is-abbvie-stock-trading-down-today-1032365547,neutral,0.8559072017669678
1909,6/1/2023 8:13:51 PM,Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed',Benzinga,/news/stocks/mark-cuban-helping-lower-cost-of-bestselling-humira-with-cost-plus-drug-company-the-game-just-changed-1032365572,negative,0.6339818239212036
1910,6/3/2023 12:56:11 PM,SVB Securities Sticks to Its Hold Rating for AbbVie (ABBV),TipRanks,/news/stocks/svb-securities-sticks-to-its-hold-rating-for-abbvie-abbv-1032368558,positive,0.9124508500099182
1911,6/5/2023 8:55:12 AM,Barclays Sticks to Its Hold Rating for AbbVie (ABBV),TipRanks,/news/stocks/barclays-sticks-to-its-hold-rating-for-abbvie-abbv-1032369662,positive,0.8851715326309204
1912,6/6/2023 4:30:17 AM,"IBM, CVX, or ABBV: Which Dividend Aristocrat Stock is the Most Compelling Pick?",TipRanks,/news/stocks/ibm-cvx-or-abbv-which-dividend-aristocrat-stock-is-the-most-compelling-pick-1032371718,positive,0.9319469332695007
1913,6/6/2023 10:42:00 AM,"Narrow market proving a headwind for mutual funds, opportunity for hedge funds",Seeking Alpha,https://seekingalpha.com/news/3977589-narrow-market-a-headwind-for-active-mutual-funds-opportunity-for-hedge-funds?utm_source=businessinsider&utm_medium=referral,positive,0.5176432132720947
1914,6/6/2023 2:00:00 PM,AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-1032372674,positive,0.8842025995254517
1915,6/8/2023 3:07:36 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields-1032378537,positive,0.8560808897018433
1916,6/9/2023 12:11:04 AM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Cardinal Health (CAH) and Intellia Therapeutics (NTLA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-cardinal-health-cah-and-intellia-therapeutics-ntla-1032379582,positive,0.9135085940361023
1917,6/9/2023 9:00:00 AM,AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients,PR Newswire,/news/stocks/abbvie-s-venclyxto-venclexta-venetoclax-continues-to-show-sustained-progression-free-survival-pfs-in-chronic-lymphocytic-leukemia-cll-patients-1032380052,negative,0.9499694108963013
1918,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral,positive,0.5447219014167786
1919,6/9/2023 4:04:49 PM,"Teva, Walgreens, CVS, AbbVie to pay $17.3B in national opioid settlement",Seeking Alpha,https://seekingalpha.com/news/3978980-teva-walgreens-cvs-abbvie-to-pay-173b-in-national-opioid-settlement?utm_source=businessinsider&utm_medium=referral,positive,0.7815471291542053
1920,6/9/2023 5:01:19 PM,Walgreens to pay $500M to settle opioid litigation in New Mexico,Seeking Alpha,https://seekingalpha.com/news/3978991-walgreens-to-pay-500m-to-settle-opioid-litigation-in-new-mexico?utm_source=businessinsider&utm_medium=referral,negative,0.6785584092140198
1921,6/11/2023 8:25:20 PM,7 Top Blue-Chip Stocks to Buy in June 2023,InvestorPlace,/news/stocks/7-top-blue-chip-stocks-to-buy-in-june-2023-1032382217,positive,0.9089648127555847
1922,6/12/2023 9:22:16 PM,Teva settles price-fixing claims with State of Kentucky for $1.41B,Seeking Alpha,https://seekingalpha.com/news/3979378-teva-settles-price-fixing-claims-with-state-of-kentucky-for-1-point-4-billion?utm_source=businessinsider&utm_medium=referral,positive,0.7794872522354126
1923,6/12/2023 9:53:16 PM,FDA approves Ironwood's constipation drug Linzess for pediatric use,Seeking Alpha,https://seekingalpha.com/news/3979388-fda-approves-ironwood-constipation-drug-linzess-for-pediatric-use?utm_source=businessinsider&utm_medium=referral,negative,0.7028313875198364
1924,6/13/2023 11:54:32 AM,Teva settles price-fixing claims with State of Kentucky for $1.41M (update),Seeking Alpha,https://seekingalpha.com/news/3979378-teva-settles-price-fixing-claims-with-state-of-kentucky?utm_source=businessinsider&utm_medium=referral,positive,0.8694736361503601
1925,6/13/2023 2:45:00 PM,BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program,PR Newswire,/news/stocks/botox-cosmetic-onabotulinumtoxina-announces-the-winners-of-the-ifundwomen-grant-program-1032386019,positive,0.7884073257446289
1926,6/15/2023 10:01:46 AM,"Biggest stock movers today: MicroVision, BeiGene and more",Seeking Alpha,https://seekingalpha.com/news/3980052-biggest-stock-movers-today-microvision-biogene-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.8907638192176819
1927,6/15/2023 10:54:18 AM,AbbVie files patent lawsuit over BeiGene’s cancer drug - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3980076-beigene-stock-down-abbvie-patent-lawsuit-brukinsa?utm_source=businessinsider&utm_medium=referral,neutral,0.8246316313743591
1928,6/15/2023 11:25:19 AM,"AbbVie, Coherus in legal battle over Humira biosimilar",Seeking Alpha,https://seekingalpha.com/news/3980098-abbvie-stock-coherus-legal-battle-humira-biosimilar?utm_source=businessinsider&utm_medium=referral,neutral,0.8191739916801453
1929,6/15/2023 2:45:00 PM,Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients,PR Newswire,/news/stocks/risankizumab-skyrizi-met-primary-and-key-secondary-endpoints-in-52-week-phase-3-maintenance-study-in-ulcerative-colitis-patients-1032391733,negative,0.9478462338447571
1930,6/15/2023 3:05:30 PM,AbbVie: Risankizumab Meets Endpoint In Phase 3 Maintenance Study In Ulcerative Colitis Patients ,RTTNews,/news/stocks/abbvie-risankizumab-meets-endpoint-in-phase-3-maintenance-study-in-ulcerative-colitis-patients-1032391868,negative,0.8692517280578613
1931,6/15/2023 5:24:25 PM,"AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry",Benzinga,/news/stocks/abbvie-vs-coherus-dispute-emerges-over-upcoming-launch-of-low-cost-biosimilar-yusimry-1032392365,neutral,0.9282793402671814
1932,6/18/2023 9:45:31 PM,Unlock the Potential of These 7 Cash-Flow Machines,InvestorPlace,/news/stocks/7-high-cash-flow-stocks-that-can-power-your-portfolio-1032395855,positive,0.728817880153656
1933,6/20/2023 6:40:09 PM,Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo,InvestorPlace,/news/stocks/ready-for-a-rebound-7-blue-chips-set-to-regain-their-market-mojo-1032400066,negative,0.7723432779312134
1934,6/20/2023 8:43:37 PM,RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence,Benzinga,/news/stocks/regenxbio-s-potential-blockbuster-analyst-is-bullish-on-stock-citing-potential-gains-from-aav-gene-therapies-resurgence-1032400076,negative,0.9310175776481628
1935,6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,neutral,0.9452309608459473
1936,6/22/2023 5:43:20 PM,AbbVie declares $1.48 dividend,Seeking Alpha,https://seekingalpha.com/news/3982049-abbvie-inc-declares-1_48-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9382003545761108
1937,6/22/2023 7:13:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1032405356,neutral,0.5513123869895935
1938,6/23/2023 12:36:12 PM,AbbVie migraine therapy endorsed in Europe,Seeking Alpha,https://seekingalpha.com/news/3982362-abbvie-migraine-therapy-endorsed-in-europe?utm_source=businessinsider&utm_medium=referral,positive,0.818220317363739
1939,6/23/2023 2:04:00 PM,AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine,PR Newswire,/news/stocks/abbvie-secures-positive-chmp-opinion-for-atogepant-for-the-preventive-treatment-of-adults-with-migraine-1032406757,negative,0.9491777420043945
1940,6/23/2023 2:13:12 PM,"Cramer Says Datadog Will 'Put Up Some Good Numbers,' And 9 More Stock Takes From 'Mad Money' Host",Benzinga,/news/stocks/cramer-says-datadog-will-put-up-some-good-numbers-and-9-more-stock-takes-from-mad-money-host-1032406785,negative,0.8705769777297974
1941,6/23/2023 3:01:54 PM,AbbVie's Atogepant Secures Positive CHMP Opinion For The Preventive Treatment Of Migraine ,RTTNews,/news/stocks/abbvie-s-atogepant-secures-positive-chmp-opinion-for-the-preventive-treatment-of-migraine-1032406938,negative,0.9478875994682312
1942,6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral,neutral,0.6917394399642944
1943,6/26/2023 7:05:14 AM,Barclays Sticks to Its Hold Rating for AbbVie (ABBV),TipRanks,/news/stocks/barclays-sticks-to-its-hold-rating-for-abbvie-abbv-1032408821,positive,0.8851715326309204
1944,6/26/2023 2:00:00 PM,"AbbVie Employees Volunteer During 8th Annual ""Week of Possibilities"" to Support Communities Globally",PR Newswire,/news/stocks/abbvie-employees-volunteer-during-8th-annual-week-of-possibilities-to-support-communities-globally-1032409443,positive,0.7730817198753357
1945,6/26/2023 3:08:45 PM,Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/check-out-3-health-care-stocks-with-over-4-dividend-yields-from-wall-street-s-most-accurate-analysts-1032409783,positive,0.7893310785293579
1946,6/26/2023 6:52:52 PM,CollPlant nabs $10M milestone from AbbVie for dermal filler product,Seeking Alpha,https://seekingalpha.com/news/3982918-collplant-stock-gains-10m-milestone-from-abbvie?utm_source=businessinsider&utm_medium=referral,negative,0.8658788800239563
1947,6/26/2023 9:14:22 PM,3 Penny Stocks with Multibagger Potential for the Second Half of 2023,InvestorPlace,/news/stocks/penny-stocks-to-watch-in-2023-with-multibagger-potential-1032410839,positive,0.7881865501403809
1948,6/27/2023 8:28:14 PM,Quant Ratings Updated on 90 Stocks,InvestorPlace,/news/stocks/20230627-quant-ratings-1032413520,positive,0.9289917945861816
1949,6/28/2023 12:50:00 AM,AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL),PR Newswire,/news/stocks/abbvie-and-genmab-announce-positive-topline-results-from-phase-1-2-epcore-nhl-1-trial-evaluating-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsed-refractory-follicular-lymphoma-fl-1032413638,negative,0.9419966340065002
1950,6/28/2023 12:52:35 AM,7 Stocks That Every 40-Year-Old Should Buy Today,InvestorPlace,/news/stocks/7-stocks-that-every-40-year-old-should-buy-today-1032413673,positive,0.9137061238288879
1951,6/28/2023 3:10:03 AM,AbbVie Announces Positive Results From Phase 1/2 Trial Of Epcoritamab In R/R Follicular Lymphoma ,RTTNews,/news/stocks/abbvie-announces-positive-results-from-phase-1-2-trial-of-epcoritamab-in-r-r-follicular-lymphoma-1032413679,negative,0.9427496194839478
1952,6/28/2023 11:05:25 AM,BMO Capital Remains a Buy on AbbVie (ABBV),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-abbvie-abbv-1032414637,positive,0.9485976099967957
1953,6/28/2023 9:00:19 PM,"Six Weeks In, AI Outpaces Wall Street's Elite: The ChatGPT Challenge",Benzinga,/news/etf/six-weeks-in-ai-outpaces-wall-street-s-elite-the-chatgpt-challenge-1032416144,negative,0.6581472754478455
1954,6/29/2023 9:08:31 AM,Morgan Stanley shakes up its global dividend portfolio,Seeking Alpha,https://seekingalpha.com/news/3983853-morgan-stanley-shakes-up-its-global-dividend-portfolio?utm_source=businessinsider&utm_medium=referral,neutral,0.947080135345459
1955,6/29/2023 10:20:11 AM,7 Top Growth Stocks to Watch for H2 2023,InvestorPlace,/news/stocks/7-top-growth-stocks-to-watch-for-h2-2023-1032417368,positive,0.8797151446342468
1956,6/29/2023 10:52:11 AM,Alvotech slips as FDA rejects Humira biosimilar again,Seeking Alpha,https://seekingalpha.com/news/3984035-alvotech-stock-slips-fda-snubs-humira-biosimilar?utm_source=businessinsider&utm_medium=referral,neutral,0.961734414100647
1957,6/29/2023 2:14:43 PM,"Biggest stock movers today: BlackBerry, FREYR Battery, BioXcel Therapeutics, and more",Seeking Alpha,https://seekingalpha.com/news/3983987-biggest-stock-movers-today-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.8924593329429626
1958,6/29/2023 9:28:11 PM,Robert Michael named president and COO at AbbVie - filing,Seeking Alpha,https://seekingalpha.com/news/3984322-robert-michael-named-president-and-coo-at-abbvie-filing?utm_source=businessinsider&utm_medium=referral,positive,0.9439555406570435
1959,6/30/2023 12:40:08 PM,Bausch + Lomb to buy dry-eye therapy from Novartis for over $1B,Seeking Alpha,https://seekingalpha.com/news/3984409-bausch--omb-to-buy-dry-eye-therapy-from-novartis?utm_source=businessinsider&utm_medium=referral,negative,0.534709095954895
1960,6/30/2023 4:39:00 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023,InvestorPlace,/news/stocks/pharma-stocks-to-buy-1032421255,positive,0.9032686352729797
1961,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.901573121547699
1962,6/30/2023 4:44:49 PM,Why This BeiGene Analyst Slashes Forecast By Almost 42%,Benzinga,/news/stocks/why-this-beigene-analyst-slashes-forecast-by-almost-42-1032420661,neutral,0.9213843941688538
1963,7/1/2023 3:03:04 PM,Organon launches biosimilar of AbbVie's Humira,Seeking Alpha,https://seekingalpha.com/news/3984821-organon-launches-biosimilar-abbvie-humira?utm_source=businessinsider&utm_medium=referral,positive,0.7537319660186768
1964,7/3/2023 3:21:43 PM,More AbbVie Humira biosimilars launched (updated),Seeking Alpha,https://seekingalpha.com/news/3985023-more-abbvie-humira-biosimilars-launched?utm_source=businessinsider&utm_medium=referral,positive,0.9374572038650513
1965,7/5/2023 1:33:37 PM,Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment,Benzinga,/news/stocks/protagonist-therapeutics-janssen-partnered-psoriasis-candidate-fall-short-of-rival-treatment-1032427164,negative,0.7201300859451294
1966,7/5/2023 4:02:44 PM,Sorrento sees promising phase 2 results for abivertinib for lymphoma,Seeking Alpha,https://seekingalpha.com/news/3985616-sorrento-promising-phase-2-results-abivertinib-lymphoma?utm_source=businessinsider&utm_medium=referral,negative,0.9508057236671448
1967,7/5/2023 4:57:34 PM,Celltrion launches biosimilar of AbbVie's Humira in US,Seeking Alpha,https://seekingalpha.com/news/3985654-celltrion-launches-biosimilar-of-abbvie-humira-in-us?utm_source=businessinsider&utm_medium=referral,positive,0.567594587802887
1968,7/5/2023 7:16:12 PM,The 7 Best Forever Stocks to Buy for July 2023,InvestorPlace,/news/stocks/the-7-best-forever-stocks-to-buy-for-july-2023-1032428438,positive,0.9323568940162659
1969,7/6/2023 2:00:00 PM,AbbVie to Host Second-Quarter 2023 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-second-quarter-2023-earnings-conference-call-1032429871,positive,0.9174003601074219
1970,7/6/2023 7:36:39 PM,The 7 Best Long-Term Stocks to Buy in July,InvestorPlace,/news/stocks/the-7-best-long-term-stocks-to-buy-in-july-1032430962,positive,0.8260964751243591
1971,7/6/2023 9:39:03 PM,AbbVie updates full-year EPS estimate range; below consensus,Seeking Alpha,https://seekingalpha.com/news/3986107-abbvie-updates-full-year-eps-estimate-range-below-consensus?utm_source=businessinsider&utm_medium=referral,positive,0.881182849407196
1972,7/7/2023 11:04:22 AM,"Dividend Roundup: Unilever, PNC Financial, Oracle, AbbVie, and more",Seeking Alpha,https://seekingalpha.com/news/3986054-dividend-roundup-unilever-pnc-financial-oracle-abbvie-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9495151042938232
1973,7/7/2023 3:41:02 PM,The 3 Best Dividend Stocks to Buy in July,InvestorPlace,/news/stocks/the-3-best-dividend-stocks-to-buy-in-july-1032432596,positive,0.8689623475074768
1974,7/9/2023 5:06:29 AM,"PEP, ABBV, or GM: Which Value Stock Could Offer the Highest Upside?",TipRanks,/news/stocks/pep-abbv-or-gm-which-value-stock-could-offer-the-highest-upside-1032433298,positive,0.9338462352752686
1975,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral,negative,0.937191367149353
1976,7/10/2023 8:15:12 AM,Barclays Reaffirms Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-abbvie-abbv-1032434235,positive,0.8249869346618652
1977,7/10/2023 5:40:24 PM,AbbVie slips as Cigna adds more Humira biosimilars for coverage,Seeking Alpha,https://seekingalpha.com/news/3986544-abbvie-stock-slips-cigna-adds-humira-biosimilars?utm_source=businessinsider&utm_medium=referral,neutral,0.9224168062210083
1978,7/12/2023 8:10:24 AM,"Analysts Conflicted on These Healthcare Names: Tandem Diabetes Care (TNDM), AbbVie (ABBV) and Immunocore Holdings (IMCR)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-tandem-diabetes-care-tndm-abbvie-abbv-and-immunocore-holdings-imcr-1032440132,neutral,0.5471087694168091
1979,7/12/2023 11:51:55 AM,3 Biotech Stocks That AI is Loving in July,InvestorPlace,/news/stocks/3-biotech-stocks-that-ai-is-loving-in-july-1032440899,positive,0.9186151623725891
1980,7/12/2023 9:33:58 PM,3 Biotech Stocks to Sell Before They Damage Your Portfolio ,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-before-they-damage-your-portfolio-1032442531,positive,0.8793624639511108
1981,7/13/2023 5:29:24 PM,7 Stocks That AI Says Will Make You a Millionaire by 2025,InvestorPlace,/news/stocks/7-stocks-that-ai-says-will-make-you-a-millionaire-by-2025-1032445565,positive,0.8657408356666565
1982,7/14/2023 4:01:10 PM,Analyst Ratings for AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1032447833,positive,0.9059829115867615
1983,7/14/2023 5:02:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-14-2023-1032447974,positive,0.4949893355369568
1984,7/14/2023 6:24:52 PM,SCHD vs. VYM: Which is the Better Dividend ETF?,TipRanks,/news/stocks/schd-vs-vym-which-is-the-better-dividend-etf-1032448246,positive,0.9081217050552368
1985,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,positive,0.4974316656589508
1986,7/17/2023 9:32:48 PM,BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View,Benzinga,/news/stocks/beigene-s-brukinsa-positioned-as-preferred-btk-inhibitor-analyst-says-survey-supports-bullish-view-1032452462,negative,0.8515817523002625
1987,7/18/2023 10:22:03 AM,3 Biotech Stocks for Getting Rich in 2023,InvestorPlace,/news/stocks/3-biotech-stocks-for-getting-rich-in-2023-1032454309,positive,0.7535070776939392
1988,7/20/2023 4:49:18 PM,7 Fantastic Forever Stocks for Long-Term Lucrative Gains,InvestorPlace,/news/stocks/7-fantastic-forever-stocks-for-long-term-lucrative-gains-1032463537,positive,0.8014901280403137
1989,7/20/2023 8:18:18 PM,3 of the Best Dividend Stocks to Buy for Passive Income Growth,InvestorPlace,/news/stocks/3-of-the-best-dividend-stocks-to-buy-for-passive-income-growth-1032463888,positive,0.8181398510932922
1990,7/21/2023 10:30:00 AM,AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),PR Newswire,/news/stocks/abbvie-receives-positive-chmp-opinion-for-epcoritamab-tepkinly-for-the-treatment-of-adults-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-1032465155,negative,0.9466580748558044
1991,7/21/2023 10:43:45 AM,AbbVie wins EU backing for Genmab-partnered lymphoma therapy,Seeking Alpha,https://seekingalpha.com/news/3989542-abbvie-wins-eu-backing-genmab-partnered-lymphoma-drug?utm_source=businessinsider&utm_medium=referral,negative,0.9258412718772888
1992,7/21/2023 11:57:48 AM,AbbVie/Genmab's Diffuse Large B-cell Lymphoma Drug A Step Away From Approval In Europe ,RTTNews,/news/stocks/abbvie-genmab-s-diffuse-large-b-cell-lymphoma-drug-a-step-away-from-approval-in-europe-1032465338,neutral,0.9312208890914917
1993,7/21/2023 7:00:10 PM,"Catalyst Watch: Earnings blitz, central bank meetings, UPS strike jitters and Barbenheimer",Seeking Alpha,https://seekingalpha.com/news/3989741-catalyst-watch-earnings-blitz-central-bank-meetings-ups-strike-jitters-and-barbenheimer?utm_source=businessinsider&utm_medium=referral,positive,0.8478363156318665
1994,7/24/2023 2:05:00 PM,AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa,PR Newswire,/news/stocks/abbvie-advances-immunology-pipeline-with-first-patient-dosed-in-global-phase-3-trial-of-upadacitinib-rinvoq-in-hidradenitis-suppurativa-1032469888,negative,0.8516626358032227
1995,7/24/2023 11:54:56 PM,The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos,InvestorPlace,/news/stocks/the-7-best-dividend-stocks-to-protect-your-portfolio-from-global-chaos-1032471701,positive,0.8291624784469604
1996,7/25/2023 2:21:12 PM,AbbVie's RINVOQ Gets Regulatory Nod In Canada For Yet Another Indication ,RTTNews,/news/stocks/abbvie-s-rinvoq-gets-regulatory-nod-in-canada-for-yet-another-indication-1032474188,negative,0.8670735359191895
1997,7/25/2023 5:00:40 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-25-2023-1032475324,positive,0.5136184096336365
1998,7/25/2023 9:35:38 PM,"Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says",Benzinga,/news/stocks/growing-competition-in-hematology-aesthetics-complicates-abbvie-s-post-humira-landscape-analyst-says-1032475950,neutral,0.7881214022636414
1999,7/26/2023 12:35:51 PM,AbbVie says Skyrizi beat Amgen’s Otezla in plaque psoriasis trial,Seeking Alpha,https://seekingalpha.com/news/3991142-abbvies-skyrizi-beats-amgens-otezla-plaque-psoriasis?utm_source=businessinsider&utm_medium=referral,negative,0.9292848706245422
2000,7/26/2023 2:05:00 PM,SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study,PR Newswire,/news/stocks/skyrizi-risankizumab-achieved-superiority-versus-apremilast-for-co-primary-endpoints-among-adult-patients-with-moderate-plaque-psoriasis-in-phase-4-head-to-head-study-1032479358,negative,0.953406572341919
2001,7/26/2023 2:12:14 PM,AbbVie expands collaboration with Calibr on early-stage assets,Seeking Alpha,https://seekingalpha.com/news/3991209-abbvie-expands-collaboration-calibr-early-stage-assets?utm_source=businessinsider&utm_medium=referral,negative,0.9023826718330383
2002,7/26/2023 3:00:00 PM,AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets,PR Newswire,/news/stocks/abbvie-and-calibr-expand-strategic-collaboration-to-advance-several-preclinical-and-early-stage-clinical-assets-1032479887,negative,0.8990208506584167
2003,7/26/2023 3:01:13 PM,AbbVie earnings preview: what to expect,Markets Insider Automation,/news/stocks/abbvie-q2-quarterly-earnings-preview-stock-1032479666,positive,0.9158738851547241
2004,7/26/2023 3:58:07 PM,AbbVie under pressure ahead of Q2 results amid Humira cliff,Seeking Alpha,https://seekingalpha.com/news/3991264-abbvie-stock-sold-off-ahead-q2-print-humira-cliff?utm_source=businessinsider&utm_medium=referral,neutral,0.9557663202285767
2005,7/27/2023 9:10:17 AM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Universal Health (UHS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-universal-health-uhs-and-structure-therapeutics-inc-sponsored-adr-gpcr-1032483469,positive,0.9151151776313782
2006,7/27/2023 11:39:51 AM,"AbbVie Non-GAAP EPS of $2.91 beats by $0.10, revenue of $13.87B beats by $350M",Seeking Alpha,https://seekingalpha.com/news/3992015-abbvie-non-gaap-eps-of-2_91-beats-0_10-revenue-of-13_87b-beats-350m?utm_source=businessinsider&utm_medium=referral,positive,0.7423163056373596
2007,7/27/2023 1:08:44 PM,Inside AbbVie: Signs of stabilization in Humira sales?,Seeking Alpha,https://seekingalpha.com/news/3992077-inside-abbvie-signs-stabilization-humira-sales?utm_source=businessinsider&utm_medium=referral,negative,0.6888917684555054
2008,7/27/2023 1:27:00 PM,"6 stocks to watch on Thursday: Netflix, Mastercard, AbbVie, McDonald's and more",Seeking Alpha,https://seekingalpha.com/news/3992133-6-stocks-to-watch-on-thursday-netflix-mastercard-abbvie-mcdonalds-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9269357323646545
2009,7/27/2023 1:51:31 PM,"AbbVie Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/abbvie-q2-profit-increases-beats-estimates-1032484211,negative,0.9299664497375488
2010,7/27/2023 2:17:01 PM,AbbVie Boosts FY23 Outlook As Q2 Results Top Estimates ,RTTNews,/news/stocks/abbvie-boosts-fy23-outlook-as-q2-results-top-estimates-1032484360,negative,0.9356784224510193
2011,7/28/2023 11:45:27 AM,BMO Capital Releases a Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/bmo-capital-releases-a-buy-rating-on-abbvie-abbv-1032489797,positive,0.9147798418998718
2012,7/28/2023 12:50:49 PM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Axonics Modulation Technologies (AXNX) and Dexcom (DXCM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-axonics-modulation-technologies-axnx-and-dexcom-dxcm-1032490029,positive,0.902630090713501
2013,7/28/2023 4:56:40 PM,3 Biotech Stocks to Buy Before Drug Trials End,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-before-drug-trials-end-1032491004,positive,0.9050287008285522
2014,8/1/2023 2:31:01 AM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), ImmunoGen (IMGN) and Axonics Modulation Technologies (AXNX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-immunogen-imgn-and-axonics-modulation-technologies-axnx-1032497521,positive,0.9028587937355042
2015,8/1/2023 2:45:00 PM,Allergan Aesthetics Announces First Ever JUVÉDERM® Day,PR Newswire,/news/stocks/allergan-aesthetics-announces-first-ever-juvéderm-day-1032500498,positive,0.8444162011146545
2016,8/2/2023 6:20:25 PM,"Amgen looks to Q2 top, bottom line beats after missing in Q1",Seeking Alpha,https://seekingalpha.com/news/3995374-amgen-looks-q2-top-bottom-line-beats-after-missing-q1?utm_source=businessinsider&utm_medium=referral,negative,0.9109312295913696
2017,8/3/2023 10:00:39 AM,Sell Alert: 3 Healthcare Stocks to Dump ASAP,InvestorPlace,/news/stocks/sell-alert-3-healthcare-stocks-to-dump-asap-1032511779,positive,0.7152862548828125
2018,8/3/2023 8:54:31 PM,Amgen guides 2023 EPS above consensus while revenue in-line,Seeking Alpha,https://seekingalpha.com/news/3997078-amgen-guides-2023-eps-above-consensus-revenue-in-line?utm_source=businessinsider&utm_medium=referral,negative,0.8801812529563904
2019,8/7/2023 9:16:17 AM,Barclays Sticks to Its Hold Rating for AbbVie (ABBV),TipRanks,/news/stocks/barclays-sticks-to-its-hold-rating-for-abbvie-abbv-1032523195,positive,0.8851715326309204
2020,8/8/2023 7:06:02 PM,3 AI Stocks You’ll Regret Not Buying Soon,InvestorPlace,/news/stocks/3-ai-stocks-youll-regret-not-buying-soon-1032530487,positive,0.9012989401817322
2021,8/10/2023 3:00:00 PM,Medicare Part D drug price increases far exceed inflation - AARP,Seeking Alpha,https://seekingalpha.com/news/4000101-medicare-part-d-drug-price-increases-far-exceed-inflation?utm_source=businessinsider&utm_medium=referral,negative,0.8962883353233337
2022,8/12/2023 12:52:29 AM,3 Pharma Stocks to Sell in August Before They Crash and Burn,InvestorPlace,/news/stocks/pharma-stocks-to-sell-in-august-1032548113,positive,0.8261821269989014
2023,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.5231574177742004
2024,8/14/2023 7:38:52 PM,7 Dividend Stocks to Buy as Investor Sentiment Falters,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-as-investor-sentiment-falters-1032552786,neutral,0.9288655519485474
2025,8/14/2023 8:25:03 PM,7 Blue-Chip Stocks Smart Investors Should Be Loading Up on Now,InvestorPlace,/news/stocks/7-blue-chip-stocks-smart-investors-should-be-loading-up-on-now-1032552948,positive,0.7331982851028442
2026,8/15/2023 1:53:55 PM,"Tudor Investment boosts stakes in Big Tech, exits VMware, BAH, HRL",Seeking Alpha,https://seekingalpha.com/news/4002924-tudor-investment-boosts-stakes-in-big-tech-exits-vmware-bah-hrl?utm_source=businessinsider&utm_medium=referral,negative,0.9253422617912292
2027,8/17/2023 8:00:00 AM,AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults,PR Newswire,/news/stocks/abbvie-announces-european-commission-approval-of-aquipta-atogepant-for-the-preventive-treatment-of-migraine-in-adults-1032561935,negative,0.87281733751297
2028,8/17/2023 8:39:07 AM,European Commission Approves AbbVie's AQUIPTA For Preventive Treatment Of Migraine In Adults ,RTTNews,/news/stocks/european-commission-approves-abbvie-s-aquipta-for-preventive-treatment-of-migraine-in-adults-1032562025,negative,0.7609356641769409
2029,8/17/2023 12:21:23 PM,AbbVie wins EU clearance for migraine therapy,Seeking Alpha,https://seekingalpha.com/news/4003910-abbvie-wins-eu-clearance-for-migraine-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8944849967956543
2030,8/18/2023 12:31:21 AM,Trillion-Dollar Trio: These 3 Super Growth Stocks Will Dominate the Market by 2035,InvestorPlace,/news/stocks/trillion-dollar-trio-these-3-super-growth-stocks-will-dominate-the-market-by-2035-1032564852,positive,0.7951418161392212
2031,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral,positive,0.8961257338523865
2032,8/21/2023 7:58:31 PM,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",Seeking Alpha,https://seekingalpha.com/news/4004913-lillys-market-cap-soared-in-q2-eclipsing-jnj-merck-novo-nordisk?utm_source=businessinsider&utm_medium=referral,negative,0.9460121989250183
2033,8/22/2023 1:03:45 AM,7 Top Dividend Stocks for Income and Stability,InvestorPlace,/news/stocks/7-top-dividend-stocks-for-income-and-stability-1032571243,positive,0.9376242160797119
2034,8/23/2023 7:16:03 PM,7 Very Oversold High-Yield Stocks to Buy Right Now,InvestorPlace,/news/stocks/7-very-oversold-high-yield-stocks-to-buy-right-now-1032577760,neutral,0.625315248966217
2035,8/23/2023 9:48:17 PM,"CVS Health launches biosimilars business, with Humira rival as first product",Seeking Alpha,https://seekingalpha.com/news/4005780-cvs-health-launches-biosimilars-business-with-humira-rival-as-first-product?utm_source=businessinsider&utm_medium=referral,positive,0.8403818011283875
2036,8/24/2023 7:35:18 AM,Barclays Keeps Their Hold Rating on AbbVie (ABBV),TipRanks,/news/stocks/barclays-keeps-their-hold-rating-on-abbvie-abbv-1032578663,positive,0.9251429438591003
2037,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral,positive,0.9293889403343201
2038,8/24/2023 4:22:27 PM,"Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories",Benzinga,/news/stocks/boeing-s-737-deliveries-delay-due-to-supplier-spirit-aerosystems-petco-health-and-wellness-stock-tumbles-astrazeneca-under-legal-lens-today-s-top-stories-1032580421,neutral,0.848749041557312
2039,8/24/2023 11:15:17 PM,FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri,Seeking Alpha,https://seekingalpha.com/news/4006231-fda-approves-sandoz-biosimilar-of-biogen-blockbuster-ms-drug-tysabri?utm_source=businessinsider&utm_medium=referral,negative,0.7177399396896362
2040,8/25/2023 10:51:17 AM,"PG, ABBV: 2 Dividend Aristocrat Stocks Hedge Funds are Bullish on",TipRanks,/news/stocks/pg-abbv-2-dividend-aristocrat-stocks-hedge-funds-are-bullish-on-1032582306,positive,0.8347331285476685
2041,8/26/2023 6:00:00 PM,Crohn's disease drugmakers set to benefit from expected rise in cases,Seeking Alpha,https://seekingalpha.com/news/4006563-crohns-disease-drugmakers-benefit-expected-rise-cases?utm_source=businessinsider&utm_medium=referral,negative,0.9470040202140808
2042,8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.8904427886009216
2043,8/28/2023 10:35:42 AM,Hedge and mutual funds rotate from tech; see the stocks they love and shun,Seeking Alpha,https://seekingalpha.com/news/4006637-hedge-and-mutual-funds-rotate-from-tech-see-the-stocks-they-love-and-shun?utm_source=businessinsider&utm_medium=referral,positive,0.6943780183792114
2044,8/28/2023 2:45:00 PM,AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis,PR Newswire,/news/stocks/abbvie-submits-regulatory-applications-to-fda-and-ema-for-risankizumab-skyrizi-in-ulcerative-colitis-1032585855,positive,0.5079320073127747
2045,8/28/2023 2:57:20 PM,"AbbVie seeks US, EU approval for Skyrizi for ulcerative colitis",Seeking Alpha,https://seekingalpha.com/news/4006752-abbvie-seeks-us-eu-approval-for-skyrizi-for-ulcerative-colitis?utm_source=businessinsider&utm_medium=referral,negative,0.8748877048492432
2046,8/28/2023 3:23:14 PM,AbbVie Submits Applications For New Indication  To FDA And EMA For Ulcerative Colitis ,RTTNews,/news/stocks/abbvie-submits-applications-for-new-indication-to-fda-and-ema-for-ulcerative-colitis-1032586047,positive,0.8209012150764465
2047,8/29/2023 1:48:17 AM,Late-Summer Steals: 7 Stocks to Buy Before Fall,InvestorPlace,/news/stocks/late-summer-steals-7-stocks-to-buy-before-fall-1032587334,positive,0.8955585360527039
2048,8/29/2023 10:10:57 AM,7 Stocks to Buy for the Rest of 2023,InvestorPlace,/news/stocks/7-stocks-to-buy-for-the-rest-of-2023-1032588372,positive,0.9267191290855408
2049,8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral,positive,0.9310519099235535
2050,8/29/2023 5:50:14 PM,Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity,InvestorPlace,/news/stocks/now-or-never-7-blue-chip-stocks-offering-a-once-in-a-lifetime-opportunity-1032590333,positive,0.607672929763794
2051,8/29/2023 7:29:57 PM,Republicans say Medicare drug negotiations will mean fewer new meds,Seeking Alpha,https://seekingalpha.com/news/4007245-republicans-say-medicare-drug-negotiations-fewer-new-meds?utm_source=businessinsider&utm_medium=referral,neutral,0.8554677963256836
2052,8/30/2023 12:58:15 AM,SPLG: The Market’s Lowest-Cost S&P 500 ETF,TipRanks,/news/stocks/splg-the-market-s-lowest-cost-s-p-500-etf-1032590792,positive,0.7738195657730103
2053,8/30/2023 3:00:00 PM,Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic),PR Newswire,/news/stocks/journal-of-cosmetic-dermatology-publishes-data-demonstrating-patient-satisfaction-with-natural-looking-outcomes-following-treatment-with-onabotulinumtoxina-botox-cosmetic-1032592793,negative,0.7265385985374451
2054,8/31/2023 9:42:17 AM,The 3 Most Promising Biotech Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-biotech-stocks-to-own-now-1032595542,positive,0.7112976908683777
2055,9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral,positive,0.7872201800346375
2056,9/5/2023 10:35:53 PM,"3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains",InvestorPlace,/news/stocks/3-biotech-stocks-to-invest-in-for-big-time-long-term-gains-1032606984,positive,0.7922794222831726
2057,9/6/2023 2:00:00 PM,AbbVie to Present at the Morgan Stanley Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-1032608702,positive,0.9129487872123718
2058,9/6/2023 2:21:15 PM,AbbVie immunology chief to lead Novartis commercial operations,Seeking Alpha,https://seekingalpha.com/news/4009511-abbvie-immunology-chief-lead-novartis-commercial-unit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9268179535865784
2059,9/6/2023 2:45:00 PM,Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs,PR Newswire,/news/stocks/join-botox-cosmetic-onabotulinumtoxina-and-ifundwomen-in-supporting-women-entrepreneurs-1032608993,positive,0.7998783588409424
2060,9/7/2023 6:12:54 PM,Alector completes enrollments in mid-stage Alzheimer’s trial,Seeking Alpha,https://seekingalpha.com/news/4010029-alector-stock-gains-after-update-alzheimers-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.774645984172821
2061,9/8/2023 3:28:03 PM,AbbVie declares $1.48 dividend,Seeking Alpha,https://seekingalpha.com/news/4010299-abbvie-inc-declares-1_48-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9382003545761108
2062,9/8/2023 5:23:00 PM,AbbVie Declares Quarterly Dividend,PR Newswire,/news/stocks/abbvie-declares-quarterly-dividend-1032616724,neutral,0.5513123869895935
2063,9/12/2023 2:22:07 PM,AbbVie's Skyrizi outperforms JNJ’s Stelara in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4010983-abbvie-skyrizi-bested-jnj-stelara-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9411659240722656
2064,9/12/2023 2:30:00 PM,AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease,PR Newswire,/news/stocks/abbvie-s-skyrizi-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-ustekinumab-in-head-to-head-study-in-crohn-s-disease-1032623138,negative,0.9420202970504761
2065,9/12/2023 2:52:01 PM,AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab ,RTTNews,/news/stocks/abbvie-reports-top-line-results-from-phase-3-sequence-clinical-trial-of-risankizumab-1032623238,positive,0.6315507292747498
2066,9/13/2023 1:55:07 AM,AbbVie (ABBV) Gets a Hold from Goldman Sachs,TipRanks,/news/stocks/abbvie-abbv-gets-a-hold-from-goldman-sachs-1032625114,positive,0.913693368434906
2067,9/13/2023 5:00:00 PM,"AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship ""Thriving Students""",PR Newswire,/news/stocks/abbvie-calls-on-public-to-vote-for-the-2023-abbvie-cystic-fibrosis-scholarship-thriving-students-1032627774,positive,0.6038012504577637
2068,9/13/2023 9:22:37 PM,Harpoon up even as AbbVie declines license option for cancer asset,Seeking Alpha,https://seekingalpha.com/news/4011601-harpoon-up-abbvie-declines-license-option-cancer-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7525016069412231
2069,9/15/2023 9:26:39 PM,"VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks",TipRanks,/news/stocks/vti-etf-this-diversified-powerhouse-owns-over-3-800-stocks-1032634771,positive,0.9168491959571838
2070,9/18/2023 3:00:00 PM,Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence,PR Newswire,/news/stocks/allergan-aesthetics-announces-positive-topline-results-from-second-phase-3-study-of-onabotulinumtoxina-botox-cosmetic-for-the-treatment-of-platysma-prominence-1032636948,negative,0.8917810320854187
2071,9/18/2023 3:36:17 PM,Allergan Aesthetics: Second Phase 3 Study With OnabotulinumtoxinA Meets Endpoints ,RTTNews,/news/stocks/allergan-aesthetics-second-phase-3-study-with-onabotulinumtoxina-meets-endpoints-1032637138,positive,0.7413567900657654
2072,9/19/2023 10:50:15 AM,The Top 7 Underrated Dividend Stocks Yielding 3% or More,InvestorPlace,/news/stocks/the-top-7-underrated-dividend-stocks-yielding-3-or-more-1032639458,positive,0.6728805303573608
2073,9/19/2023 3:36:33 PM,7 Safe and Steady Dividend Stocks to Buy for Volatile Time,InvestorPlace,/news/stocks/7-safe-and-steady-dividend-stocks-to-buy-for-volatile-time-1032641007,positive,0.7342789173126221
2074,9/25/2023 10:55:20 AM,Piper Sandler Sticks to Their Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-abbvie-abbv-1032652503,positive,0.864020049571991
2075,9/25/2023 1:45:00 PM,AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma,PR Newswire,/news/stocks/abbvie-announces-european-commission-approval-of-tepkinly-epcoritamab-for-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-1032652631,negative,0.8397577404975891
2076,9/25/2023 2:50:51 PM,"AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R Diffuse Large B-cell Lymphoma ",RTTNews,/news/stocks/abbvie-genmab-eu-approves-tepkinly-for-adults-with-r-r-diffuse-large-b-cell-lymphoma-1032652853,negative,0.8401162028312683
2077,9/26/2023 5:00:53 PM,Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher,InvestorPlace,/news/stocks/dont-miss-the-boom-3-biotech-stocks-set-to-explode-higher-1032657128,positive,0.913301944732666
2078,9/29/2023 1:15:00 PM,AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma,PR Newswire,/news/stocks/abbvie-presents-results-from-phase-3-canova-study-of-venetoclax-in-patients-with-relapsed-or-refractory-multiple-myeloma-1032666069,positive,0.6923313736915588
2079,9/29/2023 1:35:38 PM,AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/abbvie-says-phase-3-canova-trial-fails-to-meet-primary-endpoint-1032666137,neutral,0.9541829824447632
2080,9/29/2023 3:00:16 PM,What 4 Analyst Ratings Have To Say About AbbVie,Benzinga,/news/stocks/what-4-analyst-ratings-have-to-say-about-abbvie-1032666420,positive,0.936601459980011
2081,9/29/2023 5:00:35 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-29-2023-1032667068,positive,0.5253908038139343
2082,9/29/2023 7:37:04 PM,AbbVie's Promising Leap Towards Long-Term Growth: Analyst,Benzinga,/news/stocks/abbvie-s-promising-leap-towards-long-term-growth-analyst-1032667413,negative,0.9292086958885193
2083,9/30/2023 7:00:05 PM,Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs,InvestorPlace,/news/stocks/moonshot-medicine-3-stocks-to-buy-to-bet-on-long-shot-drugs-1032668021,positive,0.9284905791282654
2084,10/3/2023 1:00:00 PM,Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field,PR Newswire,/news/stocks/allergan-aesthetics-and-girls-inc-partner-to-speed-the-entry-of-young-women-into-positions-of-leadership-in-the-stem-field-1032673920,negative,0.6613060235977173
2085,10/4/2023 2:00:00 PM,AbbVie to Host Third-Quarter 2023 Earnings Conference Call,PR Newswire,/news/stocks/abbvie-to-host-third-quarter-2023-earnings-conference-call-1032677575,positive,0.9140580892562866
2086,10/4/2023 5:07:00 PM,"Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy",PR Newswire,/news/stocks/nature-publishes-discovery-and-preclinical-results-for-abbv-cls-484-a-potential-first-in-class-ptpn2-n1-inhibitor-in-cancer-immunotherapy-1032678701,positive,0.546167254447937
2087,10/5/2023 12:08:41 AM,7 Top Healthcare Stocks That Pay Dividends,InvestorPlace,/news/stocks/7-top-healthcare-stocks-that-pay-dividends-1032679547,positive,0.934146523475647
2088,10/5/2023 2:05:00 PM,"AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline",PR Newswire,/news/stocks/abbvie-exercises-exclusive-right-to-acquire-mitokinin-further-strengthening-neuroscience-pipeline-1032681171,negative,0.8875832557678223
2089,10/5/2023 3:06:48 PM,"AbbVie Exercises Exclusive Right, Completes Acquisition Of Mitokinin ",RTTNews,/news/stocks/abbvie-exercises-exclusive-right-completes-acquisition-of-mitokinin-1032681514,positive,0.8652099967002869
2090,10/5/2023 3:26:32 PM,Retirement Royalty: 3 Dividend Aristocrats for a Steady Income Stream,InvestorPlace,/news/stocks/retirement-royalty-3-dividend-aristocrats-for-a-steady-income-stream-1032682263,positive,0.8797441124916077
2091,10/7/2023 12:34:45 AM,"COWZ, SYLD: Two Unique ETFs with Scorching Returns ",TipRanks,/news/stocks/cowz-syld-two-unique-etfs-with-scorching-returns -1032685692,positive,0.8401743173599243
2092,10/9/2023 11:14:48 PM,GCOW: An ETF for Dividend and Free Cash Flow Lovers,TipRanks,/news/stocks/gcow-an-etf-for-dividend-and-free-cash-flow-lovers-1032690138,positive,0.9465109705924988
2093,10/10/2023 2:06:53 PM,3 Dividend Kings Every Investor Should Own to Survive a Market Crash,InvestorPlace,/news/stocks/3-dividend-kings-every-investor-should-own-to-survive-a-market-crash-1032693057,positive,0.8802585601806641
2094,10/10/2023 2:45:00 PM,AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023,PR Newswire,/news/stocks/abbvie-showcases-breadth-and-depth-of-research-in-crohn-s-disease-and-ulcerative-colitis-at-ueg-week-2023-1032692253,positive,0.7652442455291748
2095,10/11/2023 9:26:32 AM,The 3 Best Defensive Stocks for Nervous Investors,InvestorPlace,/news/stocks/the-3-best-defensive-stocks-for-nervous-investors-1032695676,positive,0.8510884046554565
2096,10/11/2023 2:30:00 PM,AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis,PR Newswire,/news/stocks/abbvie-presents-long-term-data-further-supporting-the-efficacy-and-safety-profile-of-rinvoq-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-1032696380,negative,0.9413845539093018
2097,10/11/2023 3:16:11 PM,AbbVie: Three Ongoing Phase 3 Studies Show Long-term Efficacy Of RINVOQ ,RTTNews,/news/stocks/abbvie-three-ongoing-phase-3-studies-show-long-term-efficacy-of-rinvoq-1032696708,negative,0.8238208889961243
2098,10/12/2023 11:25:00 AM,AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3,PR Newswire,/news/stocks/abbvie-announces-upadacitinib-rinvoq-met-the-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-as-program-advances-to-phase-3-1032699640,negative,0.9193518757820129
2099,10/12/2023 12:11:28 PM,AbbVie: Upadacitinib Phase 2b Study In Non-segmental Vitiligo Meets Primary Goal ,RTTNews,/news/stocks/abbvie-upadacitinib-phase-2b-study-in-non-segmental-vitiligo-meets-primary-goal-1032699767,positive,0.8369395136833191
2100,10/13/2023 10:30:10 AM,"ABBV Stock: Buy for the Yield, Hold for This Other Reason",InvestorPlace,/news/stocks/abbv-stock-buy-for-the-yield-hold-for-this-other-reason-1032703357,positive,0.9456968307495117
2101,10/13/2023 8:57:39 PM,7 Dividend Kings to Buy for Royal Returns,InvestorPlace,/news/stocks/7-dividend-kings-to-buy-for-royal-returns-1032705105,positive,0.9072266817092896
2102,10/15/2023 5:15:00 PM,AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints,PR Newswire,/news/stocks/abbvie-s-skyrizi-risankizumab-versus-stelara-ustekinumab-head-to-head-study-in-crohn-s-disease-meets-all-primary-and-secondary-endpoints-1032705929,negative,0.595561683177948
2103,10/16/2023 3:51:35 AM,AbbVie : Phase 3 Study Of Skyrizi In Crohn's Disease Meets All Primary And Secondary Endpoints ,RTTNews,/news/stocks/abbvie-phase-3-study-of-skyrizi-in-crohn-s-disease-meets-all-primary-and-secondary-endpoints-1032706082,positive,0.8480409979820251
2104,10/17/2023 4:45:35 AM,Hold Rating for AbbVie: Balancing Short-Term Adjustments with Long-Term Stability,TipRanks,/news/stocks/hold-rating-for-abbvie-balancing-short-term-adjustments-with-long-term-stability-1032710806,positive,0.8113513588905334
2105,10/17/2023 1:36:51 PM,"AbbVie's DLBCL Drug EPKINLY, Crohn's Disease Drug RINVOQ Get Health Canada Approval ",RTTNews,/news/stocks/abbvie-s-dlbcl-drug-epkinly-crohn-s-disease-drug-rinvoq-get-health-canada-approval-1032712040,positive,0.9054368734359741
2106,10/18/2023 4:40:25 AM,Takeda Settles Tax Dispute With Irish Revenue Commissioners Over Break Fee Received By Shire ,RTTNews,/news/stocks/takeda-settles-tax-dispute-with-irish-revenue-commissioners-over-break-fee-received-by-shire-1032714369,neutral,0.8451288938522339
2107,10/19/2023 1:15:31 PM,7 Dividend Aristocrats to Batten Down the Hatches,InvestorPlace,/news/stocks/7-dividend-aristocrats-to-batten-down-the-hatches-1032721015,positive,0.7613499164581299
2108,10/19/2023 2:45:00 PM,Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project,PR Newswire,/news/stocks/allergan-aesthetics-supports-breast-cancer-patients-and-celebrates-breast-reconstruction-patients-through-the-reblossom-project-1032720764,positive,0.8429945111274719
2109,10/20/2023 10:45:17 AM,7 Dividend Stocks to Buy and Hold Forever and Ever,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-and-hold-forever-and-ever-1032723968,positive,0.9360319375991821
2110,10/20/2023 10:08:03 PM,"Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets",Benzinga,/news/etf/investor-risk-sentiment-wavers-amid-war-interest-rate-concerns-tesla-earnings-disappoint-the-week-in-the-markets-1032725210,neutral,0.9567456245422363
2111,10/24/2023 2:30:00 PM,Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines,PR Newswire,/news/stocks/allergan-aesthetics-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-trenibotulinumtoxine-bont-e-for-the-treatment-of-glabellar-lines-1032733149,negative,0.9328603744506836
2112,10/24/2023 2:42:19 PM,Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines ,RTTNews,/news/stocks/allergan-announces-positive-results-from-phase-3-studies-of-trenibotulinumtoxine-in-glabella-lines-1032733222,negative,0.9211551547050476
2113,10/25/2023 1:43:12 AM,VTV: A Must-Watch ETF for Value Investors,TipRanks,/news/stocks/vtv-a-must-watch-etf-for-value-investors-1032739060,positive,0.8936381340026855
2114,10/25/2023 10:15:00 AM,The 7 Best Forever Stocks to Buy for October 2023,InvestorPlace,/news/stocks/the-7-best-forever-stocks-to-buy-for-october-2023-1032737998,positive,0.9330435395240784
2115,10/26/2023 3:01:13 PM,Here's what to expect from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-stock-q3-earnings-preview-1032743883,positive,0.9334648251533508
2116,10/27/2023 3:17:42 AM,Invest in Dividend Aristocrat Stocks with the NOBL ETF,TipRanks,/news/stocks/invest-in-dividend-aristocrat-stocks-with-the-nobl-etf-1032749311,positive,0.9314687252044678
2117,10/27/2023 11:10:55 AM,"Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Boston Scientific (BSX) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-arcellx-inc-aclx-boston-scientific-bsx-and-abbvie-abbv-1032750102,positive,0.9258025288581848
2118,10/27/2023 1:45:46 PM,"AbbVie Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/abbvie-q3-profit-decreases-but-beats-estimates-1032748454,neutral,0.9708675146102905
2119,10/27/2023 2:10:21 PM,AbbVie Raises 2023 Adj. EPS Guidance; Announces 2024 Dividend Increase ,RTTNews,/news/stocks/abbvie-raises-2023-adj-eps-guidance-announces-2024-dividend-increase-1032748527,negative,0.5322394967079163
2120,10/30/2023 8:06:05 AM,AbbVie’s Undervaluation and Expected Growth: A Comprehensive Review of Buy Rating Despite Market Challenges,TipRanks,/news/stocks/abbvie-s-undervaluation-and-expected-growth-a-comprehensive-review-of-buy-rating-despite-market-challenges-1032755681,positive,0.8179334998130798
2121,10/30/2023 9:46:03 AM,Robust Growth Potential and Strong Fundamentals: A Comprehensive Analysis Supporting a Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/robust-growth-potential-and-strong-fundamentals-a-comprehensive-analysis-supporting-a-buy-rating-for-abbvie-abbv-1032755870,positive,0.5649163722991943
2122,10/30/2023 12:49:38 PM,AbbVie To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Monday,Benzinga,/news/stocks/abbvie-to-rally-over-22-here-are-10-top-analyst-forecasts-for-monday-1032753768,positive,0.9043023586273193
2123,10/30/2023 7:55:04 PM,AbbVie Analysts Increase Their Forecasts After Upbeat Earnings,Benzinga,/news/stocks/abbvie-analysts-increase-their-forecasts-after-upbeat-earnings-1032755524,negative,0.8701751232147217
2124,10/31/2023 4:15:31 AM,Morgan Stanley Sticks to Their Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-buy-rating-for-abbvie-abbv-1032760475,positive,0.8486794233322144
2125,10/31/2023 6:20:50 AM,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), AbbVie (ABBV) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-dexcom-dxcm-abbvie-abbv-and-merck-company-mrk-1032760927,positive,0.9172101020812988
2126,11/1/2023 2:30:26 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), AbbVie (ABBV) and Crispr Therapeutics AG (CRSP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-abbvie-abbv-and-crispr-therapeutics-ag-crsp-1032765965,positive,0.9087266325950623
2127,11/1/2023 1:45:00 PM,BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before,PR Newswire,/news/stocks/botox-cosmetic-onabotulinumtoxina-day-is-back-like-never-before-1032764954,positive,0.7249944806098938
2128,11/1/2023 2:34:30 PM,Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?,InvestorPlace,/news/stocks/why-is-aldeyra-therapeutics-aldx-stock-up-40-today-1032765949,negative,0.9034534692764282
2129,11/2/2023 1:31:00 PM,Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS),PR Newswire,/news/stocks/roundhill-investments-launches-dividend-monarchs-etf-nyse-arca-kngs-1032770164,positive,0.8635550141334534
2130,11/2/2023 3:17:56 PM,3 Dividend Stocks That Are Investor Safe Havens,InvestorPlace,/news/stocks/3-dividend-stocks-that-are-investor-safe-havens-1032771288,positive,0.9251014590263367
2131,11/2/2023 7:25:38 PM,"EXCLUSIVE: Roundhill Launches Dividend Kings ETF With 'The Gold Standard Of Dividend Growers,' Companies With 'Incredible Resilience'",Benzinga,/news/etf/exclusive-roundhill-launches-dividend-kings-etf-with-the-gold-standard-of-dividend-growers-companies-with-incredible-resilience-1032771912,negative,0.8681634068489075
2132,11/3/2023 2:30:04 AM,Meet the Next Trillion-Dollar Companies: Our Top 3 Picks,InvestorPlace,/news/stocks/meet-the-next-trillion-dollar-companies-our-top-3-picks-1032772564,positive,0.88338303565979
2133,11/8/2023 1:41:22 AM,3 Dividend Stocks That Are Perfect for Beginning Investors,InvestorPlace,/news/stocks/3-dividend-stocks-that-are-perfect-for-beginning-investors-1032790210,positive,0.8791639804840088
2134,11/8/2023 2:45:00 PM,"Natrelle® Unveils New ""For Every BODY"" Campaign",PR Newswire,/news/stocks/natrelle-unveils-new-for-every-body-campaign-1032794331,positive,0.811428427696228
2135,11/9/2023 1:36:10 PM,Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/check-out-3-health-care-stocks-with-over-4-dividend-yields-from-wall-street-s-most-accurate-analysts-1032800327,positive,0.7893310785293579
2136,11/14/2023 5:41:31 PM,7 Dividend Stocks Every Investor Should Own to Survive a Market Crash,InvestorPlace,/news/stocks/7-dividend-stocks-every-investor-should-own-to-survive-a-market-crash-1032819053,positive,0.9202568531036377
2137,11/16/2023 1:00:00 PM,Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine,PR Newswire,/news/stocks/results-published-in-the-lancet-show-ubrelvy-ubrogepant-reduces-the-headache-phase-of-a-migraine-attack-when-dosed-during-the-prodrome-of-migraine-1032827134,negative,0.81831955909729
2138,11/16/2023 1:55:23 PM,AbbVie Says Ubrelvy Reduced Development Of Headache If Given At Prodrome Phase Of Migraine Attack ,RTTNews,/news/stocks/abbvie-says-ubrelvy-reduced-development-of-headache-if-given-at-prodrome-phase-of-migraine-attack-1032827351,negative,0.47039443254470825
2139,11/17/2023 8:23:34 PM,7 High-Yield Blue Chips Suitable for Any Retiree,InvestorPlace,/news/stocks/7-high-yield-blue-chip-stocks-suitable-for-any-reitree-1032832622,positive,0.8566922545433044
2140,11/20/2023 2:45:00 PM,Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever,PR Newswire,/news/stocks/fifth-annual-botox-cosmetic-onabotulinumtoxina-day-makes-history-as-the-biggest-day-ever-1032835496,positive,0.5227836966514587
2141,11/21/2023 12:54:21 AM,Dual Powerhouses: 7 Dividend Stocks Marrying High Yield With High Growth,InvestorPlace,/news/stocks/dual-powerhouses-7-dividend-stocks-marrying-high-yield-with-high-growth-1032837225,positive,0.5962643623352051
2142,11/21/2023 10:31:10 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bristol-myers-squibb-bmy-and-abbvie-abbv-1032840916,neutral,0.7395572066307068
2143,11/26/2023 7:00:00 PM,3 Rising Stars: Invest Now in Tomorrow’s Trillion-Dollar Companies,InvestorPlace,/news/stocks/3-rising-stars-invest-now-in-tomorrows-trillion-dollar-companies-1032849581,positive,0.8211691379547119
2144,11/27/2023 1:00:00 PM,AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma,PR Newswire,/news/stocks/abbvie-announces-u-s-food-and-drug-administration-fda-and-european-medicines-agency-ema-updates-for-epcoritamab-epkinly-tepkinly-for-the-treatment-of-relapsed-refractory-follicular-lymphoma-1032850871,negative,0.7786344289779663
2145,11/27/2023 1:27:18 PM,"AbbVie, Genmab Issue Positive FDA, EMA Updates For Epcoritamab To Treat R/R Follicular Lymphoma ",RTTNews,/news/stocks/abbvie-genmab-issue-positive-fda-ema-updates-for-epcoritamab-to-treat-r-r-follicular-lymphoma-1032850964,negative,0.9323483109474182
2146,11/29/2023 2:45:00 PM,AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC),PR Newswire,/news/stocks/abbvie-announces-positive-topline-results-from-phase-2-luminosity-trial-evaluating-telisotuzumab-vedotin-teliso-v-for-patients-with-previously-treated-non-small-cell-lung-cancer-nsclc-1032858474,negative,0.940502405166626
2147,11/29/2023 3:24:48 PM,AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin ,RTTNews,/news/stocks/abbvie-announces-topline-results-from-phase-2-luminosity-trial-of-telisotuzumab-vedotin-1032858744,positive,0.5937432050704956
2148,11/29/2023 8:35:28 PM,Buy Rating Affirmed for AbbVie on Teliso-V’s Promising Clinical Trials and Market Potential,TipRanks,/news/stocks/buy-rating-affirmed-for-abbvie-on-teliso-v-s-promising-clinical-trials-and-market-potential-1032861313,negative,0.9494421482086182
2149,11/29/2023 11:47:47 PM,Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy,InvestorPlace,/news/stocks/mastering-market-trends-the-7-best-blue-chip-stocks-for-todays-economy-1032860410,positive,0.8389677405357361
2150,11/30/2023 1:30:00 PM,"AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio",PR Newswire,/news/stocks/abbvie-to-acquire-immunogen-including-its-flagship-cancer-therapy-elahere-mirvetuximab-soravtansine-gynx-expanding-solid-tumor-portfolio-1032862115,negative,0.8073285818099976
2151,11/30/2023 1:49:13 PM,AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln ,RTTNews,/news/stocks/abbvie-to-acquire-immunogen-for-31-26-shre-in-all-cash-deal-of-about-10-1-bln-1032862192,positive,0.854209303855896
2152,11/30/2023 3:38:13 PM,Why Is ImmunoGen (IMGN) Stock Up 81% Today?,InvestorPlace,/news/stocks/why-is-immunogen-imgn-stock-up-81-today-1032863348,negative,0.7479369640350342
2153,12/1/2023 2:46:44 AM,Assessing AbbVie’s Strategic Acquisition of ImmunoGen: A Balancing Act of Growth Prospects and Financial Prudence,TipRanks,/news/stocks/assessing-abbvie-s-strategic-acquisition-of-immunogen-a-balancing-act-of-growth-prospects-and-financial-prudence-1032866553,positive,0.8359103798866272
2154,12/1/2023 2:51:55 AM,AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker,TipRanks,/news/stocks/abbvie-stock-nyse-abbv-bet-on-a-smart-drugmaker-and-dealmaker-1032866548,positive,0.788798451423645
2155,12/1/2023 8:00:47 PM,Analyst Ratings for AbbVie,Benzinga,/news/stocks/analyst-ratings-for-abbvie-1032867433,positive,0.9059829115867615
2156,12/4/2023 8:25:24 AM,AbbVie (ABBV) Gets a Buy from Raymond James,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-raymond-james-1032871863,positive,0.6537081003189087
2157,12/4/2023 4:44:53 PM,"ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note",Benzinga,/news/stocks/immunogen-abbvie-s-10b-deal-comes-at-right-time-analyst-says-in-downgrade-note-1032871243,positive,0.7281926274299622
2158,12/5/2023 9:51:55 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), AbbVie (ABBV) and Taysha Gene Therapies (TSHA)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-abbvie-abbv-and-taysha-gene-therapies-tsha-1032876061,neutral,0.5786846280097961
2159,12/5/2023 2:45:00 PM,AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies,PR Newswire,/news/stocks/abbvie-and-bighat-biosciences-announce-research-collaboration-to-leverage-artificial-intelligence-and-machine-learning-to-discover-next-generation-therapeutic-antibodies-1032874210,negative,0.7854987978935242
2160,12/5/2023 4:06:14 PM,AbbVie To Collaborate With BigHat To Discover Next-Gen Therapeutic Antibodies ,RTTNews,/news/stocks/abbvie-to-collaborate-with-bighat-to-discover-next-gen-therapeutic-antibodies-1032875079,negative,0.7084265947341919
2161,12/6/2023 8:26:31 PM,"Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch",InvestorPlace,/news/stocks/small-cap-big-potential-3-russell-2000-stocks-to-watch-1032879670,positive,0.889644205570221
2162,12/6/2023 9:21:48 PM,7 High-Dividend Stocks to Buy for a Lifetime of Passive Income,InvestorPlace,/news/stocks/7-high-dividend-stocks-to-buy-for-a-lifetime-of-passive-income-1032879815,positive,0.9036790728569031
2163,12/6/2023 10:30:00 PM,AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline,PR Newswire,/news/stocks/abbvie-to-acquire-cerevel-therapeutics-in-transformative-transaction-to-strengthen-neuroscience-pipeline-1032879767,negative,0.8719530701637268
2164,12/7/2023 3:15:12 AM,AbbVie To Acquire Cerevel Therapeutics In $8.7 Bln Deal ,RTTNews,/news/stocks/abbvie-to-acquire-cerevel-therapeutics-in-8-7-bln-deal-1032880144,positive,0.8968188762664795
2165,12/7/2023 10:16:16 AM,Maintaining Hold on AbbVie: Weighing Long-Term Neurological Franchise Prospects Against Near-Term Acquisition Risks,TipRanks,/news/stocks/maintaining-hold-on-abbvie-weighing-long-term-neurological-franchise-prospects-against-near-term-acquisition-risks-1032883695,positive,0.7589777112007141
2166,12/7/2023 10:40:20 AM,Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-insulet-podd-and-abbvie-abbv-1032883720,positive,0.9110694527626038
2167,12/7/2023 11:30:21 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Veeva Systems (VEEV) and Rhythm Pharmaceuticals (RYTM)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-veeva-systems-veev-and-rhythm-pharmaceuticals-rytm-1032883799,neutral,0.9385064244270325
2168,12/7/2023 1:59:25 PM,Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket,Benzinga,/news/stocks/why-cerevel-therapeutics-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket-1032881706,positive,0.7768687009811401
2169,12/7/2023 2:45:28 PM,Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?,InvestorPlace,/news/stocks/why-is-cerevel-therapeutics-cere-stock-up-12-today-1032882285,negative,0.8760175108909607
2170,12/7/2023 4:17:43 PM,"Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday",Benzinga,/news/stocks/verint-reports-strong-earnings-joins-semtech-alphabet-and-other-big-stocks-moving-higher-on-thursday-1032882706,negative,0.9508242607116699
2171,12/7/2023 7:13:57 PM,Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session,Benzinga,/news/stocks/why-methode-electronics-shares-are-trading-lower-by-over-14-here-are-other-stocks-moving-in-thursday-s-mid-day-session-1032883232,neutral,0.8686731457710266
2172,12/7/2023 9:19:20 PM,"AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals",Benzinga,/news/stocks/abbvie-s-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals-1032883454,positive,0.6505576372146606
2173,12/7/2023 11:00:08 PM,Healthcare Gems: 3 Essential Long-Term Stock Picks,InvestorPlace,/news/stocks/healthcare-gems-3-essential-long-term-stock-picks-1032883779,positive,0.9290483593940735
2174,12/9/2023 6:00:00 PM,"New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)",PR Newswire,/news/stocks/new-data-for-bispecific-antibody-epcoritamab-duobody-cd3xcd20-shows-strong-durable-treatment-response-for-patients-with-difficult-to-treat-relapsed-refractory-r-r-follicular-lymphoma-fl-1032887365,negative,0.9496946334838867
2175,12/10/2023 7:00:00 PM,The 3 Best Cheap Stocks to Buy in December,InvestorPlace,/news/stocks/the-3-best-cheap-stocks-to-buy-in-december-1032887807,positive,0.8340635299682617
2176,12/12/2023 3:00:06 PM,Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune,Benzinga,/news/stocks/bristol-myers-squibb-further-diversifies-oncology-portfolio-with-mega-8-4b-deal-1032893319,negative,0.6502244472503662
2177,12/12/2023 8:04:27 PM,Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings,Benzinga,/news/stocks/botox-and-similar-injections-have-associated-risks-consumer-group-pushes-for-stronger-warnings-1032894691,positive,0.5045972466468811
2178,12/13/2023 7:13:00 AM,"ABBV, NVO, or LLY: Which Healthcare Stock Could Generate the Highest Returns?",TipRanks,/news/stocks/abbv-nvo-or-lly-which-healthcare-stock-could-generate-the-highest-returns-1032898484,positive,0.9054728150367737
2179,12/13/2023 10:31:56 AM,Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now,TipRanks,/news/stocks/goldman-sachs-says-these-3-healthcare-giants-look-very-attractive-right-now-1032898893,negative,0.7411935925483704
2180,12/13/2023 1:44:56 PM,Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability,InvestorPlace,/news/stocks/economic-safety-nets-7-defensive-stocks-providing-portfolio-stability-1032897100,positive,0.8506568670272827
2181,12/13/2023 9:42:25 PM,The 7 Most Undervalued Growth Stocks to Buy in December,InvestorPlace,/news/stocks/the-7-most-undervalued-growth-stocks-to-buy-in-december-1032898795,negative,0.3542206585407257
2182,12/17/2023 7:00:00 PM,3 of the Most Attractive Dividend Stocks in the Pharma Space,InvestorPlace,/news/stocks/3-of-the-most-attractive-dividend-stocks-in-the-pharma-space-1032907116,negative,0.585765540599823
2183,12/18/2023 2:00:38 PM,8 Analysts Have This to Say About AbbVie,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-abbvie-1032908761,positive,0.9225807785987854
2184,12/19/2023 11:54:24 PM,7 ‘Bulletproof’ Stocks to Buy Ahead of a Wild New Year,InvestorPlace,/news/stocks/7-bulletproof-stocks-to-buy-ahead-of-a-wild-new-year-1032914300,positive,0.6590073108673096
2185,12/20/2023 12:08:39 AM,7 Blue-Chip Dividend Stocks to Buy Before Dec. 31,InvestorPlace,/news/stocks/7-blue-chip-dividend-stocks-to-buy-before-dec-31-1032914318,positive,0.9292315244674683
2186,1/1/2024 10:21:14 PM,The 3 Hottest Dividend Stocks to Watch in 2024,InvestorPlace,/news/stocks/the-3-hottest-dividend-stocks-to-watch-in-2024-1032935463,positive,0.8980352282524109
2187,1/2/2024 2:00:00 PM,AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/abbvie-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-1032936566,positive,0.8657839894294739
2188,1/2/2024 6:34:26 PM,3 Biotech Stocks Set for Breakthroughs in 2024,InvestorPlace,/news/stocks/3-biotech-stocks-set-for-breakthroughs-in-2024-1032937787,positive,0.5988837480545044
2189,1/2/2024 11:10:16 PM,"Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), AbbVie (ABBV) and CymaBay Therapeutics (CBAY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-irhythm-technologies-irtc-abbvie-abbv-and-cymabay-therapeutics-cbay-1032939517,positive,0.9172142744064331
2190,1/3/2024 5:56:49 PM,The 3 Best Dividend Stocks to Buy Now ,InvestorPlace,/news/stocks/best-dividend-stocks-1031565873,positive,0.8693252801895142
2191,1/3/2024 7:14:30 PM,"AbbVie Stock (NASDAQ:ABBV): Goodbye Wrinkles, Hello Profits",TipRanks,/news/stocks/abbvie-stock-nasdaq-abbv-goodbye-wrinkles-hello-profits-1032942113,positive,0.8102567791938782
2192,1/4/2024 2:06:47 AM,"J.P. Morgan Analyst Recommends Buy on AbbVie Stock, Minimizing CVS Biosimilar Switch Impact",TipRanks,/news/stocks/j-p-morgan-analyst-recommends-buy-on-abbvie-stock-minimizing-cvs-biosimilar-switch-impact-1032943273,negative,0.6376591920852661
2193,1/4/2024 2:15:37 AM,Buy Rating Affirmed: AbbVie’s Strategic Resilience Amidst Biosimilar Shifts,TipRanks,/news/stocks/buy-rating-affirmed-abbvie-s-strategic-resilience-amidst-biosimilar-shifts-1032943316,negative,0.8768044114112854
2194,1/4/2024 11:40:07 AM,Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-atricure-atrc-and-abbvie-abbv-1032944604,positive,0.9084969162940979
2195,1/4/2024 12:46:22 PM,Maintaining Buy: AbbVie’s Resilience in EPS and Strategic Growth Amidst Biosimilar Competition,TipRanks,/news/stocks/maintaining-buy-abbvie-s-resilience-in-eps-and-strategic-growth-amidst-biosimilar-competition-1032944690,negative,0.8725166320800781
2196,1/4/2024 3:45:12 PM,AbbVie Collaborates With Umoja Biopharma To Develop Novel In-Situ CAR-T Cell Therapies ,RTTNews,/news/stocks/abbvie-collaborates-with-umoja-biopharma-to-develop-novel-in-situ-car-t-cell-therapies-1032943368,negative,0.6612955927848816
2197,1/8/2024 2:53:12 PM,Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things',Benzinga,/news/stocks/cramer-says-this-major-healthcare-stock-is-ridiculously-cheap-and-doing-so-many-great-things-1032950314,negative,0.8243603706359863
2198,1/8/2024 2:57:50 PM,AbbVie Phase 2 Trial Of Lutikizumab Provides Higher Response Rate In Inflammatory Skin Disease ,RTTNews,/news/stocks/abbvie-phase-2-trial-of-lutikizumab-provides-higher-response-rate-in-inflammatory-skin-disease-1032950345,negative,0.9483959674835205
2199,1/8/2024 9:05:05 PM,TD Cowen Keeps Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/td-cowen-keeps-their-buy-rating-on-abbvie-abbv-1032952846,positive,0.9156983494758606
2200,1/9/2024 9:10:03 AM,AbbVie Announces Launch Of PRODUODOPA In The EU - Quick Facts ,RTTNews,/news/stocks/abbvie-announces-launch-of-produodopa-in-the-eu-quick-facts-1032952522,positive,0.7837255597114563
2201,1/10/2024 10:38:48 AM,Buy Rating Affirmed for AbbVie on Solid Fundamentals and Strategic Growth Prospects,TipRanks,/news/stocks/buy-rating-affirmed-for-abbvie-on-solid-fundamentals-and-strategic-growth-prospects-1032957206,negative,0.9549544453620911
2202,1/11/2024 10:21:56 AM,"Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Globus Medical (GMED) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intuitive-surgical-isrg-globus-medical-gmed-and-abbvie-abbv-1032960472,positive,0.9166401028633118
2203,1/11/2024 12:50:22 PM,"Analysts’ Top Healthcare Picks: AbbVie (ABBV), Crispr Therapeutics AG (CRSP)",TipRanks,/news/stocks/analysts-top-healthcare-picks-abbvie-abbv-crispr-therapeutics-ag-crsp-1032961335,negative,0.7790377736091614
2204,1/17/2024 9:29:34 PM,"Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness",Benzinga,/news/stocks/ocular-gene-therapy-regenxbio-data-shows-consistent-preservation-of-visual-acuity-retinal-thickness-1032975117,negative,0.9510006904602051
2205,1/19/2024 8:10:19 PM,"Alvotech stock jumps 15% on Stelara, Humira biosimilars updates (update)",Seeking Alpha,https://seekingalpha.com/news/4056530-fda-flags-possible-violation-at-alvotech-biosimilars-plant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.838801383972168
2206,1/19/2024 10:03:58 PM,S&P 500 Shatters Records: The Top-Performing Stocks In January 2024,Benzinga,/news/etf/s-p-500-shatters-records-the-top-performing-stocks-in-january-2024-1032981017,neutral,0.6330354809761047
2207,1/23/2024 4:19:07 AM,7 Dividend Aristocrats That Will Pay You for Years to Come,InvestorPlace,/news/stocks/7-dividend-aristocrats-that-will-pay-you-for-years-to-come-1032986900,positive,0.9166789650917053
2208,1/23/2024 1:29:22 PM,Teva raised to Buy at Jefferies citing a positive setup ahead of 2024 outlook,Seeking Alpha,https://seekingalpha.com/news/4057313-teva-stock-raised-buy-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8827788829803467
2209,1/23/2024 3:00:57 PM,Breaking Down AbbVie: 7 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-abbvie-7-analysts-share-their-views-1032987931,positive,0.8990688323974609
2210,1/24/2024 11:44:18 PM,3 Dividend Stars Every Investor Should Own to Survive a Market Crash,InvestorPlace,/news/stocks/3-dividend-stars-every-investor-should-own-to-survive-a-market-crash-1032994434,positive,0.8540420532226562
2211,1/25/2024 10:50:29 AM,"Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Elevance Health (ELV) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbott-labs-abt-elevance-health-elv-and-abbvie-abbv-1032996806,positive,0.9162739515304565
2212,1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9376139640808105
2213,1/26/2024 1:49:40 PM,"American Riviera Bank  GAAP EPS of $0.38, revenue of $11.07M",Seeking Alpha,https://seekingalpha.com/news/4059043-american-riviera-bank-and-nbsp-gaap-eps-of-0_38-revenue-of-11_07m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9270706176757812
2214,1/26/2024 8:00:55 PM,"Catalyst watch: Apple earnings, Boeing on the hot seat, FOMC meeting and Amer Sports IPO",Seeking Alpha,https://seekingalpha.com/news/4059230-catalyst-watch-apple-earnings-boeing-on-the-hot-seat-fomc-meeting-and-amer-sports-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9197294116020203
2215,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8954368233680725
2216,1/29/2024 1:30:18 PM,AbbVie raised to Outperform at William Blair ahead of earnings,Seeking Alpha,https://seekingalpha.com/news/4059465-abbvie-stock-upgraded-william-blair?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8045328855514526
2217,1/29/2024 1:45:11 PM,"Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), AbbVie (ABBV) and ESSA Pharma (EPIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-abbvie-abbv-and-essa-pharma-epix-1033006637,positive,0.9112706184387207
2218,1/29/2024 5:14:01 PM,"Marathon Petroleum, Exxon among BofA picks for options opportunity on earnings surprise",Seeking Alpha,https://seekingalpha.com/news/4059539-marathon-petroleum-exxon-among-bofa-picks-for-options-opportunity-on-earnings-surprise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7842940092086792
2219,1/29/2024 6:28:50 PM,"Evolus, Alvotech gain as Barclays raises to Ovrweight",Seeking Alpha,https://seekingalpha.com/news/4059650-evolus-stock-alvotech-stock-gain-barclays-upgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.915669322013855
2220,1/29/2024 8:04:57 PM,"AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures",Benzinga,/news/stocks/abbvie-s-transformational-2023-analyst-anticipates-growth-in-2024-amid-competitive-pressures-1033006930,negative,0.9475904703140259
2221,1/31/2024 5:03:34 PM,Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-january-2024-1033016369,negative,0.8527645468711853
2222,2/1/2024 3:00:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4061340-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8830810189247131
2223,2/1/2024 3:01:13 PM,Here's what to expect from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-stock-q4-earnings-preview-1033020700,positive,0.9334648251533508
2224,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49058476090431213
2225,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49058476090431213
2226,2/1/2024 5:10:01 PM,AbbVie Q4 in focus as Humira patent cliff reaches one-year mark,Seeking Alpha,https://seekingalpha.com/news/4061472-abbvie-q4-focus-humira-patent-cliff-reaches-one-year?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.44625481963157654
2227,2/2/2024 1:16:10 AM,Hold Rating on AbbVie Amid Anticipated Revenue and EPS Declines,TipRanks,/news/stocks/hold-rating-on-abbvie-amid-anticipated-revenue-and-eps-declines-1033022911,neutral,0.9623011350631714
2228,2/2/2024 12:41:43 PM,AbbVie reports mixed Q4 results; raises FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4061963-abbvie-reports-mixed-q4-results-raises-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.857483446598053
2229,2/2/2024 1:22:44 PM,AbbVie posts Q4 revenue beat despite Humira patent cliff,Seeking Alpha,https://seekingalpha.com/news/4061992-abbvie-posts-q4-revenue-beat-humira-patent-cliff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.920086681842804
2230,2/2/2024 1:54:29 PM,"AbbVie Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/abbvie-q4-profit-decreases-but-beats-estimates-1033024744,neutral,0.9705538153648376
2231,2/2/2024 2:21:46 PM,AbbVie Expects Annual Earnings In Line With View ,RTTNews,/news/stocks/abbvie-expects-annual-earnings-in-line-with-view-1033024892,negative,0.8615230917930603
2232,2/2/2024 6:06:23 PM,AbbVie cites tailwinds to Botox business from weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4062286-abbvie-cites-tailwinds-botox-sales-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9681975841522217
2233,2/4/2024 5:00:49 PM,Pharma giants turn to China in search of targeted cancer drugs,Seeking Alpha,https://seekingalpha.com/news/4062374-pharma-antibody-drug-conjugates-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8160377740859985
2234,2/4/2024 8:30:25 PM,Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Cigna (CI),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-and-cigna-ci-1033027470,positive,0.9225240349769592
2235,2/5/2024 7:55:30 AM,AbbVie (ABBV) Gets a Buy from Barclays,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-barclays-1033029371,positive,0.5565902590751648
2236,2/5/2024 11:30:16 AM,"Analysts’ Top Healthcare Picks: Werewolf Therapeutics (HOWL), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-top-healthcare-picks-werewolf-therapeutics-howl-abbvie-abbv-1033030430,negative,0.5593757033348083
2237,2/5/2024 1:01:21 PM,"Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-4d-molecular-therapeutics-fdmt-valeo-pharma-othervphif-and-abbvie-abbv-1033031051,positive,0.9004209637641907
2238,2/5/2024 1:40:14 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033031135,negative,0.5521676540374756
2239,2/5/2024 2:09:27 PM,Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday,Benzinga,/news/stocks/pinterest-to-rally-over-20-here-are-10-top-analyst-forecasts-for-monday-1033029912,positive,0.9111997485160828
2240,2/5/2024 2:50:27 PM,AbbVie Analysts Boost Their Forecasts Following Strong Earnings,Benzinga,/news/stocks/abbvie-analysts-boost-their-forecasts-following-strong-earnings-1033030053,negative,0.9412469863891602
2241,2/6/2024 2:11:29 PM,7 Dividend Stocks Worth Holding for the Long Haul,InvestorPlace,/news/stocks/7-dividend-stocks-worth-holding-for-the-long-haul-1033035440,positive,0.8526890873908997
2242,2/6/2024 7:38:48 PM,7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024,InvestorPlace,/news/stocks/7-russell-2000-stocks-to-buy-for-the-next-bull-run-february-2024-1033036609,positive,0.9307746291160583
2243,2/6/2024 8:19:40 PM,"UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst",Benzinga,/news/stocks/ubs-bullish-on-this-depression-drug-maker-says-alzheimer-s-agitation-data-is-attractive-catalyst-1033036588,negative,0.8985598683357239
2244,2/6/2024 9:00:00 PM,3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List,InvestorPlace,/news/stocks/3-strong-buy-biotech-stocks-to-add-to-your-february-must-watch-list-1033036854,positive,0.8592283129692078
2245,2/7/2024 3:12:17 AM,"Calibr-Skaggs, AbbVie To Develop Novel Cell Therapies For Solid Tumors And Autoimmune Diseases ",RTTNews,/news/stocks/calibr-skaggs-abbvie-to-develop-novel-cell-therapies-for-solid-tumors-and-autoimmune-diseases-1033037249,positive,0.5214558839797974
2246,2/7/2024 1:27:31 PM,AbbVie’s Hold Rating Maintained Amid Positive Growth Outlook and Pending Acquisition Outcomes,TipRanks,/news/stocks/abbvie-s-hold-rating-maintained-amid-positive-growth-outlook-and-pending-acquisition-outcomes-1033042009,negative,0.9563568830490112
2247,2/8/2024 1:30:45 PM,ImmunoGen spikes as HSR waiting period for AbbVie deal expires,Seeking Alpha,https://seekingalpha.com/news/4064537-immunogen-stock-spikes-hsr-period-abbvie-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9188785552978516
2248,2/8/2024 3:03:57 PM,AbbVie's Vyalev Now Available For Advanced Parkinson's Disease In Canada ,RTTNews,/news/stocks/abbvie-s-vyalev-now-available-for-advanced-parkinson-s-disease-in-canada-1033046608,positive,0.7251848578453064
2249,2/8/2024 11:18:15 PM,3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying?,InvestorPlace,/news/stocks/3-stocks-just-hit-new-52-week-highs-should-you-still-be-buying-1033048502,positive,0.8102244138717651
2250,2/9/2024 12:10:52 PM,Analysts Conflicted on These Healthcare Names: Doximity (DOCS) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-doximity-docs-and-abbvie-abbv-1033051700,neutral,0.5401695370674133
2251,2/9/2024 2:33:43 PM,"Jim Cramer Looks At Blackstone, Praises MercadoLibre: 'They're Incredibly Smart'",Benzinga,/news/stocks/jim-cramer-looks-at-blackstone-praises-mercadolibre-they-re-incredibly-smart-1033051060,negative,0.5332719683647156
2252,2/9/2024 8:00:09 PM,"Catalyst Watch: Coca-Cola earnings, Instacart lockup, 13F filings and more NYCB drama",Seeking Alpha,https://seekingalpha.com/news/4065216-catalyst-watch-coca-cola-earnings-instacart-lockup-13f-filings-and-more-nycb-drama?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5400356650352478
2253,2/12/2024 1:14:34 PM,AbbVie revises Q1 earnings outlook as ImmunoGen deal closes,Seeking Alpha,https://seekingalpha.com/news/4065467-abbvie-revises-q1-earnings-outlook-as-immunogen-deal-closes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5837476849555969
2254,2/12/2024 2:40:03 PM,"AbbVie Cuts Q1 Earnings Outlook, Below View ",RTTNews,/news/stocks/abbvie-cuts-q1-earnings-outlook-below-view-1033056849,neutral,0.5294947028160095
2255,2/12/2024 11:01:45 PM,The 7 Best Momentum Stocks You Can Purchase Today,InvestorPlace,/news/stocks/the-7-best-momentum-stocks-you-can-purchase-today-1033058723,positive,0.9128717184066772
2256,2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6178923845291138
2257,2/14/2024 8:14:49 PM,Beyond Nvidia: How To Navigate Investing In Your 40s — Insights From Reddit,Benzinga,/news/stocks/beyond-nvidia-how-to-navigate-investing-in-your-40s-—-insights-from-reddit-1033068015,positive,0.8934212327003479
2258,2/15/2024 5:06:18 PM,AbbVie declares $1.55 dividend,Seeking Alpha,https://seekingalpha.com/news/4067750-abbvie-inc-declares-1_55-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.940312922000885
2259,2/16/2024 12:50:56 PM,"Dividend Roundup: Target, Meta Platforms, AbbVie, CSX, and more",Seeking Alpha,https://seekingalpha.com/news/4068114-dividend-roundup-target-meta-platforms-abbvie-csx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9520387053489685
2260,2/16/2024 4:50:13 PM,SpringWorks Therapeutics jumps amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4068311-springworks-therapeutics-jumps-amid-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7746416330337524
2261,2/16/2024 10:56:00 PM,"Cerevel, AbbVie get FTC Second Requests for more merger info",Seeking Alpha,https://seekingalpha.com/news/4068478-cerevel-abbvie-get-ftc-second-request-for-more-merger-info?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9005503058433533
2262,2/18/2024 8:20:31 PM,3 Cash Cows to Boost Your Confidence During the February Chill,InvestorPlace,/news/stocks/3-cash-cows-to-boost-your-confidence-during-the-february-chill-1033078339,negative,0.8716313242912292
2263,2/20/2024 2:18:51 PM,AbbVie names Robert A. Michael as CEO and Richard A. Gonzalez as Executive Chairman,Seeking Alpha,https://seekingalpha.com/news/4068871-abbvie-names-robert-a-michael-as-ceo-and-richard-a-gonzalez-as-executive-chairman?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9473791122436523
2264,2/20/2024 3:29:01 PM,AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO ,RTTNews,/news/stocks/abbvie-appoints-president-and-coo-robert-michael-to-addl-role-of-ceo-1033083508,positive,0.9232987761497498
2265,2/21/2024 12:13:01 PM,"Regeneron, Vertex Pharma join $100B club in biotech",Seeking Alpha,https://seekingalpha.com/news/4069456-regeneron-vertex-pharma-join-100b-club-biotech?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6630005836486816
2266,2/21/2024 6:26:32 PM,"AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals",Seeking Alpha,https://seekingalpha.com/news/4069792-abbvie-plans-offer-senior-notes-fund-immunogen-cerevel-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.853481113910675
2267,2/22/2024 3:37:10 PM,"AbbVie Teams Up With Tentarix To Develop Multi-specific Biologics For Oncology, Immunology ",RTTNews,/news/stocks/abbvie-teams-up-with-tentarix-to-develop-multi-specific-biologics-for-oncology-immunology-1033093264,negative,0.6400228142738342
2268,2/22/2024 7:06:13 PM,"AbbVie, Tentarix team up for immunology, oncology drug discovery",Seeking Alpha,https://seekingalpha.com/news/4070527-abbvie-tenatrix-team-up-for-immunology-oncology-drug-discovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9000136852264404
2269,2/26/2024 10:04:34 AM,Alvotech/Teva win FDA approval for Humira biosimilar,Seeking Alpha,https://seekingalpha.com/news/4071435-alvotechteva-win-fda-approval-for-humira-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9285361170768738
2270,2/27/2024 11:50:35 AM,AbbVie/ Genmab win FDA priority review for lymphoma therapy,Seeking Alpha,https://seekingalpha.com/news/4072110-abbvie-genmab-fda-priority-review-lymphoma-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.934434175491333
2271,2/27/2024 2:52:23 PM,Genmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDA ,RTTNews,/news/stocks/genmab-s-sbla-for-epcoritamab-bysp-granted-priority-review-by-fda-1033107364,negative,0.8130228519439697
2272,2/28/2024 6:35:31 AM,AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics ,RTTNews,/news/stocks/abbvie-to-receive-global-license-to-develop-ose-230-from-ose-immunotherapeutics-1033110412,negative,0.8706650733947754
2273,2/28/2024 7:02:15 AM,AbbVie partners with OSE Immunotherapeutics to develop novel nonoclonal antibody,Seeking Alpha,https://seekingalpha.com/news/4072798-abbvie-partners-with-ose-immunotherapeutics-to-develop-novel-nonoclonal-antibody?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5860713124275208
2274,3/1/2024 12:30:00 PM,The Hot List: 3 AI Stocks Worth Buying on Weakness,InvestorPlace,/news/stocks/the-hot-list-3-ai-stocks-worth-buying-on-weakness-1033123124,positive,0.8718504905700684
2275,3/1/2024 1:52:54 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033123155,positive,0.7807832360267639
2276,3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8509966135025024
2277,3/2/2024 7:00:00 PM,"Pfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugates",Seeking Alpha,https://seekingalpha.com/news/4074834-pfizer-gilead-roche-seen-benefitting-most-antibody-drug-conjugates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9174003601074219
2278,3/4/2024 11:25:00 AM,Secure Your Future: 7 Dividend Kings with Solid Growth Potential,InvestorPlace,/news/stocks/7-dividend-kings-that-offer-more-than-just-a-pretty-dividend-1033127903,negative,0.8111752867698669
2279,3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8006861805915833
2280,3/5/2024 3:22:04 PM,AbbVie's Allergan Aesthetics Gets FDA Nod For Juvederm Voluma XC For Temple Hollows ,RTTNews,/news/stocks/abbvie-s-allergan-aesthetics-gets-fda-nod-for-juvederm-voluma-xc-for-temple-hollows-1033133104,negative,0.8307128548622131
2281,3/6/2024 11:17:00 AM,The Top 7 Dividend Stocks to Buy in March 2024,InvestorPlace,/news/stocks/the-top-7-dividend-stocks-to-buy-in-march-2024-1033136900,positive,0.9411417245864868
2282,3/6/2024 7:43:57 PM,3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates,InvestorPlace,/news/stocks/3-dividend-aristocrats-with-the-largest-10-year-dividend-growth-rates-1033139286,positive,0.8020398020744324
2283,3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7659493088722229
2284,3/7/2024 7:13:09 PM,Cigna eyes $0 out-of-pocket for Humira biosimilar this year,Seeking Alpha,https://seekingalpha.com/news/4077324-cigna-eyes-0-out-of-pocket-humira-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8490453362464905
2285,3/8/2024 8:00:00 PM,"Catalyst Watch: Oracle earnings, Arm IPO lockup, and triple-witching day",Seeking Alpha,https://seekingalpha.com/news/4076911-catalyst-watch-oracle-earnings-arm-ipo-lockup-and-triple-witching-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7499241232872009
2286,3/9/2024 7:46:00 PM,3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024,InvestorPlace,/news/stocks/3-unstoppable-mega-cap-stocks-that-every-investor-should-own-in-2024-1033148095,positive,0.8595952987670898
2287,3/11/2024 10:21:42 PM,Trouble-Proof Dividend Darlings: 7 Stocks That Keep Paying No Matter What,InvestorPlace,/news/stocks/trouble-proof-dividend-darlings-7-stocks-that-keep-paying-no-matter-what-1033152792,positive,0.8745550513267517
2288,3/12/2024 12:09:00 PM,3 Must-Have Dividend Kings for a Steady Income Stream,InvestorPlace,/news/stocks/3-must-have-dividend-kings-for-a-steady-income-stream-1033154748,positive,0.6209182739257812
2289,3/12/2024 12:40:21 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-incyte-incy-abbvie-abbv-and-acadia-pharmaceuticals-acad-1033155948,neutral,0.7346109747886658
2290,3/13/2024 10:30:00 AM,SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster,InvestorPlace,/news/stocks/schd-etf-spotlight-the-top-6-stocks-inside-this-dividend-monster-1033158747,positive,0.9299678206443787
2291,3/14/2024 3:22:56 PM,Coherus gains as oncology focus leads to job cuts,Seeking Alpha,https://seekingalpha.com/news/4079554-coherus-stock-gains-amid-oncology-focus-job-cuts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9221501350402832
2292,3/17/2024 9:09:16 PM,Survey finds GLP-1 users more inclined to get aesthetic procedures,Seeking Alpha,https://seekingalpha.com/news/4080286-survey-finds-glp-1-users-more-inclined-to-get-aesthetic-procedures?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4846843183040619
2293,3/19/2024 6:05:34 PM,AbbVie CEO marks final year at the helm with $25.7M as pay,Seeking Alpha,https://seekingalpha.com/news/4081242-abbvie-ceo-earns-257m-pay-2023?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.905885636806488
2294,3/22/2024 8:01:09 PM,The Latest Analyst Ratings For AbbVie,Benzinga,/news/stocks/the-latest-analyst-ratings-for-abbvie-1033189969,positive,0.9348931312561035
2295,3/22/2024 10:01:23 PM,FDA grants full approval to AbbVie/ImmunoGen drug Elahere,Seeking Alpha,https://seekingalpha.com/news/4083054-fda-grants-full-approval-to-abbvie-immunogen-drug-elahere?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8124356269836426
2296,3/24/2024 9:03:41 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-and-gilead-sciences-gild-1033190921,neutral,0.9346736073493958
2297,3/24/2024 9:04:56 AM,Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-and-legend-biotech-legn-1033190916,positive,0.8968160152435303
2298,3/24/2024 1:54:31 PM,FDA Fully Approves AbbVie's Elahere For Ovarian Cancer ,RTTNews,/news/stocks/fda-fully-approves-abbvie-s-elahere-for-ovarian-cancer-1033190955,negative,0.6708789467811584
2299,3/25/2024 1:42:32 PM,AbbVie To Acquire Landos Biopharma At $20.42/share In Cash ,RTTNews,/news/stocks/abbvie-to-acquire-landos-biopharma-at-20-42-share-in-cash-1033193012,positive,0.91154545545578
2300,3/25/2024 3:05:30 PM,Landos shares rocket 170% on AbbVie takeover deal,Seeking Alpha,https://seekingalpha.com/news/4083345-landos-shares-rocket-170-percent-on-abbvie-takeover-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.502791166305542
2301,3/25/2024 4:17:33 PM,Why Is Landos Biopharma (LABP) Stock Up 168% Today?,InvestorPlace,/news/stocks/why-is-landos-biopharma-labp-stock-up-168-today-1033194067,negative,0.8598542213439941
2302,3/25/2024 4:54:42 PM,Crude Oil Moves Higher; US New Home Sales Fall In February,Benzinga,/news/stocks/crude-oil-moves-higher-us-new-home-sales-fall-in-february-1033193987,neutral,0.9721682071685791
2303,3/25/2024 7:44:09 PM,Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-monday-s-mid-day-session-1033194442,positive,0.8729574084281921
2304,3/25/2024 8:00:39 PM,Nasdaq Turns Higher; Akanda Shares Plunge,Benzinga,/news/stocks/nasdaq-turns-higher-akanda-shares-plunge-1033194478,negative,0.7384706735610962
2305,3/26/2024 1:10:28 AM,Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-and-abbvie-abbv-1033194940,positive,0.9086956977844238
2306,3/28/2024 10:00:00 AM,Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio,InvestorPlace,/news/stocks/long-live-the-dividend-kings-3-top-picks-to-build-an-income-portfolio-1033204500,positive,0.7830474376678467
2307,3/28/2024 5:42:43 PM,Aldeyra gains on plans for AbbVie-partnered eye disease drug,Seeking Alpha,https://seekingalpha.com/news/4085094-aldeyra-stock-gains-plans-abbvie-partnered-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8759976625442505
2308,4/2/2024 7:24:46 PM,The 3 Best Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-best-stocks-to-buy-in-april-2024-1033216542,positive,0.9010857939720154
2309,4/3/2024 9:20:34 AM,Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-and-abbvie-abbv-1033218696,positive,0.906800389289856
2310,4/3/2024 1:01:58 PM,Aldeyra gains as Oppenheimer upgrades on revised plans for lead asset,Seeking Alpha,https://seekingalpha.com/news/4086748-aldeyra-stock-gains-oppenheimer-upgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7259100675582886
2311,4/3/2024 4:02:28 PM,"FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape",Benzinga,/news/stocks/fibrogen-unveils-early-data-from-prostate-cancer-candidate-analyst-advocates-further-exploration-in-the-landscape-1033219424,negative,0.6916196346282959
2312,4/4/2024 1:28:32 PM,"Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year",InvestorPlace,/news/stocks/passive-income-perfection-7-dividend-stocks-to-generate-50000-per-year-1033222647,positive,0.9235104322433472
2313,4/4/2024 2:16:45 PM,Aldeyra gains as Perceptive Advisors boosts stake,Seeking Alpha,https://seekingalpha.com/news/4087290-aldeyra-stock-gains-perceptive-boosts-stake?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9391756653785706
2314,4/4/2024 7:12:29 PM,AbbVie slips after revising guidance to reflect earnings impact,Seeking Alpha,https://seekingalpha.com/news/4087378-abbvie-stock-slips-revised-guidance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9653295874595642
2315,4/5/2024 12:05:41 PM,"Dividend Roundup: Citigroup, Mastercard, AT&T, PNC Financial, and more",Seeking Alpha,https://seekingalpha.com/news/4087529-dividend-roundup-citigroup-mastercard-att-pnc-financial-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9476285576820374
2316,4/5/2024 12:30:53 PM,AbbVie’s Humira outperforms forcing biosimilar maker to cut sales staff,Seeking Alpha,https://seekingalpha.com/news/4087542-abbvies-humira-outperforms-boehringer-ingelheim-cuts-staff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9702324867248535
2317,4/7/2024 5:31:00 PM,Morgan Stanley sees Fed rate cut fueling biotech stocks,Seeking Alpha,https://seekingalpha.com/news/4087727-fed-rate-cut-should-fuel-biotech-outperformance-morgan-stanley-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5271168947219849
2318,4/8/2024 7:31:41 AM,"Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Universal Health (UHS) and Teladoc (TDOC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-abbvie-abbv-universal-health-uhs-and-teladoc-tdoc-1033229139,neutral,0.7336107492446899
2319,4/8/2024 7:50:25 AM,"Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-genmab-gmab-abbvie-abbv-and-immunome-imnm-1033229155,positive,0.9143707156181335
2320,4/9/2024 3:00:51 PM,Syros jumps on FDA fast track tag for leukemia drug,Seeking Alpha,https://seekingalpha.com/news/4088283-syros-stock-jumps-fda-fast-track-tag-leukemia-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8377195596694946
2321,4/10/2024 9:10:38 AM,"Analysts Conflicted on These Healthcare Names: Conmed (CNMD), AbbVie (ABBV) and Nurix Therapeutics (NRIX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-conmed-cnmd-abbvie-abbv-and-nurix-therapeutics-nrix-1033236917,neutral,0.7703367471694946
2322,4/10/2024 12:25:30 PM,Buy Rating on AbbVie: Resilient Humira Market Position and Promising Pipeline Outlook,TipRanks,/news/stocks/buy-rating-on-abbvie-resilient-humira-market-position-and-promising-pipeline-outlook-1033238061,negative,0.9493510127067566
2323,4/10/2024 9:19:01 PM,"Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says",Benzinga,/news/stocks/blindness-focused-lenz-therapeutics-investigational-eye-drop-ready-to-revolutionize-presbyopia-landscape-analyst-says-1033238699,negative,0.6587009429931641
2324,4/11/2024 1:47:56 PM,The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today,InvestorPlace,/news/stocks/the-5-billion-reason-alpine-immune-sciences-alpn-stock-is-up-30-today-1033241236,negative,0.9471536874771118
2325,4/11/2024 5:10:22 PM,Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-april-2024-1033242187,negative,0.8188539743423462
2326,4/12/2024 4:02:53 PM,GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma,Seeking Alpha,https://seekingalpha.com/news/4089307-glp-1s-benefit-parkinsons-barclays-sees-biopharma-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6429069638252258
2327,4/13/2024 2:52:04 PM,AbbVie keeps Humira market share near 100% despite biosimilars: report,Seeking Alpha,https://seekingalpha.com/news/4089412-abbvie-retains-humira-market-despite-copycats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5874672532081604
2328,4/16/2024 2:47:43 PM,AbbVie working with FDA after reports of fake Botox versions,Seeking Alpha,https://seekingalpha.com/news/4090109-abbvie-fda-probe-fake-botox-versions?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.845323920249939
2329,4/16/2024 4:54:17 PM,AbbVie to develop long-acting injectables in a deal worth up to $1.9B,Seeking Alpha,https://seekingalpha.com/news/4090182-abbvie-spend-19b-long-acting-injectables?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6788371801376343
2330,4/16/2024 6:56:16 PM,"Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now",InvestorPlace,/news/stocks/steady-income-steady-growth-7-blue-chip-dividend-stocks-to-buy-now-1033254806,positive,0.7678641676902771
2331,4/16/2024 8:25:01 PM,"Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades",Benzinga,/news/stocks/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-hidradenitis-suppurativa-market-analyst-upgrades-1033254721,negative,0.9143946170806885
2332,4/17/2024 7:25:56 AM,AbbVie (ABBV) Gets a Buy from Barclays,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-barclays-1033257111,positive,0.5565902590751648
2333,4/17/2024 1:26:31 PM,CVS favors Humira copycats hurting AbbVie’s market share: Evercore,Seeking Alpha,https://seekingalpha.com/news/4090466-cvs-favors-humira-copycats-hurting-abbvies-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8803040981292725
2334,4/17/2024 6:33:19 PM,14 companies with a near-term catalyst around 1Q earnings - MS,Seeking Alpha,https://seekingalpha.com/news/4090654-14-companies-with-a-near-term-catalyst-around-1q-earnings-ms?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7848201990127563
2335,4/18/2024 11:00:23 AM,AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug,Seeking Alpha,https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9050068259239197
2336,4/18/2024 1:30:06 PM,AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition,Seeking Alpha,https://seekingalpha.com/news/4091031-abbvie-stock-gains-rinvoq-succeeds-giant-cell-arteritis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8217974901199341
2337,4/18/2024 3:10:15 PM,AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis ,RTTNews,/news/stocks/abbvie-s-phase-3-study-of-upadacitinib-achieves-primary-endpoint-in-giant-cell-arteritis-1033262163,negative,0.8438290357589722
2338,4/19/2024 9:45:49 AM,Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-abbvie-abbv-1033266003,positive,0.8298686742782593
2339,4/19/2024 10:55:31 AM,Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.,Seeking Alpha,https://seekingalpha.com/news/4091382-alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-high-concentration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9145915508270264
2340,4/19/2024 6:30:20 PM,These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?,InvestorPlace,/news/stocks/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher-1033267239,negative,0.692104697227478
2341,4/19/2024 7:00:19 PM,"Catalyst Watch: Tesla, Boeing and General Motors brace for earnings fireworks",Seeking Alpha,https://seekingalpha.com/news/4091531-catalyst-watch-tesla-boeing-and-general-motors-brace-for-earnings-fireworks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8319826126098633
2342,4/19/2024 7:19:41 PM,At least 70% of the S&P 500 names that reported results this week topped estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4091620-at-least-70-of-the-sp-500-names-that-reported-results-this-week-topped-estimates-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8400577902793884
2343,4/21/2024 12:00:00 PM,"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",Seeking Alpha,https://seekingalpha.com/news/4091495-earnings-week-ahead-tesla-meta-platforms-google-microsoft-intel-exxon-mobil-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9310646057128906
2344,4/22/2024 12:00:00 PM,3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip,InvestorPlace,/news/stocks/3-dividend-kings-down-11-youll-regret-not-buying-on-the-dip-1033270787,neutral,0.9647071361541748
2345,4/22/2024 12:27:36 PM,AbbVie (ABBV) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-piper-sandler-1033271869,positive,0.5950971841812134
2346,4/22/2024 2:14:17 PM,EU regulators approve Pfizer antibiotic Emblaveo,Seeking Alpha,https://seekingalpha.com/news/4091933-eu-regulators-approve-pfizer-antibiotic-emblaveo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.698655903339386
2347,4/23/2024 8:41:25 PM,Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes,InvestorPlace,/news/stocks/dividend-growth-stars-7-stocks-with-10-year-double-digit-rate-hikes-1033278029,negative,0.8532738089561462
2348,4/24/2024 8:20:17 AM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1033281209,neutral,0.700346827507019
2349,4/25/2024 10:00:00 AM,3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-be-multibaggers-in-the-making-april-edition-1033286958,positive,0.9219697117805481
2350,4/25/2024 2:22:29 PM,AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1,Seeking Alpha,https://seekingalpha.com/news/4094181-abbvie-q1-preview-skyrizi-and-rinvoqs-launches-could-help-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9367481470108032
2351,4/25/2024 3:01:13 PM,Here's what Wall Street expects from AbbVie's earnings report,Markets Insider Automation,/news/stocks/abbvie-q1-earnings-preview-1033287920,positive,0.9177791476249695
2352,4/25/2024 3:01:30 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4094208-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8830810189247131
2353,4/25/2024 3:24:05 PM,AbbVie reports positive results from Rinvoq versus Dupixent study,Seeking Alpha,https://seekingalpha.com/news/4094231-abbvie-reports-positive-results-from-rinoq-versus-dupixent-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9530646204948425
2354,4/25/2024 4:15:22 PM,AbbVie's Rinvoq Shows Positive Results Over Dupixent In Atopic Dermatitis Study ,RTTNews,/news/stocks/abbvie-s-rinvoq-shows-positive-results-over-dupixent-in-atopic-dermatitis-study-1033288730,negative,0.9530843496322632
2355,4/26/2024 9:06:31 AM,Hold Rating on AbbVie Amid Revenue Decline and Profitability Concerns,TipRanks,/news/stocks/hold-rating-on-abbvie-amid-revenue-decline-and-profitability-concerns-1033293725,neutral,0.9673869609832764
2356,4/26/2024 11:36:36 AM,"AbbVie Non-GAAP EPS of $2.31 beats by $0.05, revenue of $12.31B beats by $370M",Seeking Alpha,https://seekingalpha.com/news/4094791-abbvie-non-gaap-eps-of-2_31-beats-0_05-revenue-of-12_31b-beats-370m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5593721866607666
2357,4/26/2024 1:08:00 PM,"5 stocks to watch on Friday: XOM, CVX, ABBV and more",Seeking Alpha,https://seekingalpha.com/news/4094875-5-stocks-to-watch-on-friday-xom-cvx-abbv-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9277185201644897
2358,4/26/2024 1:10:34 PM,"AbbVie in charts: Q1 Skyrizi, Rinvoq sales jump, while revenue from Humira continues to fall",Seeking Alpha,https://seekingalpha.com/news/4094878-abbvie-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8614738583564758
2359,4/26/2024 1:45:28 PM,"AbbVie Q1 Profit Increases, beats estimates",RTTNews,/news/stocks/abbvie-q1-profit-increases-beats-estimates-1033293534,negative,0.9267570376396179
2360,4/26/2024 2:07:07 PM,AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update ,RTTNews,/news/stocks/abbvie-lifts-fy24-outlook-after-higher-q1-results-update-1033293695,negative,0.8933690190315247
2361,4/26/2024 2:33:56 PM,"AbbVie off 3% despite quarterly beats, 2024 guidance raise",Seeking Alpha,https://seekingalpha.com/news/4094948-abbvie-off-3-despite-quarterly-beats-2024-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9680272936820984
2362,4/26/2024 2:45:00 PM,AbbVie Inc hosts conference call for investors,Markets Insider Automation,/news/stocks/abbvie_conference-1030850241,positive,0.9422962069511414
2363,4/26/2024 3:20:12 PM,AbbVie Q1 report beats Street despite plunging Humira sales,Seeking Alpha,https://seekingalpha.com/news/4094987-abbvie-q1-report-beats-street-despite-plunging-humira-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6916598081588745
2364,4/26/2024 3:52:41 PM,"ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024",InvestorPlace,/news/stocks/abbv-stock-earnings-abbvie-for-q1-of-2024-1033295131,negative,0.7187970280647278
2365,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6158705353736877
2366,4/26/2024 6:09:10 PM,AbbVie stock slides 6% amid concerns about falling Humira sales,Seeking Alpha,https://seekingalpha.com/news/4095090-abbvie-stock-falls-amid-concerns-about-falling-humira-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9555572867393494
2367,4/26/2024 7:11:32 PM,More than half of the S&P 500 names that reported results this week beat top and bottom line - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095089-more-than-half-of-the-sp-500-names-that-reported-results-this-week-beat-top-and-bottom-line-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5653102397918701
2368,4/26/2024 7:45:43 PM,"Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?",Benzinga,/news/stocks/tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-what-s-driving-markets-friday-1033295482,neutral,0.5526121854782104
2369,4/28/2024 5:00:22 PM,"J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade",Seeking Alpha,https://seekingalpha.com/news/4095228-johnson-johnson-roche-astrazeneca-poised-have-highest-orphan-drug-sales-by-end-decade?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9317450523376465
2370,4/29/2024 9:50:35 AM,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-dexcom-dxcm-optimizerx-oprx-and-abbvie-abbv-1033300066,positive,0.8976631164550781
2371,4/29/2024 10:47:04 AM,Buy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira’s Competition,TipRanks,/news/stocks/buy-rating-reaffirmed-for-abbvie-future-growth-beyond-humira-s-competition-1033300626,negative,0.8828195929527283
2372,4/29/2024 11:27:16 AM,Buy Rating Affirmed: AbbVie’s Strong Performance and Positive Growth Outlook,TipRanks,/news/stocks/buy-rating-affirmed-abbvie-s-strong-performance-and-positive-growth-outlook-1033301044,negative,0.9529480338096619
2373,4/29/2024 11:50:01 AM,Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-abbvie-abbv-1033301155,positive,0.5576676726341248
2374,4/29/2024 11:53:00 AM,"Analysts’ Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)",TipRanks,/news/stocks/analysts-top-healthcare-picks-abbvie-abbv-wave-life-sciences-wve-1033301142,negative,0.6223720908164978
2375,4/29/2024 5:01:10 PM,Peeling Back The Layers: Exploring AbbVie Through Analyst Insights,Benzinga,/news/stocks/peeling-back-the-layers-exploring-abbvie-through-analyst-insights-1033301172,positive,0.8876813054084778
2376,4/30/2024 6:05:55 AM,Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects,TipRanks,/news/stocks/hold-rating-on-abbvie-amidst-humira-concerns-and-biosimilar-competition-despite-strong-pipeline-prospects-1033304880,neutral,0.49923405051231384
2377,4/30/2024 7:11:17 AM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-molina-healthcare-moh-and-cytokinetics-cytk-1033305110,positive,0.9108465313911438
2378,4/30/2024 10:32:00 AM,Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing,InvestorPlace,/news/stocks/inflation-proof-fortunes-7-dividend-aristocrats-to-keep-your-wealth-growing-1033305312,positive,0.913800060749054
2379,4/30/2024 3:56:42 PM,Alvotech to produce Humira biosimilar for Cigna's Quallent,Seeking Alpha,https://seekingalpha.com/news/4096484-alvotech-to-produce-humira-biosimilar-for-cignas-quallent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.744411051273346
2380,4/30/2024 4:18:17 PM,"Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents",Seeking Alpha,https://seekingalpha.com/news/4096525-novo-teva-astrazeneca-issued-ftc-warnings-over-bogus-patents?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9514713287353516
2381,4/30/2024 5:50:57 PM,7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns,InvestorPlace,/news/stocks/7-safe-haven-stocks-that-can-withstand-the-markets-worst-meltdowns-1033308490,positive,0.5131520628929138
2382,5/1/2024 8:12:21 PM,"BeiGene, AbbVie patent spat to get trial from USPTO appeals board",Seeking Alpha,https://seekingalpha.com/news/4097839-beigene-abbvie-patent-spat-get-trial-uspto-appeals-board?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6186614036560059
2383,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9528807997703552
2384,5/6/2024 6:30:17 PM,3 Biotech Stocks to Double Your Money in the Next 24 Months,InvestorPlace,/news/stocks/3-biotech-stocks-to-double-your-money-in-the-next-24-months-1033334986,negative,0.7702029347419739
2385,5/7/2024 6:04:24 PM,Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare,InvestorPlace,/news/stocks/biotech-breakthroughs-7-stocks-driving-the-next-wave-in-healthcare-1033341676,positive,0.8313630819320679
2386,5/8/2024 3:28:27 PM,"BofA starts Sutro at buy, cites ovarian cancer drug candidate",Seeking Alpha,https://seekingalpha.com/news/4102617-bofa-starts-sutro-at-buy-cites-ovarian-cancer-drug-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8877923488616943
2387,5/8/2024 3:36:57 PM,AbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In Adults ,RTTNews,/news/stocks/abbvie-s-qulipta-gets-health-canada-approval-for-chronic-migraine-in-adults-1033347917,negative,0.9317842721939087
2388,5/13/2024 3:17:25 PM,AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies ,RTTNews,/news/stocks/abbvie-to-collaborate-with-gilgamesh-to-develop-next-gen-psychiatric-therapies-1033370766,negative,0.7484301924705505
2389,5/13/2024 3:49:48 PM,"AbbVie, Gilgamesh to develop next-generation psychedelic drugs",Seeking Alpha,https://seekingalpha.com/news/4105275-abbvie-gilgamesh-to-develop-next-generation-psychedelic-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7313826680183411
2390,5/13/2024 10:50:10 PM,"Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cytokinetics-cytk-abbvie-abbv-and-establishment-labs-holdings-esta-1033373028,positive,0.9098888039588928
2391,5/14/2024 10:55:40 AM,Buy Rating Affirmed: AbbVie’s Promising Growth Trajectory and Financial Outlook,TipRanks,/news/stocks/buy-rating-affirmed-abbvie-s-promising-growth-trajectory-and-financial-outlook-1033376822,negative,0.9341726899147034
2392,5/16/2024 10:00:00 AM,Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-retirement-stocks-with-strong-buy-ratings-for-may-2024-1033391923,positive,0.5588862895965576
2393,5/17/2024 11:11:00 AM,7 Value Stocks to Buy and Hold for a Decade of Dominance,InvestorPlace,/news/stocks/7-value-stocks-to-buy-and-hold-for-a-decade-of-dominance-1033398745,positive,0.9146937727928162
2394,5/17/2024 3:00:44 PM,The Analyst Verdict: AbbVie In The Eyes Of 5 Experts,Benzinga,/news/stocks/the-analyst-verdict-abbvie-in-the-eyes-of-5-experts-1033399116,positive,0.6888390183448792
2395,5/17/2024 7:47:17 PM,AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion':  Analyst,Benzinga,/news/stocks/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst-1033400477,negative,0.9092691540718079
2396,5/18/2024 4:19:14 PM,"Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch",Benzinga,/news/stocks/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch-1033400987,positive,0.9329438805580139
2397,5/19/2024 7:05:03 PM,SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?,Seeking Alpha,https://seekingalpha.com/news/4108152-sa-roundtable-are-eli-lilly-and-novo-nordisk-overvalued?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8515272736549377
2398,5/20/2024 6:47:45 PM,3 S&P 500 Stocks That Have Proven Themselves Recession-Proof,InvestorPlace,/news/stocks/3-sp-500-stocks-that-have-proven-themselves-recession-proof-1033404557,positive,0.39710932970046997
2399,5/21/2024 10:51:13 AM,"Teva, Alvotech launch biosimilar against AbbVie’s Humira",Seeking Alpha,https://seekingalpha.com/news/4108668-teva-alvotech-launch-biosimilar-against-humira?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5384867191314697
2400,5/22/2024 9:50:08 AM,"Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-abbvie-abbv-aerovate-therapeutics-avte-1033411483,positive,0.5337945222854614
2401,5/22/2024 1:48:14 PM,7 Safe-Haven Stocks to Weather Any Storm,InvestorPlace,/news/stocks/7-safe-haven-stocks-to-weather-any-storm-1033411814,positive,0.6809397339820862
2402,5/23/2024 12:50:47 AM,The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains,InvestorPlace,/news/stocks/the-100-club-piper-sandlers-3-top-picks-for-triple-digit-gains-1033413558,positive,0.8413352370262146
2403,5/23/2024 6:01:14 PM,3 Biotech Stocks to Buy on the Dip: May 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-on-the-dip-may-2024-1033417162,positive,0.8900653719902039
2404,5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9204940795898438
2405,5/27/2024 4:32:15 PM,7 Biotech Stocks to Put on Your Breakthrough Radar,InvestorPlace,/news/stocks/7-biotech-stocks-to-put-on-your-breakthrough-radar-1033424831,positive,0.8720806837081909
2406,5/31/2024 8:45:38 AM,AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis ,RTTNews,/news/stocks/abbvie-risankizumab-recommended-for-eu-approval-for-moderately-severely-active-ulcerative-colitis-1033439907,negative,0.8253443241119385
2407,5/31/2024 11:10:02 AM,AbbVie wins EU backing for Skyrizi in bowel disorder,Seeking Alpha,https://seekingalpha.com/news/4111879-abbvie-skyrizi-endorsed-eu-bowel-disorder?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8550794124603271
2408,6/2/2024 6:00:00 PM,Emerging and Chinese pharmas playing greater role in oncology drug development,Seeking Alpha,https://seekingalpha.com/news/4112099-emerging-chinese-pharmas-playing-greater-role-oncology-drug-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5788828134536743
2409,6/3/2024 1:15:32 AM,Strong Financial Outlook and Strategic Initiatives Underpin Buy Rating for AbbVie,TipRanks,/news/stocks/strong-financial-outlook-and-strategic-initiatives-underpin-buy-rating-for-abbvie-1033443832,negative,0.9264497756958008
2410,6/3/2024 10:00:00 AM,7 Overlooked Stocks That Belong in Every Portfolio ,InvestorPlace,/news/stocks/7-must-own-overlooked-stocks-that-can-work-in-any-portfolio-1033445074,positive,0.9365252256393433
2411,6/3/2024 9:32:12 PM,AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU,Benzinga,/news/stocks/abbvie-skyrizi-gets-chmp-nod-for-ulcerative-colitis-in-eu-1033447137,negative,0.8817382454872131
2412,6/4/2024 2:59:48 PM,AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients ,RTTNews,/news/stocks/abbvie-says-new-weight-based-oral-solution-rinvoq-lq-now-available-as-option-for-pediatric-patients-1033449400,negative,0.7120586633682251
2413,6/5/2024 11:30:00 AM,The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme,InvestorPlace,/news/stocks/the-dividend-dominators-3-stocks-that-will-make-your-portfolio-reign-supreme-1033453081,positive,0.9256895780563354
2414,6/5/2024 2:01:15 PM,Analyst Scoreboard: 6 Ratings For AbbVie,Benzinga,/news/stocks/analyst-scoreboard-6-ratings-for-abbvie-1033453101,positive,0.8953391313552856
2415,6/5/2024 2:10:34 PM,AbbVie doses first patient in phase 3 trial of multiple myeloma asset,Seeking Alpha,https://seekingalpha.com/news/4113186-abbvie-doses-first-patient-phase-3-trial-multiple-myeloma-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6102330088615417
2416,6/5/2024 9:37:13 PM,Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential,InvestorPlace,/news/stocks/biotech-blockbusters-3-pharma-stocks-to-buy-in-june-for-breakthrough-potential-1033455451,negative,0.5901241898536682
2417,6/6/2024 10:00:00 AM,Hedge Fund Favorites: 7 Stocks to Buy When You’re Feeling Jittery,InvestorPlace,/news/stocks/hedge-fund-favorites-7-stocks-to-buy-when-youre-feeling-jittery-1033456768,positive,0.904039204120636
2418,6/6/2024 10:19:00 AM,7 Stocks That Could Safely 10X by 2030,InvestorPlace,/news/stocks/7-stocks-that-could-safely-10x-by-2030-1033456760,positive,0.5836676359176636
2419,6/6/2024 1:08:10 PM,"AbbVie succeeds in mid-stage trial for ovarian cancer drug, Elahere",Seeking Alpha,https://seekingalpha.com/news/4113625-abbvie-posts-mid-stage-trial-win-elahere?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8217176198959351
2420,6/6/2024 3:34:39 PM,AbbVie Reports Positive Results From Phase 2 PICCOLO Trial Of Mirvetuximab Soravtansine In PSOC ,RTTNews,/news/stocks/abbvie-reports-positive-results-from-phase-2-piccolo-trial-of-mirvetuximab-soravtansine-in-psoc-1033457605,negative,0.9483020901679993
2421,6/6/2024 9:36:29 PM,Halozyme's ENHANZE Product Gets New Patent Grant in EU,Benzinga,/news/stocks/halozyme-s-enhanze-product-gets-new-patent-grant-in-eu-1033459113,negative,0.7392569780349731
2422,6/7/2024 12:19:26 AM,Hold Rating for AbbVie’s Elahere Amidst Market Expansion Potential and Need for Further Data,TipRanks,/news/stocks/hold-rating-for-abbvie-s-elahere-amidst-market-expansion-potential-and-need-for-further-data-1033459528,negative,0.8978680372238159
2423,6/7/2024 11:59:30 AM,AbbVie-partnered therapy selected for FDA’s rare disease pilot program,Seeking Alpha,https://seekingalpha.com/news/4114016-abbvie-therapy-selected-fda-rare-disease-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7199091911315918
2424,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8829660415649414
2425,6/7/2024 8:30:54 PM,"Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside",Benzinga,/news/stocks/goldman-sachs-optimistic-about-regenxbio-s-gene-therapy-pipeline-sees-over-160-upside-1033462338,negative,0.8103159666061401
2426,6/11/2024 8:33:48 AM,Alvotech and Stada add to strategic alliance through denosumab partnership,Seeking Alpha,https://seekingalpha.com/news/4114679-alvotech-and-stada-add-to-strategic-alliance-through-denosumab-partnership?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8855556845664978
2427,6/12/2024 3:30:31 PM,Cerevel Therapeutics gains after AbbVie says making good progress with FTC,Seeking Alpha,https://seekingalpha.com/news/4115228-cerevel-therapeutics-gains-after-abbvie-says-making-good-progress-with-ftc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9500210285186768
2428,6/12/2024 7:39:23 PM,Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts,InvestorPlace,/news/stocks/blue-chip-bonanzas-3-industry-leaders-trading-at-unbelievable-discounts-1033474098,positive,0.9104120135307312
2429,6/13/2024 11:03:17 AM,"Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-perspective-therapeutics-catx-abbvie-abbv-1033476717,negative,0.7197862863540649
2430,6/13/2024 12:25:53 PM,AbbVie inks licensing pact for bowel disorder therapy,Seeking Alpha,https://seekingalpha.com/news/4115520-abbvie-inks-licensing-pact-ibd-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8740695714950562
2431,6/13/2024 2:30:54 PM,"AbbVie To Receive License From FutureGen To Develop, Commercialize FG-M701 ",RTTNews,/news/stocks/abbvie-to-receive-license-from-futuregen-to-develop-commercialize-fg-m701-1033475921,negative,0.760078489780426
2432,6/13/2024 5:54:33 PM,Cerevel Therapeutics seesaws amid FTC notice on closed door meeting,Seeking Alpha,https://seekingalpha.com/news/4115854-cerevel-therapeutics-seesaws-amid-ftc-notice-on-closed-door-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9429758191108704
2433,6/14/2024 9:25:57 AM,Hold Rating Maintained for AbbVie Amidst Revenue Erosion and Strategic Uncertainties,TipRanks,/news/stocks/hold-rating-maintained-for-abbvie-amidst-revenue-erosion-and-strategic-uncertainties-1033479480,neutral,0.811567485332489
2434,6/14/2024 10:15:00 AM,The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks,InvestorPlace,/news/stocks/the-dividend-defenders-3-stocks-that-will-protect-and-grow-your-wealth-dividend-stocks-1033479176,positive,0.8916819095611572
2435,6/14/2024 11:15:00 AM,7 A-Rated Biotech Stocks Worth Betting on in June,InvestorPlace,/news/stocks/7-a-rated-biotech-stocks-worth-betting-on-in-june-1033479361,positive,0.8425543308258057
2436,6/14/2024 7:39:10 PM,"Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails",Benzinga,/news/stocks/pharma-stock-roundup-fda-panel-endorses-lly-s-donanemab-pfe-s-dmd-therapy-study-fails-1033480819,positive,0.6571053266525269
2437,6/14/2024 9:03:24 PM,AbbVie urges shareholders to reject mini-tender offer,Seeking Alpha,https://seekingalpha.com/news/4116435-abbvie-urges-shareholders-reject-mini-tender-offer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7273761630058289
2438,6/15/2024 7:37:28 PM,ALS therapy market seen increasing to nearly $1.3B by 2029,Seeking Alpha,https://seekingalpha.com/news/4116487-als-therapy-market-seen-increasing-nearly-13b-2029?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8988732695579529
2439,6/18/2024 11:00:22 AM,"Analysts’ Top Healthcare Picks: Merit Medical Systems (MMSI), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-top-healthcare-picks-merit-medical-systems-mmsi-abbvie-abbv-1033487643,negative,0.7667816281318665
2440,6/18/2024 3:44:28 PM,Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/nvidia-to-rally-around-53-here-are-10-top-analyst-forecasts-for-tuesday-1033487209,positive,0.9223056435585022
2441,6/19/2024 7:25:58 AM,AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis ,RTTNews,/news/stocks/abbvie-s-skyrizi-gets-approval-in-us-for-ulcerative-colitis-1033489128,negative,0.9203891754150391
2442,6/20/2024 10:00:00 AM,3 High-Dividend Stocks to Buy and Hold Forever: June 2024 Edition,InvestorPlace,/news/stocks/3-high-dividend-stocks-to-buy-and-hold-forever-june-2024-edition-1033492304,positive,0.9488995671272278
2443,6/20/2024 10:38:57 AM,AbbVie wins FDA nod for new Skyrizi indication,Seeking Alpha,https://seekingalpha.com/news/4117383-abbvie-wins-fda-nod-for-new-skyrizi-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.885458767414093
2444,6/20/2024 11:00:56 AM,"Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), AbbVie (ABBV) and LENSAR (LNSR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-abbvie-abbv-and-lensar-lnsr-1033493306,positive,0.9113914966583252
2445,6/20/2024 11:10:10 AM,"Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), AbbVie (ABBV) and Emergent Biosolutions (EBS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-korro-bio-krro-abbvie-abbv-and-emergent-biosolutions-ebs-1033493299,positive,0.8893043398857117
2446,6/20/2024 11:30:00 AM,7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027,InvestorPlace,/news/stocks/7-high-value-blue-chip-stocks-to-boost-your-wealth-by-2027-1033492560,negative,0.8014839887619019
2447,6/20/2024 1:00:00 PM,Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-retirement-stocks-with-strong-buy-ratings-for-june-2024-1033492963,positive,0.5746885538101196
2448,6/21/2024 4:25:49 AM,AbbVie (ABBV) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-cantor-fitzgerald-1033494965,positive,0.8193526864051819
2449,6/21/2024 12:03:06 PM,AbbVie declares $1.55 dividend,Seeking Alpha,https://seekingalpha.com/news/4117878-abbvie-declares-155-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.940312922000885
2450,6/21/2024 6:00:00 PM,3 Biotech Stocks to Buy Now: June 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-now-june-2024-1033497074,positive,0.9347099661827087
2451,6/24/2024 3:25:55 PM,Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income,InvestorPlace,/news/stocks/hot-summer-dividends-3-sizzling-stocks-to-buy-for-reliable-income-1033500901,positive,0.9036083817481995
2452,6/25/2024 1:26:41 PM,FDA snubs AbbVie Parkinson's combo,Seeking Alpha,https://seekingalpha.com/news/4118864-fda-snubs-abbvie-parkinsons-combo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7432488203048706
2453,6/25/2024 2:28:00 PM,AbbVie: FDA Issues CRL For ABBV-951 ,RTTNews,/news/stocks/abbvie-fda-issues-crl-for-abbv-951-1033503482,positive,0.8534901142120361
2454,6/25/2024 7:11:25 PM,Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal,Seeking Alpha,https://seekingalpha.com/news/4119124-cerevel-therapeutics-sinks-amid-some-worry-on-ftc-review-of-abbvie-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8795492053031921
2455,6/26/2024 7:12:51 AM,"Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), AbbVie (ABBV) and Insmed (INSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-teva-pharmaceutical-teva-abbvie-abbv-and-insmed-insm-1033506912,positive,0.9330943822860718
2456,6/26/2024 9:36:21 AM,Buy Rating Affirmed for AbbVie Despite ABBV-951’s CRL: Minimal Impact and Positive Financial Projections,TipRanks,/news/stocks/buy-rating-affirmed-for-abbvie-despite-abbv-951-s-crl-minimal-impact-and-positive-financial-projections-1033507441,negative,0.9483712315559387
2457,6/26/2024 4:07:34 PM,Tempur Sealy seesaws amid FTC notice for closed door meeting,Seeking Alpha,https://seekingalpha.com/news/4119672-tempur-sealy-seesaws-amid-ftc-notice-for-closed-door-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9282986521720886
2458,6/27/2024 2:51:55 AM,Genmab's EPKINLY Receives FDA Accelerated Approval For R/R Follicular Lymphoma ,RTTNews,/news/stocks/genmab-s-epkinly-receives-fda-accelerated-approval-for-r-r-follicular-lymphoma-1033509373,negative,0.9464328289031982
2459,6/27/2024 9:34:44 AM,"Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy",Seeking Alpha,https://seekingalpha.com/news/4119919-genmab-abbvie-win-fda-nod-for-rr-follicular-lymphoma-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8914054036140442
2460,6/27/2024 1:48:45 PM,AbbVie buys bowel disease drug developer Celsius for $250M,Seeking Alpha,https://seekingalpha.com/news/4120076-abbvie-buys-bowel-disease-drug-developer-celsius?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9090253710746765
2461,6/27/2024 5:00:33 PM,AbbVie Acquires Celsius Therapeutics For $250 Mln ,RTTNews,/news/stocks/abbvie-acquires-celsius-therapeutics-for-250-mln-1033512159,positive,0.9205106496810913
2462,6/27/2024 6:07:44 PM,Coherus to divest biosimilar against AbbVie’s Humira for $40M,Seeking Alpha,https://seekingalpha.com/news/4120260-coherus-to-divest-biosimilar-against-abbvies-humira-for-40m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.861237645149231
2463,6/27/2024 7:22:09 PM,"AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway",Benzinga,/news/stocks/abbvie-genmab-s-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway-1033512703,negative,0.9408528208732605
2464,6/27/2024 8:39:20 PM,Merck's Lung Cancer Candidate Faces FDA Rejection,Benzinga,/news/stocks/merck-s-lung-cancer-candidate-faces-fda-rejection-1033512884,positive,0.8145422339439392
2465,6/27/2024 9:13:30 PM,Cerevel Therapeutics gains on report Tempur Sealy will be the subject of FTC meeting (update),Seeking Alpha,https://seekingalpha.com/news/4120249-cerevel-therapeutics-gains-on-report-tempur-sealy-will-be-the-subject-of-ftc-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9074770212173462
2466,6/28/2024 8:13:57 AM,AbbVie: CHMP Adopts Positive Opinion Recommending Conditional Marketing Authorization Of Epcoritamab ,RTTNews,/news/stocks/abbvie-chmp-adopts-positive-opinion-recommending-conditional-marketing-authorization-of-epcoritamab-1033513779,negative,0.8355957269668579
2467,6/28/2024 10:13:00 AM,7 Dividend Kings to Buy With Your Roth IRA Money in 2024,InvestorPlace,/news/stocks/7-dividend-kings-to-buy-with-your-roth-ira-money-in-2024-1033514444,positive,0.9169039726257324
2468,6/28/2024 1:29:56 PM,"AbbVie, Genmab blood cancer therapy endorsed in EU",Seeking Alpha,https://seekingalpha.com/news/4120581-abbvie-genmab-blood-cancer-therapy-endorsed-in-eu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8387516736984253
2469,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7290322184562683
2470,6/30/2024 2:13:35 PM,Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet,InvestorPlace,/news/stocks/treasure-hunt-3-small-cap-stocks-wall-street-hasnt-discovered-yet-1033517243,positive,0.9144801497459412
2471,7/1/2024 12:23:23 PM,AbbVie names Robert A. Michael to CEO role,Seeking Alpha,https://seekingalpha.com/news/4120973-abbvie-names-robert-a-michael-to-ceo-role?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9396939873695374
2472,7/1/2024 2:17:18 PM,AbbVie's Robert Michael Assumes Role Of CEO ,RTTNews,/news/stocks/abbvie-s-robert-michael-assumes-role-of-ceo-1033519348,positive,0.910917341709137
2473,7/1/2024 5:40:23 PM,Cash Flow Alert: 3 Stocks That Just Raised Their Dividends,InvestorPlace,/news/stocks/cash-flow-alert-3-stocks-that-just-raised-their-dividends-1033520789,positive,0.4409911036491394
2474,7/1/2024 8:30:00 PM,3 Retirement All-Stars for Steady Growth and Income,InvestorPlace,/news/stocks/3-retirement-all-stars-for-steady-growth-and-income-1033521039,negative,0.5756692290306091
2475,7/2/2024 1:26:54 AM,Buy Rating Affirmed for AbbVie on Strong Aesthetics Market Position and Positive Sales Outlook,TipRanks,/news/stocks/buy-rating-affirmed-for-abbvie-on-strong-aesthetics-market-position-and-positive-sales-outlook-1033521403,negative,0.9530813097953796
2476,7/2/2024 10:24:00 AM,3 Under-the-Radar Biotech Stocks With Blockbuster Potential,InvestorPlace,/news/stocks/3-under-the-radar-biotech-stocks-with-blockbuster-potential-1033522419,positive,0.6027738451957703
2477,7/2/2024 10:36:11 AM,Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/piper-sandler-keeps-their-buy-rating-on-abbvie-abbv-1033523144,positive,0.916959822177887
2478,7/2/2024 6:38:28 PM,5 Strong Buy Dividend Stocks for July,TipRanks,/news/stocks/5-strong-buy-dividend-stocks-for-july-1033524622,positive,0.888429582118988
2479,7/2/2024 8:00:25 PM,A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts,Benzinga,/news/stocks/a-glimpse-into-the-expert-outlook-on-abbvie-through-7-analysts-1033524245,positive,0.8784602284431458
2480,7/2/2024 8:45:00 PM,7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven,InvestorPlace,/news/stocks/7-dividend-aristocrats-that-will-have-investors-in-high-yield-heaven-1033524556,positive,0.8748617172241211
2481,7/3/2024 4:04:34 PM,Cerevel Therapeutics drops amid report on FTC review of AbbVie deal,Seeking Alpha,https://seekingalpha.com/news/4122133-cerevel-therapeutics-drops-amid-report-on-ftc-review-of-abbvie-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9220414757728577
2482,7/3/2024 6:55:01 PM,AbbVie Q2 IPR&D expenses to lower EPS by $0.52,Seeking Alpha,https://seekingalpha.com/news/4122207-abbvie-q2-iprd-expenses-to-lower-eps-by-52-cents?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7019425630569458
2483,7/7/2024 3:39:52 PM,"EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",Benzinga,/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664,positive,0.6258196830749512
2484,7/9/2024 11:40:00 AM,The 7 Best Warren Buffett Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-best-warren-buffett-stocks-7-names-to-buy-in-july-1033539110,positive,0.930526614189148
2485,7/9/2024 12:07:21 PM,AbbVie (ABBV) Receives a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/abbvie-abbv-receives-a-buy-from-cantor-fitzgerald-1033540256,positive,0.8255311250686646
2486,7/10/2024 8:58:22 AM,AbbVie (ABBV) Gets a Buy from Barclays,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-barclays-1033543037,positive,0.5565902590751648
2487,7/10/2024 9:01:07 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-neurocrine-nbix-and-abbvie-abbv-1033543003,neutral,0.7859089970588684
2488,7/10/2024 9:10:11 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: R1 RCM (RCM) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-r1-rcm-rcm-and-abbvie-abbv-1033542990,neutral,0.8125759363174438
2489,7/10/2024 12:47:39 PM,AbbVie names new R&D head,Seeking Alpha,https://seekingalpha.com/news/4123266-abbvie-stock-watch-after-new-rd-head?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9259082078933716
2490,7/10/2024 2:45:15 PM,"AbbVie Appoints Thakkar As EVP Of R&D, Chief Scientific Officer ",RTTNews,/news/stocks/abbvie-appoints-thakkar-as-evp-of-r-d-chief-scientific-officer-1033543160,positive,0.9185194969177246
2491,7/11/2024 9:40:36 AM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Roche Holding AG (OtherRHHVF) and UnitedHealth (UNH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-roche-holding-ag-otherrhhvf-and-unitedhealth-unh-1033546915,positive,0.9263616800308228
2492,7/12/2024 12:13:20 PM,"Dividend Roundup: Procter & Gamble, Costco, CVS Health, Colgate-Palmolive, and more",Seeking Alpha,https://seekingalpha.com/news/4123917-dividend-roundup-procter-gamble-costco-cvs-health-colgate-palmolive-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9423165917396545
2493,7/12/2024 2:47:50 PM,AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis ,RTTNews,/news/stocks/abbvie-seeking-fda-and-ema-approval-for-upadacitinib-in-giant-cell-arteritis-1033550323,negative,0.8939110636711121
2494,7/12/2024 5:28:20 PM,AbbVie Gains As Market Dips: What You Should Know,Benzinga,/news/stocks/abbvie-gains-as-market-dips-what-you-should-know-1033551111,positive,0.7955591678619385
2495,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8902468085289001
2496,7/15/2024 4:31:04 PM,3 Spinoff Stocks You Should Buy Now: July 2024,InvestorPlace,/news/stocks/3-spinoff-stocks-you-should-buy-now-july-2024-1033556404,positive,0.9416065812110901
2497,7/16/2024 10:00:00 AM,7 Recession-Proof Stocks to Shield Your Portfolio in 2024,InvestorPlace,/news/stocks/7-recession-proof-stocks-to-shield-your-portfolio-in-2024-1033558601,positive,0.8382173180580139
2498,7/16/2024 10:30:00 AM,3 Quantum AI Stocks That Could Redefine Computing,InvestorPlace,/news/stocks/3-quantum-ai-stocks-that-could-redefine-computing-1033558686,positive,0.8941410779953003
2499,7/16/2024 1:12:31 PM,AbbVie invests in Sionna as part of licensing deal for CF drugs,Seeking Alpha,https://seekingalpha.com/news/4124595-abbvie-invests-sionna-licensing-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8242208361625671
2500,7/16/2024 6:00:00 PM,7 High-Yield Dividend Stocks Beating Inflation,InvestorPlace,/news/stocks/7-high-yield-dividend-stocks-beating-inflation-1033560590,negative,0.795750617980957
2501,7/17/2024 4:21:06 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), GoodRx Holdings (GDRX) and Organon (OGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-abbvie-abbv-goodrx-holdings-gdrx-and-organon-ogn-1033565543,neutral,0.947489321231842
2502,7/17/2024 6:09:20 PM,Big pharma rally after J&J earnings,Seeking Alpha,https://seekingalpha.com/news/4125149-big-pharma-rally-after-jj-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5109472870826721
2503,7/17/2024 6:18:30 PM,7 High-Yield Dividend Stocks to Help Pay Your Bills,InvestorPlace,/news/stocks/7-high-yield-dividend-stocks-to-help-pay-your-bills-1033565174,positive,0.9018194079399109
2504,7/18/2024 10:50:20 AM,GoodRx offers exclusive discount to biosimilar targeting AbbVie’s Humira,Seeking Alpha,https://seekingalpha.com/news/4125378-goodrx-offers-discount-humira-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7141033411026001
2505,7/19/2024 7:00:00 PM,"Catalyst watch: Earnings deluge, Farnborough Airshow, Paris Olympics, and Trump talks crypto",Seeking Alpha,https://seekingalpha.com/news/4125573-catalyst-watch-earnings-deluge-farnborough-airshow-paris-olympics-and-trump-talks-crypto?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8376867771148682
2506,7/19/2024 7:00:14 PM,Peeling Back The Layers: Exploring AbbVie Through Analyst Insights,Benzinga,/news/stocks/peeling-back-the-layers-exploring-abbvie-through-analyst-insights-1033573328,positive,0.8876813054084778
2507,7/20/2024 7:58:00 PM,Financials dominate in Q2 as Wall Street slides amidst concerns on tech - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4125975-financials-dominate-in-q2-as-wall-street-slides-amidst-concerns-on-tech-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9675024151802063
2508,7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7739253044128418
2509,7/21/2024 12:01:00 PM,"Earnings week ahead: TSLA, GOOG, IBM, AAL, GM, F, VZ, T, and more",Seeking Alpha,https://seekingalpha.com/news/4125930-earnings-week-ahead-tsla-goog-ibm-aal-gm-f-vz-t-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9146556854248047
2510,7/22/2024 1:02:13 AM,Kamala Harris' potential impact on health care stocks,Seeking Alpha,https://seekingalpha.com/news/4126065-kamala-harris-potential-impact-health-care-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49974918365478516
2511,7/22/2024 8:03:14 PM,Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie,Seeking Alpha,https://seekingalpha.com/news/4126455-cerevel-therapeutics-gains-as-investors-appear-more-confident-on-ftc-approval-for-abbvie?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9504120945930481
2512,7/23/2024 10:39:22 AM,Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-abbvie-abbv-1033582776,positive,0.8173244595527649
2513,7/24/2024 4:08:08 PM,AbbVie Q2 Earnings Preview: Focus on the new era of the company,Seeking Alpha,https://seekingalpha.com/news/4127665-abbvie-q2-earnings-preview-focus-on-the-new-era-of-the-company?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8908677101135254
2514,7/24/2024 8:18:53 PM,7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio,InvestorPlace,/news/stocks/7-trustworthy-dividend-stocks-to-steadily-build-your-portfolio-1033590875,negative,0.798680305480957
2515,7/25/2024 11:37:14 AM,"AbbVie Non-GAAP EPS of $2.65 misses by $0.01, revenue of $14.46B beats by $430M",Seeking Alpha,https://seekingalpha.com/news/4128225-abbvie-non-gaap-eps-of-2_65-misses-0_01-revenue-of-14_46b-beats-430m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5687713027000427
2516,7/25/2024 11:47:51 AM,Earnings summary: AbbVie reports mixed Q2 results; raises FY24 EPS outlook,Seeking Alpha,https://seekingalpha.com/news/4128236-earnings-summary-abbvie-reports-mixed-q2-results-raises-fy24-eps-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9396466612815857
2517,7/25/2024 11:48:21 AM,"AbbVie in charts: Skyrizi, Rinvoq sales jump, while Humira revenue falls ~30% Y/Y in Q2",Seeking Alpha,https://seekingalpha.com/news/4128232-abbvie-q2-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9501991271972656
2518,7/25/2024 12:19:08 PM,AbbVie raises outlook as new immunology drugs offset Humira impact,Seeking Alpha,https://seekingalpha.com/news/4128262-abbvie-stock-in-focus-improved-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9508212208747864
2519,7/25/2024 1:17:00 PM,"4 stocks to watch on Thursday: LUV, LINE and more",Seeking Alpha,https://seekingalpha.com/news/4128343-4-stocks-to-watch-on-thursday-luv-line-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9196087121963501
2520,7/25/2024 1:42:22 PM,"AbbVie Q2 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/abbvie-q2-profit-decreases-but-beats-estimates-1033594105,neutral,0.9707385301589966
2521,7/25/2024 1:44:24 PM,Cerevel gains as AbbVie says it expects deal to close soon (update),Seeking Alpha,https://seekingalpha.com/news/4128352-cerevel-ticks-higher-as-abbvie-says-it-expects-deal-to-close-soon?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5972436666488647
2522,7/25/2024 1:47:44 PM,AbbVie Boosts FY24 Outlook - Update ,RTTNews,/news/stocks/abbvie-boosts-fy24-outlook-update-1033594116,negative,0.8363978862762451
2523,7/25/2024 2:31:57 PM,AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today,InvestorPlace,/news/stocks/abbvie-stock-news-why-abbv-is-the-top-trending-ticker-today-1033595449,positive,0.9128079414367676
2524,7/25/2024 3:52:54 PM,"ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024",InvestorPlace,/news/stocks/abbv-stock-earnings-abbvie-for-q2-of-2024-1033595928,negative,0.7141971588134766
2525,7/26/2024 8:37:24 AM,Barclays Reaffirms Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-abbvie-abbv-1033599789,positive,0.8019400238990784
2526,7/26/2024 8:46:14 AM,European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis ,RTTNews,/news/stocks/european-commission-approves-abbvie-s-skyrizi-to-treat-ulcerative-colitis-1033598540,negative,0.7284817099571228
2527,7/26/2024 8:47:25 AM,Buy Rating Affirmed for AbbVie Amidst Strong Financials and Strategic Management,TipRanks,/news/stocks/buy-rating-affirmed-for-abbvie-amidst-strong-financials-and-strategic-management-1033599915,negative,0.9513617157936096
2528,7/26/2024 11:26:17 AM,Buy Rating Affirmed for AbbVie: Strong Commercial Execution and Strategic Growth Post-Humira,TipRanks,/news/stocks/buy-rating-affirmed-for-abbvie-strong-commercial-execution-and-strategic-growth-post-humira-1033600815,negative,0.9500490427017212
2529,7/26/2024 11:35:26 AM,Cantor Fitzgerald Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-abbvie-abbv-1033600918,positive,0.8811273574829102
2530,7/26/2024 11:36:52 AM,Truist Financial Sticks to Their Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-abbvie-abbv-1033600903,positive,0.7924084067344666
2531,7/26/2024 12:19:35 PM,Morgan Stanley Sticks to Their Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-buy-rating-for-abbvie-abbv-1033601143,positive,0.8486794233322144
2532,7/26/2024 3:18:45 PM,AbbVie exits Alzheimer’s program on lack of differentiation,Seeking Alpha,https://seekingalpha.com/news/4129035-abbvie-axes-alzheimers-drug-mid-stage-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7185733914375305
2533,7/28/2024 2:00:00 PM,Most U.S. pharmas don't pay any U.S. income tax,Seeking Alpha,https://seekingalpha.com/news/4129257-most-us-pharmas-dont-pay-any-us-income-tax?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9261671304702759
2534,7/29/2024 10:00:00 AM,3 Dividend-Paying ETFs to Secure Your Passive Income Stream,InvestorPlace,/news/stocks/3-dividend-paying-etfs-to-secure-your-passive-income-stream-1033605444,positive,0.8814241290092468
2535,7/29/2024 1:50:18 PM,3 High-Yield Dividend Stocks That Are Looking Super Hot,InvestorPlace,/news/stocks/3-high-yield-dividend-stocks-that-are-looking-super-hot-1033606477,positive,0.6259255409240723
2536,7/30/2024 6:12:56 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-aptargroup-atr-and-abbvie-abbv-1033610735,neutral,0.8324587941169739
2537,7/30/2024 10:52:03 AM,"Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-top-healthcare-picks-edwards-lifesciences-ew-abbvie-abbv-1033612401,negative,0.65068519115448
2538,7/30/2024 12:45:09 PM,Evercore ISI Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/evercore-isi-sticks-to-its-buy-rating-for-abbvie-abbv-1033613267,positive,0.7726407647132874
2539,7/31/2024 10:15:00 AM,3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle,InvestorPlace,/news/stocks/3-powerhouse-growth-stocks-to-load-up-on-during-this-bull-market-cycle-1033617155,positive,0.6731215715408325
2540,7/31/2024 10:22:00 AM,7 Stocks Set for a Major Bull Run,InvestorPlace,/news/stocks/7-stocks-set-for-a-major-bull-run-1033617152,positive,0.6159676909446716
2541,7/31/2024 11:00:00 AM,Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?,InvestorPlace,/news/stocks/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making-1033617326,positive,0.9267992377281189
2542,7/31/2024 12:50:23 PM,Cerevel Therapeutics ticks higher amid Nasdaq delisting notice for AbbVie deal,Seeking Alpha,https://seekingalpha.com/news/4131025-cerevel-therapeutics-ticks-higher-amid-nasdaq-delisting-notice-for-abbvie-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5454814434051514
2543,8/1/2024 2:56:30 PM,AbbVie completes acquisition of Cerevel Therapeutics,Seeking Alpha,https://seekingalpha.com/news/4132380-abbvie-completes-acquisition-cerevel-therapeutics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7550035119056702
2544,8/1/2024 3:40:54 PM,AbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance Range ,RTTNews,/news/stocks/abbvie-completes-acquisition-of-cerevel-reaffirms-full-year-adj-eps-guidance-range-1033626945,negative,0.82888263463974
2545,8/8/2024 4:26:50 PM,Aldeyra climbs after late-stage success for dry eye disease therapy,Seeking Alpha,https://seekingalpha.com/news/4137394-aldeyra-stock-climbs-after-trial-success?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8822839260101318
2546,8/15/2024 4:49:05 AM,The 3 Best Stocks to Buy to Survive Another S&P 500 Crash,InvestorPlace,/news/stocks/the-3-best-stocks-to-buy-to-survive-another-sp-500-crash-1033693227,positive,0.785976231098175
2547,8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9052250385284424
2548,8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.802365779876709
2549,8/17/2024 2:09:07 PM,Trending stocks this week as U.S. equities notch their best week of 2024,Seeking Alpha,https://seekingalpha.com/news/4141247-trending-stocks-this-week-as-us-equities-notch-their-best-week-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7283941507339478
2550,8/19/2024 6:41:48 PM,"AbbVie, Genmab receive European approval for Tepkinly in follicular lymphoma",Seeking Alpha,https://seekingalpha.com/news/4141587-abbvie--genmab-receives-european-approval-tepkinly-indication-follicular-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9298211932182312
2551,8/19/2024 7:07:33 PM,Small-cap and mid-cap Health Care has room to rally - Roth MKM,Seeking Alpha,https://seekingalpha.com/news/4141609-small-cap-and-mid-cap-health-care-has-room-to-rally-roth-mkm?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7902520298957825
2552,8/20/2024 2:59:02 AM,AbbVie's Tepkinly Gets Conditional EU Approval For Relapsed Or Refractory Follicular Lymphoma ,RTTNews,/news/stocks/abbvie-s-tepkinly-gets-conditional-eu-approval-for-relapsed-or-refractory-follicular-lymphoma-1033705439,negative,0.9398688673973083
2553,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5784038305282593
2554,8/23/2024 11:07:35 AM,Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-abbvie-abbv-1033718552,positive,0.8173244595527649
2555,8/28/2024 12:05:51 PM,Neurocrine stock dips even as schizophrenia drug meets main goal in study,Seeking Alpha,https://seekingalpha.com/news/4144517-neurocrine-stock-dips-even-as-schizophrenia-drug-meets-main-goal-in-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9590901136398315
2556,8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8434954881668091
2557,8/29/2024 2:30:37 PM,"Neurocrine upped to overweight by Piper, sees '568 as still viable",Seeking Alpha,https://seekingalpha.com/news/4145099-piper-ups-neurocrine-to-overweight-says-568-still-in-the-game?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7126744985580444
2558,8/30/2024 6:45:18 AM,AbbVie Stock Hold Rating with Revised EPS and Pipeline Prospects,TipRanks,/news/stocks/abbvie-stock-hold-rating-with-revised-eps-and-pipeline-prospects-1033736213,positive,0.8342920541763306
2559,9/3/2024 8:57:02 AM,Positive Outlook for AbbVie: Buy Rating Affirmed Amid Strong Aesthetics Sales and Market Share Stability,TipRanks,/news/stocks/positive-outlook-for-abbvie-buy-rating-affirmed-amid-strong-aesthetics-sales-and-market-share-stability-1033743126,negative,0.955528199672699
2560,9/4/2024 2:19:06 PM,AbbVie: CDA Issues Positive Reimbursement Recommendation For VRAYLAR In Treatment Of Schizophrenia ,RTTNews,/news/stocks/abbvie-cda-issues-positive-reimbursement-recommendation-for-vraylar-in-treatment-of-schizophrenia-1033746891,negative,0.9534429907798767
2561,9/5/2024 6:07:36 PM,Cigna to offer biosimilar to J&J’s arthritis drug Stelara at $0 out-of-pocket,Seeking Alpha,https://seekingalpha.com/news/4147414-cigna-touts-biosimilar-jj-arthritis-drug-stelara?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7320741415023804
2562,9/6/2024 2:16:11 PM,AbbVie declares $1.55 dividend,Seeking Alpha,https://seekingalpha.com/news/4147689-abbvie-declares-1_55-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.940312922000885
2563,9/6/2024 10:01:11 PM,"Piper Sandler ups Intra-Cellular to overweight, cites Caplyta potential",Seeking Alpha,https://seekingalpha.com/news/4147815-piper-sandler-ups-intra-cellular-to-overweight-cites-caplyta-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7418096661567688
2564,9/10/2024 1:08:31 PM,AbbVie Says Health Canada Approves CONSTELLA To Treat Functional Constipation In Pediatric Patients ,RTTNews,/news/stocks/abbvie-says-health-canada-approves-constella-to-treat-functional-constipation-in-pediatric-patients-1033759986,negative,0.8120850324630737
2565,9/10/2024 5:19:09 PM,"UnitedHealth joins Cigna, CVS in removing AbbVie's Humira from formularies: report",Seeking Alpha,https://seekingalpha.com/news/4148432-abbvie-stock-slips-unitedhealth-removing-humira?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8532680869102478
2566,9/11/2024 4:21:29 PM,Abbvie's Botox launches for wide jaw appearance in China,Seeking Alpha,https://seekingalpha.com/news/4148734-abbvie-botox-launches-for-wide-jaw-appearance-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6034117341041565
2567,9/13/2024 8:07:30 AM,Maintaining a Hold: Balancing AbbVie’s Strategic Successes Against Market Challenges,TipRanks,/news/stocks/maintaining-a-hold-balancing-abbvie-s-strategic-successes-against-market-challenges-1033769849,positive,0.5736782550811768
2568,9/18/2024 8:18:20 PM,BeiGene initiated at outperform at JMP Securities on strength of Brukinsa,Seeking Alpha,https://seekingalpha.com/news/4150909-beigene-initiated-outperform-jmp-securities-strength-brukinsa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9050130844116211
2569,9/20/2024 1:54:52 PM,AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts ,RTTNews,/news/stocks/abbvie-chmp-adopts-positive-opinion-for-mirvetuximab-soravtansine-quick-facts-1033786172,negative,0.9277493953704834
2570,9/23/2024 7:17:40 PM,UCB gets expanded FDA approval for psoriasis drug Bimzelx,Seeking Alpha,https://seekingalpha.com/news/4152277-ucb-gets-expanded-fda-approval-for-psoriasis-drug-bimzelx?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9338517189025879
2571,9/25/2024 2:30:55 PM,AbbVie Rinvoq shows effectiveness for atopic dermatitis in head and neck,Seeking Alpha,https://seekingalpha.com/news/4153135-abbvie-rinvoq-shows-effectiveness-atopic-dermatitis-head-and-neck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9374812841415405
2572,9/25/2024 2:47:21 PM,AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis ,RTTNews,/news/stocks/abbvie-upadacitinib-phase-3-trials-post-hoc-analysis-show-positive-results-in-atopic-dermatitis-1033796725,negative,0.9457392692565918
2573,9/25/2024 6:29:49 PM,Amgen stock slides 5% as analysts weigh in on drug study results,Seeking Alpha,https://seekingalpha.com/news/4153393-amgen-stock-slides-as-analysts-weigh-in-on-drug-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.941432535648346
2574,9/26/2024 12:34:36 PM,AbbVie Parkinson's disease therapy hits main goal in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4153652-abbvie-posts-trial-win-parkinsons-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.812262773513794
2575,9/26/2024 2:40:32 PM,"AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease ",RTTNews,/news/stocks/abbvie-tavapadon-meets-primary-secondary-endpoints-in-phase-3-trial-in-early-parkinson-s-disease-1033800514,negative,0.9257956147193909
2576,9/27/2024 11:20:12 AM,"Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-abbvie-abbv-acadia-pharmaceuticals-acad-1033804209,positive,0.49678975343704224
2577,9/27/2024 4:42:14 PM,AbbVie submits BLA for antibody-drug conjugate Teliso-V for NSCLC,Seeking Alpha,https://seekingalpha.com/news/4154185-abbvie-submits-bla-antibody-drug-conjugate-teliso-v-nsclc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7778570652008057
2578,9/27/2024 5:17:01 PM,AbbVie’s Parkinson’s Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials,TipRanks,/news/stocks/abbvie-s-parkinson-s-drug-tavapadon-a-market-perform-rating-amidst-competitive-landscape-and-clinical-trials-1033804865,negative,0.6472848057746887
2579,9/27/2024 5:59:43 PM,"Bristol Cobenfy approval draws optimism from Street, though with caveats",Seeking Alpha,https://seekingalpha.com/news/4154179-bristol-cobenfy-approval-draws-optimism-from-street-though-with-caveats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.862154483795166
2580,9/28/2024 8:43:01 AM,AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer ,RTTNews,/news/stocks/abbvie-submits-bla-to-fda-for-telisotuzumab-vedotin-in-previously-treated-non-small-cell-lung-cancer-1033805061,negative,0.6144348382949829
2581,9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.941364049911499
2582,9/29/2024 4:12:57 PM,"Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales",Seeking Alpha,https://seekingalpha.com/news/4154326-novo-nordisk-ozempic-regeneron-sanofi-dupixent-advance-top-drug-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9307808876037598
2583,10/1/2024 5:51:12 PM,AbbVie withdraws Exviera from EU market for commercial reasons,Seeking Alpha,https://seekingalpha.com/news/4155153-abbvie-withdraws-exviera-from-eu-market-for-commercial-reasons?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8888517022132874
2584,10/1/2024 6:26:37 PM,"CVS, Cigna PBMs targeted as lawmakers criticize new ""anti-competitive"" move",Seeking Alpha,https://seekingalpha.com/news/4155176-cvs-cigna-pbms-railed-anticompetitive-move?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7786320447921753
2585,10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7824940085411072
2586,10/3/2024 10:09:45 PM,AbbVie lowers 2024 earnings forecast by $0.04 per share,Seeking Alpha,https://seekingalpha.com/news/4156300-abbvie-lowers-2024-earnings-forecast-by-004-per-share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9457460045814514
2587,10/3/2024 11:22:02 PM,"AbbVie Cuts Q3, FY Adj. EPS Outlook ",RTTNews,/news/stocks/abbvie-cuts-q3-fy-adj-eps-outlook-1033819529,positive,0.532462477684021
2588,10/7/2024 2:15:06 AM,AbbVie (ABBV) Gets a Buy from Barclays,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-barclays-1033823285,positive,0.5565902590751648
2589,10/8/2024 6:03:33 PM,Harris home health care benefit likely funded through Medicare drug negotiations savings,Seeking Alpha,https://seekingalpha.com/news/4157079-harris-home-health-care-benefit-could-funded-through-medicare-drug-negotiations-savings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8432395458221436
2590,10/9/2024 8:05:16 PM,"AbbVie snaps six days of losses, trades in the green",Seeking Alpha,https://seekingalpha.com/news/4157380-abbvie-snaps-six-days-of-losses-trades-in-the-green?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.48011183738708496
2591,10/11/2024 12:29:30 PM,"Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and more",Seeking Alpha,https://seekingalpha.com/news/4157846-dividend-roundup-pfizer-caterpillar-pnc-financial-abbvie-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9448760747909546
2592,10/11/2024 12:30:36 PM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-ionis-pharmaceuticals-ions-and-amicus-fold-1033839292,positive,0.9105093479156494
2593,10/16/2024 8:45:35 AM,Optimistic Outlook for AbbVie: Strong Performance of Skyrizi and Rinvoq Drive Buy Rating,TipRanks,/news/stocks/optimistic-outlook-for-abbvie-strong-performance-of-skyrizi-and-rinvoq-drive-buy-rating-1033851024,negative,0.9531354308128357
2594,10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7325470447540283
2595,10/17/2024 12:27:06 PM,AbbVie wins FDA nod for advanced Parkinson's therapy,Seeking Alpha,https://seekingalpha.com/news/4169184-abbvie-wins-fda-nod-for-advanced-parkinsons-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8751168251037598
2596,10/17/2024 2:25:42 PM,FDA Approves AbbVie's Parkinson's Disease Drug Vyalev ,RTTNews,/news/stocks/fda-approves-abbvie-s-parkinson-s-disease-drug-vyalev-1033855291,negative,0.6317475438117981
2597,10/18/2024 1:20:09 PM,"Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merit-medical-systems-mmsi-abbvie-abbv-and-elevance-health-elv-1033859917,positive,0.9128952622413635
2598,10/19/2024 12:30:13 AM,Allergan’s BOTOX Cosmetic gets FDA approval in jaw-neck bands,TipRanks,/news/stocks/allergan-s-botox-cosmetic-gets-fda-approval-in-jaw-neck-bands-1033860998,negative,0.8668288588523865
2599,10/19/2024 1:23:45 PM,Allergan Aesthetics: FDA Approves BOTOX® Cosmetic For The Treatment Of Platysma Bands ,RTTNews,/news/stocks/allergan-aesthetics-fda-approves-botox-cosmetic-for-the-treatment-of-platysma-bands-1033860431,negative,0.7841256260871887
2600,10/21/2024 11:10:14 AM,Regenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMD,TipRanks,/news/stocks/regenxbio-presents-positive-phase-2-data-of-abbv-rgx-314-in-wet-amd-1033864943,negative,0.9451046586036682
2601,10/21/2024 4:28:09 PM,AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces ,RTTNews,/news/stocks/abbvie-gets-accelerated-public-reimbursement-approval-of-epkinly-in-nine-canadian-provinces-1033865066,negative,0.9405264258384705
2602,10/23/2024 6:46:04 AM,AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating,TipRanks,/news/stocks/abbvie-balanced-outlook-amid-eps-adjustments-and-pipeline-uncertainties-warrants-hold-rating-1033877219,negative,0.9423061013221741
2603,10/23/2024 11:39:12 AM,AbbVie (ABBV) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/abbvie-abbv-gets-a-buy-from-piper-sandler-1033879434,positive,0.5950971841812134
2604,10/24/2024 3:35:09 PM,"AbbVie, Gedeon Richter collaborate for discovery, development of novel targets",TipRanks,/news/stocks/abbvie-gedeon-richter-collaborate-for-discovery-development-of-novel-targets-1033888557,positive,0.7506893873214722
2605,10/25/2024 10:20:47 AM,AbbVie price target raised to $215 from $170 at Citi,TipRanks,/news/stocks/abbvie-price-target-raised-to-215-from-170-at-citi-1033892714,negative,0.9423768520355225
2606,10/26/2024 5:46:00 PM,About 75% of companies that reported earnings this week delivered EPS wins-Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4205854-about-75-of-companies-that-reported-earnings-this-week-delivered-eps-wins-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8234386444091797
2607,10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9362694025039673
2608,10/28/2024 12:06:09 PM,AbbVie to acquire Aliada Therapeutics for $1.4B in cash,TipRanks,/news/stocks/abbvie-to-acquire-aliada-therapeutics-for-1-4b-in-cash-1033902647,positive,0.9131810665130615
2609,10/28/2024 12:06:28 PM,AbbVie to acquire Aliada Therapeutics for $1.4B in cash,TipRanks,/news/stocks/abbvie-to-acquire-aliada-therapeutics-for-1-4b-in-cash-1033902641,positive,0.9131810665130615
2610,10/28/2024 12:14:47 PM,AbbVie to buy Aliada Therapeutics for $1.4B in cash,Seeking Alpha,https://seekingalpha.com/news/4213047-abbvie-to-buy-aliada-therapeutics-for-14b-in-cash?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8785801529884338
2611,10/28/2024 1:19:42 PM,AbbVie Agrees To Acquire Aliada Therapeutics For $1.4 Bln In Cash ,RTTNews,/news/stocks/abbvie-agrees-to-acquire-aliada-therapeutics-for-1-4-bln-in-cash-1033901268,positive,0.8102081418037415
2612,10/29/2024 12:06:34 PM,Cautious Hold Rating on AbbVie Amid Uncertainty of Aliada Acquisition’s Long-term Impact,TipRanks,/news/stocks/cautious-hold-rating-on-abbvie-amid-uncertainty-of-aliada-acquisition-s-long-term-impact-1033910322,negative,0.5706976056098938
2613,10/29/2024 6:00:55 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033911969,positive,0.9220908284187317
2614,10/29/2024 6:33:40 PM,AbbVie Q3 Earnings Preview: Modest guidance raise expected,Seeking Alpha,https://seekingalpha.com/news/4220268-abbvie-q3-earnings-preview-modest-guidance-raise-expected?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9065552949905396
2615,10/29/2024 7:00:39 PM,AbbVie small cell lung cancer treatment granted FDA orphan designation,TipRanks,/news/stocks/abbvie-small-cell-lung-cancer-treatment-granted-fda-orphan-designation-1033912196,negative,0.553713858127594
2616,10/30/2024 11:40:14 AM,"AbbVie Non-GAAP EPS of $3.00 beats by $0.08, revenue of $14.46B beats by $180M",Seeking Alpha,https://seekingalpha.com/news/4222559-abbvie-non-gaap-eps-of-3_00-beats-0_08-revenue-of-14_46b-beats-180m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5997108817100525
2617,10/30/2024 11:41:07 AM,AbbVie raises FY24 adjusted EPS view to $10.90-$10.94 from $10.67-$10.87,TipRanks,/news/stocks/abbvie-raises-fy24-adjusted-eps-view-to-10-90--10-94-from-10-67--10-87-1033918355,negative,0.9380530714988708
2618,10/30/2024 11:41:39 AM,"AbbVie reports Q3 adjusted EPS $3.00, consensus $2.91",TipRanks,/news/stocks/abbvie-reports-q3-adjusted-eps-3-00-consensus-2-91-1033918347,positive,0.81337571144104
2619,10/30/2024 11:46:32 AM,AbbVie announces 2025 dividend increase of 5.8% to $1.64 from $1.55 per share,TipRanks,/news/stocks/abbvie-announces-2025-dividend-increase-of-5-8-to-1-64-from-1-55-per-share-1033918585,negative,0.9463093280792236
2620,10/30/2024 11:48:05 AM,AbbVie lifts dividend by 5.8% to $1.64/share,Seeking Alpha,https://seekingalpha.com/news/4222566-abbvie-lifts-dividend-by-58-to-164share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9238550066947937
2621,10/30/2024 12:00:13 PM,"Earnings Snapshot: AbbVie FY profit guidance beats forecast, Q3 Humira revenue lags",Seeking Alpha,https://seekingalpha.com/news/4222569-earnings-snapshot-abbvie-fy-profit-guidance-beats-forecast-q3-humira-revenue-lags?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9678685665130615
2622,10/30/2024 12:10:44 PM,AbbVie lifts outlook again on immunology demand; dividend raised,Seeking Alpha,https://seekingalpha.com/news/4222641-abbvie-lifts-outlook-again-on-immunology-demand-dividend-raised?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9375719428062439
2623,10/30/2024 12:11:39 PM,"AbbVie in charts: Humira Q3 revenues of $2.23B plunges 37%, Skyrizi, Rinvoq gain Y/Y",Seeking Alpha,https://seekingalpha.com/news/4222642-abbvie-in-charts-humira-q3-skyrizi-rinvoq?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8765246868133545
2624,10/30/2024 12:47:54 PM,"AbbVie Q3 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/abbvie-q3-profit-decreases-but-beats-estimates-1033916720,neutral,0.9708675146102905
2625,10/30/2024 12:52:54 PM,AbbVie Boosts FY24 Outlook; Boosts Dividend 5.8% - Update ,RTTNews,/news/stocks/abbvie-boosts-fy24-outlook-boosts-dividend-5-8-update-1033916730,negative,0.9449489712715149
2626,10/30/2024 1:01:23 PM,Morning Movers: Caterpillar and Eli Lilly sink following quarterly reports,TipRanks,/news/stocks/morning-movers-caterpillar-and-eli-lilly-sink-following-quarterly-reports-1033919565,positive,0.9493290185928345
2627,10/30/2024 1:12:10 PM,AbbVie says performing ‘exceptionally well’,TipRanks,/news/stocks/abbvie-says-performing-exceptionally-well-1033919507,negative,0.9506629705429077
2628,10/30/2024 1:20:00 PM,"5 stocks to watch on Wednesday: MSFT, META, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4223018-5-stocks-to-watch-on-wednesday-msft-meta-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9399659037590027
2629,10/30/2024 1:30:17 PM,AbbVie says ‘pleased’ with progress advancing product pipeline,TipRanks,/news/stocks/abbvie-says-pleased-with-progress-advancing-product-pipeline-1033919765,negative,0.9136379361152649
2630,10/30/2024 1:35:14 PM,AbbVie sees FY24 adjusted gross margin 84%,TipRanks,/news/stocks/abbvie-sees-fy24-adjusted-gross-margin-84-1033919753,negative,0.9092658162117004
2631,10/30/2024 1:35:41 PM,"AbbVie sees Q4 adjusted EPS $2.94-$2.98, consensus $2.95",TipRanks,/news/stocks/abbvie-sees-q4-adjusted-eps-2-94--2-98-consensus-2-95-1033919748,negative,0.6226762533187866
2632,10/30/2024 1:36:00 PM,"AbbVie raises FY24 revenue view to ~$56B from  ~$55.5B, consensus $55.73B",TipRanks,/news/stocks/abbvie-raises-fy24-revenue-view-to-~-56b-from-~-55-5b-consensus-55-73b-1033919745,negative,0.9427297115325928
2633,10/30/2024 1:45:13 PM,AbbVie: Shift in Humira sales volume to biosimilar ‘playing out as anticipated’,TipRanks,/news/stocks/abbvie-shift-in-humira-sales-volume-to-biosimilar-playing-out-as-anticipated-1033919871,negative,0.9410499930381775
2634,10/30/2024 4:15:41 PM,"Alphabet, AMD report Q3 earnings beats: Morning Buzz",TipRanks,/news/stocks/alphabet-amd-report-q3-earnings-beats-morning-buzz-1033920421,positive,0.8454447984695435
2635,10/30/2024 5:58:22 PM,What’s behind AbbVie's Q3 revenue beat?,Seeking Alpha,https://seekingalpha.com/news/4225082-reasons-behind-abbvie-q-3-revenue-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8657066822052002
2636,10/31/2024 2:11:47 AM,AbbVie: Strong Financial Performance and Optimistic Outlook with Key Product Growth,TipRanks,/news/stocks/abbvie-strong-financial-performance-and-optimistic-outlook-with-key-product-growth-1033922504,negative,0.9398108720779419
2637,10/31/2024 2:12:03 AM,AbbVie: Strong Growth Momentum and Strategic Shifts Highlight Compelling Investment Opportunity,TipRanks,/news/stocks/abbvie-strong-growth-momentum-and-strategic-shifts-highlight-compelling-investment-opportunity-1033922502,negative,0.9511050581932068
2638,10/31/2024 2:17:02 AM,"AbbVie Buy Rating: Strategic Growth Through Skyrizi, Rinvoq, and Pipeline Expansion",TipRanks,/news/stocks/abbvie-buy-rating-strategic-growth-through-skyrizi-rinvoq-and-pipeline-expansion-1033922476,negative,0.6221070289611816
2639,10/31/2024 2:18:40 AM,AbbVie’s Strong Market Position and Promising Pipeline Justify Buy Rating,TipRanks,/news/stocks/abbvie-s-strong-market-position-and-promising-pipeline-justify-buy-rating-1033922466,negative,0.924476683139801
2640,10/31/2024 4:43:19 AM,AbbVie Reports Solid Q3 2024 Financial Performance,TipRanks,/news/stocks/abbvie-reports-solid-q3-2024-financial-performance-1033925637,negative,0.9477289915084839
2641,10/31/2024 8:38:09 AM,Barclays Reaffirms Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-abbvie-abbv-1033927215,positive,0.8019400238990784
2642,10/31/2024 9:20:12 AM,AbbVie price target raised to $226 from $215 at Citi,TipRanks,/news/stocks/abbvie-price-target-raised-to-226-from-215-at-citi-1033927651,negative,0.9433810114860535
2643,10/31/2024 10:08:07 AM,AbbVie: Strong Q3 Performance and Raised 2024 Guidance Amid Aesthetics Uncertainty and Market Volatility Risks,TipRanks,/news/stocks/abbvie-strong-q3-performance-and-raised-2024-guidance-amid-aesthetics-uncertainty-and-market-volatility-risks-1033928093,negative,0.9549420475959778
2644,10/31/2024 11:04:47 AM,Cantor Fitzgerald Keeps Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-abbvie-abbv-1033928693,positive,0.9304285645484924
2645,10/31/2024 11:46:02 AM,AbbVie price target raised to $210 from $195 at BofA,TipRanks,/news/stocks/abbvie-price-target-raised-to-210-from-195-at-bofa-1033929143,negative,0.9480431079864502
2646,10/31/2024 1:50:33 PM,"AbbVie, EvolveImmune To Develop Multispecific Biologics For Multiple Targets In Oncology ",RTTNews,/news/stocks/abbvie-evolveimmune-to-develop-multispecific-biologics-for-multiple-targets-in-oncology-1033927893,positive,0.7096874117851257
2647,10/31/2024 2:05:53 PM,AbbVie price target raised to $200 from $195 at UBS,TipRanks,/news/stocks/abbvie-price-target-raised-to-200-from-195-at-ubs-1033930676,negative,0.9454188942909241
2648,11/2/2024 7:34:00 PM,"M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more",Seeking Alpha,https://seekingalpha.com/news/4233378-ma-deals-roundup-abbvie-blackstone-take-two-interactive-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9349594116210938
2649,11/4/2024 12:31:03 PM,AbbVie upgraded to Buy from Hold at Argus,TipRanks,/news/stocks/abbvie-upgraded-to-buy-from-hold-at-argus-1033945203,positive,0.5042711496353149
2650,11/4/2024 2:00:47 PM,"AbbVie upgraded to Buy at Argus amid Skyrizi/Rinvoq sales growth, stable margins",TipRanks,/news/stocks/abbvie-upgraded-to-buy-at-argus-amid-skyrizi-rinvoq-sales-growth-stable-margins-1033946005,negative,0.9523741006851196
2651,11/4/2024 2:50:17 PM,"Roblox, Peloton upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/roblox-peloton-upgraded-wall-street-s-top-analyst-calls-1033946237,positive,0.731393039226532
2652,11/5/2024 1:36:11 PM,AbbVie price target raised to $180 from $175 at Deutsche Bank,TipRanks,/news/stocks/abbvie-price-target-raised-to-180-from-175-at-deutsche-bank-1033953496,negative,0.9465169906616211
2653,11/6/2024 12:02:23 PM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-neogenomics-neo-and-ultragenyx-pharmaceutical-rare-1033962090,positive,0.9009093046188354
2654,11/6/2024 12:33:47 PM,Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-abbvie-abbv-1033962374,positive,0.5576676726341248
2655,11/6/2024 12:37:56 PM,AbbVie price target raised to $221 from $212 at Guggenheim,TipRanks,/news/stocks/abbvie-price-target-raised-to-221-from-212-at-guggenheim-1033962324,negative,0.9445570111274719
2656,11/6/2024 8:17:19 PM,SA Asks: How will the U.S. election results impact healthcare stocks?,Seeking Alpha,https://seekingalpha.com/news/4257322-sa-asks-how-will-the-us-election-results-impact-healthcare-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7067018747329712
2657,11/11/2024 1:35:32 PM,AbbVie’s emraclidine did not meet endpoint in Phase 2 schizophrenia trials,TipRanks,/news/stocks/abbvie-s-emraclidine-did-not-meet-endpoint-in-phase-2-schizophrenia-trials-1033993484,neutral,0.4821295142173767
2658,11/11/2024 2:32:24 PM,AbbVie declines after missing main goal in schizophrenia treatment trials,Seeking Alpha,https://seekingalpha.com/news/4274511-abbvie-declines-after-missing-main-goal-in-schizophrenia-treatment-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9513044953346252
2659,11/11/2024 2:45:15 PM,"Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets",TipRanks,/news/stocks/bristol-myers-rises-abbvie-sinks-after-schizophrenia-trials-miss-targets-1033993919,neutral,0.5984260439872742
2660,11/11/2024 2:50:30 PM,"Biggest stock movers Monday: Crypto stocks, TSLA, ABBV, and more",Seeking Alpha,https://seekingalpha.com/news/4272963-biggest-stock-movers-monday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9217734932899475
2661,11/11/2024 2:50:34 PM,AbbVie falls -11.1%,TipRanks,/news/stocks/abbvie-falls--11-1-1033993908,neutral,0.9390301704406738
2662,11/11/2024 2:50:36 PM,AbbVie Says Phase 2 Trials Of Emraclidine In Schizophrenia Did Not Meet Primary Endpoint ,RTTNews,/news/stocks/abbvie-says-phase-2-trials-of-emraclidine-in-schizophrenia-did-not-meet-primary-endpoint-1033991900,neutral,0.8933966755867004
2663,11/11/2024 3:05:25 PM,"AbbVie ‘pain’ is Bristol Myers ‘gain’ after emraclidine fails, says Truist",TipRanks,/news/stocks/abbvie-pain-is-bristol-myers-gain-after-emraclidine-fails-says-truist-1033993966,negative,0.6405274868011475
2664,11/11/2024 3:06:05 PM,AbbVie falls -12.2%,TipRanks,/news/stocks/abbvie-falls--12-2-1033993961,neutral,0.9399250149726868
2665,11/11/2024 3:15:16 PM,"JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news",TipRanks,/news/stocks/jpmorgan-sees-abbvie-off-about-10-bristol-up-10--15-on-emraclidine-news-1033994006,neutral,0.8750483393669128
2666,11/11/2024 3:15:23 PM,Positive Long-Term Growth Outlook for AbbVie Despite Emraclidine Setback: Analyst Maintains Buy Rating,TipRanks,/news/stocks/positive-long-term-growth-outlook-for-abbvie-despite-emraclidine-setback-analyst-maintains-buy-rating-1033994005,negative,0.9438502788543701
2667,11/11/2024 3:15:24 PM,Barclays still likes AbbVie into 2025 despite schizophrenia failures,TipRanks,/news/stocks/barclays-still-likes-abbvie-into-2025-despite-schizophrenia-failures-1033994004,negative,0.727849006652832
2668,11/11/2024 3:35:15 PM,Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers,TipRanks,/news/stocks/leerink-sees-abbvie-s-trial-results-as-clear-positive-for-bristol-myers-1033994048,negative,0.9484250545501709
2669,11/11/2024 4:10:06 PM,AbbVie under pressure as schizophrenia drug fails two trials,TipRanks,/news/stocks/abbvie-under-pressure-as-schizophrenia-drug-fails-two-trials-1033994121,neutral,0.9643561244010925
2670,11/11/2024 4:35:39 PM,Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive,TipRanks,/news/stocks/evercore-says-failure-of-emraclidine-may-be-substantial-neurocrine-positive-1033994161,neutral,0.7097480893135071
2671,11/11/2024 5:06:23 PM,Cigna drops pursuit of Humana: Morning Buzz,TipRanks,/news/stocks/cigna-drops-pursuit-of-humana-morning-buzz-1033994222,positive,0.9280061721801758
2672,11/11/2024 5:38:20 PM,How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback,Seeking Alpha,https://seekingalpha.com/news/4275200-how-abbvie-can-still-benefit-cerevel-acquisition-despite-emraclidine-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8106690049171448
2673,11/11/2024 9:04:10 PM,Dow ends session on top while S&P and Nasdaq inch up with CPI data looming,Seeking Alpha,https://seekingalpha.com/news/4276605-dow-ends-on-top-while-sp-and-nasdaq-finish-near-flat-with-cpi-data-looming?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.38556158542633057
2674,11/12/2024 11:00:12 AM,AbbVie price target lowered to $215 from $226 at Citi,TipRanks,/news/stocks/abbvie-price-target-lowered-to-215-from-226-at-citi-1033999327,neutral,0.9092493653297424
2675,11/12/2024 11:06:37 AM,Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges,TipRanks,/news/stocks/positive-outlook-on-abbvie-geoff-meacham-s-buy-rating-and-potential-of-emraclidine-amid-schizophrenia-trial-challenges-1033999303,negative,0.8078053593635559
2676,11/12/2024 11:08:31 AM,"AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven by Skyrizi and Rinvoq Growth",TipRanks,/news/stocks/abbvie-buy-rating-affirmed-despite-emraclidine-setback-driven-by-skyrizi-and-rinvoq-growth-1033999285,negative,0.915656566619873
2677,11/12/2024 11:20:30 AM,Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure,TipRanks,/news/stocks/leerink-upgrades-bristol-to-outperform-after-abbvie-schizophrenia-failure-1033999384,negative,0.767173707485199
2678,11/12/2024 12:31:40 PM,AbbVie price target lowered to $224 from $231 at Morgan Stanley,TipRanks,/news/stocks/abbvie-price-target-lowered-to-224-from-231-at-morgan-stanley-1034000363,neutral,0.9160743951797485
2679,11/12/2024 12:31:53 PM,Bristol Myers price target raised to $39 from $36 at Morgan Stanley,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-39-from-36-at-morgan-stanley-1034000362,negative,0.9449411034584045
2680,11/12/2024 1:22:50 PM,Bristol-Myers upgraded at Leerink after AbbVie setback,Seeking Alpha,https://seekingalpha.com/news/4279606-bristol-myers-stock-upgraded-leerink?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7898422479629517
2681,11/12/2024 1:45:49 PM,AbbVie price target lowered to $208 from $228 at BMO Capital,TipRanks,/news/stocks/abbvie-price-target-lowered-to-208-from-228-at-bmo-capital-1034000985,neutral,0.8848164677619934
2682,11/12/2024 2:45:47 PM,"Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/nvidia-initiated-airbnb-downgraded-wall-street-s-top-analyst-calls-1034001381,neutral,0.6238356232643127
2683,11/12/2024 2:45:59 PM,Bristol Myers price target raised to $61 from $57 at BMO Capital,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-61-from-57-at-bmo-capital-1034001380,negative,0.9454479813575745
2684,11/12/2024 5:05:59 PM,"Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/elliott-confirms-big-honeywell-stake-home-deport-reports-q3-beat-morning-buzz-1034001929,positive,0.8393925428390503
2685,11/13/2024 7:07:57 AM,AbbVie Hold Rating Maintained Amid Emraclidine Trial Challenges and Competitive Pressure,TipRanks,/news/stocks/abbvie-hold-rating-maintained-amid-emraclidine-trial-challenges-and-competitive-pressure-1034006909,neutral,0.801138699054718
2686,11/13/2024 11:50:36 AM,"JPMorgan trims AbbVie target, removes from Analyst Focus List",TipRanks,/news/stocks/jpmorgan-trims-abbvie-target-removes-from-analyst-focus-list-1034008758,positive,0.5342537760734558
2687,11/14/2024 9:11:55 PM,AbbVie initiated with an Outperform at Wolfe Research,TipRanks,/news/stocks/abbvie-initiated-with-an-outperform-at-wolfe-research-1034021103,neutral,0.5126968026161194
2688,11/14/2024 11:55:18 PM,"Wolfe starts AbbVie at Outperform, says valuation an attractive entry point",TipRanks,/news/stocks/wolfe-starts-abbvie-at-outperform-says-valuation-an-attractive-entry-point-1034021595,negative,0.9094835519790649
2689,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9049097299575806
2690,11/16/2024 5:09:00 PM,Trending stocks this week as Wall Street sells off amid Fed remarks,Seeking Alpha,https://seekingalpha.com/news/4297347-trending-stocks-this-week-as-wall-street-sells-off-amid-fed-remarks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8001051545143127
2691,11/18/2024 7:14:29 AM,European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment ,RTTNews,/news/stocks/european-commission-approves-abbvie-s-elahere-for-platinum-resistant-ovarian-cancer-treatment-1034028480,negative,0.6834845542907715
2692,11/18/2024 10:30:38 AM,AbbVie receives EC approval of Elahere,TipRanks,/news/stocks/abbvie-receives-ec-approval-of-elahere-1034030412,negative,0.5530049800872803
2693,11/18/2024 2:05:37 PM,Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-abbvie-abbv-1034032163,positive,0.8298686742782593
2694,11/18/2024 5:09:16 PM,Aldeyra announces FDA acceptance of resubmitted reproxalap application,Seeking Alpha,https://seekingalpha.com/news/4303372-aldeyra-announces-fda-acceptance-of-resubmitted-reproxalap-application?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8032193183898926
2695,11/18/2024 10:51:47 PM,AbbVie snaps eight straight sessions of losses,Seeking Alpha,https://seekingalpha.com/news/4303728-abbvie-snaps-eight-straight-sessions-of-losses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8407017588615417
2696,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7575292587280273
2697,11/22/2024 11:11:01 AM,AbbVie upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/abbvie-upgraded-to-outperform-from-market-perform-at-leerink-1034054721,negative,0.9400712251663208
2698,11/22/2024 11:20:51 AM,AbbVie upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/abbvie-upgraded-to-outperform-from-market-perform-at-leerink-1034054822,negative,0.9400712251663208
2699,11/22/2024 2:35:33 PM,"AbbVie upgraded, Baidu downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/abbvie-upgraded-baidu-downgraded-wall-street-s-top-analyst-calls-1034056271,positive,0.6567429900169373
2700,11/22/2024 3:46:27 PM,AbbVie upgraded to outperform by Leerink on recent sell-off,Seeking Alpha,https://seekingalpha.com/news/4321979-abbvie-upgraded-to-outperform-by-leerink-on-recent-sell-off?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8841786980628967
2701,11/22/2024 4:30:23 PM,Trump Trade: Trump Media considers developing crypto payment service,TipRanks,/news/stocks/trump-trade-trump-media-considers-developing-crypto-payment-service-1034056553,positive,0.8859369158744812
2702,11/22/2024 5:05:33 PM,"Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/amazon-invests-4b-more-in-anthropic-gap-reports-q3-beat-morning-buzz-1034056598,positive,0.6480697989463806
2703,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9368929862976074
2704,11/29/2024 5:00:00 PM,"Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings",Seeking Alpha,https://seekingalpha.com/news/4340728-catalyst-watch-november-jobs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8812246322631836
2705,12/4/2024 11:16:04 AM,Alector downgraded to Underperform at BofA after Alzheimer’s trial miss,TipRanks,/news/stocks/alector-downgraded-to-underperform-at-bofa-after-alzheimer-s-trial-miss-1034096905,neutral,0.934700071811676
2706,12/4/2024 5:24:52 PM,Alector downgraded to Underperform at BofA after Alzheimer's trial miss,Seeking Alpha,https://seekingalpha.com/news/4362647-alector-downgraded-to-underperform-at-bofa-after-alzheimers-trial-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9308172464370728
2707,12/5/2024 1:00:17 AM,AbbVie downgraded to Neutral from Outperform at Daiwa,TipRanks,/news/stocks/abbvie-downgraded-to-neutral-from-outperform-at-daiwa-1034099651,neutral,0.8754563927650452
2708,12/5/2024 4:02:43 PM,AbbVie: Resilient Market Position and Growth Potential Justify Buy Rating,TipRanks,/news/stocks/abbvie-resilient-market-position-and-growth-potential-justify-buy-rating-1034103943,negative,0.7465251684188843
2709,12/6/2024 9:21:18 PM,Lilly tops Morgan Stanley's biopharma pick list for 2025,Seeking Alpha,https://seekingalpha.com/news/4372587-lilly-tops-morgan-stanleys-biopharma-pick-list-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6062930822372437
2710,12/8/2024 2:40:09 AM,AbbVie: Epcoritamab Combo Shows High Response Rates In R/R Follicular Lymphoma Trial ,RTTNews,/news/stocks/abbvie-epcoritamab-combo-shows-high-response-rates-in-r-r-follicular-lymphoma-trial-1034110561,negative,0.8836294412612915
2711,12/8/2024 12:10:07 PM,AbbVie announces updated results from Phase 1b/2 EPCORE NHL-2 trial,TipRanks,/news/stocks/abbvie-announces-updated-results-from-phase-1b-2-epcore-nhl-2-trial-1034110946,positive,0.8836565017700195
2712,12/9/2024 1:12:08 PM,AbbVie reports ‘positive’ results from Phase 3 TEMPO-2 trial,TipRanks,/news/stocks/abbvie-reports-positive-results-from-phase-3-tempo-2-trial-1034114748,negative,0.9167162179946899
2713,12/9/2024 2:50:55 PM,AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal ,RTTNews,/news/stocks/abbvie-says-phase-3-tempo-2-study-of-tavapadon-in-early-parkinson-s-disease-met-main-goal-1034113631,positive,0.7743103504180908
2714,12/9/2024 4:40:59 PM,AbbVie reports Phase 3 data for tavapadon in Parkinson's disease,Seeking Alpha,https://seekingalpha.com/news/4378775-abbvie-reports-phase-3-data-for-tavapadon-in-parkinsons-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6078941226005554
2715,12/9/2024 5:30:15 PM,AbbVie to present results from two clinical trials of epcoritamab,TipRanks,/news/stocks/abbvie-to-present-results-from-two-clinical-trials-of-epcoritamab-1034115868,positive,0.7165757417678833
2716,12/10/2024 10:46:39 AM,AbbVie: Strong Buy Rating Based on Growth Potential and Strategic Positioning,TipRanks,/news/stocks/abbvie-strong-buy-rating-based-on-growth-potential-and-strategic-positioning-1034118861,negative,0.8151229619979858
2717,12/10/2024 11:40:29 AM,"Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-abbvie-abbv-protagonist-therapeutics-ptgx-1034119126,negative,0.5021383166313171
2718,12/10/2024 12:11:01 PM,AbbVie reinstated with a Neutral at BofA,TipRanks,/news/stocks/abbvie-reinstated-with-a-neutral-at-bofa-1034119657,positive,0.7728253602981567
2719,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783,positive,0.8453127145767212
2720,12/10/2024 8:00:13 PM,AbbVie treatment of multiple myeloma granted FDA orphan designation,TipRanks,/news/stocks/abbvie-treatment-of-multiple-myeloma-granted-fda-orphan-designation-1034121533,negative,0.576238751411438
2721,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8290336728096008
2722,12/11/2024 2:20:57 PM,AbbVie completes acquisition of Aliada Therapeutics,TipRanks,/news/stocks/abbvie-completes-acquisition-of-aliada-therapeutics-1034126109,positive,0.7902830243110657
2723,12/13/2024 2:20:35 PM,AbbVie to acquire Nimble Therapeutics for $200M cash at closing,TipRanks,/news/stocks/abbvie-to-acquire-nimble-therapeutics-for-200m-cash-at-closing-1034136362,positive,0.9273673295974731
2724,12/13/2024 4:20:54 PM,AbbVie to acquire Roche spinout Nimble for $200M upfront,Seeking Alpha,https://seekingalpha.com/news/4386408-abbvie-to-acquire-roche-spinout-nimble-for-200m-upfront?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.873516857624054
2725,12/13/2024 4:41:39 PM,AbbVie To Acquire Nimble Therapeutics For $200 Mln In Cash ,RTTNews,/news/stocks/abbvie-to-acquire-nimble-therapeutics-for-200-mln-in-cash-1034135902,positive,0.8962727189064026
2726,12/13/2024 9:29:17 PM,AbbVie Announces Leadership Change with New Appointment,TipRanks,/news/stocks/abbvie-announces-leadership-change-with-new-appointment-1034137147,positive,0.8816643953323364
2727,12/17/2024 12:10:50 PM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-alcon-alc-and-humana-hum-1034146453,positive,0.9147616624832153
2728,12/17/2024 1:50:16 PM,AbbVie price target raised to $220 from $212 at Piper Sandler,TipRanks,/news/stocks/abbvie-price-target-raised-to-220-from-212-at-piper-sandler-1034147143,negative,0.9461857080459595
2729,12/17/2024 6:45:36 PM,Barclays fact-checked Trump comments on pharmacy benefit managers,TipRanks,/news/stocks/barclays-fact-checked-trump-comments-on-pharmacy-benefit-managers-1034148099,positive,0.9219222068786621
2730,12/18/2024 2:50:54 PM,"PBMs took payments from manufacturers to allow free flow of opioids, NYT reports",TipRanks,/news/stocks/pbms-took-payments-from-manufacturers-to-allow-free-flow-of-opioids-nyt-reports-1034152640,positive,0.7021377086639404
2731,12/18/2024 3:20:29 PM,Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla,TipRanks,/news/stocks/trump-trade-analyst-says-trump-win-not-as-positive-as-you-d-think-for-tesla-1034152752,positive,0.7262119650840759
2732,12/19/2024 3:21:22 PM,"AbbVie Says Canadian Headache Society Backs Atogepant, OnabotulinumtoxinA ",RTTNews,/news/stocks/abbvie-says-canadian-headache-society-backs-atogepant-onabotulinumtoxina-1034156223,positive,0.6456950306892395
2733,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9418226480484009
2734,12/23/2024 3:45:07 PM,AbbVie call volume above normal and directionally bullish,TipRanks,/news/stocks/abbvie-call-volume-above-normal-and-directionally-bullish-1034169255,negative,0.9039035439491272
2735,1/3/2025 11:22:54 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1034190142,negative,0.5521676540374756
2736,1/6/2025 10:31:45 PM,"AbbVie lowers Q4, 2024 EPS estimates by $0.88",Seeking Alpha,https://seekingalpha.com/news/4392858-abbvie-lowers-q4-2024-eps-estimates-by-0_88?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9381502866744995
2737,1/6/2025 11:30:15 PM,"AbbVie cuts Q4, FY24 adjusted EPS views due to acquisition expenses",TipRanks,/news/stocks/abbvie-cuts-q4-fy24-adjusted-eps-views-due-to-acquisition-expenses-1034197454,neutral,0.9594173431396484
2738,1/8/2025 1:05:34 AM,AbbVie price target lowered to $211 from $215 at Truist,TipRanks,/news/stocks/abbvie-price-target-lowered-to-211-from-215-at-truist-1034202834,neutral,0.8384307622909546
2739,1/8/2025 1:15:48 AM,Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-abbvie-abbv-1034202851,positive,0.5576676726341248
2740,1/9/2025 7:25:26 AM,AbbVie’s Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments,TipRanks,/news/stocks/abbvie-s-strategic-acquisition-and-long-term-growth-potential-justify-buy-rating-despite-short-term-eps-adjustments-1034209296,negative,0.9197667241096497
2741,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6913239359855652
2742,1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9193293452262878
2743,1/10/2025 1:41:00 PM,AbbVie sees $3.5B impairment charge related to emraclidine,TipRanks,/news/stocks/abbvie-sees-3-5b-impairment-charge-related-to-emraclidine-1034215555,neutral,0.9566314220428467
2744,1/10/2025 2:26:53 PM,AbbVie to record $3.5B impairment charge for Cerevel drug,Seeking Alpha,https://seekingalpha.com/news/4394091-abbvie-to-record-3_5b-impairment-charge-for-cerevel-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7459713816642761
2745,1/10/2025 2:46:12 PM,AbbVie terminates Alector collaboration agreement,Seeking Alpha,https://seekingalpha.com/news/4394093-abbvie-terminates-alector-collaboration-agreement?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7671796679496765
2746,1/10/2025 8:17:47 PM,SpringWorks Therapeutics jumps amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4394228-springworks-therapeutics-jumps-amid-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7746416330337524
2747,1/13/2025 1:50:23 PM,"AbbVie, Regenxbio provide updates on ABBV-RGX-314 clinical program",TipRanks,/news/stocks/abbvie-regenxbio-provide-updates-on-abbv-rgx-314-clinical-program-1034221997,positive,0.9397346377372742
2748,1/13/2025 2:16:38 PM,"AbbVie, Simcere Zaiming announce partnership to develop SIM0500",TipRanks,/news/stocks/abbvie-simcere-zaiming-announce-partnership-to-develop-sim0500-1034222227,negative,0.8212751746177673
2749,1/13/2025 2:25:57 PM,AbCellera expands collaboration with AbbVie,TipRanks,/news/stocks/abcellera-expands-collaboration-with-abbvie-1034222192,negative,0.9382086396217346
2750,1/13/2025 4:01:10 PM,"AbbVie, AbCellera expand collaboration into T-cell engagers",Seeking Alpha,https://seekingalpha.com/news/4394549-abbvie-abcellera-expand-collaboration-into-t-cell-engagers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7977323532104492
2751,1/13/2025 7:20:44 PM,AbbVie And Simcere Zaiming Partner To Develop Innovative Cancer Drug SIM0500 ,RTTNews,/news/stocks/abbvie-and-simcere-zaiming-partner-to-develop-innovative-cancer-drug-sim0500-1034222461,negative,0.75847327709198
2752,1/14/2025 2:53:34 PM,AbbVie goes ex dividend tomorrow,Seeking Alpha,https://seekingalpha.com/news/4394944-abbvie-goes-ex-dividend-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8069489002227783
2753,1/15/2025 8:17:17 PM,AbbVie may commit less capital to psych drugs: report,Seeking Alpha,https://seekingalpha.com/news/4395395-abbvie-may-commit-less-capital-to-psych-drugs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9089224338531494
2754,1/16/2025 4:27:08 PM,AbbVie keeps Humira lead as biosimilar entry nears two-year mark,Seeking Alpha,https://seekingalpha.com/news/4395783-abbvie-retains-humira-market-share-biosimilars?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8774941563606262
2755,1/17/2025 6:07:44 AM,Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity,TipRanks,/news/stocks/optimistic-outlook-on-abbvie-s-emraclidine-strategy-a-high-reward-investment-opportunity-1034238927,negative,0.8827686309814453
2756,1/17/2025 12:21:51 PM,AbbVie price target lowered to $212 from $221 at Guggenheim,TipRanks,/news/stocks/abbvie-price-target-lowered-to-212-from-221-at-guggenheim-1034240589,neutral,0.8744286894798279
2757,1/17/2025 1:19:18 PM,Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4396094-wegovy-latest-medicare-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9195981025695801
2758,1/17/2025 1:20:48 PM,"Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",TipRanks,/news/stocks/ozempic-xtandi-among-next-15-drugs-selected-for-u-s-price-talks-1034240882,positive,0.6648421883583069
2759,1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.826055109500885
2760,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772,positive,0.4902459383010864
2761,1/17/2025 10:01:19 PM,Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market,TipRanks,/news/stocks/count-on-dividend-king-pepsi-pep-for-stability-in-a-volatile-market-1034241826,negative,0.7234762907028198
2762,1/18/2025 8:56:17 PM,Chinese biotech dominance in R&D is on the rise,Seeking Alpha,https://seekingalpha.com/news/4396390-chinese-biotech-dominance-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7791072726249695
2763,1/22/2025 6:26:03 AM,Berenberg Bank Sticks to Its Hold Rating for AbbVie (ABBV),TipRanks,/news/stocks/berenberg-bank-sticks-to-its-hold-rating-for-abbvie-abbv-1034253549,positive,0.8314464688301086
2764,1/23/2025 11:30:12 AM,"Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-abbvie-abbv-johnson-johnson-jnj-1034260045,positive,0.6329234838485718
2765,1/23/2025 2:05:37 PM,AbbVie and Neomorph to codevelop molecular glue degraders for onchology,TipRanks,/news/stocks/abbvie-and-neomorph-to-codevelop-molecular-glue-degraders-for-onchology-1034261307,positive,0.7559887170791626
2766,1/23/2025 2:20:48 PM,AbbVie completes acquisition of Nimble Therapeutics,TipRanks,/news/stocks/abbvie-completes-acquisition-of-nimble-therapeutics-1034261382,positive,0.7889646291732788
2767,1/23/2025 2:47:38 PM,"AbbVie, Neomorph to develop molecular glue degraders",Seeking Alpha,https://seekingalpha.com/news/4397866-abbvie-neomorph-to-develop-molecular-glue-degraders?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7971917986869812
2768,1/23/2025 3:20:58 PM,AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology ,RTTNews,/news/stocks/abbvie-to-collaborate-with-neomorph-to-develop-molecular-glue-degraders-for-oncology-and-immunology-1034259823,negative,0.7253887057304382
2769,1/23/2025 3:48:58 PM,AbbVie closes $200M Nimble Therapeutics acquisition,Seeking Alpha,https://seekingalpha.com/news/4397920-abbvie-closes-200m-nimble-therapeutics-acquisition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8695962429046631
2770,1/24/2025 1:18:45 PM,AbbVie (ABBV) Receives a Buy from Morgan Stanley,TipRanks,/news/stocks/abbvie-abbv-receives-a-buy-from-morgan-stanley-1034266992,positive,0.6779022216796875
2771,1/24/2025 8:00:45 PM,"Catalyst Watch: Microsoft, Meta, and Tesla report, FOMC and a Chinese New Year wildcard",Seeking Alpha,https://seekingalpha.com/news/4398457-catalyst-watch-microsoft-meta-and-tesla-report-fomc-and-a-chinese-new-year-wildcard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9276567697525024
2772,1/25/2025 6:46:00 PM,Over 80% of companies deliver EPS wins this week-Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4398494-over-80-companies-deliver-eps-wins-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6900730729103088
2773,1/26/2025 1:01:00 PM,"Earnings week ahead: TSLA, META, AAPL, MSFT, INTC, MA, XOM, LUV and more",Seeking Alpha,https://seekingalpha.com/news/4398397-earnings-week-ahead-tsla-meta-aapl-msft-intc-ma-xom-luv-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9343207478523254
2774,1/27/2025 12:00:55 PM,Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-abbvie-abbv-1034272493,positive,0.8173244595527649
2775,1/27/2025 1:50:54 PM,AbbVie price target raised to $227 from $220 at Piper Sandler,TipRanks,/news/stocks/abbvie-price-target-raised-to-227-from-220-at-piper-sandler-1034273090,negative,0.9451029300689697
2776,1/27/2025 3:59:54 PM,"FDA accepts Teva, Alvotech BLAs for Simponi biosimilars",Seeking Alpha,https://seekingalpha.com/news/4398859-fda-accepts-teva-alvotech-blas-for-simponi-biosimilars?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6550996899604797
2777,1/28/2025 11:37:06 AM,AbbVie price target lowered to $205 from $215 at Citi,TipRanks,/news/stocks/abbvie-price-target-lowered-to-205-from-215-at-citi-1034277148,neutral,0.8876000642776489
2778,1/28/2025 1:26:33 PM,Neutral Rating for AbbVie Amid Revenue Challenges and Limited Upside Potential,TipRanks,/news/stocks/neutral-rating-for-abbvie-amid-revenue-challenges-and-limited-upside-potential-1034278165,neutral,0.5743138194084167
2779,1/29/2025 9:27:39 AM,Allergan Aesthetics launches new AA signature program at IMCAS 2025,Seeking Alpha,https://seekingalpha.com/news/4399857-allergan-aesthetics-launches-new-aa-signature-program-at-imcas-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7604652643203735
2780,1/29/2025 7:30:50 PM,CMS aiming for more transparency in drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4400241-cms-aiming-for-more-transparency-in-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7420770525932312
2781,1/30/2025 10:20:18 AM,Wells downgrades Vertex to Equal Weight on lack of catalysts,TipRanks,/news/stocks/wells-downgrades-vertex-to-equal-weight-on-lack-of-catalysts-1034287994,neutral,0.8586761355400085
2782,1/30/2025 5:27:47 PM,Global stocks with the highest market share within their product groups,Seeking Alpha,https://seekingalpha.com/news/4400904-global-stocks-with-the-highest-market-share-within-their-product-groups?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6993017792701721
2783,1/30/2025 5:50:08 PM,"AbbVie Q4 2024 Earnings Preview: Strong results expected on Skyrizi, Rinvoq growth trajectory",Seeking Alpha,https://seekingalpha.com/news/4400928-abbvie-q4-2024-earnings-preview-strong-results-expected-on-skyrizi-rinvoq-growth-trajectory?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9512879252433777
2784,1/30/2025 7:20:24 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034291433,positive,0.9220908284187317
2785,1/30/2025 11:00:01 PM,Here's the major earnings before the open tomorrow,Seeking Alpha,https://seekingalpha.com/news/4400942-heres-the-major-earnings-before-the-open-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9330109357833862
2786,1/31/2025 12:05:23 PM,"Options Volatility and Implied Earnings Moves Today, January 31, 2025",TipRanks,/news/stocks/options-volatility-and-implied-earnings-moves-today-january-31-2025-1034295092,positive,0.9152857065200806
2787,1/31/2025 12:38:04 PM,"AbbVie Non-GAAP EPS of $2.16 misses by $0.10, revenue of $15.1B beats by $270M",Seeking Alpha,https://seekingalpha.com/news/4401343-abbvie-non-gaap-eps-of-2_16-misses-by-0_10-revenue-of-15_1b-beats-by-270m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5143115520477295
2788,1/31/2025 12:40:09 PM,AbbVie backs high single-digit compound annual revenue growth through 2029,TipRanks,/news/stocks/abbvie-backs-high-single-digit-compound-annual-revenue-growth-through-2029-1034295353,negative,0.9486547708511353
2789,1/31/2025 12:40:36 PM,"AbbVie sees FY25 adjusted EPS $12.12-$12.32, consensus $12.13",TipRanks,/news/stocks/abbvie-sees-fy25-adjusted-eps-12-12--12-32-consensus-12-13-1034295349,positive,0.5934330821037292
2790,1/31/2025 12:41:08 PM,"AbbVie reports Q4 adjusted EPS $2.16, consensus $2.26",TipRanks,/news/stocks/abbvie-reports-q4-adjusted-eps-2-16-consensus-2-26-1034295344,neutral,0.45777180790901184
2791,1/31/2025 12:55:05 PM,"AbbVie in charts: Revenues from Humira -49%, Skyrizi +57.8%, Rinvoq +46% Y/Y",Seeking Alpha,https://seekingalpha.com/news/4401352-abbvie-in-charts-revenues-from-humira-49-skyrizi-578-rinvoq-46-yy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9011969566345215
2792,1/31/2025 1:01:12 PM,Earnings Snapshot: AbbVie Q4 top-line beats estimates; 2025 EPS outlook beat expectations,Seeking Alpha,https://seekingalpha.com/news/4401354-earnings-snapshot-abbvie-q4-top-line-beats-estimates-2025-eps-outlook-beat-expectations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8192062377929688
2793,1/31/2025 1:25:06 PM,AbbVie swings to Q4 loss amid Cerevel impact; sets in-line guidance,Seeking Alpha,https://seekingalpha.com/news/4401344-abbvie-stock-spikes-q4-revenue-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9237610697746277
2794,1/31/2025 1:46:47 PM,AbbVie Q4 Earnings Summary ,RTTNews,/news/stocks/abbvie-q4-earnings-summary-1034295430,neutral,0.40863674879074097
2795,1/31/2025 1:50:19 PM,AbbVie Guides FY25 Adj. EPS In Line With Estimates - Update ,RTTNews,/news/stocks/abbvie-guides-fy25-adj-eps-in-line-with-estimates-update-1034295428,positive,0.9033623337745667
2796,1/31/2025 2:01:03 PM,Morning Movers: Apple and Exxon higher following quarterly earnings,TipRanks,/news/stocks/morning-movers-apple-and-exxon-higher-following-quarterly-earnings-1034296094,negative,0.8736249804496765
2797,1/31/2025 2:02:17 PM,"5 stocks to watch on Friday: XOM, ABBV, WBA and more",Seeking Alpha,https://seekingalpha.com/news/4401372-5-stocks-to-watch-on-friday-xom-abbv-wba-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9304909110069275
2798,1/31/2025 2:09:49 PM,ABBV Earnings: AbbVie Rallies Alongside Q4 Beats,TipRanks,/news/stocks/abbv-earnings-abbvie-rallies-alongside-q4-beats-1034296064,negative,0.9340481758117676
2799,1/31/2025 2:10:40 PM,"AbbVie says ‘very pleased’ with progress in 2024, sees ‘strong growth’ in 2025",TipRanks,/news/stocks/abbvie-says-very-pleased-with-progress-in-2024-sees-strong-growth-in-2025-1034296062,negative,0.9413007497787476
2800,1/31/2025 2:26:05 PM,AbbVie expects Humira access to decrease throughout 2025,TipRanks,/news/stocks/abbvie-expects-humira-access-to-decrease-throughout-2025-1034296142,neutral,0.9457269906997681
2801,1/31/2025 2:35:53 PM,"AbbVie sees FY25 revenue ~$59B, consensus $59.07B",TipRanks,/news/stocks/abbvie-sees-fy25-revenue-~-59b-consensus-59-07b-1034296229,positive,0.6534698605537415
2802,1/31/2025 2:36:09 PM,AbbVie seeing ‘significant advancements’ across entire pipeline,TipRanks,/news/stocks/abbvie-seeing-significant-advancements-across-entire-pipeline-1034296226,negative,0.9414806962013245
2803,1/31/2025 2:40:26 PM,AbbVie sees FY25 adjusted gross margin 84% of sales,TipRanks,/news/stocks/abbvie-sees-fy25-adjusted-gross-margin-84-of-sales-1034296221,positive,0.8157268762588501
2804,1/31/2025 2:40:33 PM,"AbbVie sees Q1 adjusted EPS $2.47-$2.51, consensus $2.59",TipRanks,/news/stocks/abbvie-sees-q1-adjusted-eps-2-47--2-51-consensus-2-59-1034296220,negative,0.5632758140563965
2805,1/31/2025 2:45:22 PM,Unusually active option classes on open January 31st,TipRanks,/news/stocks/unusually-active-option-classes-on-open-january-31st-1034296310,positive,0.7174770832061768
2806,1/31/2025 2:50:45 PM,AbbVie rises 7.4%,TipRanks,/news/stocks/abbvie-rises-7-4-1034296306,negative,0.8872469067573547
2807,1/31/2025 2:55:14 PM,Early notable gainers among liquid option names on January 31st,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-january-31st-1034296301,negative,0.9077146053314209
2808,1/31/2025 3:06:06 PM,AbbVie rises 7.8%,TipRanks,/news/stocks/abbvie-rises-7-8-1034296653,negative,0.8793752789497375
2809,1/31/2025 3:24:15 PM,"Biggest stock movers Friday:  ABBV, TEAM, and more",Seeking Alpha,https://seekingalpha.com/news/4401273-biggest-stock-movers-friday-aapl-team-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9204309582710266
2810,1/31/2025 5:00:56 PM,"Apple, Intel little changed near noon following earnings: Morning Buzz",TipRanks,/news/stocks/apple-intel-little-changed-near-noon-following-earnings-morning-buzz-1034297283,positive,0.8414871692657471
2811,2/1/2025 12:53:24 PM,Are healthcare stocks on the rebound?,Seeking Alpha,https://seekingalpha.com/news/4401695-are-healthcare-stocks-rebound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7119130492210388
2812,2/1/2025 11:45:00 PM,"Notable Healthcare headlines for the week: Moderna, AbbVie, Thermo Fisher, J&J in focus",Seeking Alpha,https://seekingalpha.com/news/4400864-notable-healthcare-headlines-for-the-week-moderna-thermo-fisher-jj-in-focus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9122067093849182
2813,2/3/2025 11:25:04 AM,AbbVie price target raised to $215 from $205 at Citi,TipRanks,/news/stocks/abbvie-price-target-raised-to-215-from-205-at-citi-1034302552,negative,0.9422266483306885
2814,2/3/2025 11:51:13 AM,"Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Boston Scientific (BSX) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbvie-abbv-boston-scientific-bsx-and-sanofi-othersnynf-1034302757,positive,0.9157636165618896
2815,2/3/2025 12:15:29 PM,Truist Financial Keeps Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-abbvie-abbv-1034303093,positive,0.8977684378623962
2816,2/3/2025 12:31:25 PM,AbbVie price target raised to $214 from $212 at Guggenheim,TipRanks,/news/stocks/abbvie-price-target-raised-to-214-from-212-at-guggenheim-1034303218,negative,0.9452173113822937
2817,2/3/2025 12:36:43 PM,AbbVie price target raised to $215 from $208 at BMO Capital,TipRanks,/news/stocks/abbvie-price-target-raised-to-215-from-208-at-bmo-capital-1034303199,negative,0.9457839727401733
2818,2/3/2025 12:37:19 PM,AbbVie (ABBV) Receives a Buy from Guggenheim,TipRanks,/news/stocks/abbvie-abbv-receives-a-buy-from-guggenheim-1034303198,positive,0.8797456622123718
2819,2/3/2025 1:35:41 PM,Morgan Stanley Reaffirms Their Buy Rating on AbbVie (ABBV),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-abbvie-abbv-1034303622,positive,0.8407372236251831
2820,2/3/2025 1:40:42 PM,AbbVie price target raised to $220 from $218 at Raymond James,TipRanks,/news/stocks/abbvie-price-target-raised-to-220-from-218-at-raymond-james-1034303580,negative,0.9413718581199646
2821,2/3/2025 1:55:28 PM,AbbVie price target raised to $217 from $211 at Truist,TipRanks,/news/stocks/abbvie-price-target-raised-to-217-from-211-at-truist-1034303701,negative,0.947150707244873
2822,2/3/2025 2:55:10 PM,Early notable gainers among liquid option names on February 3rd,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-february-3rd-1034304068,negative,0.9167259335517883
2823,2/3/2025 3:26:14 PM,AbbVie (ABBV) Receives a Buy from Argus Research,TipRanks,/news/stocks/abbvie-abbv-receives-a-buy-from-argus-research-1034304493,positive,0.8351854085922241
2824,2/4/2025 10:18:52 PM,"Amgen sets 2025 revenue, EPS guidance ranges that include consensus",Seeking Alpha,https://seekingalpha.com/news/4403151-amgen-sets-2025-revenue-eps-guidance-ranges-that-include-consensus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9494784474372864
2825,2/6/2025 6:22:57 PM,Equillium stock rallies 26% on itolizumab study data,Seeking Alpha,https://seekingalpha.com/news/4404602-equillium-stock-rallies-on-itolizumab-study-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9191905856132507
2826,2/7/2025 6:36:13 PM,AbbVie says FDA approves Emblaveo in combination with metronidazole in adults,TipRanks,/news/stocks/abbvie-says-fda-approves-emblaveo-in-combination-with-metronidazole-in-adults-1034329111,negative,0.557700514793396
2827,2/7/2025 7:42:50 PM,AbbVie gets FDA approval for antibiotic treatment Emblaveo (update),Seeking Alpha,https://seekingalpha.com/news/4405254-abbvie-gets-fda-approval-for-antibiotic-treatment-emblaveo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5456146597862244
2828,2/8/2025 1:51:26 AM,AbbVie: FDA Approves Emblaveo - Metronidazole Combination For Complicated Intra-Abdominal Infections ,RTTNews,/news/stocks/abbvie-fda-approves-emblaveo-metronidazole-combination-for-complicated-intra-abdominal-infections-1034329518,negative,0.9221829771995544
